
<html lang="en"     class="pb-page"  data-request-id="c985f0a4-c718-4aec-95da-028b55221c4c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00480;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs" /></meta><meta name="dc.Creator" content="Qianqian  Zhao" /></meta><meta name="dc.Creator" content="Liang  Xin" /></meta><meta name="dc.Creator" content="Yuzhi  Liu" /></meta><meta name="dc.Creator" content="Chengyuan  Liang" /></meta><meta name="dc.Creator" content="Jingyi  Li" /></meta><meta name="dc.Creator" content="Yanlin  Jian" /></meta><meta name="dc.Creator" content="Han  Li" /></meta><meta name="dc.Creator" content="Zhenfeng  Shi" /></meta><meta name="dc.Creator" content="Hong  Liu" /></meta><meta name="dc.Creator" content="Wenqiang  Cao" /></meta><meta name="dc.Description" content="The widespread use of antibiotics has made the problem of bacterial resistance increasingly serious, and the study of new drug-resistant bacteria has become the main direction of antibacterial drug..." /></meta><meta name="Description" content="The widespread use of antibiotics has made the problem of bacterial resistance increasingly serious, and the study of new drug-resistant bacteria has become the main direction of antibacterial drug..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 14, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00480" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00480" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00480" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00480" /></link>
        
    
    

<title>Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00480" /></meta><meta property="og:title" content="Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0028.jpeg" /></meta><meta property="og:description" content="The widespread use of antibiotics has made the problem of bacterial resistance increasingly serious, and the study of new drug-resistant bacteria has become the main direction of antibacterial drug research. Among antibiotics, the fully synthetic oxazolidinone antibacterial drugs linezolid and tedizolid have been successfully marketed and have achieved good clinical treatment effects. Oxazolidinone antibacterial drugs have good pharmacokinetic and pharmacodynamic characteristics and unique antibacterial mechanisms, and resistant bacteria are sensitive to them. This Perspective focuses on reviewing oxazolidinones based on the structural modification of linezolid and new potential oxazolidinone drugs in the past 10 years, mainly describing their structure, antibacterial activity, safety, druggability, and so on, and discusses their structure–activity relationships, providing insight into the reasonable design of safer and more potent oxazolidinone antibacterial drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00480"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00480">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00480&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00480&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00480&amp;href=/doi/10.1021/acs.jmedchem.1c00480" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00344" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00820" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Qianqian Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qianqian Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qianqian++Zhao">Qianqian Zhao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liang Xin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Xin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div><div class="loa-info-affiliations-info">Xi’an Xuri Shengchang Pharmaceutical Technology Co., Ltd., High-tech Zone, Xi’an 710075, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Xin">Liang Xin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuzhi Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuzhi Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuzhi++Liu">Yuzhi Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chengyuan Liang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chengyuan Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#ee8d868b8089979b8f8082878f8089ae89838f8782c08d8183"><span class="__cf_email__" data-cfemail="debdb6bbb0b9a7abbfb0b2b7bfb0b99eb9b3bfb7b2f0bdb1b3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chengyuan++Liang">Chengyuan Liang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7360-8998" title="Orcid link">https://orcid.org/0000-0001-7360-8998</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingyi Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingyi Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingyi++Li">Jingyi Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanlin Jian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanlin Jian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanlin++Jian">Yanlin Jian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Han Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Han Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi’an 710021, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Han++Li">Han Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenfeng Shi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenfeng Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Urology Surgery Center, Xinjiang Uyghur People’s Hospital, Urumqi 830002, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a2d8cac7ccc4c7ccc5d1cacbe29394918cc1cdcf"><span class="__cf_email__" data-cfemail="98e2f0fdf6fefdf6ffebf0f1d8a9aeabb6fbf7f5">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenfeng++Shi">Zhenfeng Shi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d1a2b4a2bea4a3b2b48ebdb8a4b9bebfb691e0e7e2ffb2bebc"><span class="__cf_email__" data-cfemail="631006100c161100063c0f0a160b0c0d04235255504d000c0e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liu">Hong Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenqiang Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenqiang Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenqiang++Cao">Wenqiang Cao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath10">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00480&amp;href=/doi/10.1021%2Facs.jmedchem.1c00480" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 14, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 March 2021</li><li><span class="item_label"><b>Published</b> online</span>14 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00480" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00480</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQianqian%2BZhao%252C%2BLiang%2BXin%252C%2BYuzhi%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00480%26title%3DCurrent%2BLandscape%2Band%2BFuture%2BPerspective%2Bof%2BOxazolidinone%2BScaffolds%2BContaining%2BAntibacterial%2BDrugs%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D24%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00480"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">615</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00480" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qianqian&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Yuzhi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Chengyuan&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Jingyi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yanlin&quot;,&quot;last_name&quot;:&quot;Jian&quot;},{&quot;first_name&quot;:&quot;Han&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhenfeng&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Wenqiang&quot;,&quot;last_name&quot;:&quot;Cao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00480&quot;},&quot;abstract&quot;:&quot;The widespread use of antibiotics has made the problem of bacterial resistance increasingly serious, and the study of new drug-resistant bacteria has become the main direction of antibacterial drug research. Among antibiotics, the fully synthetic oxazolidinone antibacterial drugs linezolid and tedizolid have been successfully marketed and have achieved good clinical treatment effects. Oxazolidinone antibacterial drugs have good pharmacokinetic and pharmacodynamic characteristics and unique antibacterial mechanisms, and resistant bacteria are sensitive to them. This Perspective focuses on reviewing oxazolidinones based on the structural modification of linezolid and new potential oxazolidinone drugs in the past 10 years, mainly describing their structure, antibacterial activity, safety, druggability, and so on, and discusses their structure–activity relationships, providing insight into the reasonable design of safer and more potent oxazolidinone antibacterial drugs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00480&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00480" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00480&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00480" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00480&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00480" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00480&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00480&amp;href=/doi/10.1021/acs.jmedchem.1c00480" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00480" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00480" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00480%26sid%3Dliteratum%253Aachs%26pmid%3D34260235%26genre%3Darticle%26aulast%3DZhao%26date%3D2021%26atitle%3DCurrent%2BLandscape%2Band%2BFuture%2BPerspective%2Bof%2BOxazolidinone%2BScaffolds%2BContaining%2BAntibacterial%2BDrugs%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291214" title="Bacteria">Bacteria</a>,</li><li><a href="/action/doSearch?ConceptID=291676" title="Antibacterial activity">Antibacterial activity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The widespread use of antibiotics has made the problem of bacterial resistance increasingly serious, and the study of new drug-resistant bacteria has become the main direction of antibacterial drug research. Among antibiotics, the fully synthetic oxazolidinone antibacterial drugs linezolid and tedizolid have been successfully marketed and have achieved good clinical treatment effects. Oxazolidinone antibacterial drugs have good pharmacokinetic and pharmacodynamic characteristics and unique antibacterial mechanisms, and resistant bacteria are sensitive to them. This Perspective focuses on reviewing oxazolidinones based on the structural modification of linezolid and new potential oxazolidinone drugs in the past 10 years, mainly describing their structure, antibacterial activity, safety, druggability, and so on, and discusses their structure–activity relationships, providing insight into the reasonable design of safer and more potent oxazolidinone antibacterial drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the discovery of penicillin in 1928, antibiotics have become commonly used drugs for treating a variety of clinical diseases.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Whereas the variety and quantity of antibiotics endlessly grow, under the influence of various man-made and external factors, the difficulty of drug selection and the obvious increase in drug overuse and abuse are high. This makes both Gram-positive and Gram-negative bacteria appear severely resistant.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Horizontal transfer by bacteria to obtain exogenous drug-resistance genes also accelerates the production of drug-resistant strains.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> According to statistics from the World Health Organization (WHO), ∼50 000 patients die from infectious diseases every day worldwide, seriously threatening human health and social development; as a result, drug-resistant strains have attracted increasing attention.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Of these, the trouble of multi-drug-resistant bacteria is especially prominent. In particular, methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), methicillin-resistant <i>Staphylococcus epidermidis</i> (MRSE), penicillin-resistant multi-drug-resistant <i>tuberculosis</i> (MDR-TB), vancomycin-resistant <i>Enterococcus</i> (VRE), <i>Streptococcus pneumoniae</i> (PRSP), and other Gram-positive bacteria are the most prevalent, and they make clinical treatment very difficult.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a> The vicious circle of “drug resistance–new drug development–drug resistance” and the fact that existing drugs still have difficulty effectively controlling the infection by new drug-resistant bacteria make the development of new anti-drug-resistant antibacterial drugs particularly urgent.</div><div class="NLM_p">At present, medicinal chemists are working hard to develop new antibacterial drugs with new structures, unique mechanisms of action, and new targets as well as hybrid drugs that work with other drugs. Oxazolidinone antibacterial agents are a group of synthetic antibacterial agents with completely new chemical structures that have been marketed after sulfonamides and quinolones.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> They inhibit multi-drug-resistant Gram-positive bacteria and have antibacterial activity against MRSA, <i>Staphylococcus epidermidis</i> (<i>S. epidermidis</i>), VRE, PRSP, and anaerobic bacteria.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Because of the unique antibacterial mechanism of action of oxazolidinone agents,<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> they can inhibit the initial stage of protein synthesis and have no cross-resistance with other antibacterial drugs; therefore, they have attracted much attention and show good development prospects. In 2000, the first fully synthetic oxazolidinone antibacterial drug, linezolid, was approved by the U.S. Food and Drug Administration (FDA) for treating infective diseases caused by Gram-positive bacteria, including <i>Streptococcus</i>, VRE, and MRSA. It is used for the treatment of skin and skin tissue infections, pneumonia, VRE infections and other infective diseases caused by multiple Gram-positive bacteria.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> However, since it was marketed, although linezolid showed satisfactory therapeutic effects in the initial stage of use, drug-resistant <i>Enterococcus</i> appeared after long-term use, accompanied by adverse reactions such as thrombocytopenia.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> This has prompted medicinal chemists to continue to develop oxazolidinone antibacterial agents with higher antibacterial activity with increased safety of use to solve these problems.</div><div class="NLM_p last">In this Perspective, we discuss two oxazolidinone antibacterial drugs currently on the market, antibacterial agents that have been modified based on linezolid, and new antibacterial agents containing oxazolidinone parts in the past 10 years, and the critical aspects of the design and structure–activity relationships (SARs) of these antibacterial agents are also summarized.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Launched Oxazolidinone Antibacterial Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Linezolid</h3><div class="NLM_p">Linezolid (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), <i>N</i>-([S]-[3-[3-fluoro-4-mor-pholinophenyl]-2-oxo-5-oxazolidinyl] methyl) acetamide, was the first synthetic oxazolidinone approved for clinical use.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> It can bind to the 23S peptidyl transferase center (PTC) of the 50S ribosomal subunit, preventing the combination of mRNA and tRNA with the 50S and 30S ribosomal subunits to form a 70S initiation complex, which is different from the mechanisms of most other protein synthesis inhibitors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In this compound, the morpholino group is the key to improving the pharmacokinetic characteristics and water solubility, the fluorine atom greatly improves the activity, and the <i>N</i>-aryl group is required for activity. At the same time, a 5-R configuration is necessary to maintain the activity.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Linezolid exhibits good oral bioavailability and excellent tissue penetration, and it has been demonstrated to be effective against multi-drug-resistant Gram-positive bacteria (MRSA, MRSE, PRSP, VRE, etc.).<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Linezolid is metabolized by the oxidation of the morpholine ring in the liver without the participation of the cytochrome P450 (CYP450) system. Linezolid neither induces nor inhibits CYP450 subtypes in rats and humans;<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> however, linezolid is limited by its toxicity issues. The primary toxicity issues center on myelosuppression and monoamine oxidase (MAO) inhibition, which have been considered to be the two main factors leading to major adverse reactions in linezolid therapy. The direct side effects mainly include thrombocytopenia, leukopenia, pancytopenia, anemia, and serotonin toxicity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure–activity relationship for linezolid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some clinical trials have been conducted in many countries/regions to study the clinical treatment of linezolid (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and they have mainly focused on antimeningitis, anti-TB, antipneumonia, and antibacterial infection/skin infection applications, and so on. Moreover, linezolid can also treat eye diseases/visual disorders and cystic fibrosis. In a study of animal models of meningitis caused by <i>Streptococcus pneumoniae</i> (<i>S. pneumoniae</i>) infection, linezolid penetrated well into the cerebrospinal fluid, but its effect was not as good as those of other antibiotics.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Nonetheless, linezolid has successfully treated many cases of central nervous system infections (e.g., meningitis) resulting from sensitive bacteria, and it can also be used as a suitable therapeutic drug when the choice of treatment is limited or other antibiotics are ineffective.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> A study showed that VRE meningitis in immunosuppressed patients after transplantation can be effectively treated with linezolid. Despite the risk of aggravating myelosuppression, bone marrow suppression caused by linezolid is reversible.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> At the same time, the guidelines of the American Academy of Infectious Diseases also regard linezolid as the first choice for the treatment of meningitis caused by VRE infection, and it is recommended to use linezolid instead of vancomycin in the treatment of meningitis caused by MRSA.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clinical Trials of Linezolid<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">study name</th><th class="colsep0 rowsep0" align="center">study design</th><th class="colsep0 rowsep0" align="center">condition</th><th class="colsep0 rowsep0" align="center">identifier (phase)</th><th class="colsep0 rowsep0" align="center" char=".">population number</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid in pulmonary TB</td><td class="colsep0 rowsep0" align="left">open, randomized</td><td class="colsep0 rowsep0" align="left">pulmonary TB</td><td class="colsep0 rowsep0" align="left">NCT02279875 (Phase 2 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid in TB meningitis</td><td class="colsep0 rowsep0" align="left">open, randomized</td><td class="colsep0 rowsep0" align="left">TB meningitis</td><td class="colsep0 rowsep0" align="left">NCT03537495 (Phase 2 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifampin plus linezolid in tuberculous: the ALTER</td><td class="colsep0 rowsep0" align="left">open, randomized</td><td class="colsep0 rowsep0" align="left">TB</td><td class="colsep0 rowsep0" align="left">NCT04021121 (Phase 2 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid in cystic fibrosis</td><td class="colsep0 rowsep0" align="left">open</td><td class="colsep0 rowsep0" align="left">fibrosis, cystic, hospitalization</td><td class="colsep0 rowsep0" align="left">NCT00625703 (Phase 2 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RX-1741 vs linezolid in skin infection</td><td class="colsep0 rowsep0" align="left">comparative, multicenter, open, randomized</td><td class="colsep0 rowsep0" align="left">infection</td><td class="colsep0 rowsep0" align="left">NCT00646958 (Phase 2 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid in pneumonia</td><td class="colsep0 rowsep0" align="left">open</td><td class="colsep0 rowsep0" align="left">infection, respiratory tract infection, respiratory tract (lower) pneumonia</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">178</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">omadacycline vs linezolid in acute bacterial skin and skin structure infection</td><td class="colsep0 rowsep0" align="left">comparative, double-blind, randomized</td><td class="colsep0 rowsep0" align="left">infection, bacterial, cutaneous (skin-soft tissue)</td><td class="colsep0 rowsep0" align="left">NCT02378480 (Phase 3 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">650</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid in eye disorder/visual disturbance</td><td class="colsep0 rowsep0" align="left">multicenter, open</td><td class="colsep0 rowsep0" align="left">eye disorders, visual disturbances</td><td class="colsep0 rowsep0" align="left">NCT00359632 (Phase 3 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">omadacycline vs linezolid in bacterial infection</td><td class="colsep0 rowsep0" align="left">open, randomized</td><td class="colsep0 rowsep0" align="left">infection, bacterial</td><td class="colsep0 rowsep0" align="left">NCT02877927 (Phase 3 Clinical)</td><td class="colsep0 rowsep0" align="char" char=".">704</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">TB, tuberculosis.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Tedizolid</h3><div class="NLM_p">Tedizolid (TR-700, formerly torezolid, trade name Sivextro) is a second-generation oxazolidinone drug.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Tedizolid was approved by the FDA on June 20, 2014 for treating acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Perhaps most importantly, compared with linezolid, tedizolid is 4 to 16 times more effective against <i>Staphylococcus</i> and <i>Enterococcus</i>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Tedizolid has good oral bioavailability and needs to be administered only once a day.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Phosphate-modified tedizolid (TR-701) has many advantages, and the introduction of phosphate significantly improves the water solubility and bioavailability of the drug compared with the parent molecule.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Tedizolid phosphate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and linezolid are very similar in structure. The 5-R configuration on the A ring and the B ring of the <i>N</i>-aryl are both necessary for antibacterial activity.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The fluorine atom on the B ring can improve the antibacterial activity. The group at the C-5 position of tedizolid is different from that of linezolid. The hydroxymethyl group at the C-5 position plays an important role.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Tedizolid phosphate and some other oxazolidinone antibacterial agents containing hydroxymethyl or 1,2,3-triazole at the C-5 position were reported by Locke et al.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> to be effective against strains with <i>cfr</i> genes, with significantly higher activity than that with the acetamide substituent. In addition to the modification of the C-5 position, tedizolid uses a biaryl ring system instead of the morpholine group at the C-ring position of linezolid. The C- and D-ring systems are pyridine and tetrazole, respectively, which can have additional interactions with the upper area of the PTC of the 50S ribosomal subunit. Like linezolid, the toxicity (mainly including myelosuppression and MAO inhibition) of tedizolid has not been significantly improved. At present, many experimental studies on tedizolid are still continuing, mainly focusing on the treatment of skin/bacterial infections, and it is a promising antimicrobial choice for treating cystic fibrosis patients with <i>Staphylococcus aureus</i> (<i>S. aureus</i>) infection (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure–activity relationship for tedizolid phosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Tedizolid Trials<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">experimental activity</th><th class="colsep0 rowsep0" align="center">pharmacological activity</th><th class="colsep0 rowsep0" align="center">experimental activity</th><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relieve/reduce <i>S. aureus</i> and methicillin-resistant <i>S. aureus</i> infections <i>in vivo</i></td><td class="colsep0 rowsep0" align="left">protection against <i>S. aureus</i> (methicillin/tedizolid) (23S rRNA [G2576T-mutated]) infection</td><td class="colsep0 rowsep0" align="left"><i>Galleria mellonella</i> (greater wax moth)/<i>Staphylococcal</i> infection (lung), <i>S. aureus</i> (methicillin-resistant)-induced, in mouse</td><td class="colsep0 rowsep0" align="left">survival rate assay</td><td class="colsep0 rowsep0" align="left">MED = 2 mg/L</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">relieve/reduce <i>Streptococcal</i> infections <i>in vivo</i></td><td class="colsep0 rowsep0" align="left">antibacterial activity of <i>Streptococcus</i> species (beta-hemolytic)</td><td class="colsep0 rowsep0" align="left">wild-type isolates</td><td class="colsep0 rowsep0" align="left">broth dilution</td><td class="colsep0 rowsep0" align="left">MIC<sub>90</sub> = 250 μg/mL</td><td class="colsep0 rowsep0" rowspan="2" align="left"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">antibacterial activity of <i>Streptococcus</i> species</td><td class="colsep0 rowsep0" align="left">wild-type isolates</td><td class="colsep0 rowsep0" align="left">broth dilution</td><td class="colsep0 rowsep0" align="left">MIC<sub>90</sub> = 250 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relieve/reduce <i>Streptococcal</i> infections <i>in vivo</i></td><td class="colsep0 rowsep0" align="left">antibacterial activity linezolid-resistant <i>Streptococcus</i> species</td><td class="colsep0 rowsep0" align="left">wild-type isolates</td><td class="colsep0 rowsep0" align="left">broth dilution</td><td class="colsep0 rowsep0" align="left">MIC<sub>90</sub> = 8 μg/mL</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>S. aureus</i>, <i>Staphylococcus aureus</i>; MIC<sub>90</sub>, minimum inhibitory concentration (MIC) of tedizolid for 90% of isolates; MED: minimum effect dose.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3.  Structural Modification of Oxazolidinone Drugs Based on Linezolid</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unfortunately, shortly after linezolid was marketed, linezolid-resistant strains (MRSA and vancomycin-resistant <i>Enterococcus faecium</i> (VREF)) began to appear clinically.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Beyond that, the toxicity of linezolid was also a key point that needed to be improved. The most commonly used method to overcome antibiotic resistance and reduce toxicity is to modify existing antibiotics to obtain classes of novel antibacterial agents with improved properties. Previous studies on the SAR of linezolid and the crystal structure of the 50S ribosomal subunit showed that<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> the morpholine ring of linezolid did not significantly interact with the ribosomal subunits and that when many different functional groups replaced the morpholine ring, the activity was not significantly reduced. From the perspective of drug design, the pharmacological properties of the entire drug molecule could be improved by adjusting this area, and the binding interaction necessary for the antibacterial activity would not be affected. The acetamido group at the C-5 position of linezolid is not necessary for activity. Moreover, many compounds with other substituents at the C-5 position have significant activity <i>in vitro</i> and improved safety profiles.<a onclick="showRef(event, 'ref25 ref47'); return false;" href="javascript:void(0);" class="ref ref25 ref47">(25,47)</a> Therefore, a series of oxazolidinone compounds based on the previously described two sites have emerged. In addition, another class of tricyclic fused oxazolidinone compounds based on the transformation of linezolid also displayed excellent inhibitory activity against Gram-positive bacteria and broad-spectrum antibacterial properties, and these compounds also exhibited excellent druggability.</div><div class="NLM_p">In general, the currently reported linezolid-based oxazolidinone antibacterial agents are divided into four main categories according to their structures: (1) modified morpholine ring, (2) modified at the C-5 position, (3) simultaneous modification of the morpholine ring and the C-5 position, and (4) tricyclic fused oxazolidinone.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.1.  Modification of Only the Morpholine Ring or the C-5 Position</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.1.1.  Modification of the Morpholine Ring</h4><div class="NLM_p">Ranbezolid (<b>1</b>) is an oxazolidinone antibacterial agent developed by Ranbaxy Research Laboratories based on linezolid that was in a phase I clinical trial. It exhibited good activity in the <i>in vitro</i> assay against Gram-positive bacteria.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The nitrofuran part of ranbezolid interacts with the binding site of the bacterial ribosome to strengthen its interaction with the target pathogen.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Zhao et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> designed and synthesized a class of oxazolidinone derivatives with a nitro aromatic ring or a nitro heteroaromatic ring in the “tail” based on ranbezolid (<b>2a</b>–<b>i</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). They introduced hydrazone as the linker between the piperazinyl ring and the heteroaromatic ring to increase the basicity of the nitrogen, which was proven to enhance the antibacterial potency.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Among these derivatives, compound <b>2d</b> showed good antibacterial activity (<i>S. aureus</i>, MIC: 0.25 mg/L; MRSA, MIC: 1 mg/L; VRE, MIC: 1 mg/L), and its activity was higher than that of ranbezolid. SAR studies showed that the antibacterial activities of compounds <b>2d</b> and <b>2e</b> were better than that of ranbezolid, which demonstrated that the addition of methyl hydrazone moieties of nitrofuryl or nitrothiophene increased the antibacterial potency. Substituting a nitro-substituted imidazole ring for the nitrofuran ring would result in varying degrees of activity reduction. In addition, when the nitro group was replaced with an amino group (<b>2a</b>), the antibacterial activity was also significantly reduced. To further investigate the antibacterial potency, a series of phenyl-containing analogues were synthesized. The compounds with substituents in the ortho and meta positions were more active than those in the para position; however, the antibacterial activity of disubstituted compounds (such as <b>2f</b>) was poor.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy and antibacterial activities of oxazolidinone compounds <b>2a</b>–<b>i</b> (<i>S. aureus</i>, <i>Staphylococcus aureus</i>; MRSA, methicillin-resistant <i>Staphylococcus aureus</i>; VRE, vancomycin-resistant <i>Enterococcus</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In continuously developing new drug candidates, this research team further discovered that antibacterial compounds containing nitrofuran groups could have these groups catalytically transformed into nitro groups through active nitroso radical intermediates <i>in vivo</i> by related enzymes, thereby causing cytotoxicity. In addition, the existence of an acylhydrazone bond made the compounds rigid and difficult to dissolve, easy to hydrolyze, and not conducive to metabolic stability. Therefore, they combined the phenoxypiperidinyl group, which was necessary for the activity of the antibacterial drug delamanid, with compound <b>2d</b> to yield a series of piperidinyl-containing oxazolidinone derivatives (<b>3a</b>–<b>m</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In these compounds, various phenyl and benzyl groups were used to replace the nitro heteroaromatic ring of compound <b>2d</b> to reduce toxicity, and the piperidinyl moiety was used to replace the piperazinyl group because of its bioisosteric equivalence regarding the hydrazone. Meanwhile, NH was introduced as a donor for hydrogen bonds between the piperidinyl moiety and the benzene ring to improve the antibacterial potency. Among these compounds, <b>3a</b> and <b>3h</b> showed significant inhibitory effects against linezolid-resistant <i>Enterococcus faecium</i> (LREFA), <i>S. aureus</i>, MRSA, methicillin-sensitive <i>S. aureus</i> (MSSA), and VREF (<b>3a</b>: MIC: 0. 5–1 μg/mL; <b>3h</b>: MIC: 0. 25–1 μg/mL). Moreover, the drug-susceptible and drug-resistant clinical isolates were treated with compounds <b>3a</b> and <b>3h</b>. Compound <b>3a</b> showed moderate activity against four clinical isolates tested, including linezolid-resistant <i>Enterococcus faecalis</i> (LREF), MRSA, MSSA, and VREF (MIC: 0.125–1 μg/mL). Compound <b>3h</b> exhibited excellent inhibitory potency against four clinical isolates tested (MIC: 0.0625–1 μg/mL), and its efficacy against clinical strains of LREF was 64 times stronger than that of linezolid (<b>3h</b>: MIC: 0.625–0.25 μg/mL; linezolid: MIC > 16 μg/mL). Therefore, <b>3a</b> and <b>3h</b> could be used as lead compounds for further modification and transformation.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design strategy and chemical structures of oxazolidinone compounds <b>3a</b>–<b>m</b> containing piperidinyl moieties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A class of teraryl oxazolidinone antibacterial agents was designed and synthesized to balance the potency and toxicology of oxazolidinones, and they were found to be candidates that showed reduced myelosuppression and improved efficacy and pharmacokinetic (PK) profiles compared with linezolid.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> SAR studies revealed that compounds containing a pyrazole moiety substituted with a heteroaromatic ring group at the four-position exhibited high inhibitory efficacy and identified some oxazolidinones (<b>4a</b>–<b>e</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) with excellent antibacterial activity against MSSA and MRSA (<b>4a</b>–<b>e</b>: MIC: 0.5–2 μg/mL; linezolid: MIC: 1–2 μg/mL). Among them, <b>4d</b> exhibited a promising safety profile in MTT assays (CC<sub>50</sub>(mammalian cells) > 70 μM) and in the hERG K<sup>+</sup> channel inhibition test (IC<sub>50</sub> > 40 μM). Moreover, phosphate (<b>5</b>) showed high water solubility (47.1 mg/mL) and significantly increased the survival probability compared with linezolid in systematic MRSA infection mouse models. It also exhibited good oral bioavailability (<i>F</i> = 99.1%) and an improved safety profile, including reduced myelosuppression. These satisfactory results made compound <b>5</b> a promising antibacterial drug candidate.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of compounds <b>4a</b>–<b>e</b> and <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">3.1.2.  Modification of the C-5 Position</h4><div class="NLM_p">Lithgow et al. exploited common structural characteristics that exist in linezolid-resistant (LZDR) forms of both MRSA and VRE to design antibacterial agents. The rapid and easy acquisition of cryo-electron microscopy structures enabled modification of the C-5 position of linezolid, which identified a series of linezolid derivatives (compounds <b>6a</b>–<b>g</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Among them, <b>6c</b> (MIC: 0.25–1 μg/mL) and <b>6d</b> (MIC: 0.13–0.25 μg/mL) significantly inhibited the ribosomal development and function of LZDR MRSA and VRE.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> When <b>6d</b> formed a complex with the 50S ribosomal subunit (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DDG">6DDG</a>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B), the acyl tail rotated around the amide bond to form a more favorable interaction with the surrounding rRNA. In the ribosome, <b>6d</b> was assisted by additional interactions with surrounding rRNA residues, and 2-chloroacyl formed hydrogen bonds with the A2530 ribose. The glycoside part of A2478 can form hydrogen bonds with the oxygen on morpholine. At the same time, it had hydrophobic interactions with the purine ring of A2530 and p–p interactions with the purine ring of G2088. These interactions allowed the 2-oxazolidinone ring to form a good hydrophobic interaction with the pyrimidine ring of U2531.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Oxazolidinone derivatives modified at the C-5 position of linezolid. (B) Interaction of oxazolidinone antibiotic <b>6d</b> with the residues in the 50S ribosomal subunit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.2.  Simultaneous Modification of the Morpholine Ring and C-5 Position</h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.2.1.  Biphenyl Chalcone Hybrid Oxazolidinone Derivatives</h4><div class="NLM_p">Panigrahi et al. coupled oxazolidinone and a biphenyl chalcone, which both have strong antibacterial activity, by using a green chemistry approach for Buchwald’s protocol under ultrasound irradiation and obtained a series of novel oxazolidinone–biphenyl chalcone hybrid derivatives (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><i>In vitro</i> antibacterial and antifungal activity studies showed that compared with the standard drugs ciprofloxacin and linezolid, compounds <b>7a</b>–<b>i</b> showed significant antibacterial activity against both Gram-positive bacteria (<i>S. aureus</i>, <i>Bacillus subtilis</i> (<i>B. subtilis</i>), and <i>Streptococcus faecalis</i> (<i>S. faecalis</i>)) and Gram-negative bacteria (<i>Escherichia coli</i> (<i>E. coli</i>), <i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>), and <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>)) (MIC: 3.125–6.25 μg/mL). In the case of antifungal studies, compared with fluconazole (MIC: 6.25 μg/L against <i>Candida albicans</i> (<i>C. albicans</i>) and <i>Aspergillus niger</i> (<i>A. niger</i>)), <b>7c</b>–<b>e</b> exhibited medium potency against <i>A. niger</i> and <i>C. albicans</i> (MIC: 12.5 μg/mL). A systematic SAR study on screened compounds revealed that the effects of substitutions on ring R on the antibacterial potency were mainly steric; only the small or linear substituents (F < Cl < NO<sub>2</sub>═OH < CH<sub>3</sub> < OCH<sub>3</sub>) could be tolerated by the ribosomal binding site, whereas increases in the bulk of substituents were not tolerated. The results of this study may be able to guide researchers to further modify novel oxazolidinone–biphenyl chalcone hybrid derivatives and design more effective and selective antibacterial and antifungal agents.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of newly synthesized oxazolidinone-biphenyl chalcone hybrid derivatives (<b>7a</b>–<b>i</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.2.2.  Spiropyrimidinetrione Oxazolidinone Derivatives</h4><div class="NLM_p">In recent years, AstraZeneca and Pfizer announced compounds <b>8</b> and <b>9</b>. These compounds have unique spiropyrimidinone skeletons and powerful antibacterial activities.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Siddiqui’s research team introduced spiropyrimidinone into the molecular framework of linezolid to replace the morpholine ring and modified the C-5 position to obtain a new type of linezolid analogue (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Subsequently, SAR studies were conducted on these compounds (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). First, it was found that methylcarbamates (<b>10f</b>) and acetamide (<b>10a</b>) showed better activity than other morpholine derivatives (<b>10d</b>, <b>10h</b>, <b>10i</b>, <b>10j</b>). Second, the antibacterial activity of barbituric acid derivatives <b>10a</b> and <b>10c</b> was better than those of dimethyl malonate (<b>10n</b>) and pyrazolidine-3,5-dione (<b>10m</b>) derivatives. Third, pyrrolidine (<b>10c</b>, <b>10l</b>) and piperidine (<b>10b</b>, <b>10k</b>) derivatives showed better antibacterial spectra than morpholine derivatives (<b>10a</b>, <b>10j</b>). These compounds all had significant <i>in vitro</i> antibacterial activity, and compounds <b>10b</b>, <b>10c</b>, <b>10g</b>, and <b>10k</b> showed high inhibitory potency against multi-drug-resistant pathogens (MIC: 0.25–2 μg/mL). The inhibitory activities of these four effective compounds on LREFA and VREF were further analyzed (<b>10b</b>: MIC: 1–16 μg/mL; <b>10c</b>: MIC: 2–16 μg/mL; <b>10g</b>: MIC: 16–32 μg/mL; <b>10k</b>: MIC = 0.25–2 μg/mL), and it was found that the activity of <b>10k</b> was even better than those of linezolid (MIC: 2–32 μg/mL) and vancomycin (MIC: 0.5–32 μg/mL). Therefore, compound <b>10k</b> was expected to become a new oxazolidinone antibacterial drug for further optimization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Design Strategy, Chemical Structures, and MICs (μg/mL) of Compounds <b>10a–n</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0023.gif" alt="" id="GRAPHIC-d7e1379-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center">A<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="."><i>S. aureus</i><a class="ref internalNav" href="#tbl3-fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MRSA<a class="ref internalNav" href="#tbl3-fn2" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."><i>S. aureus</i><a class="ref internalNav" href="#tbl3-fn3" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>S. epidermidis</i><a class="ref internalNav" href="#tbl3-fn4" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">MRSE<a class="ref internalNav" href="#tbl3-fn5" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>a</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>b</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>c</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>d</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>e</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">–NHCOCF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>f</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>g</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>h</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>i</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">–NHSO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>j</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">–OH</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>k</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–OH</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>l</b></td><td class="colsep0 rowsep0" align="left">BA</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–OH</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>m</b></td><td class="colsep0 rowsep0" align="left">PD</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>n</b></td><td class="colsep0 rowsep0" align="left">DM</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">–NHCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">linezolid</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">BA, barbituric acid; DM, dimethyl malonate; PD, pyrazolidine-3,5-dione.</p></div><div class="footnote" id="tbl3-fn1"><sup><sup>b</sup></sup><p class="last"><i>Staphylococcus aureus</i> ATCC 29 213.</p></div><div class="footnote" id="tbl3-fn2"><sup><sup>c</sup></sup><p class="last">Methicillin-resistant <i>Staphylococcus aureus</i> 562.</p></div><div class="footnote" id="tbl3-fn3"><sup><sup>d</sup></sup><p class="last">Linezolid-resistant <i>Staphylococcus aureus</i> ATCC 13 709 Smith.</p></div><div class="footnote" id="tbl3-fn4"><sup><sup>e</sup></sup><p class="last"><i>Staphylococcus epidermidis</i> ATCC 12 228.</p></div><div class="footnote" id="tbl3-fn5"><sup><sup>f</sup></sup><p class="last">Methicillin-resistant <i>Staphylococcus epidermidis</i> ATCC 35 984.</p></div></div></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure–activity relationships of the synthesized spiropyrimidinetrione oxazolidinone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.3.  [1,2,5]Triazepane or [1,2,5]Oxadiazepane Oxazolidinone Derivatives</h4><div class="NLM_p">Eperezolid (<b>11</b>) was also an effective drug candidate for oxazolidinone, and it was developed in parallel with linezolid (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In fact, eperezolid showed stronger antibacterial activity <i>in vitro</i> and better therapeutic efficacy <i>in vivo</i> than linezolid,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> but due to concerns about the issues of its safety and human PK, linezolid was selected as the first choice for clinical applications as a candidate drug.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Suzuki et al.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> used [1,2,5] triazepane and [1,2,5] oxadiazepane to replace the piperazine ring in eperezolid to synthesize a series of oxazolidinone compounds (<b>12a</b>–<b>d</b>, <b>13a</b>–<b>d</b>, <b>14a</b>–<b>d</b>). These compounds exhibited high antibacterial potency against both Gram-positive bacteria and Gram-negative bacteria <i>in vitro</i>. Preliminary SAR studies have shown that oxazolidinone analogues containing acetamide side-chain units exhibited equivalent antibacterial potency against <i>Enterococcus faecalis</i> (<i>E. faecalis</i>), <i>Enterococcus faecium</i> (<i>E. faecium</i>), <i>Haemophilus influenzae</i> (<i>H. influenzae</i>), linezolid-resistant <i>Staphylococcus aureus</i> (LRSA), <i>Moraxella catarrhalis</i> (<i>M. catarrhalis</i>), <i>S. aureus</i>, and <i>S. pneumoniae</i> (<b>12–14a</b>: MIC: 0.25–16 μg/mL) that was comparable to those of linezolid (MIC: 2–16 μg/mL) and eperezolid (MIC: 0.125–32 μg/mL) <i>in vitro</i>. The antibacterial potency of compounds containing thioacetamide (<b>12</b>–<b>14b</b>: MIC: 0.125–8 μg/mL), thiocarbamate (<b>12–14c</b>: MIC: 0.25–4 μg/mL), and isoxazol-3-ylamino side-chain units at the C-5 position (<b>12–14d</b>: MIC: 1–64 μg/mL) was 4 to 16 times higher than those of linezolid and eperezolid <i>in vitro</i>. This indicated that the thioamide at the C-5 position and the isoxazol-3-ylamino side chain enhanced the activity. In addition, analogues with 3,5-difluorophenyl in the B-ring moiety are more active than lipophilic 3-fluorophenyl analogues (<b>12a</b>–<b>d</b> vs <b>13a</b>–<b>d</b>). Compounds <b>12c</b> and <b>13c</b> showed particularly strong antibacterial activity in <i>in vitro</i> and <i>in vivo</i> tests (MIC: 0.036–2 μg/mL); moreover, preliminary safety studies showed that they were not effective inhibitors of MAO A or B or four CYP450 subtypes. Therefore, the seven-membered heterocyclic unit seemed to be a significant part of the new oxazolidinone antibiotics. Compounds <b>12c</b> and <b>13c</b> were considered promising antibacterial candidates, but further investigation is needed.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design strategy and chemical structures of compounds <b>11</b>–<b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.4.  Oxazolidinone Antibiotics with a Heteroaromatic C-Ring Unit</h4><div class="NLM_p">1,2,4-Triazolo[4,3-<i>a</i>]pyrimidine was previously reported by Kumar and Prakash et al. as an effective antibacterial agent.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> Subsequently, Khera et al. coupled 1,2,4-triazolo[4,3-<i>a</i>]pyrimidine to the oxazolidinone heterocycle of linezolid to obtain a class of linezolid analogues (compounds <b>15a</b>–<b>f</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The morpholine ring in linezolid was replaced by 1,2,4-triazolo[4,3-<i>a</i>] pyrimidine, and a series of modifications were made at the C-5 position. These compounds showed varying degrees of efficacy against Gram-positive bacteria (MIC: 0.5–16 μg/mL), including <i>E. faecalis</i>, <i>S. aureus</i>, <i>S. epidermidis</i>, and <i>E. coli</i>. Sulfamide derivatives <b>15e</b>,<b>f</b> exhibited great efficacy against all Gram-positive bacteria tested. The potency of <b>15e</b> (MIC: 0.5–16 μg/mL) was two to four times higher than that of linezolid (MIC: 1–2 μg/mL), and the compound was stable in human liver microsomes and had no CYP-related liabilities at concentrations up to 10 μM. The reason why these compounds failed to achieve satisfactory activity may be due to the removal of the original fluorine substituent on the benzene ring. Overall, this class of compounds containing the triazolopyrimidine ring deserves further research and discussion.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of compounds <b>15a</b>–<b>f</b>, <b>16a</b>–<b>d</b>, <b>17a</b>–<b>d</b>, <b>18a</b>–<b>f</b>, and <b>19a-f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The introduction of pyrazolo[1,5-<i>a</i>]pyridine or a scaffold similar to the C ring into linezolid (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) was proven to result in high inhibitory potency against LRSA, MRSA, <i>S. aureus</i>, and VRE (<b>16a</b>–<b>d</b>, <b>17a</b>–<b>d</b>: MIC: 0.125–8 μg/mL; linezolid: MIC: 2–32 μg/mL).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Among them, compound <b>16d</b> showed four to six times better <i>in vivo</i> efficacy than linezolid in the therapy of systematic MRSA infection mouse models. The PK profile of compound <b>16d</b> was also excellent and showed a sufficient area under the PK curves (AUC), even at a dose ten times lower than that of linezolid. This matches the <i>in vivo</i> therapeutic effect of compound <b>16</b>. In addition, active compounds <b>16b</b>, <b>16d</b>, and <b>17d</b> demonstrated similar or improved levels of CYP inhibition (IC<sub>50</sub> > 10 μM) and MAO-A inhibition in comparison with linezolid. These results are basically satisfactory from the perspective of safety but are still worthy of further improvement.</div><div class="NLM_p last">A class of oxazolidinone derivatives containing multiple fused heteroaryl C rings with hydrogen-bond donor and acceptor functions were reported to show superior antibacterial activity to linezolid (compounds <b>18a</b>–<b>f</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The compound containing a benzoxazinone C ring (<b>18c</b>) has the most potential, with an MIC of 0.06–1 μg/mL against <i>E. faecium</i>, LRSA, MRSA, <i>S. aureus</i>, and <i>S. pneumoniae</i>. Modifying the C-5 chain of compound <b>18c</b> led to a series of effective analogues (compounds <b>19a</b>–<b>f</b>), some of which displayed greater antibacterial efficacy than the existing antibacterial drugs <i>in vitro</i> (<b>18c</b>, <b>19a</b>, <b>19b</b>, <b>19e</b>, and <b>19f</b>: MIC: 0.03–1 μg/mL; linezolid: MIC: 0.5–16 μg/mL; levofloxacin: MIC: 0.125–32 μg/mL; vancomycin: MIC: 0.5–2 μg/mL). Importantly, compounds <b>18c</b> and <b>19a</b> were metabolically stable in the presence of mouse liver microsomes. Moreover, they also exhibited no obvious inhibitory effect on CYP450 enzymes at a concentration of 10 μM. Hence, these compounds are worthy of further study to improve the PK and safety profiles.</div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.5.  N-Substituted Glycinyl 1<i>H</i>-1,2,3-Triazolyl Oxazolidinone Derivatives</h4><div class="NLM_p">The incorporation of “spacer groups” with hydrogen-bond donors or acceptors at the end of the C ring of the oxazolidinone analogues could improve the antibacterial activities by enhancing the interaction at the bacterial 50S ribosome binding site.<a onclick="showRef(event, 'ref42 ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref42 ref71 ref72 ref73">(42,71−73)</a> Phillips et al., based on previous studies<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> of triazolyl oxazolidinone derivatives with effective antibacterial activity (<b>20</b> PH051), introduced substituted glycinyl moieties as spacers at the 4N-piperazinyl position of PH051, yielding a series of N-substituted glycinyl 1<i>H</i>-1,2,3-triazolyl oxazolidinones (compounds <b>21a</b>–<b>f</b>, <b>22a</b>–<b>f</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> All of them exhibited moderate to high inhibitory activities against susceptible and resistant Gram-positive (MRSA, MSSA, VRE, and vancomycin-susceptible <i>Enterococcus</i> (VSE)) and selected Gram-negative bacteria (<i>E. coli</i>, <i>H. influenzae</i>, <i>S. pneumoniae</i>, and <i>M. catarrhalis</i>), including clinical isolates. Moreover, the compounds with <i>N</i>-aroyl- and <i>N</i>-heteroaroyl-glycinyl (<b>21b</b>–<b>f</b> and <b>22b</b>–<b>f</b>: MIC: 0.06–4 μg/mL) were more effective than those with <i>N</i>-acylglycinyl (<b>21a</b> and <b>21b</b>: MIC: 2–8 μg/mL) against MRSA, MSSA, VRE, and VSE. Furthermore, the derivatives containing nitro-substituted aryl and heteroaryl rings exhibited better inhibitory effects against Gram-positive bacteria (<b>21c</b> and <b>22c</b>: MIC: 0.25–0.5 μg/mL; <b>21f</b> and <b>22f</b>:MIC: 0.06–0.5 μg/mL). Satisfactorily, these nitro analogues also showed stronger potency against <i>M. catarrhalis</i> than linezolid (<b>21c</b>, <b>22c</b>, <b>21f</b>, and <b>22f</b>: MIC: 0.25–1 μg/mL; linezolid: MIC: 8 μg/mL). These results indicated that the <i>N</i>-aroyl or <i>N</i>-heteroaroyl glycyl motifs as “spacer groups” significantly improved the antibacterial efficacy of 1<i>H</i>-1,2,3-triazolyl oxazolidinone derivatives and enhanced their interaction with bacterial ribosome binding sites.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design strategy and chemical structures of compounds <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.2.6.  Oxazolidinone Antibiotics with a Substituted Ligustrazine C-Ring Unit</h4><div class="NLM_p">Ligustrazine (tetramethylpyrazine (TMP)) was found to be a major effective component of the traditional Chinese medicine herb Chuanxiong.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Studies have shown that ligustrazine has some degree of anti-inflammatory activity.<a onclick="showRef(event, 'ref77 ref78 ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79 ref80 ref81 ref82">(77−82)</a> Taking linezolid as the starting compound and using the skeleton skipping strategy to hybridize it with TMP, a series of compounds with C-ring units substituted for TMP and different substituent groups on the C-5 side chain were designed and synthesized (compounds <b>23a</b>–<b>n</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This class of compounds is a new class of oxazolidinone antibacterial agents that have anti-inflammatory and antibacterial effects.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Almost all of these compounds exhibited moderate to good inhibitory activities against Gram-positive bacteria (<i>E. faecalis</i>, <i>S. aureus</i>, <i>S. epidermidis</i>, and MRSA). Among them, compounds <b>23f</b>–<b>j</b> had the strongest antibacterial activity. A SAR analysis of this new type of oxazolidinone found that the introduction of fluorine into the molecule, such as that found in compounds <b>23g</b> and <b>23h</b>, enhanced its anti-inflammatory and antibacterial potencies. The chlorine-substituted acetyl group at the C-5 side chain helped to improve anti-inflammatory and antibacterial potencies. Obviously, the compounds with monochloro or dichloroacetamide (compounds <b>23g</b>–<b>j</b>) had strong antibacterial activity. Both <b>23g</b> and <b>23h</b> had potent inhibitory effects on the generation of inflammatory factors such as nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), but linezolid did not show significant anti-inflammatory activity. Therefore, these derivatives may become valuable candidates in the development of antibiotics for treating chronic wound infections.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Design Strategy, Chemical Structures, and MICs (μg/mL) of Compounds <b>23a</b>–<b>n</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0024.gif" alt="" id="GRAPHIC-d7e2629-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0025.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">MRSA, methicillin-resistant <i>Staphylococcus aureus</i>; <i>S. aureus</i>, <i>Staphylococcus aureus</i>; <i>S. epidermidis</i>, <i>Staphylococcus epidermidis</i>; <i>E. faecalis</i>, <i>Enterococcus faecalis</i>.</p></div></div><div></div></div></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.2.7.  Oxazolidinone Antibiotics with the Incorporation of Silicon</h4><div class="NLM_p">To obtain lipophilic antibacterial drugs with a high permeability of the blood–brain barrier (BBB) for the treatment of brain infections, Reddy et al.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> incorporated silicon into the morpholine ring of linezolid to replace the oxygen atom, leading to a series of lipophilic molecules (compounds <b>24a</b>–<b>h</b>, <b>25a</b>–<b>d</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Among these oxazolidinones, compounds <b>24a</b>, <b>24c</b>, and <b>25a</b> were more active against <i>S. aureus</i>, MRSA, <i>S. epidermidis</i>, MRSE, <i>E. faecalis</i>, and <i>E. faecium</i> (<b>24a</b>: MIC: 8–16 μg/mL; <b>24c</b>: MIC: 8–32 μg/mL; <b>25a</b>: MIC: 1–8 μg/mL; linezolid: MIC: 0.5–4 μg/mL). ADME research showed that compounds <b>24a</b> and <b>24c</b> displayed moderate stability in both mouse and human liver microsomes, and compound <b>25a</b> was poorly stable in rodent liver microsomes but favorably stable in human liver microsomes. Apart from this, brain PK data showed that compounds <b>24a</b>, <b>24c</b>, and <b>25a</b> had 14, 22, and 29 times higher brain/plasma (B/P) ratios than linezolid (B/P ratio, <i>C</i><sub>max</sub><b>24a</b>: 1.27, <b>24c</b>: 2.76, <b>25a</b>: 3.96, linezolid: 0.12; AUC<sub>0-t</sub><b>24a</b>: 1.69, <b>24c</b>: 2.54, <b>25a</b>: 3.57, linezolid: 0.11; AUC<sub>0-inf</sub><b>24a</b>: 1.69, <b>24c</b>: 2.65, <b>25a</b>: 3.49, linezolid: 0.12), which indicated that the incorporation of silicon significantly improved the BBB penetration of these compounds. Although the antibacterial potencies of these silicon compounds are still lower than those of linezolid, they have great potential as antibiotics for further modification for the treatment of brain infections.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of compounds <b>24a</b>–<b>d</b> and <b>25a</b>–<b>d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.2.8.  Oxazolidinone Antibiotics with a Dihydropyridone C-Ring Unit</h4><div class="NLM_p">The new antibacterial oxazolidinone (MRX-I, contezolid, <b>26</b>) obtained by introducing dihydropyridone and isoxazole into the scaffold of linezolid is an effective antibacterial agent with broad Gram-positive antibacterial activity (<i>Staphylococci</i>, <i>Enterococci</i>, <i>Streptococci</i>: MIC: 0.06–2 μg/mL).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> SAR studies showed that the introduction of dihydropyridone not only enhanced the antibacterial efficacy but also exhibited significantly reduced MAO inhibition. Remarkably, the 2,4,6-trifluorophenyl B ring in MRX-I did not affect the antibacterial activity but displayed reduced MAO-A inhibition, which deviated from the classical SAR. MRX-I had improved linezolid efficacy against the widespread pathogen MRSA. Additionally, MRX-I had an improved safety profile with significantly reduced potential for myelosuppression and MAO inhibition compared with linezolid (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Currently, MRX-I is in a phase II clinical trial to evaluate whether it is as safe and effective as linezolid in the treatment of adult patients with ABSSSIs.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Design strategy and chemical structures of compound <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.3.  Tricyclic Fused Oxazolidinone Derivatives</h3><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">3.3.1.  (Pyridin-3-yl) Benzo[1,4]oxazinyl-oxazolidinones</h4><div class="NLM_p">[6,5,5] Tricyclic fused oxazolidinones were first reported by Gleave et al.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Subsequently, Yang et al. discovered that a [6,6,5] tricyclic fused benzoxazinyl–oxazolidinone scaffold was an appropriate framework for developing efficient antibacterial agents with improved druggability and deserved further exploration.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> On the basis of the above, a series of biaryl [6,6,5] tricyclic fused benzoxazinyl–oxazolidinone derivatives (five- or six-membered aryl C rings) were designed and synthesized<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> (compounds <b>27a</b>–<b>f</b>, <b>28a</b>–<b>c</b>, <b>29a</b>–<b>i</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Most target compounds effectively inhibited <i>S. aureus</i>, MRSA, MRSE, PRSP, <i>E. faecalis</i>, and other Gram-positive bacteria (MIC: 0.125–8 μg/mL). SAR studies have shown that the priority order of substituents at the C-ring position is pyridyl > phenyl > pyrimidyl > thienyl according to the <i>in vitro</i> antibacterial potency. Interestingly, the fluorine atom on the phenyl B ring has usually helped to improve the antibacterial activity in the past SAR analysis of linezolid and its analogues. In contrast, in [6,6,5] studies, fluorinated benzoxazinyl oxazolidinones <b>28a</b>, <b>28b</b>, and <b>28c</b> were less active (LREF, MIC: 1–4 μg/mL; LREFA, MIC: 0.5–1 μg/mL). Moreover, compound <b>27f</b> displayed a satisfactory PK profile, and its efficacy <i>in vivo</i> was three to four times better than that of linezolid, which made it a very promising drug candidate. The assessment of the safety of this compound is ongoing.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Design strategy and chemical structures of compounds <b>28</b>–<b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>27f</b> had high antibacterial activity and excellent PK characteristics, but its poor solubility limited the route of drug administration, and it was difficult to purify. Therefore, the team focused on the modification of different substituents on the pyridine ring and the side chain of the oxazolidinone ring to increase the solubility to obtain compounds <b>30a</b>–<b>j</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The main strategies were (1) the introduction of polar groups, (2) breaking of the molecular planarity, and (3) a prodrug strategy. SAR studies of these compounds found that smaller and nonbasic substituents (<b>30a</b> and <b>30b</b>: MIC: 0.125–2 μg/mL) were more sterically demanding and that basic substituents (<b>30c</b> and <b>30d</b>: MIC: 4–32 μg/mL) were preferable. On the basis of lead compound <b>30e</b>, further SAR studies were conducted, which led to some potent compounds with powerful antibacterial potency (compounds <b>30f</b>–<b>j</b>). In particular, compound <b>31</b> (the prodrug of compound <b>30j</b>) showed potent <i>in vivo</i> efficacy for the treatment of MRSA and MSSA infections in mice (MSSA, ED<sub>50</sub> = 6.65 mg/kg; MRSA, ED<sub>50</sub> = 5.00 mg/kg). In addition, it had high water solubility (227 mg/mL in water) and excellent PK characteristics, was rapidly converted into active antibacterial compounds, and exhibited a long half life and high oral bioavailability. Currently, compound <b>31</b> is undergoing further preclinical evaluation and may become a new type of antibacterial drug.</div><div class="NLM_p">At the same time, 1,2,3-triazole (such as that in compound <b>32</b>) and reverse amide (such as that in compound <b>33</b>) have also been reported as good substitutes for the conventional acetamide functional group in oxazolidinones.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> These compounds significantly reduced the inhibitory effect of MAO-A compared with that of linezolid. To develop new oxazolidinones that were highly effective and safer in inhibiting MAO-A, Yang et al. designed and synthesized a series of benzoxazinyl–oxazoles containing 3-triazolylmethyl or 3-carboxamide side chains on the basis of the highly effective oxazolidinone antibacterial agent <b>27f</b>, which had been previously studied<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Most of the analogues with 3-triazolyl methyl groups (compounds <b>34a</b>–<b>h</b>) showed moderate to high inhibitory effects against <i>E. faecalis</i>, MRSA, MSSA, MRSE, methicillin-sensitive <i>Staphylococcus epidermidis</i> (MSSE), and PRSP (MIC: 0.25–4 μg/mL); in particular, compound <b>34a</b>, was the most potent compound, with MIC values of 0.25 to 1 μg/mL. Surprisingly, all analogues with 3-carboxamide side chains (<b>35a</b>–<b>d</b>) lacked antibacterial activity.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design strategy and chemical structures of compounds <b>32</b>–<b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the above cases, Yang et al. also studied the effects of the modification of the A and D rings and C-3 positions on the antibacterial activity (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> When the oxazolidinone ring was transformed into thiazolidinone and imidazolidinone, there was almost no antibacterial activity (compounds <b>37</b> and <b>38</b>). When the four-position of the D ring was an S atom (compound <b>39</b>), the antibacterial activity of the compound was great against <i>E. faecalis</i>, MRSA, MSSA, MRSE, MSSE, and PRSP (MIC: 1–4 μg/mL), but when it became NH or NBoc (compounds <b>40</b>, <b>41</b>), the antibacterial activity was almost completely lost. In addition, benzothiazinyl–oxazolidinone compounds with acetamide or sulfamide as the C-3 side chain, such as compounds <b>39</b> (MIC: 1–4 μg/mL) and <b>42</b> (MIC: 1–2 μg/mL), showed moderate to good antibacterial activity.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of compounds <b>36</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.3.2.  (Tetrahydropyridine-4-yl) Benzo[1,4]oxazinyl-oxazolidinones</h4><div class="NLM_p">Zhang and coworkers<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> introduced the tetrahydropyridine moiety, which seemed to be able to destroy the molecular planarity and improve the hydrophilicity of the molecule into the drug-like scaffold–tricyclic fused benzoxazinyl–oxazolidinone to obtain a series of antibacterial agents (compounds <b>43a</b>–<b>f</b>, <b>44a</b>–<b>f</b>, <b>45a</b>–<b>f</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). These compounds showed moderate to good anti-TB activity (compounds <b>43a</b>–<b>f</b>, <b>44a</b>–<b>f</b>, and <b>45a</b>–<b>f</b>: MIC: 0.391–10.900 μg/mL; linezolid: MIC: 0.304 μg/mL). SAR studies indicated that the fluorine atom on the benzene ring could improve the cytotoxicity (<b>43e</b>: IC<sub>50</sub>(Vero) > 64 μg/mL; <b>43f</b>: IC<sub>50</sub>(Vero) = 13.76 μg/mL). Almost all compounds with fluorine-substituted benzene showed nearly no cytotoxicity (IC<sub>50</sub>(Vero) > 64 μg/mL). The replacement of the 4-tetrahydropyridine with 4-piperidine caused a significant loss of activity. This result demonstrated that the double bond is required for potency. Notably, compound <b>43e</b> displayed promising anti-TB activity against drug-sensitive and drug-resistant strains, such as H37Rv (MIC: 0.25–0.50 μg/mL), and favorable preliminary <i>in vitro</i> safety profiles with negligible cytotoxicity and cardiotoxicity (HepG2 cytotoxicity: IC<sub>50</sub> > 30 μg/mL; hERG K<sup>+</sup> inhibition: IC<sub>50</sub> > 30 μM). Additionally, it also exhibited excellent oral bioavailability (<i>F</i> = 102%) in mice and a relatively long half life. Hence, compound <b>43e</b> could be used as a promising potential anti-TB lead compound for further investigation and development.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of compounds <b>43a</b>–<b>f</b>, <b>44a</b>–<b>f</b>, and <b>45a</b>–<b>f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">3.3.3.  Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidinones</h4><div class="NLM_p">To identify an oxazolidinone with enhanced anti-TB potency, improved drug-like properties, and reduced toxicity, based on the previously studied compound <b>43e</b>, Zhang et al.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> focused on the variation of the substituents on the phenyl ring and oxazolidinone ring (R<sub>1</sub> and R<sub>2</sub>). Groups such as thiomorpholine, 2-oxa-6-azaspiro [3.3] heptane, and 4,4-difluoro-piperidine were introduced into the R<sub>1</sub> position, and amides, heterocycles, methyl carbamate, and so on were introduced into the R<sub>2</sub> position (compounds <b>46a</b>–<b>i</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The anti-TB activity and cytotoxicity results showed that compounds <b>46a</b>–<b>e</b> with thiomorpholine at the R<sub>1</sub> position exhibited the best activity, and several compounds with amides (<b>46a</b>), cyclopropanecarboxamido (<b>46b</b>), cyclobutanecarboxamido (<b>46c</b>), methyl carbamate (<b>46d</b>), and isoxazolamino (<b>46e</b>) at the R<sub>2</sub> position all exhibited excellent potent anti-TB activity and better activity than sutezolid. In addition, the (3<i>S</i>,3a<i>S</i>) configuration is essential for activity. It is worth noting that compound <b>46a</b> not only showed better activity than linezolid and sutezolid against drug-resistant TB (<b>46a</b>: MIC: 0.03–0.24 μg/mL; linezolid: MIC: 0.23–3.92 μg/mL; sutezolid: MIC: 0.06–0.96 μg/mL) but also possessed favorable mouse and human microsomal stability, low cytotoxicity (IC<sub>50</sub>(Vero) > 64 μg/mL), low liability for drug–drug interactions (CYP450 inhibition: IC<sub>50</sub> > 45 μM), and an excellent PK profile (oral bioavailability: <i>F</i> = 55.9%). Apart from that, compound <b>46a</b> exhibited an excellent safety profile (hERG K<sup>+</sup>: IC<sub>50</sub> > 30 μM; hCav1.2: IC<sub>50</sub> > 30 μM; Nav1.5: IC<sub>50</sub> > 30 μM; MAO-A <b>46a</b>: IC<sub>50</sub> = 44.8 μΜ, sutezolid: IC<sub>50</sub> = 13 μΜ; monoamine oxidase B (MAO-B) <b>46a</b>: IC<sub>50</sub> = 3.2 μΜ, sutezolid: IC<sub>50</sub> = 0.7 μM) and reduced potential for myelosuppression in the 4-week repeated dose toxicity study. All of these results make compound <b>46a</b> a potential anti-TB drug candidate, and preclinical development is underway.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Design Strategy, Chemical Structures, Anti-TB Activity, Cytotoxicity, and MPS Inhibition of Compounds <b>46a</b>–<b>i</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0026.gif" alt="" id="GRAPHIC-d7e3327-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0027.gif" alt="" id="gr24" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">MPSi, mitochondrial protein synthesis (MPS) inhibition.</p></div></div><div></div></div></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">3.3.4.  Benzo[1,3]oxazinyl-oxazolidinones</h4><div class="NLM_p">A series of conformationally constrained (3<i>S</i>,3a<i>S</i>) novel benzo[1,3]oxazinyl-oxazolidinones were designed and synthesized by Zhang et al.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Among them, compounds <b>47a</b>–<b>c</b> showed moderate to good antibacterial activity against <i>Mycobacterium tuberculosis</i> (<i>M. tuberculosis</i>) (H37Rv <b>47a</b>–<b>c</b>: MIC: 0.48–32.70 μg/mL, linezolid: MIC: 0.88 μg/mL) and Gram-positive bacteria (<i>S. aureus</i>, <i>B. subtilis</i>, <b>47a</b>–<b>c</b>: MIC: 0.125–2 μg/mL; linezolid: MIC: 0.125 μg/mL). SAR studies suggested that heteroaromatic substituents in the R position and fluorine on the benzene ring were both beneficial for antibacterial activity; interestingly, when the groups in the two positions exchanged, the antibacterial activity was greatly reduced. For these studies, a potential antibacterial agent was identified (compound <b>47a</b>), which showed potent antibacterial (MRSA, MIC: 0.25–0.5 μg/mL; MRSE, MIC: 1 μg/mL; VRE, MIC: 0.25 μg/mL) and antitubercular potency (extensively drug-resistant TB (MDR-TB and XDR-TB), MIC: 0.48–0.82 μg/mL) as well as certain activities against some linezolid-resistant strains (MIC: 1–4 μg/mL). Notably, compound <b>47a</b> demonstrated great druggability, such as no cytotoxicity against Vero cells, comparable MPS inhibition, high microsomal stability, satisfactory MAO inhibition, and low hERG K<sup>+</sup> channel inhibition (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). In addition, compound <b>47a</b> displayed an attractive PK profile with a proper half life and high bioavailability after oral administration in the mouse model. These results indicated that compound <b>47a</b> could be used as a promising candidate worthy of further development. Beyond this point, this novel conformationally constrained benzo[1,3]oxazinyl-oxazolidinone scaffold provides a new idea for the development of a new generation of oxazolidinone antibacterial agents for treating drug-resistant infections.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of compounds <b>47a</b>–<b>c</b> and antibacterial activity, toxicity, and PK of compound <b>47a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">4.  Other Novel Oxazolidinone Derivatives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.1.  Azetidinone Moieties</h3><div class="NLM_p">A series of new oxazolidinone antibacterial agents (compounds <b>48</b>–<b>50</b>) containing azetidinone moieties were reported by Baruah et al. (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> These compounds exhibited moderate to high inhibitory activity against <i>B. subtilis</i> and <i>E. coli</i>. Among these compounds, <b>49</b> had the highest activity for <i>B. subtilis</i> (inhibitory zone: 23 mm at 100 μg/mL), and <b>48</b> displayed the strongest potency against <i>E. coli</i> (inhibitory zone: 24 mm at 100 μg/mL). It was also found that a methoxy (−OCH<sub>3</sub>)-substituted azetidinone (<b>49</b>) had only a moderate inhibitory effect on Gram-positive bacteria, whereas chlorine-substituted azetidinones (<b>48</b> and <b>50</b>) had broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria. Although the inhibitory activity of these compounds is still slightly lower than that of the comparative drug chloramphenicol (inhibitory zone for <i>E. coli</i>: 38 mm at 100 μg/mL, inhibitory zone for <i>B. subtilis</i>: 37 mm at 100 μg/mL), azetidinone oxazolidinone compounds are worthy of further optimization as a new type of antibacterial agent.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of compounds <b>48</b>–<b>65</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.2.  Amide, Sulfonamide, and Thiourea Moieties</h3><div class="NLM_p last">1,3-Oxazolidinone derivatives with amide (compounds <b>51a</b>–<b>g</b>), sulfonamide (compounds <b>52a</b>–<b>g</b>), or thiourea (compounds <b>53a</b>–<b>h</b>) are also a new series of antibacterial drugs (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Among the compounds, only the methoxy-substituted thiourea derivative <b>53f</b> showed the same inhibitory activity (MIC: 50 μg/mL) as the control chloramphenicol (MIC: 50 μg/mL) against Gram-negative bacteria (<i>P. aeruginosa</i>), and other test compounds had no inhibitory effect against Gram-negative bacteria. Additionally, thiourea-based compounds <b>53a</b>–<b>c</b> showed better antibacterial efficacy than sulfonamide and amide compounds against Gram-positive bacteria <i>Listeria monocytogenes</i>, <i>S. aureus</i>, and <i>E. faecalis</i>). The inhibitory activity of the bromine-substituted thiourea derivative compound <b>53b</b> against the tested Gram-positive bacteria was better than that of the control chloramphenicol (<b>53b</b>, MIC: 25–50 μg/mL; chloramphenicol MIC: 50–100 μg/mL). Safety evaluation of compound <b>53b</b> showed that this compound was nonmutagenic and noncytotoxic at a concentration that exhibits antibacterial activity, which made it a good drug candidate.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.3.  Chloroquinoline Moieties</h3><div class="NLM_p last">Chloroquinoline is a common element used in the design of antibacterial agents.<a onclick="showRef(event, 'ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref100 ref101 ref102">(100−102)</a> When chloroquinoline and oxazolidinone rings were combined to obtain chloroquinoline oxazolidinone analogues (compounds <b>54</b>–<b>56</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>),<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> they showed good antibacterial activity (inhibitory zone for <i>E. coli</i>: <b>54</b>: 13 mm at 200 μg/mL, <b>55</b>: 14 mm at 200 μg/mL, <b>56</b>: 11 mm at 200 μg/mL; inhibitory zone for <i>B. subtilis</i>: <b>54</b>: 14 mm at 200 μg/mL, <b>55</b>: 14 mm at 200 μg/mL, <b>56</b>: 10 mm at 200 μg/mL) and antifungal activity (inhibitory zone for <i>Fusarium oxysporum</i>: <b>54</b>: 10 mm at 200 μg/mL, <b>55</b>: 14 mm at 200 μg/mL, <b>56</b>: 9 mm at 200 μg/mL, fluconazole: 23 mm at 200 μg/mL). Compound <b>54</b> also effectively inhibited MCF7 (hormone-dependent breast carcinoma cell line), HT29 (colon carcinoma cell line on leukemia), and other cancer cells (MCF7: IC<sub>50</sub> = 16.1 μg/mL, HT29: IC<sub>50</sub> = 32.4 μg/mL). These compounds may be further studied to obtain more effective antibacterial and antifungal drugs or anticancer drugs.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.4.  Thiazole Hybrid Moieties</h3><div class="NLM_p last">The development of pharmacologically active compounds containing thiazole motifs has attracted increasing attention.<a onclick="showRef(event, 'ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref104 ref105 ref106">(104−106)</a> Several powerful drugs, such as penicillin (an effective antibiotic), sulfathiazole (an antibacterial drug), and abafungin (an antifungal drug), have thiazole cores.<a onclick="showRef(event, 'ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109">(107−109)</a> Therefore, Kaur et al. designed and synthesized a class of hybrids with both thiazole and oxazolidinone moieties (compounds <b>57</b>–<b>65</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>)<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> and evaluated their antibacterial potency (Gram-positive bacteria: <i>B. subtilis</i>, <i>S. aureus</i>, MIC: 6.25–50 μg/100 μL; Gram-negative bacteria: <i>E. coli</i>, <i>P. aeruginosa</i>, MIC: 12.5–50 μg/100 μL; fungi: <i>C. albicans</i>, <i>Saccharomyces cerevisiae</i>, MIC: 12.5–50 μg/100 μL). SAR studies showed that compound <b>63</b>, which contained a biphenyl substituent attached to the four-position of the thiazole moiety, showed the same excellent inhibitory effect on the tested bacterial and fungal strains as the control drugs ciprofloxacin and amphotericin-B (MIC: 6.25–25 μg/100 μL). Compounds with <i>p</i>-fluorophenyl (<b>60</b>), <i>o</i>-fluorophenyl (<b>61</b>), or <i>m</i>-chlorophenyl (<b>62</b>) substituents on the thiazole moiety also showed promising antibacterial activity (MIC: 12.5–50 μg/100 μL). Compound <b>63</b> showed high inhibitory potential (MIC: 12.5 μg/100 μL) against <i>E. coli</i>, whereas <b>64</b> and <b>65</b> selectively showed moderate inhibitory activity against <i>B. subtilis</i> (MIC: 25 μg/100 μL). Thus these compounds hold promise as new and potent broad-spectrum antibacterial drugs in the future.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.5.  Oxazolidinone-Derivative-based LpxC Inhibitor</h3><div class="NLM_p">Since the discovery of L-161,240 (<b>66</b>)<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> in 1996, UDP-3-<i>O</i>-acyl-<i>N</i>-acetylglucosamine deacetylase (LpxC) inhibitors have been developed as new antibacterial agents against Gram-negative bacterial infections.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> Among these well-characterized oxazolidinone derivatives, threosyl hydroxamate derivatives such as CHIR-090 (<b>67</b>) and LPC-009 (<b>68</b>) are representative LpxC inhibitors<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>A). Based on a detailed analysis of the crystal structure and binding site of <i>E. coli</i> LpxC bound by LPC-009,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> a series of oxazolidinone-derivative-based LpxC inhibitors<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> (compounds <b>69a</b>–<b>i</b>) were designed and synthesized by Kurasaki et al. using oxazolidinone instead of threonine (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>B). These compounds showed excellent activity against wild-type <i>E. coli</i>, efflux mutant (AcrB) <i>E. coli</i>, and wild-type <i>K. pneumoniae</i> (MIC: 0.004–32 μg/mL). SAR studies have shown that the introduction of a methoxy group at the ortho position of <i>N</i>-phenyl sharply decreased the activity (<b>69e</b>, MIC: 0.5–32 μg/mL), and the introduction of electron-withdrawing and small lipophilic substituent F atoms at the meta position can remarkably increase the potency (<b>69i</b>, MIC: 0.004–0.063 μg/mL). The most effective compound (<b>69i</b>) showed nanomolar activity (IC<sub>50</sub> = 6 nM) against the <i>E. coli</i> LpxC enzyme, significant antibacterial efficacy against <i>E. coli</i> and <i>K. pneumoniae</i> (MIC: 0.004–0.063 μg/mL), and a low efflux ratio. All of these meaningful results provide new insights and promising clues into the rational design and development of oxazolidinone-based LpxC inhibitors as antibacterial agents.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Design of oxazolidinone antibiotics based on LpxC inhibitors. (B) Chemical structures of compounds <b>69a–i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further understand the SAR and druggability of the new oxazolidinone-based LpxC inhibitor as a Gram-negative antibacterial agent, Liu et al. designed and synthesized a class of oxazolidinone-based LpxC inhibitors containing hydrophobic tails with different lengths and terminal substituents (<b>70a</b>–<b>i</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> These compounds all had stronger inhibitory activity against <i>E. coli</i> than against <i>P. aeruginosa</i> (MIC: 0.03–50 μg/mL against <i>E. coli</i>; MIC: ≥ 10 μg/mL against <i>P. aeruginosa</i>). Moreover, the inhibitory potency on <i>E. coli</i> was enhanced with increasing length of the hydrophobic tail (<b>70a</b> vs <b>70d</b> vs <b>70e</b>). Furthermore, the compounds with linear tails exhibited better inhibitory activity than the compounds with nonlinear tails (<b>70e</b> vs <b>70b</b>,<b>c</b>). Interestingly, the introduction of small terminal substituents enhanced the antibacterial activity for compounds containing the “phenyl–alkyne–alkyne–benzene” structure (<b>70e</b> vs <b>70f</b> vs <b>70g</b>). Compound <b>70h</b>, obtained by replacing the benzene ring of <b>70e</b> with an aliphatic ring, had the strongest antibacterial activity against <i>E. coli</i> (MIC: 0.015–0.020 μg/mL). Tests against clinically isolated multi-drug-resistant strains showed that the compounds containing oxazolidinone backbones (<b>70f</b>, <b>70i</b>) were active against only <i>E. coli</i> and multi-drug-resistant <i>K</i>. <i>pneumoniae</i> and thus showed a narrower antibacterial spectrum than CHIR-090.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of compounds <b>70a</b>–<b>i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.6.  3-Amino-2-oxazolidinone Derivatives</h3><div class="NLM_p">Some studies have revealed that ∼65% of bacterial resistance is associated with bacterial biofilm formation.<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> When the number of bacteria meets a threshold, the behavior of the bacterial group (for instance, the formation of biofilms and the production of virulence factors) will be controlled by a procedure called quorum sensing (QS).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Lin et al., building upon previous studies and according to the structural features of the QS transcription regulatory protein CviR, designed and synthesized a series of new oxazolidinone antibacterial agents (<b>71a</b>–<b>l</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>), and their inhibitory potency of QS <i>in vitro</i> was evaluated.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> These compounds showed a good inhibitory effect on <i>Chromobacterium violaceum</i> (IC<sub>50</sub> = 3.69–61.63 μM), and the inhibitory activity of compound <b>71j</b> was the strongest (IC<sub>50</sub> = 3.69 μM). <i>In vitro</i>, <b>71j</b> exhibited potent inhibitory activity in the formation of <i>P. aeruginosa</i> PAO1 biofilms (inhibition rate: 17.67–42.98%), the generation of virulence factors (e.g., elastase, rhamnolipid, protease, and pyocyanin), and bacterial movement, and the inhibition of virulence factors was concentration-dependent. A combination of <b>71j</b> and the antibiotic Meropenem trihydrate effectively reduced <i>P. aeruginosa</i> PAO1 biofilm growth. <i>In vivo</i>, <b>71j</b> extended the lifespan of wild-type <i>Caenorhabditis elegans</i> N2 infected with <i>P. aeruginosa</i> PAO1, and the combination of <b>71j</b> and trimethoprim significantly increased the survival rate of nematodes. In short, <b>71j</b> was a drug candidate for <i>P. aeruginosa</i> PAO1 and provided a route to develop new antibacterial drugs.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of compounds <b>71a–l</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">5.  Summary and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bacterial drug resistance has seriously threatened the quality of human life, and the spread of multi-drug resistance is rapidly surpassing the research and development of new antibacterial agents, bringing a heavy burden to the world health system. Oxazolidinone antibacterial drugs have attracted attention because of their unique mechanism of action, through which they inhibit the initial stage of protein synthesis and rarely show cross-resistance. Linezolid, the first marketed oxazolidinone antibacterial drug, mainly showed good activity against Gram-positive bacteria. However, with linezolid-resistant bacteria as well as linezolid bone marrow suppression and other adverse reactions gradually appearing, the development of new oxazolidinone antibacterial drugs is particularly urgent.</div><div class="NLM_p">In addition to linezolid, another marketed oxazolidinone antibacterial drug, torezolid phosphate, has the advantage of effectively modifying the hydroxymethyl group at the C-5 position of the oxazolidinone ring, reducing the inhibitory effect of MAO. This is important because the adverse effects of linezolid may include reversible interactions with MAO, which may lead to harmful interactions with epinephrine and serotonin drugs. Its other advantage is effectively solving the problem of water solubility. With the exception of the two drugs currently on the market, the drug sutezolid (PNU-100480), which has completed a phase II clinical trial, is also an excellent oxazolidinone antibacterial agent that was developed by Pfizer for the therapy of TB.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Compared with linezolid, sutezolid has a shorter treatment time,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> better PK characteristics,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and a stronger antibacterial effect <i>in vivo</i>, and it is safer at the same dose.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Notably, sutezolid can be used in combination with rifampicin to kill <i>M. tuberculosis</i> more effectively.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The existing research data indicate that sutezolid can be further studied as an oxazolidinone antibacterial agent and has the potential to be marketed in the future.</div><div class="NLM_p">It is precisely because of the good antibacterial effect of oxazolidinone drugs that scientists have structurally modified oxazolidinone antibacterial drugs to improve their efficacy, PK, and safety profiles. On the one hand, the research strategy is based on the structural modification of linezolid. The modification sites mainly focus on the modification of the morpholine ring and the C-5 position of linezolid, which can be divided into (1) modification of only the morpholine ring, (2) modification of only the C-5 position, and (3) modification of the morpholine ring and the C-5 position at the same time. Among these new oxazolidinone antibacterial agents, there are many iconic examples. For example, compound <b>3h</b>, obtained by modifying the morpholine ring alone, had a potency 64 times stronger than that of linezolid for LREF clinical strains. Compounds <b>12c</b> and <b>13c</b>, produced by replacing the morpholine ring with azepine, showed strong antibacterial potency in <i>in vitro</i> and <i>in vivo</i> tests, significantly reduced the effects on MAO and CYP450 subtypes, and improved the safety of the drug. Teraryl oxazolidinone compound <b>4d</b> not only exhibited excellent antibacterial efficacy against MSSA and MRSA but also demonstrated a satisfactory safety profile in MTT assays (CC<sub>50</sub>(mammalian cells) > 70 μM) and in the hERG K<sup>+</sup> channel inhibition test (IC<sub>50</sub> > 40 μM); moreover, its phosphate (<b>5</b>) displayed a high water solubility of 47.1 mg/mL, good oral bioavailability (<i>F</i> = 99.1%), and improved myelosuppression. Beyond these, compounds <b>16d</b> and <b>26</b> (MRX-I) exhibited excellent antibacterial activity and significantly improved safety profiles compared with linezolid (mainly including myelosuppression and MAO inhibition). These meaningful results revealed that some groups, such as 2-(pyrazol-4-yl)pyridine, [1,2,5]triazepane, triazolo[1,5-<i>a</i>]pyridine, and dihydropyridone, which replaced the morpholino group at the C ring of linezolid, could improve the safety of oxazolidinone antibacterial agents. On the other hand, tricyclic fused oxazolidinones based on linezolid are a class of promising antibacterial agents. The modified tricyclic fused oxazolidinones (<b>27f</b>, <b>31</b>, and <b>47a</b>) exhibited excellent antibacterial activity and good druggability (high water solubility, good PK and oral bioavailability, excellent metabolic stability, low cytotoxicity and CYP450 enzyme inhibition). Of note, tricyclic fused oxazolidinones with a thiomorpholine C ring (<b>46a</b>) and a 1,2,3-triazole C-3 position (<b>34a</b>) had significantly reduced toxicity, mainly including improvements in myelosuppression and MAO inhibition. These results make the research of tricyclic fused oxazolidinones a popular direction, and it is worthy of further investigation to develop novel oxazolidinone antibiotics with improved PK, safety, and efficacy profiles.</div><div class="NLM_p last">Furthermore, new types of oxazolidinone drugs are emerging. These compounds have new structures and significant antibacterial activity resulting from the combination of oxazolidinone backbones with other antibacterial agents. The oxazolidinone antibacterial agent based on the LpxC inhibitor showed excellent activity against Gram-negative bacteria (<b>69i</b>, MIC: 0.004–0.063 μg/mL). Compound <b>63</b> containing the thiazole motif not only showed excellent activity against Gram-positive bacteria and Gram-negative bacteria but also displayed good antifungal activity. All of these results proved the important role of the oxazolidinone scaffold in the development of novel and effective antibacterial agents, thus making it worthy of further research. In summary, this Perspective covers the latest research progress in oxazolidinone antibacterial agents and mainly includes oxazolidinone antibacterial drugs currently on the market, oxazolidinone antibacterial agents modified based on linezolid, and new antibacterial agents containing oxazolidinone backbones. The SAR, safety, and druggability were also discussed, and these discussions may pave the way for the further rational exploration and development of new oxazolidinone antibacterial agents.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00480" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengyuan Liang</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7360-8998" title="Orcid link">https://orcid.org/0000-0001-7360-8998</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6d0e0508030a14180c0301040c030a2d0a000c0401430e0200"><span class="__cf_email__" data-cfemail="8ae9e2efe4edf3ffebe4e6e3ebe4edcaede7ebe3e6a4e9e5e7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenfeng Shi</span> - <span class="hlFld-Affiliation affiliation">Department
of Urology Surgery Center, Xinjiang Uyghur
People’s Hospital, Urumqi 830002, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97edfff2f9f1f2f9f0e4fffed7a6a1a4b9f4f8fa"><span class="__cf_email__" data-cfemail="ea90828f848c8f848d998283aadbdcd9c4898587">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liu</span> - <span class="hlFld-Affiliation affiliation">Zhuhai
Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ee9d8b9d819b9c8d8bb182879b86818089aedfd8ddc08d8183"><span class="__cf_email__" data-cfemail="9deef8eef2e8effef8c2f1f4e8f5f2f3faddacabaeb3fef2f0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qianqian Zhao</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Xin</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Xi’an
Xuri Shengchang Pharmaceutical Technology Co., Ltd., High-tech Zone, Xi’an 710075, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuzhi Liu</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingyi Li</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanlin Jian</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Han Li</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Shaanxi University of Science
& Technology, Xi’an 710021, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenqiang Cao</span> - <span class="hlFld-Affiliation affiliation">Zhuhai
Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Qianqian Zhao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4525-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Qianqian Zhao</b> received her Ph.D. at the National Key Laboratory of Natural Organic Chemistry of Lanzhou University in 2016. She is currently a senior lecturer at the Faculty of Pharmacy of Shaanxi University of Science and Technology. She is engaged in natural product chemistry, active ingredient separation and purification of medicinal plants, and herbal medicines and microorganisms, including structure determination and biological activity research of target compounds.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Liang Xin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4530-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Liang Xin</b> received his bachelor’s degree in pharmaceutical engineering from Shaanxi University of Science and Technology in 2020. Currently, he is a master’s degree candidate majoring in biomedicine at the Faculty of Pharmacy at Shaanxi University of Science and Technology. Xin is currently engaged in medicinal chemistry, especially the separation and modification of active ingredients from traditional Chinese medicine, as well as biological activity studies.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Yuzhi Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4535-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yuzhi Liu</b> received her bachelor’s degree in pharmacy from Xi’an Medical College in 2018. She has recently received a master’s degree at the Faculty of Pharmacy at Shaanxi University of Science and Technology. She is currently engaged in research on improving the quality standard of Chinese medicine formulation.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Chengyuan Liang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4540-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chengyuan Liang</b> received his Ph.D. in medicinal chemistry from China Pharmaceutical University in 2013. He is currently an associate professor in the Faculty of Pharmacy of Shaanxi University of Science and Technology. He is engaged in medicinal chemistry, functional food, natural product modification, and biological activity research.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Jingyi Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4545-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jingyi Li</b> received a bachelor’s degree in pharmaceutical engineering from Shaanxi University of Science and Technology in 2020. She is currently studying for a master’s degree at the School of Pharmacy of Shaanxi University of Science and Technology. She is working on the design and synthesis of antibiotics against multi-drug-resistant bacteria.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Yanlin Jian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4550-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yanlin Jian</b> received her Ph.D. in medicinal chemistry from the Laboratory for Medicinal Chemistry (FFW), Ghent University. She is now a lecturer at the School of Pharmacy, Shaanxi University of Science and Technology, Xi’an, Shaanxi. Her research focuses on the design and synthesis of <i>M. tuberculosis</i> thymidylate kinase inhibitors towards active whole-cell antimycobacterial agents.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Han Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4558-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Han Li</b> received her Ph.D. in medicinal chemistry from China Pharmaceutical University in 2016. She is currently a lecturer at the School of Pharmacy of Shaanxi University of Science and Technology. She is engaged in research on traditional Chinese medicine pharmacology and toxicology and food nutrition.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Zhenfeng Shi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4563-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhenfeng Shi</b> received his Ph.D. in surgery from Xinjiang Medical University, Urumqi, Xinjiang. He is a deputy director of the Xinjiang Uygur Autonomous Region People’s Hospital. He is passionate about tumor research.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Hong Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4568-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong Liu</b> received his Ph.D. in materials science and engineering from Sun Yat-sen University, Zhongshan, Guangdong. His research focuses on polymer material chemistry and application in nanomedicine. He is currently engaged in research work at Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Wenqiang Cao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=BIO-d7e4573-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenqiang Cao</b> received his Ph.D. from Jinan University, Guangzhou, Guangdong. He is currently engaged in research work at Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (nos. 81602967, 82003699, and 81803784) and Xinjiang Tianshan Innovation Team Foundation Funded Project (no. 2020D14029), the Basic Research Program of Natural Science of Shaanxi Province (nos. 2020CGXNG-044, 2019JQ-252, 2019JQ-779, and 2019JQ-484), the Basic Research Plan of the Education Department of Shaanxi Province (no. 19JC006), and the China Postdoctoral Science Foundation (nos. 2016M592898XB and 2019M663921XB).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABSSSI</td><td class="NLM_def"><p class="first last">Acute bacterial skin and skin structure infections</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term"><i>A. niger</i></td><td class="NLM_def"><p class="first last"><i>Aspergillus niger</i></p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the pharmacokinetic curve</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">barbituric acid</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">B/P</td><td class="NLM_def"><p class="first last">brain/plasm</p></td></tr><tr><td class="NLM_term"><i>B. subtilis</i></td><td class="NLM_def"><p class="first last"><i>Bacillus subtilis</i></p></td></tr><tr><td class="NLM_term"><i>C. albicans</i></td><td class="NLM_def"><p class="first last"><i>Candida albicans</i></p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">dimethyl malonate</p></td></tr><tr><td class="NLM_term"><i>E. coli</i></td><td class="NLM_def"><p class="first last"><i>Escherichia coli</i></p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">dose effective in 50% of test subjects</p></td></tr><tr><td class="NLM_term"><i>E. faecalis</i></td><td class="NLM_def"><p class="first last"><i>Enterococcus faecalis</i></p></td></tr><tr><td class="NLM_term"><i>E. faecium</i></td><td class="NLM_def"><p class="first last"><i>Enterococcus faecium</i></p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term"><i>H. influenzae</i></td><td class="NLM_def"><p class="first last"><i>Haemophilus influenzae</i></p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">IL-6</td><td class="NLM_def"><p class="first last">interleukin-6</p></td></tr><tr><td class="NLM_term"><i>K. pneumoniae</i></td><td class="NLM_def"><p class="first last"><i>Klebsiella pneumoniae</i></p></td></tr><tr><td class="NLM_term">LpxC</td><td class="NLM_def"><p class="first last">UDP-3-<i>O</i>-acyl-<i>N</i>-acetylglucosamine deacetylase</p></td></tr><tr><td class="NLM_term">LREF</td><td class="NLM_def"><p class="first last">linezolid-resistant <i>Enterococcus faecalis</i></p></td></tr><tr><td class="NLM_term">LREFA</td><td class="NLM_def"><p class="first last">linezolid-resistant <i>Enterococcus faecium</i></p></td></tr><tr><td class="NLM_term">LRSA</td><td class="NLM_def"><p class="first last">linezolid-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">LRSE</td><td class="NLM_def"><p class="first last">linezolid-resistant <i>Staphylococcus epidermidis</i></p></td></tr><tr><td class="NLM_term">LZDR</td><td class="NLM_def"><p class="first last">linezolid-resistant</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term"><i>M. catarrhalis</i></td><td class="NLM_def"><p class="first last"><i>Moraxella catarrhalis</i></p></td></tr><tr><td class="NLM_term">MDR-TB</td><td class="NLM_def"><p class="first last">multi-drug-resistant <i>Tuberculosis</i></p></td></tr><tr><td class="NLM_term">MED</td><td class="NLM_def"><p class="first last">minimum effect dose</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">messenger RNA</p></td></tr><tr><td class="NLM_term">MPS</td><td class="NLM_def"><p class="first last">mitochondrial protein synthesis</p></td></tr><tr><td class="NLM_term">MPSi</td><td class="NLM_def"><p class="first last">mitochondrial protein synthesis inhibition</p></td></tr><tr><td class="NLM_term">MRSA</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">MRSE</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus epidermidis</i></p></td></tr><tr><td class="NLM_term">MSSA</td><td class="NLM_def"><p class="first last">methicillin-sensitive <i>S. aureus</i></p></td></tr><tr><td class="NLM_term"><i>M. tuberculosis</i></td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term"><i>P. aeruginosa</i></td><td class="NLM_def"><p class="first last"><i>Pseudomonas aeruginosa</i></p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pyrazolidine-3,5-dione</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PRSP</td><td class="NLM_def"><p class="first last">penicillin-resistant <i>Streptococcus pneumoniae</i></p></td></tr><tr><td class="NLM_term">PTC</td><td class="NLM_def"><p class="first last">peptidyl transferase center</p></td></tr><tr><td class="NLM_term">QS</td><td class="NLM_def"><p class="first last">quorum sensing</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term"><i>S. aureus</i></td><td class="NLM_def"><p class="first last"><i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term"><i>S. epidermidis</i></td><td class="NLM_def"><p class="first last"><i>Staphylococcus epidermidis</i></p></td></tr><tr><td class="NLM_term"><i>S. faecalis</i></td><td class="NLM_def"><p class="first last"><i>Streptococcus faecalis</i></p></td></tr><tr><td class="NLM_term"><i>S. pneumoniae</i></td><td class="NLM_def"><p class="first last"><i>Streptococcus pneumoniae</i></p></td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">tuberculosis</p></td></tr><tr><td class="NLM_term">TMP</td><td class="NLM_def"><p class="first last">tetramethylpyrazine</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">VRE</td><td class="NLM_def"><p class="first last">vancomycin-resistant <i>Enterococcus</i></p></td></tr><tr><td class="NLM_term">VREF</td><td class="NLM_def"><p class="first last">vancomycin-resistant <i>Enterococcus</i> faecium</p></td></tr><tr><td class="NLM_term">XDR-TB</td><td class="NLM_def"><p class="first last">extensively drug-resistant TB</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 127 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truman, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span> <span> </span><span class="NLM_article-title">Antibiotics: past, present and future</span>. <i>Curr. Opin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.mib.2019.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.mib.2019.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31733401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2msbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=72-80&author=M.+I.+Hutchingsauthor=A.+W.+Trumanauthor=B.+Wilkinson&title=Antibiotics%3A+past%2C+present+and+future&doi=10.1016%2Fj.mib.2019.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics: past, present and future</span></div><div class="casAuthors">Hutchings, Matt; Truman, Andrew; Wilkinson, Barrie</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-80</span>CODEN:
                <span class="NLM_cas:coden">COMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1369-5274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The first antibiotic, salvarsan, was deployed in 1910.  In just over 100 years antibiotics have drastically changed modern medicine and extended the av. human lifespan by 23 years.  The discovery of penicillin in 1928 started the golden age of natural product antibiotic discovery that peaked in the mid-1950s.  Since then, a gradual decline in antibiotic discovery and development and the evolution of drug resistance in many human pathogens has led to the current antimicrobial resistance crisis.  Here we give an overview of the history of antibiotic discovery, the major classes of antibiotics and where they come from.  We argue that the future of antibiotic discovery looks bright as new technologies such as genome mining and editing are deployed to discover new natural products with diverse bioactivities.  We also report on the current state of antibiotic development, with 45 drugs currently going through the clin. trials pipeline, including several new classes with novel modes of action that are in phase 3 clin. trials.  Overall, there are promising signs for antibiotic discovery, but changes in financial models are required to translate scientific advances into clin. approved antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY6ZUsf1XmrVg90H21EOLACvtfcHk0liepjYtOgN5EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2msbjP&md5=cdb3445303ef36cbe05f5ec1d2a0e37a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.mib.2019.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mib.2019.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutchings%26aufirst%3DM.%2BI.%26aulast%3DTruman%26aufirst%3DA.%2BW.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DAntibiotics%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCurr.%2520Opin.%2520Microbiol.%26date%3D2019%26volume%3D51%26spage%3D72%26epage%3D80%26doi%3D10.1016%2Fj.mib.2019.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasz, A.</span></span> <span> </span><span class="NLM_article-title">Microbiology. Weapons of microbial drug resistance abound in soil flora</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1126/science.1123982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.1123982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16424327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsVWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2006&pages=342-343&author=A.+Tomasz&title=Microbiology.+Weapons+of+microbial+drug+resistance+abound+in+soil+flora&doi=10.1126%2Fscience.1123982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Weapons of Microbial Drug Resistance Abound in Soil Flora</span></div><div class="casAuthors">Tomasz, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5759</span>),
    <span class="NLM_cas:pages">342-343</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Bacteria found in soils show robust resistance to many antibiotics.  These protective mechanisms may offer clues for generating a new arsenal of therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX6Uw3Cb0547Vg90H21EOLACvtfcHk0lj2zRBr1y2sig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsVWrsA%253D%253D&md5=1da4aadf997472af304d48e2dc580bb2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1123982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1123982%26sid%3Dliteratum%253Aachs%26aulast%3DTomasz%26aufirst%3DA.%26atitle%3DMicrobiology.%2520Weapons%2520of%2520microbial%2520drug%2520resistance%2520abound%2520in%2520soil%2520flora%26jtitle%3DScience%26date%3D2006%26volume%3D311%26spage%3D342%26epage%3D343%26doi%3D10.1126%2Fscience.1123982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaston, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presbury, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarkowsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vichinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falletta, J. M.</span></span> <span> </span><span class="NLM_article-title">Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1056/NEJM198606193142501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1056%2FNEJM198606193142501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=3086721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADyaL283jtVOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=1986&pages=1593-1599&author=M.+H.+Gastonauthor=J.+I.+Verterauthor=G.+Woodsauthor=C.+Pegelowauthor=J.+Kelleherauthor=G.+Presburyauthor=H.+Zarkowskyauthor=E.+Vichinskyauthor=R.+Iyerauthor=J.+S.+Lobelauthor=S.+Diamondauthor=C.+T.+Holbrookauthor=F.+M.+Gillauthor=K.+Ritcheyauthor=J.+M.+Falletta&title=Prophylaxis+with+oral+penicillin+in+children+with+sickle+cell+anemia.+A+randomized+trial&doi=10.1056%2FNEJM198606193142501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial</span></div><div class="casAuthors">Gaston M H; Verter J I; Woods G; Pegelow C; Kelleher J; Presbury G; Zarkowsky H; Vichinsky E; Iyer R; Lobel J S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1593-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Children with sickle cell anemia have an increased susceptibility to bacterial infections, especially to those caused by Streptococcus pneumoniae.  We therefore conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial to test whether the regular, daily administration of oral penicillin would reduce the incidence of documented septicemia due to S.pneumoniae in children with sickle cell anemia who were under the age of three years at the time of entry.  The children were randomly assigned to receive either 125 mg of penicillin V potassium (105 children) or placebo (110 children) twice daily.  The trial was terminated 8 months early, after an average of 15 months of follow-up, when an 84 percent reduction in the incidence of infection was observed in the group treated with penicillin, as compared with the group given placebo (13 of 110 patients vs. 2 of 105; P = 0.0025), with no deaths from pneumococcal septicemia occurring in the penicillin group but three deaths from the infection occurring in the placebo group.  On the basis of these results, we conclude that children should be screened in the neonatal period for sickle cell hemoglobinopathy and that those with sickle cell anemia should receive prophylactic therapy with oral penicillin by four months of age to decrease the morbidity and mortality associated with pneumococcal septicemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWPn7gNIRgrrYtC3U5jeOifW6udTcc2ebyjy0mneiJerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL283jtVOhsA%253D%253D&md5=5203a5ab53e9148913fdd83d0c1b2547</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM198606193142501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198606193142501%26sid%3Dliteratum%253Aachs%26aulast%3DGaston%26aufirst%3DM.%2BH.%26aulast%3DVerter%26aufirst%3DJ.%2BI.%26aulast%3DWoods%26aufirst%3DG.%26aulast%3DPegelow%26aufirst%3DC.%26aulast%3DKelleher%26aufirst%3DJ.%26aulast%3DPresbury%26aufirst%3DG.%26aulast%3DZarkowsky%26aufirst%3DH.%26aulast%3DVichinsky%26aufirst%3DE.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLobel%26aufirst%3DJ.%2BS.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DC.%2BT.%26aulast%3DGill%26aufirst%3DF.%2BM.%26aulast%3DRitchey%26aufirst%3DK.%26aulast%3DFalletta%26aufirst%3DJ.%2BM.%26atitle%3DProphylaxis%2520with%2520oral%2520penicillin%2520in%2520children%2520with%2520sickle%2520cell%2520anemia.%2520A%2520randomized%2520trial%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1986%26volume%3D314%26spage%3D1593%26epage%3D1599%26doi%3D10.1056%2FNEJM198606193142501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plésiat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span> <span> </span><span class="NLM_article-title">The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1128/CMR.00117-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FCMR.00117-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25788514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlyhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=337-418&author=X.+Z.+Liauthor=P.+Pl%C3%A9siatauthor=H.+Nikaido&title=The+challenge+of+efflux-mediated+antibiotic+resistance+in+Gram-negative+bacteria&doi=10.1128%2FCMR.00117-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria</span></div><div class="casAuthors">Li, Xian-Zhi; Plesiat, Patrick; Nikaido, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-418</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global emergence of multidrug-resistant Gram-neg. bacteria is a growing threat to antibiotic therapy.  The chromosomally encoded drug efflux mechanisms that are ubiquitous in these bacteria greatly contribute to antibiotic resistance and present a major challenge for antibiotic development.  Multidrug pumps, particularly those represented by the clin. relevant AcrAB-TolC and Mex pumps of the resistance-nodulation-division (RND) superfamily, not only mediate intrinsic and acquired multidrug resistance (MDR) but also are involved in other functions, including the bacterial stress response and pathogenicity.  Addnl., efflux pumps interact synergistically with other resistance mechanisms (e.g., with the outer membrane permeability barrier) to increase resistance levels.  Since the discovery of RND pumps in the early 1990s, remarkable scientific and technol. advances have allowed for an in-depth understanding of the structural and biochem. basis, substrate profiles, mol. regulation, and inhibition of MDR pumps.  However, the development of clin. useful efflux pump inhibitors and/or new antibiotics that can bypass pump effects continues to be a challenge.  Plasmid-borne efflux pump genes (including those for RND pumps) have increasingly been identified.  This article highlights the recent progress obtained for organisms of clin. significance, together with methodol. considerations for the characterization of MDR pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8mBa4pi9DV7Vg90H21EOLACvtfcHk0ljp_ijMCz4nmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlyhs7o%253D&md5=f481bdc9d3813f008c4c69502e9c9639</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FCMR.00117-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00117-14%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BZ.%26aulast%3DPl%25C3%25A9siat%26aufirst%3DP.%26aulast%3DNikaido%26aufirst%3DH.%26atitle%3DThe%2520challenge%2520of%2520efflux-mediated%2520antibiotic%2520resistance%2520in%2520Gram-negative%2520bacteria%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2015%26volume%3D28%26spage%3D337%26epage%3D418%26doi%3D10.1128%2FCMR.00117-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance patterns of Gram-negative and Gram-positive strains isolated from inpatients with nosocomial infections in a tertiary hospital in Beijing, China from 2011 to 2014</span>. <i>J. Chemother. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1080/1120009X.2016.1157946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1080%2F1120009X.2016.1157946" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2017&pages=317-320&author=X.+Zhuauthor=A.+Tongauthor=D.+Wangauthor=H.+Sunauthor=L.+Chenauthor=M.+Dong&title=Antibiotic+resistance+patterns+of+Gram-negative+and+Gram-positive+strains+isolated+from+inpatients+with+nosocomial+infections+in+a+tertiary+hospital+in+Beijing%2C+China+from+2011+to+2014&doi=10.1080%2F1120009X.2016.1157946"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F1120009X.2016.1157946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1120009X.2016.1157946%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DM.%26atitle%3DAntibiotic%2520resistance%2520patterns%2520of%2520Gram-negative%2520and%2520Gram-positive%2520strains%2520isolated%2520from%2520inpatients%2520with%2520nosocomial%2520infections%2520in%2520a%2520tertiary%2520hospital%2520in%2520Beijing%252C%2520China%2520from%25202011%2520to%25202014%26jtitle%3DJ.%2520Chemother.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2017%26volume%3D29%26spage%3D317%26epage%3D320%26doi%3D10.1080%2F1120009X.2016.1157946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neu, H. C.</span></span> <span> </span><span class="NLM_article-title">The crisis in antibiotic resistance</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1126/science.257.5073.1064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.257.5073.1064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1509257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK38Xls1OhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1992&pages=1064-1073&author=H.+C.+Neu&title=The+crisis+in+antibiotic+resistance&doi=10.1126%2Fscience.257.5073.1064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The crisis in antibiotic resistance</span></div><div class="casAuthors">Neu, Harold C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5073</span>),
    <span class="NLM_cas:pages">1064-72</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with >64 refs.  The synthesis of large nos. of antibiotics over the past three decades has caused complacency about the threat of bacterial resistance.  Bacteria have become resistant to antimicrobial agents as a result of chromosomal changes or the exchange of genetic material via plasmids and transposons.  Streptococcus pneumoniae, Streptococcus pyogenes, and staphylococci, organisms that cause respiratory and cutaneous infections, and members of the Enterobacteriaceae and Pseudomonas families, organisms that cause diarrhea, urinary infection, and sepsis, are now resistant to virtually all of the older antibiotics.  The extensive use of antibiotics in the community and hospitals has fueled this crisis.  Mechanisms such as antibiotic control programs, better hygiene, and synthesis of agents with improved antimicrobial activity need to be adopted in order to limit bacterial resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmntDmhDYAKrVg90H21EOLACvtfcHk0ljp_ijMCz4nmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1OhsbY%253D&md5=02b98676a76f669ffde4dbb1f10a3876</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.257.5073.1064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.257.5073.1064%26sid%3Dliteratum%253Aachs%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DThe%2520crisis%2520in%2520antibiotic%2520resistance%26jtitle%3DScience%26date%3D1992%26volume%3D257%26spage%3D1064%26epage%3D1073%26doi%3D10.1126%2Fscience.257.5073.1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumental, S.</span></span> <span> </span><span class="NLM_article-title">Specialty Grand Challenge In Pediatric Infectious Diseases</span>. <i>Front. pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>, <span class="refDoi"> DOI: 10.3389/fped.2017.00185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.3389%2Ffped.2017.00185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28894730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmvFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=185&author=P.+Lepageauthor=S.+Blumental&title=Specialty+Grand+Challenge+In+Pediatric+Infectious+Diseases&doi=10.3389%2Ffped.2017.00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Specialty Grand Challenge In Pediatric Infectious Diseases</span></div><div class="casAuthors">Lepage Philippe; Blumental Sophie; Lepage Philippe; Blumental Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6GJEjgZePFpNiNltV31zlfW6udTcc2eauLBT5apbxJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmvFymsg%253D%253D&md5=95c131a56638492dfea30db241a71626</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffped.2017.00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2017.00185%26sid%3Dliteratum%253Aachs%26aulast%3DLepage%26aufirst%3DP.%26aulast%3DBlumental%26aufirst%3DS.%26atitle%3DSpecialty%2520Grand%2520Challenge%2520In%2520Pediatric%2520Infectious%2520Diseases%26jtitle%3DFront.%2520pediatr.%26date%3D2017%26volume%3D5%26spage%3D185%26doi%3D10.3389%2Ffped.2017.00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi
Bialvaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgharzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi Kafil, H.</span></span> <span> </span><span class="NLM_article-title">Linezolid: a promising option in the treatment of Gram-positives</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1093/jac/dkw450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkw450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=27999068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=354-364&author=A.+Zahedi%0ABialvaeiauthor=M.+Rahbarauthor=M.+Yousefiauthor=M.+Asgharzadehauthor=H.+Samadi+Kafil&title=Linezolid%3A+a+promising+option+in+the+treatment+of+Gram-positives&doi=10.1093%2Fjac%2Fdkw450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid: a promising option in the treatment of Gram-positives</span></div><div class="casAuthors">Zahedi Bialvaei Abed; Rahbar Mohammad; Yousefi Mehdi; Asgharzadeh Mohammad; Samadi Kafil Hossein</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antimicrobial chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Linezolid, an oxazolidinone antimicrobial agent that acts by inhibiting protein synthesis in a unique fashion, is used in the treatment of community-acquired pneumonia, skin and soft-tissue infections and other infections caused by Gram-positive bacteria including VRE and methicillin-resistant staphylococci.  Currently, linezolid resistance among these pathogens remains low, commonly <1.0%, although the prevalence of antibiotic resistance is increasing in many countries.  Therefore, the development of resistance by clinical isolates should prompt increased attention of clinical laboratories to routinely perform linezolid susceptibility testing for this important agent and should be taken into account when considering its therapeutic use.  Considering the importance of linezolid in the treatment of infections caused by Gram-positive bacteria, this review was undertaken to optimize the clinical use of this antibiotic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6wL2yu320D2gRQsDqrjW_fW6udTcc2eausEF2XQ5rXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmvFWitQ%253D%253D&md5=7b7621e958610ab9288e0d7cff155b2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkw450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkw450%26sid%3Dliteratum%253Aachs%26aulast%3DZahedi%2BBialvaei%26aufirst%3DA.%26aulast%3DRahbar%26aufirst%3DM.%26aulast%3DYousefi%26aufirst%3DM.%26aulast%3DAsgharzadeh%26aufirst%3DM.%26aulast%3DSamadi%2BKafil%26aufirst%3DH.%26atitle%3DLinezolid%253A%2520a%2520promising%2520option%2520in%2520the%2520treatment%2520of%2520Gram-positives%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2017%26volume%3D72%26spage%3D354%26epage%3D364%26doi%3D10.1093%2Fjac%2Fdkw450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanamori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumaru, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani-Ui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuzaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanehisa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, K.</span></span> <span> </span><span class="NLM_article-title">Whole genome sequencing of meticillin-resistant Staphylococcus aureus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)04403-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2800%2904403-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11418146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvVClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=1225-1240&author=M.+Kurodaauthor=T.+Ohtaauthor=I.+Uchiyamaauthor=T.+Babaauthor=H.+Yuzawaauthor=I.+Kobayashiauthor=L.+Cuiauthor=A.+Oguchiauthor=K.+Aokiauthor=Y.+Nagaiauthor=J.+Lianauthor=T.+Itoauthor=M.+Kanamoriauthor=H.+Matsumaruauthor=A.+Maruyamaauthor=H.+Murakamiauthor=A.+Hosoyamaauthor=Y.+Mizutani-Uiauthor=N.+K.+Takahashiauthor=T.+Sawanoauthor=R.+Inoueauthor=C.+Kaitoauthor=K.+Sekimizuauthor=H.+Hirakawaauthor=S.+Kuharaauthor=S.+Gotoauthor=J.+Yabuzakiauthor=M.+Kanehisaauthor=A.+Yamashitaauthor=K.+Oshimaauthor=K.+Furuyaauthor=C.+Yoshinoauthor=T.+Shibaauthor=M.+Hattoriauthor=N.+Ogasawaraauthor=H.+Hayashiauthor=K.+Hiramatsu&title=Whole+genome+sequencing+of+meticillin-resistant+Staphylococcus+aureus&doi=10.1016%2FS0140-6736%2800%2904403-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Whole genome sequencing of meticillin-resistant Staphylococcus aureus</span></div><div class="casAuthors">Kuroda, Makoto; Ohta, Toshiko; Uchiyama, Ikuo; Baba, Tadashi; Yuzawa, Harumi; Kobayashi, Ichizo; Cui, Longzhu; Oguchi, Akio; Aoki, Ken-ichi; Nagai, Yoshimi; Lian, JianQi; Ito, Teruyo; Kanamori, Mutsumi; Matsumaru, Hiroyuki; Maruyama, Atsushi; Murakami, Hiroyuki; Hosoyama, Akira; Mizutani-Ui, Yoko; Takahashi, Noriko K.; Sawano, Toshihiko; Inoue, Ryu-ichi; Kaito, Chikara; Sekimizu, Kazuhisa; Hirakawa, Hideki; Kuhara, Satoru; Goto, Susumu; Yabuzaki, Junko; Kanehisa, Minoru; Yamashita, Atsushi; Oshima, Kenshiro; Furuya, Keiko; Yoshino, Chie; Shiba, Tadayoshi; Hattori, Masahira; Ogasawara, Naotake; Hayashi, Hideo; Hiramatsu, Keiichi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">9264</span>),
    <span class="NLM_cas:pages">1225-1240</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Staphylococcus aureus is one of the major causes of community-acquired and hospital-acquired infections.  It produces numerous toxins including superantigens that cause unique disease entities such as toxic-shock syndrome and staphylococcal scarlet fever, and has acquired resistance to practically all antibiotics.  Whole genome anal. is a necessary step towards future development of countermeasures against this organism.  Whole genome sequences of two related S aureus strains (N315 and Mu50) were detd. by shot-gun random sequencing.  N315 is a meticillin-resistant S aureus (MRSA) strain isolated in 1982, and Mu50 is an MRSA strain with vancomycin resistance isolated in 1997.  The open reading frames were identified by use of GAMBLER and GLIMMER programs, and annotation of each was done with a BLAST homol. search, motif anal., and protein localization prediction.  The Staphylococcus genome was composed of a complex mixt. of genes, many of which seem to have been acquired by lateral gene transfer.  Most of the antibiotic resistance genes were carried either by plasmids or by mobile genetic elements including a unique resistance island.  Three classes of new pathogenicity islands were identified in the genome: a toxic shock syndrome toxin island family, exotoxin islands, and enterotoxin islands.  In the latter two pathogenicity islands, clusters of exotoxin and enterotoxin genes were found closely linked with other gene clusters encoding putative pathogenic factors.  The anal. also identified 70 candidates for new virulence factors.  The remarkable ability of S aureus to acquire useful genes from various organisms was revealed through the observation of genome complexity and evidence of lateral gene transfer.  Repeated duplication of genes encoding superantigens explains why S aureus is capable of infecting humans of diverse genetic backgrounds, eliciting severe immune reactions.  Investigation of many newly identified gene products, including the 70 putative virulence factors, will greatly improve our understanding of the biol. of staphylococci and the processes of infectious diseases caused by S aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpU6n9OxpCX7Vg90H21EOLACvtfcHk0lgoEtdz65lUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvVClur0%253D&md5=3b46b4b35182e65e5794bd2e689b740b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2904403-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252904403-2%26sid%3Dliteratum%253Aachs%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DI.%26aulast%3DBaba%26aufirst%3DT.%26aulast%3DYuzawa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DI.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DOguchi%26aufirst%3DA.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DLian%26aufirst%3DJ.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKanamori%26aufirst%3DM.%26aulast%3DMatsumaru%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DHosoyama%26aufirst%3DA.%26aulast%3DMizutani-Ui%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%2BK.%26aulast%3DSawano%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DR.%26aulast%3DKaito%26aufirst%3DC.%26aulast%3DSekimizu%26aufirst%3DK.%26aulast%3DHirakawa%26aufirst%3DH.%26aulast%3DKuhara%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DYabuzaki%26aufirst%3DJ.%26aulast%3DKanehisa%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DA.%26aulast%3DOshima%26aufirst%3DK.%26aulast%3DFuruya%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DC.%26aulast%3DShiba%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DM.%26aulast%3DOgasawara%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DHiramatsu%26aufirst%3DK.%26atitle%3DWhole%2520genome%2520sequencing%2520of%2520meticillin-resistant%2520Staphylococcus%2520aureus%26jtitle%3DLancet%26date%3D2001%26volume%3D357%26spage%3D1225%26epage%3D1240%26doi%3D10.1016%2FS0140-6736%2800%2904403-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouts, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mongodin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deboy, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beanan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madupu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiuoli, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haft, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamathevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utterback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hance, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C. M.</span></span> <span> </span><span class="NLM_article-title">Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">2426</span>– <span class="NLM_lpage">2438</span>, <span class="refDoi"> DOI: 10.1128/JB.187.7.2426-2438.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FJB.187.7.2426-2438.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15774886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1Kqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2005&pages=2426-2438&author=S.+R.+Gillauthor=D.+E.+Foutsauthor=G.+L.+Archerauthor=E.+F.+Mongodinauthor=R.+T.+Deboyauthor=J.+Ravelauthor=I.+T.+Paulsenauthor=J.+F.+Kolonayauthor=L.+Brinkacauthor=M.+Beananauthor=R.+J.+Dodsonauthor=S.+C.+Daughertyauthor=R.+Madupuauthor=S.+V.+Angiuoliauthor=A.+S.+Durkinauthor=D.+H.+Haftauthor=J.+Vamathevanauthor=H.+Khouriauthor=T.+Utterbackauthor=C.+Leeauthor=G.+Dimitrovauthor=L.+Jiangauthor=H.+Qinauthor=J.+Weidmanauthor=K.+Tranauthor=K.+Kangauthor=I.+R.+Hanceauthor=K.+E.+Nelsonauthor=C.+M.+Fraser&title=Insights+on+evolution+of+virulence+and+resistance+from+the+complete+genome+analysis+of+an+early+methicillin-resistant+Staphylococcus+aureus+strain+and+a+biofilm-producing+methicillin-resistant+Staphylococcus+epidermidis+strain&doi=10.1128%2FJB.187.7.2426-2438.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Streptococcus epidermidis strain</span></div><div class="casAuthors">Gill, Steven R.; Fouts, Derrick E.; Archer, Gordon L.; Mongodin, Emmanuel F.; DeBoy, Robert T.; Ravel, Jacques; Paulsen, Ian T.; Kolonay, James F.; Brinkac, Lauren; Beanan, Mauren; Dodson, Robert J.; Daugherty, Sean C.; Madupu, Ramana; Angiuoli, Samuel V.; Durkin, A. Scott; Haft, Daniel H.; Vamathevan, Jessica; Khouri, Hoda; Utterback, Terry; Lee, Chris; Dimitrov, George; Jiang, Lingxia; Qin, Haiying; Weidman, Jan; Tran, Kevin; Kang, Kathy; Hance, Ioana R.; Nelson, Karen E.; Fraser, Claire M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2426-2438</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcus aureus is an opportunistic pathogen and the major causative agent of numerous hospital- and community-acquired infections.  Staphylococcus epidermidis has emerged as a causative agent of infections often assocd. with implanted medical devices.  The ∼2.8-Mb genome of S. aureus COL, an early methicillin-resistant isolate, and the ∼2.6-Mb genome of S. epidermidis RP62a, a methicillin-resistant biofilm isolate, were sequenced.  Comparative anal. of these and other staphylococcal genomes was used to explore the evolution of virulence and resistance between these two species.  The S. aureus and S. epidermidis genomes are syntenic throughout their lengths and share a core set of 1681 open reading frames.  Genome islands in nonsyntenic regions are the primary source of variations in pathogenicity and resistance.  Gene transfer between staphylococci and low-GC-content gram-pos. bacteria appears to have shaped their virulence and resistance profiles.  Integrated plasmids in S. epidermidis carry genes encoding resistance to cadmium and species-specific LPXTG surface proteins.  A novel genome island encodes multiple phenol-sol. modulins, a potential S. epidermidis virulence factor.  S. epidermidis contains the cap operon, encoding the polyglutamate capsule, a major virulence factor in Bacillus anthracis.  Addnl. phenotypic differences are likely the result of single nucleotide polymorphisms, which are most numerous in cell envelope proteins.  Overall differences in pathogenicity can be attributed to genome islands in S. aureus which encode enterotoxins, exotoxins, leukocidins, and leukotoxins not found in S. epidermidis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQCOEqBmlu3rVg90H21EOLACvtfcHk0lgoEtdz65lUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1Kqs7s%253D&md5=b4485eb277352166ed70e211eeef47dd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FJB.187.7.2426-2438.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.187.7.2426-2438.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BR.%26aulast%3DFouts%26aufirst%3DD.%2BE.%26aulast%3DArcher%26aufirst%3DG.%2BL.%26aulast%3DMongodin%26aufirst%3DE.%2BF.%26aulast%3DDeboy%26aufirst%3DR.%2BT.%26aulast%3DRavel%26aufirst%3DJ.%26aulast%3DPaulsen%26aufirst%3DI.%2BT.%26aulast%3DKolonay%26aufirst%3DJ.%2BF.%26aulast%3DBrinkac%26aufirst%3DL.%26aulast%3DBeanan%26aufirst%3DM.%26aulast%3DDodson%26aufirst%3DR.%2BJ.%26aulast%3DDaugherty%26aufirst%3DS.%2BC.%26aulast%3DMadupu%26aufirst%3DR.%26aulast%3DAngiuoli%26aufirst%3DS.%2BV.%26aulast%3DDurkin%26aufirst%3DA.%2BS.%26aulast%3DHaft%26aufirst%3DD.%2BH.%26aulast%3DVamathevan%26aufirst%3DJ.%26aulast%3DKhouri%26aufirst%3DH.%26aulast%3DUtterback%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDimitrov%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DWeidman%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DK.%26aulast%3DHance%26aufirst%3DI.%2BR.%26aulast%3DNelson%26aufirst%3DK.%2BE.%26aulast%3DFraser%26aufirst%3DC.%2BM.%26atitle%3DInsights%2520on%2520evolution%2520of%2520virulence%2520and%2520resistance%2520from%2520the%2520complete%2520genome%2520analysis%2520of%2520an%2520early%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520strain%2520and%2520a%2520biofilm-producing%2520methicillin-resistant%2520Staphylococcus%2520epidermidis%2520strain%26jtitle%3DJ.%2520Bacteriol.%26date%3D2005%26volume%3D187%26spage%3D2426%26epage%3D2438%26doi%3D10.1128%2FJB.187.7.2426-2438.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshadri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouts, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidelberg, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettelin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umayam, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beanan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBoy, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madupu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamathevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utterback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radune, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketchum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C. M.</span></span> <span> </span><span class="NLM_article-title">Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">2071</span>– <span class="NLM_lpage">2074</span>, <span class="refDoi"> DOI: 10.1126/science.1080613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.1080613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12663927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlCisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=2071-2074&author=I.+T.+Paulsenauthor=L.+Banerjeiauthor=G.+S.+Myersauthor=K.+E.+Nelsonauthor=R.+Seshadriauthor=T.+D.+Readauthor=D.+E.+Foutsauthor=J.+A.+Eisenauthor=S.+R.+Gillauthor=J.+F.+Heidelbergauthor=H.+Tettelinauthor=R.+J.+Dodsonauthor=L.+Umayamauthor=L.+Brinkacauthor=M.+Beananauthor=S.+Daughertyauthor=R.+T.+DeBoyauthor=S.+Durkinauthor=J.+Kolonayauthor=R.+Madupuauthor=W.+Nelsonauthor=J.+Vamathevanauthor=B.+Tranauthor=J.+Uptonauthor=T.+Hansenauthor=J.+Shettyauthor=H.+Khouriauthor=T.+Utterbackauthor=D.+Raduneauthor=K.+A.+Ketchumauthor=B.+A.+Doughertyauthor=C.+M.+Fraser&title=Role+of+mobile+DNA+in+the+evolution+of+vancomycin-resistant+Enterococcus+faecalis&doi=10.1126%2Fscience.1080613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis</span></div><div class="casAuthors">Paulsen, I. T.; Banerjei, L.; Myers, G. S. A.; Nelson, K. E.; Seshadri, R.; Read, T. D.; Fouts, D. E.; Eisen, J. A.; Gill, S. R.; Heidelberg, J. F.; Tettelin, H.; Dodson, R. J.; Umayam, L.; Brinkac, L.; Beanan, M.; Daugherty, S.; DeBoy, R. T.; Durkin, S.; Kolonay, J.; Madupu, R.; Nelson, W.; Vamathevan, J.; Tran, B.; Upton, J.; Hansen, T.; Shetty, J.; Khouri, H.; Utterback, T.; Radune, D.; Ketchum, K. A.; Dougherty, B. A.; Fraser, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5615</span>),
    <span class="NLM_cas:pages">2071-2074</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The complete genome sequence of Enterococcus faecalis V583, a vancomycin-resistant clin. isolate, revealed that more than a quarter of the genome consists of probable mobile or foreign DNA.  One of the predicted mobile elements is a previously unknown vanB vancomycin-resistance conjugative transposon.  Three plasmids were identified, including two pheromone-sensing conjugative plasmids, one encoding a previously undescribed pheromone inhibitor.  The apparent propensity for the incorporation of mobile elements probably contributed to the rapid acquisition and dissemination of drug resistance in the enterococci.  The genome sequence is deposited in GenBank/EMBL/DDBJ under accession no. AE016830 and in the RefSeq database under accession no. NC_004668.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX6y7SjuOTKbVg90H21EOLACvtfcHk0ljf0UEEZJVcpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlCisLw%253D&md5=ca314c76de2ea22cb758ed8c431f42fd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1080613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1080613%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DI.%2BT.%26aulast%3DBanerjei%26aufirst%3DL.%26aulast%3DMyers%26aufirst%3DG.%2BS.%26aulast%3DNelson%26aufirst%3DK.%2BE.%26aulast%3DSeshadri%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DT.%2BD.%26aulast%3DFouts%26aufirst%3DD.%2BE.%26aulast%3DEisen%26aufirst%3DJ.%2BA.%26aulast%3DGill%26aufirst%3DS.%2BR.%26aulast%3DHeidelberg%26aufirst%3DJ.%2BF.%26aulast%3DTettelin%26aufirst%3DH.%26aulast%3DDodson%26aufirst%3DR.%2BJ.%26aulast%3DUmayam%26aufirst%3DL.%26aulast%3DBrinkac%26aufirst%3DL.%26aulast%3DBeanan%26aufirst%3DM.%26aulast%3DDaugherty%26aufirst%3DS.%26aulast%3DDeBoy%26aufirst%3DR.%2BT.%26aulast%3DDurkin%26aufirst%3DS.%26aulast%3DKolonay%26aufirst%3DJ.%26aulast%3DMadupu%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DW.%26aulast%3DVamathevan%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DB.%26aulast%3DUpton%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DShetty%26aufirst%3DJ.%26aulast%3DKhouri%26aufirst%3DH.%26aulast%3DUtterback%26aufirst%3DT.%26aulast%3DRadune%26aufirst%3DD.%26aulast%3DKetchum%26aufirst%3DK.%2BA.%26aulast%3DDougherty%26aufirst%3DB.%2BA.%26aulast%3DFraser%26aufirst%3DC.%2BM.%26atitle%3DRole%2520of%2520mobile%2520DNA%2520in%2520the%2520evolution%2520of%2520vancomycin-resistant%2520Enterococcus%2520faecalis%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D2071%26epage%3D2074%26doi%3D10.1126%2Fscience.1080613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.4.839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.40.4.839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=8849237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XitVWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=839-845&author=G.+E.+Zurenkoauthor=B.+H.+Yagiauthor=R.+D.+Schaadtauthor=J.+W.+Allisonauthor=J.+O.+Kilburnauthor=S.+E.+Glickmanauthor=D.+K.+Hutchinsonauthor=M.+R.+Barbachynauthor=S.+J.+Brickner&title=In+vitro+activities+of+U-100592+and+U-100766%2C+novel+oxazolidinone+antibacterial+agents&doi=10.1128%2FAAC.40.4.839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents</span></div><div class="casAuthors">Zurenko, Gary E.; Yagi, Betty H.; Schaadt, Ronda D.; Allison, John W.; Kilburn, James O.; Glickman, Suzanne E.; Hutchinson, Douglas K.; Barbachyn, Michael R.; Brickner, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">839-45</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition.  U-100592 {(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} and U-100766 {(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} are novel oxazolidinone analogs from a directed chem. modification program.  MICs were detd. for a variety of bacterial clin. isolates; the resp. MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 μg/mL; methicillin-resistant S. aureus, 4 and 4 μg/mL; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 μg/mL; methicillin-resistant S. epidermidis, 1 and 2 μg/mL; Enterococcus faecalis, 2 and 4 μg/mL; Enterococcus faecium, 2 and 4 μg/mL; Streptococcus pyogenes, 1 and 2 μg/mL; Streptococcus pneumoniae, 0.50 and 1 μg/mL; Corynebacterium spp., 0.50 and 0.50 μg/mL; Moraxella catarrhalis, 4 and 4 μg/mL; Listeria monocytogenes, 8 and 2 μg/mL; and Bacteroides fragilis, 16 and 4 μg/mL.  Most strains of Mycobacterium tuberculosis and the gram-pos. anaerobes were inhibited in the range of 0.50 to 2 μg/mL.  Enterococcal strains resistant to vancomycin (VanA, VanB, and VanC resistance phenotypes), pneumococcal strains resistant to penicillin, and M. tuberculosis strains resistant to common antitubercular agents (isoniazid, streptomycin, rifampin, ethionamide, and ethambutol) were not cross-resistant to the oxazolidinones.  The presence of 10, 20, and 40% pooled human serum did not affect the antibacterial activities of the oxazolidinones.  Time-kill studies demonstrated a bacteriostatic effect of the analogs against staphylococci and enterococci but a bactericidal effect against streptococci.  The spontaneous mutation frequencies of S. aureus ATCC 29213 were <3.8 × 10-10 and <8 × 10-11 for U-100592 and U-100766, resp.  Serial transfer of three staphylococcal and two enterococcal strains on drug gradient plates produced no evidence of rapid resistance development.  Thus, these new oxazolidinone analogs demonstrated in vitro antibacterial activities against a variety of clin. important human pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnq8VHb5v2UrVg90H21EOLACvtfcHk0ljf0UEEZJVcpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVWqs74%253D&md5=772cd4103720083e338e250db8ba9458</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.4.839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.4.839%26sid%3Dliteratum%253Aachs%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DYagi%26aufirst%3DB.%2BH.%26aulast%3DSchaadt%26aufirst%3DR.%2BD.%26aulast%3DAllison%26aufirst%3DJ.%2BW.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26atitle%3DIn%2520vitro%2520activities%2520of%2520U-100592%2520and%2520U-100766%252C%2520novel%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D839%26epage%3D845%26doi%3D10.1128%2FAAC.40.4.839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boger, W. P.</span></span> <span> </span><span class="NLM_article-title">Sulfaphenazol (orisul), a long-acting antibacterial sulfonamide</span>. <i>J. Am. Geriatr. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1111/j.1532-5415.1959.tb01072.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fj.1532-5415.1959.tb01072.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=13640890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaF3cXmvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1959&pages=314-321&author=W.+P.+Boger&title=Sulfaphenazol+%28orisul%29%2C+a+long-acting+antibacterial+sulfonamide&doi=10.1111%2Fj.1532-5415.1959.tb01072.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfaphenazol, a long-acting antibacterial sulfonamide</span></div><div class="casAuthors">Boger, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314-21</span>CODEN:
                <span class="NLM_cas:coden">JAGSAF</span>;
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    </div><div class="casAbstract">In 9 subjects a single oral dose of 2.0 g. N1-(phenylpyrazolyl)sulfanilamide gave peak plasma levels (free + conjugated) of 17.2 mg./100 ml. at 6 hrs.  After similar doses of sulfamethoxypyridazine and sulfisoxazole max. concns. of 23.9 and 20.4, resp., were reached at 4 hrs.  Ranges of the conjugated form of the 3 drugs in plasma were 12-16, 8-20, and 13-34%, resp.  In 38 patients receiving the 1st compd., no evidence was found that it diffused into cerebrospinal fluid, despite high blood concns.  Approx. 21% of the administered dose was recovered in urine within 8 hrs. and 30% of it in the conjugated form.  For the other 2 drugs 8-hr. urinary excretions were 10 and 53%, with 50 and 24%, resp., being in the conjugated form.  The av. clearance of free sulfaphenazol was between 1.03 and 1.79 ml./min.  It did not show any evidence of toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIpWGok55p17Vg90H21EOLACvtfcHk0ljfBkrCKxgP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXmvFyisQ%253D%253D&md5=cfe85fdc228e74bab824d2ffe16529f5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1532-5415.1959.tb01072.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1532-5415.1959.tb01072.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoger%26aufirst%3DW.%2BP.%26atitle%3DSulfaphenazol%2520%2528orisul%2529%252C%2520a%2520long-acting%2520antibacterial%2520sulfonamide%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D1959%26volume%3D7%26spage%3D314%26epage%3D321%26doi%3D10.1111%2Fj.1532-5415.1959.tb01072.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of novel oxazolidinone analogs and 13 conventional antimicrobial agents against clinical isolates of Staphylococcus aureus in Beijing, China</span>. <i>Jpn. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.7883/yoken.67.402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.7883%2Fyoken.67.402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25241696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVynt7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=402-404&author=H.+Leiauthor=Y.+Jiangauthor=D.+Wangauthor=P.+Gongauthor=Y.+Liauthor=Y.+Dongauthor=M.+Dong&title=In+vitro+activity+of+novel+oxazolidinone+analogs+and+13+conventional+antimicrobial+agents+against+clinical+isolates+of+Staphylococcus+aureus+in+Beijing%2C+China&doi=10.7883%2Fyoken.67.402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of novel oxazolidinone analogs and 13 conventional antimicrobial agents against clinical isolates of Staphylococcus aureus in Beijing, China</span></div><div class="casAuthors">Lei, Hong; Jiang, Ying; Wang, Di; Gong, Ping; Li, Yanyan; Dong, Yueming; Dong, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">402-404</span>CODEN:
                <span class="NLM_cas:coden">JJIDFE</span>;
        ISSN:<span class="NLM_cas:issn">1344-6304</span>.
    
            (<span class="NLM_cas:orgname">National Institute of Infectious Diseases</span>)
        </div><div class="casAbstract">Methicillin-resistant Staphylococcus aureus (MRSA) has been a public health concern since it was first identified in the United Kingdom in 1961.  In this study, we investigated the prevalence of MRSA in the PLA 309 Hospital located in Beijing, China, and we detd. the susceptibility of S. aureus to novel oxazolidinone analogs and 13 conventional antimicrobial agents.  It was shown that drug resistant patterns were severe among the clin. isolates, and the av. rate of MRSA among the S. aureus strains was 56.3z.  All the S. aureus strains tested were completely susceptible to linezolid, but the min. inhibitory concn. distribution drifted upwards.  Among the novel oxazolidinone analogs, sy142 exhibited more potent antimicrobial activity than linezolid against both the std. and clin. S. aureus strains.  This observation provides an impetus for the development of potential novel agents based on sy142 in the near future to combat MRSA and linezolid-resistant S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnCTecrk8YtrVg90H21EOLACvtfcHk0ljfBkrCKxgP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVynt7jE&md5=adc9f1f9f3d764c1f1379c78b09ba7cc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.7883%2Fyoken.67.402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7883%252Fyoken.67.402%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520activity%2520of%2520novel%2520oxazolidinone%2520analogs%2520and%252013%2520conventional%2520antimicrobial%2520agents%2520against%2520clinical%2520isolates%2520of%2520Staphylococcus%2520aureus%2520in%2520Beijing%252C%2520China%26jtitle%3DJpn.%2520J.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D67%26spage%3D402%26epage%3D404%26doi%3D10.7883%2Fyoken.67.402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidmar, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1128/AAC.41.10.2127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.41.10.2127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9333036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Snsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=2127-2131&author=A.+H.+Linauthor=R.+W.+Murrayauthor=T.+J.+Vidmarauthor=K.+R.+Marotti&title=The+oxazolidinone+eperezolid+binds+to+the+50S+ribosomal+subunit+and+competes+with+binding+of+chloramphenicol+and+lincomycin&doi=10.1128%2FAAC.41.10.2127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin</span></div><div class="casAuthors">Lin, Alice H.; Murray, Robert W.; Vidmar, Thomas J.; Marotti, Keith R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2131</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones are a novel class of antibiotics that act by inhibiting protein synthesis.  It as been reported that the drug exerts its primary activity on the initiation phase of translation.  In order to study the possibility of direct interaction between the drug and the ribosome, the authors have developed a binding assay using 14C-labeled eperezolid (PNU-100592; formerly U-100592).  Eperezolid binds specifically to the 50S ribosomal subunit of Escherichia coli.  The specific binding of eperezolid is dose dependent and is proportional to the ribosome concns.  Scatchard anal. of the binding data reveals that the dissocn. const. (Kd) is about 20 μM.  The binding of eperezolid to the ribosome is competitively inhibited by chloramphenicol and lincomycin.  However, unlike chloramphenicol and lincomycin, eperezolid does not inhibit the puromycin reaction, indicating that the oxazolidinones have no effect on peptidyl transferase.  In addn., whereas lincomycin and, to some extent, chloramphenicol inhibit translation termination, eperezolid has no effect.  Therefore, it is concluded that the oxazolidinones inhibit protein synthesis by binding to the 50S ribosomal subunit at a site close to the site(s) to which chloramphenicol and lincomycin bind but that the oxazolidinones are mechanistically distinct from these two antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdNVfxAmkfbVg90H21EOLACvtfcHk0ljfBkrCKxgP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Snsr8%253D&md5=d1018ceacedb23aa1c7110743d348bf9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.41.10.2127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.41.10.2127%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DA.%2BH.%26aulast%3DMurray%26aufirst%3DR.%2BW.%26aulast%3DVidmar%26aufirst%3DT.%2BJ.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26atitle%3DThe%2520oxazolidinone%2520eperezolid%2520binds%2520to%2520the%252050S%2520ribosomal%2520subunit%2520and%2520competes%2520with%2520binding%2520of%2520chloramphenicol%2520and%2520lincomycin%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D2127%26epage%3D2131%26doi%3D10.1128%2FAAC.41.10.2127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganoza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D. L.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3251</span>– <span class="NLM_lpage">3255</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.12.3251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.42.12.3251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9835522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3251-3255&author=S.+M.+Swaneyauthor=H.+Aokiauthor=M.+C.+Ganozaauthor=D.+L.+Shinabarger&title=The+oxazolidinone+linezolid+inhibits+initiation+of+protein+synthesis+in+bacteria&doi=10.1128%2FAAC.42.12.3251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria</span></div><div class="casAuthors">Swaney, Steve M.; Aoki, Hiroyuki; Ganoza, M. Clelia; Shinabarger, Dean L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3251-3255</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones represent a new class of antimicrobial agents which are active against multidrug-resistant staphylococci, streptococci, and enterococci.  Previous studies have demonstrated that oxazolidinones inhibit bacterial translation in vitro at a step preceding elongation but after the charging of N-formylmethionine to the initiator tRNA mol.  The event that occurs between these two steps is termed initiation.  Initiation of protein synthesis requires the simultaneous presence of N-formylmethionine-tRNA, the 30S ribosomal subunit, mRNA, GTP, and the initiation factors IF1, IF2, and IF3.  An initiation complex assay measuring the binding of [3H]N-formylmethionyl-tRNA to ribosomes in response to mRNA binding was used in order to investigate the mechanism of oxazolidinone action.  Linezolid inhibited initiation complex formation with either the 30S or the 70S ribosomal subunits from Escherichia coli.  In addn., complex formation with Staphylococcus aureus 70S tight-couple ribosomes was inhibited by linezolid.  Linezolid did not inhibit the independent binding of either mRNA or N-formylmethionyl-tRNA to E. coli 30S ribosomal subunits, nor did it prevent the formation of the IF2-N-formylmethionyl-tRNA binary complex.  The results demonstrate that oxazolidinones inhibit the formation of the initiation complex in bacterial translation systems by preventing formation of the N-formylmethionyl-tRNA-ribosome-mRNA ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7APXXFOUkbVg90H21EOLACvtfcHk0li0DU2CKJE_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOqt7c%253D&md5=f5d7848e6074f7a178cda7b54eded6f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.12.3251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.12.3251%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DAoki%26aufirst%3DH.%26aulast%3DGanoza%26aufirst%3DM.%2BC.%26aulast%3DShinabarger%26aufirst%3DD.%2BL.%26atitle%3DThe%2520oxazolidinone%2520linezolid%2520inhibits%2520initiation%2520of%2520protein%2520synthesis%2520in%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3251%26epage%3D3255%26doi%3D10.1128%2FAAC.42.12.3251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockman, B. J.</span></span> <span> </span><span class="NLM_article-title">1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.3.625-629.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.46.3.625-629.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11850240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVKht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=625-629&author=C.+C.+Zhouauthor=S.+M.+Swaneyauthor=D.+L.+Shinabargerauthor=B.+J.+Stockman&title=1H+nuclear+magnetic+resonance+study+of+oxazolidinone+binding+to+bacterial+ribosomes&doi=10.1128%2FAAC.46.3.625-629.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes</span></div><div class="casAuthors">Zhou, Casey Chun; Swaney, Steven M.; Shinabarger, Dean L.; Stockman, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-629</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones are a novel class of antibiotics that inhibit initiation of protein synthesis in bacteria.  In order to investigate their novel mechanism of action, the interactions of several oxazolidinones with bacterial 70S ribosomes, 50S subunits, and 30S subunits have been characterized by 1H NMR line-broadening analyses and transferred nuclear Overhauser enhancement (TRNOE) expts.  PNU-177553 and PNU-100592 (eperezolid) and their corresponding enantiomers, PNU-184414 and PNU-107112, were studied.  The dissocn. consts. were detd. to be 94±44 μM and 195±40 μM for PNU-177553 and eperezolid, resp.  There was a ∼4-fold decrease in affinity for their corresponding enantiomers.  The NMR-derived dissocn. consts. are consistent with their antibacterial activity.  PNU-177553 and eperezolid were found to bind only to the 50S subunit, with similar affinity as to the 70S ribosome, and to have no affinity for the 30S subunit.  Specific binding of PNU-177553 was further confirmed in TRNOE expts. in which pos. NOEs obsd. for the small mol. alone were changed to neg. NOEs in the presence of bacterial 70S ribosomes.  The obsd. NOEs indicated that PNU-177553 did not adopt a significantly different conformation when bound to the 70S ribosome, compared to the extended conformation that exists when free in soln.  Since this is likeliest the case for each of the four compds. included in this study, the A ring C5 side chain may be positioned in the proper orientation for antibacterial activity in PNU-177553 and eperezolid but not in their inactive enantiomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBSW3ou9t1P7Vg90H21EOLACvtfcHk0li0DU2CKJE_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVKht7g%253D&md5=39813208b8dfc2597741d7e8324bcba8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.3.625-629.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.3.625-629.2002%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DShinabarger%26aufirst%3DD.%2BL.%26aulast%3DStockman%26aufirst%3DB.%2BJ.%26atitle%3D1H%2520nuclear%2520magnetic%2520resonance%2520study%2520of%2520oxazolidinone%2520binding%2520to%2520bacterial%2520ribosomes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D625%26epage%3D629%26doi%3D10.1128%2FAAC.46.3.625-629.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M. H.</span></span> <span> </span><span class="NLM_article-title">Update on linezolid: the first oxazolidinone antibiotic</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1517/14656566.6.13.2315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1517%2F14656566.6.13.2315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16218891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2315-26&author=M.+H.+Wilcox&title=Update+on+linezolid%3A+the+first+oxazolidinone+antibiotic&doi=10.1517%2F14656566.6.13.2315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Update on linezolid: the first oxazolidinone antibiotic</span></div><div class="casAuthors">Wilcox, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2315-2326</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Linezolid is the first of an entirely new class of antibiotics, the oxazolidinones, in decades.  It has a spectrum of activity against virtually all important Gram-pos. pathogens.  The unique mechanism of action of linezolid makes cross-resistance with other antimicrobial agents unlikely.  Linezolid has both i.v. and oral formulations and the latter is 100% bioavailable.  Since its first approval and marketing in Mar. 2000 in the US, linezolid has gained approval for use in many other countries for the treatment of community-acquired and nosocomial pneumonia, complicated and uncomplicated skin and soft-tissue infections, and infections caused by methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, including cases with concurrent bacteremia.  Several earlier comprehensive reviews summarised the chem., mechanism of action, pharmacokinetics, clin. efficacy and safety profile of linezolid.  The present review provides an update on the latest data regarding the antimicrobial activity of linezolid vs. other commonly used agents, the clin. and health-economic outcomes of linezolid vs. vancomycin and teicoplanin, and safety issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS883zstYuHrVg90H21EOLACvtfcHk0ljs7I7eUzXxCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbvI&md5=aad1b478428b9c22bf04ac18845f74b7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.13.2315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.13.2315%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DM.%2BH.%26atitle%3DUpdate%2520on%2520linezolid%253A%2520the%2520first%2520oxazolidinone%2520antibiotic%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2315%26epage%3D26%26doi%3D10.1517%2F14656566.6.13.2315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampiris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batts, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, B.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1086/340353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F340353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12015695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFamtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=1481-1490&author=D.+L.+Stevensauthor=D.+Herrauthor=H.+Lampirisauthor=J.+L.+Huntauthor=D.+H.+Battsauthor=B.+Hafkin&title=Linezolid+versus+vancomycin+for+the+treatment+of+methicillin-resistant+Staphylococcus+aureus+infections&doi=10.1086%2F340353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections</span></div><div class="casAuthors">Stevens, Dennis L.; Herr, Daniel; Lampiris, Harry; Hunt, John Lee; Batts, Donald H.; Hafkin, Barry</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-1490</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-pos. bacteria, including drug-resistant strains.  In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n = 240) or vancomycin (1 g twice daily; n = 220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA.  Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection.  At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clin. cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiol. success rates (58.9% in the linezolid group and 63.2% in the vancomycin group).  Both regimens were well tolerated, with similar rates of adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IbjTJICYhbVg90H21EOLACvtfcHk0ljs7I7eUzXxCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFamtrk%253D&md5=eac34e7cb0bc1598026918055d68bd02</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1086%2F340353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F340353%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DD.%2BL.%26aulast%3DHerr%26aufirst%3DD.%26aulast%3DLampiris%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DJ.%2BL.%26aulast%3DBatts%26aufirst%3DD.%2BH.%26aulast%3DHafkin%26aufirst%3DB.%26atitle%3DLinezolid%2520versus%2520vancomycin%2520for%2520the%2520treatment%2520of%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520infections%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2002%26volume%3D34%26spage%3D1481%26epage%3D1490%26doi%3D10.1086%2F340353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. J.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus vancomycin for skin and soft tissue infections</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">CD008056</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD008056.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2F14651858.CD008056.pub3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26758498" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=CD008056&author=J.+Yueauthor=B.+R.+Dongauthor=M.+Yangauthor=X.+Chenauthor=T.+Wuauthor=G.+J.+Liu&title=Linezolid+versus+vancomycin+for+skin+and+soft+tissue+infections&doi=10.1002%2F14651858.CD008056.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD008056.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD008056.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DB.%2BR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DG.%2BJ.%26atitle%3DLinezolid%2520versus%2520vancomycin%2520for%2520skin%2520and%2520soft%2520tissue%2520infections%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26spage%3DCD008056%26doi%3D10.1002%2F14651858.CD008056.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliphant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderink, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1086/318486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F318486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11170948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Whur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=402-412&author=E.+Rubinsteinauthor=S.+Cammarataauthor=T.+Oliphantauthor=R.+Wunderink&title=Linezolid+%28PNU-100766%29+versus+vancomycin+in+the+treatment+of+hospitalized+patients+with+nosocomial+pneumonia%3A+a+randomized%2C+double-blind%2C+multicenter+study&doi=10.1086%2F318486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study</span></div><div class="casAuthors">Rubinstein, Ethan; Cammarata, Sue K.; Oliphant, Thomas H.; Wunderink, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-412</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linezolid, the first oxazolidinone, is active against gram-pos. bacteria, including multidrug-resistant strains.  This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia.  A total of 203 patients received i.v. linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g i.v. twice daily, plus aztreonam for 7-21 days.  Clin. and microbiol. outcomes were evaluated at test of cure 12-28 days after treatment.  Clin. cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiol. success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, resp.) for evaluable patients were equiv. between treatment groups.  Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups.  Resistance to either treatment was not detected.  Linezolid is a well-tolerated, effective treatment for adults with gram-pos. nosocomial pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9r4oDwHfyM7Vg90H21EOLACvtfcHk0ljs7I7eUzXxCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Whur0%253D&md5=87c2552d05e938a67225778f4908073b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1086%2F318486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F318486%26sid%3Dliteratum%253Aachs%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DCammarata%26aufirst%3DS.%26aulast%3DOliphant%26aufirst%3DT.%26aulast%3DWunderink%26aufirst%3DR.%26atitle%3DLinezolid%2520%2528PNU-100766%2529%2520versus%2520vancomycin%2520in%2520the%2520treatment%2520of%2520hospitalized%2520patients%2520with%2520nosocomial%2520pneumonia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520multicenter%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D32%26spage%3D402%26epage%3D412%26doi%3D10.1086%2F318486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D. J.</span></span> <span> </span><span class="NLM_article-title">Hematologic effects of linezolid: summary of clinical experience</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2723</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.8.2723-2726.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.46.8.2723-2726.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12121967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFGiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=2723-2726&author=S.+L.+Gersonauthor=S.+L.+Kaplanauthor=J.+B.+Brussauthor=V.+Leauthor=F.+M.+Arellanoauthor=B.+Hafkinauthor=D.+J.+Kuter&title=Hematologic+effects+of+linezolid%3A+summary+of+clinical+experience&doi=10.1128%2FAAC.46.8.2723-2726.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Hematologic effects of linezolid: summary of clinical experience</span></div><div class="casAuthors">Gerson, Stanton L.; Kaplan, Sheldon L.; Bruss, Jon B.; Le, Vu; Arellano, Felix M.; Hafkin, Barry; Kuter, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2723-2726</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Linezolid has been assocd. with reversible myelosuppression.  Clin. trial data were evaluated for anemia, thrombocytopenia, and neutropenia.  Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 wk of linezolid treatment.  Hematol. abnormalities were consistent with mild, reversible, duration-dependent myelosuppression.  Appropriate monitoring is warranted with linezolid use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnT1YIKN07e7Vg90H21EOLACvtfcHk0ljqoaxcv3TIMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFGiu70%253D&md5=4b0a0b10715d1feb8287fb8f4789b8c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.8.2723-2726.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.8.2723-2726.2002%26sid%3Dliteratum%253Aachs%26aulast%3DGerson%26aufirst%3DS.%2BL.%26aulast%3DKaplan%26aufirst%3DS.%2BL.%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DArellano%26aufirst%3DF.%2BM.%26aulast%3DHafkin%26aufirst%3DB.%26aulast%3DKuter%26aufirst%3DD.%2BJ.%26atitle%3DHematologic%2520effects%2520of%2520linezolid%253A%2520summary%2520of%2520clinical%2520experience%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D2723%26epage%3D2726%26doi%3D10.1128%2FAAC.46.8.2723-2726.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, G.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of linezolid</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">Suppl 2</span>), <span class="NLM_elocation-id">45ii</span> <span class="refDoi"> DOI: 10.1093/jac/dkg253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkg253" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&issue=Suppl+2&author=G.+French&title=Safety+and+tolerability+of+linezolid&doi=10.1093%2Fjac%2Fdkg253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg253%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DG.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520linezolid%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3DSuppl%25202%26doi%3D10.1093%2Fjac%2Fdkg253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manninen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulanowicz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmon, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1021/jm9509556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9509556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=673-679&author=S.+J.+Bricknerauthor=D.+K.+Hutchinsonauthor=M.+R.+Barbachynauthor=P.+R.+Manninenauthor=D.+A.+Ulanowiczauthor=S.+A.+Garmonauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Synthesis+and+antibacterial+activity+of+U-100592+and+U-100766%2C+two+oxazolidinone+antibacterial+agents+for+the+potential+treatment+of+multidrug-resistant+gram-positive+bacterial+infections&doi=10.1021%2Fjm9509556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections</span></div><div class="casAuthors">Brickner, Steven J.; Hutchinson, Douglas K.; Barbachyn, Michael R.; Manninen, Peter R.; Ulanowicz, Debra A.; Garmon, Stuart A.; Grega, Kevin C.; Hendges, Susan K.; Toops, Dana S.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bacterial resistance development has become a very serious clin. problem for many classes of antibiotics.  The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis.  Two potent, synthetic oxazolidinones, U-100592 [i.e., (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] and U-100766 [i.e., (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] were prepd., which are currently in clin. development for the treatment of serious multidrug-resistant Gram-pos. bacterial infections caused by strains of staphylococci, streptococci, and enterococci.  The in vitro and in vivo (po and i.v.) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin.  U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis.  A novel and practical asym. synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones was developed and was employed for the synthesis of U-100592 and U-100766.  This involved the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMNrR9x9ErrVg90H21EOLACvtfcHk0ljqoaxcv3TIMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisA%253D%253D&md5=fe1733b71f4953ec67853fe4284a33ac</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm9509556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9509556%26sid%3Dliteratum%253Aachs%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DUlanowicz%26aufirst%3DD.%2BA.%26aulast%3DGarmon%26aufirst%3DS.%2BA.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520U-100592%2520and%2520U-100766%252C%2520two%2520oxazolidinone%2520antibacterial%2520agents%2520for%2520the%2520potential%2520treatment%2520of%2520multidrug-resistant%2520gram-positive%2520bacterial%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D673%26epage%3D679%26doi%3D10.1021%2Fjm9509556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madaras-Kelly, K.</span></span> <span> </span><span class="NLM_article-title">A review of linezolid: the first oxazolidinone antibiotic</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1586/14787210.2.1.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1586%2F14787210.2.1.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15482171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=51-59&author=D.+L.+Stevensauthor=B.+Dotterauthor=K.+Madaras-Kelly&title=A+review+of+linezolid%3A+the+first+oxazolidinone+antibiotic&doi=10.1586%2F14787210.2.1.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A review of linezolid: the first oxazolidinone antibiotic</span></div><div class="casAuthors">Stevens, Dennis L.; Dotter, Brian; Madaras-Kelly, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Resistance of Gram-pos. bacterial pathogens, such as Staphylococcus aureus and Enterococcus faecium, to existing antibiotics continues to increase, and new antibiotics with activity against these pathogens are in demand.  Linezolid (Zyvox, Pharmacia and Upjohn) is the first agent of a new class of antibiotics called the oxazolidinones.  Linezolid possesses excellent microbial activity against a wide variety of Gram-pos. pathogens including those resistant to methicillin and vancomycin (Vancocin, Eli Lilly).  Linezolid is available for i.v. and oral administration and possesses excellent bioavailability.  It exhibits good penetration into pulmonary, as well as skin and related structure tissues, and does not require dosage adjustment in hepatic or renal dysfunction.  Linezolid is generally well-tolerated, with the predominant adverse effect manifesting as a duration dependent, reversible thrombocytopenia.  Linezolid possesses monoamine oxidase inhibitor activity and caution is warranted with coadministration of adrenergic or serotonergic medications.  Clin. trials conducted with linezolid in skin and structure infections, lower respiratory tract infections and vancomycin-resistant enterococcal infections demonstrate that linezolid is an effective therapy.  Recent data suggest that linezolid may be superior to vancomycin for the treatment of infections caused by methicillin-resistant S. aureus.  Linezolid is an excellent and promising new antibiotic for the treatment of resistant Gram-pos. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7oEdTlj5Q3rVg90H21EOLACvtfcHk0ljVNGNqOfadYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFCqsbw%253D&md5=985d26f3e42a6143858b0b902db649cc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2F14787210.2.1.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.2.1.51%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DD.%2BL.%26aulast%3DDotter%26aufirst%3DB.%26aulast%3DMadaras-Kelly%26aufirst%3DK.%26atitle%3DA%2520review%2520of%2520linezolid%253A%2520the%2520first%2520oxazolidinone%2520antibiotic%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2004%26volume%3D2%26spage%3D51%26epage%3D59%26doi%3D10.1586%2F14787210.2.1.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, K.</span></span> <span> </span><span class="NLM_article-title">Clinical update on linezolid in the treatment of Gram-positive bacterial infections</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.2147/IDR.S25890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2147%2FIDR.S25890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22787406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVakurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=87-102&author=S.+Agerauthor=K.+Gould&title=Clinical+update+on+linezolid+in+the+treatment+of+Gram-positive+bacterial+infections&doi=10.2147%2FIDR.S25890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical update on linezolid in the treatment of Gram-positive bacterial infections</span></div><div class="casAuthors">Ager, Sally; Gould, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87-102</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Gram-pos. pathogens are a significant cause of morbidity and mortality in both community and health care settings.  Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-pos. pathogens but there are problems with their use, including the emergence of glycopeptide-resistant strains, tissue penetration and achieving and monitoring adequate serum levels.  Newer antibiotics such as linezolid, a synthetic oxazolidinone, are available for the treatment of resistant Gram-pos. bacteria.  Linezolid is active against a wide range of Gram-pos. bacteria and has been generally available for the treatment of Gram-pos. infections since 2000.  There are potential problems with linezolid use, including its bacteriostatic action and the relatively high incidence of reported adverse effects, particularly with long-term use.  Long-term use may also be complicated by the development of resistance.  However, linezolid has been shown to be clin. useful in the treatment of several serious infections where traditionally bacteriocidal agents have been required and many of its adverse effects are reversible on cessation.  It has also been shown to be a cost-effective treatment option in several studies, with its high oral bioavailability allowing an early change from i.v. to oral formulations with consequent earlier patient discharge and lower inpatient costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gZNul36oJ7Vg90H21EOLACvtfcHk0ljVNGNqOfadYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVakurzE&md5=a8209a0f4421280292d2cd1762857577</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2147%2FIDR.S25890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S25890%26sid%3Dliteratum%253Aachs%26aulast%3DAger%26aufirst%3DS.%26aulast%3DGould%26aufirst%3DK.%26atitle%3DClinical%2520update%2520on%2520linezolid%2520in%2520the%2520treatment%2520of%2520Gram-positive%2520bacterial%2520infections%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2012%26volume%3D5%26spage%3D87%26epage%3D102%26doi%3D10.2147%2FIDR.S25890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howden, B. P.</span></span> <span> </span><span class="NLM_article-title">What’s new in the treatment of serious MRSA infection?</span>. <i>Curr. Opin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1097/QCO.0000000000000101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1097%2FQCO.0000000000000101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25211361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=471-478&author=N.+E.+Holmesauthor=B.+P.+Howden&title=What%E2%80%99s+new+in+the+treatment+of+serious+MRSA+infection%3F&doi=10.1097%2FQCO.0000000000000101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">What's new in the treatment of serious MRSA infection?</span></div><div class="casAuthors">Holmes, Natasha E.; Howden, Benjamin P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">471-478</span>CODEN:
                <span class="NLM_cas:coden">COIDE5</span>;
        ISSN:<span class="NLM_cas:issn">0951-7375</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections.  This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance.  Recent findings: Elevations in the vancomycin min. inhibitory concn. within the susceptible range are assocd. with treatment failure and mortality in the treatment of MRSA infections.  Ceftaroline and ceftobiprole are anti-MRSA cephalosporins and are noninferior to comparator agents in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia.  Tedizolid is more potent than linezolid, has improved pharmacokinetics and reduced toxicity and is active against cfr-contg. S. aureus.  Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. aureus bacteremia.  Dalbavancin and oritavancin are administered once weekly and are noninferior to comparators for acute bacterial skin and skin structure infections.  Resistance has emerged against many new anti-MRSA antimicrobials including ceftaroline.  Combination therapy of β-lactams with vancomycin or daptomycin is increasing.  Summary: Several new MRSA-active agents are now approved for use, although much of the data is derived from treatment of acute bacterial skin and skin structure infections or pneumonia.  Further studies are required for more invasive infections, such as bacteremia and endocarditis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXib3GRCQHqbVg90H21EOLACvtfcHk0ljVNGNqOfadYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsL3N&md5=5e89d932f3618b2055c55abaf2b531d3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FQCO.0000000000000101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0000000000000101%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DN.%2BE.%26aulast%3DHowden%26aufirst%3DB.%2BP.%26atitle%3DWhat%25E2%2580%2599s%2520new%2520in%2520the%2520treatment%2520of%2520serious%2520MRSA%2520infection%253F%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D27%26spage%3D471%26epage%3D478%26doi%3D10.1097%2FQCO.0000000000000101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slatter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feenstra, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welshman, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagerness, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryd, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shobe, E. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11454733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVChtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1136-1145&author=J.+G.+Slatterauthor=D.+J.+Stalkerauthor=K.+L.+Feenstraauthor=I.+R.+Welshmanauthor=J.+B.+Brussauthor=J.+P.+Samsauthor=M.+G.+Johnsonauthor=P.+E.+Sandersauthor=M.+J.+Hauerauthor=P.+E.+Fagernessauthor=R.+P.+Strydauthor=G.+W.+Pengauthor=E.+M.+Shobe&title=Pharmacokinetics%2C+metabolism%2C+and+excretion+of+linezolid+following+an+oral+dose+of+%5B%2814%29C%5Dlinezolid+to+healthy+human+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects</span></div><div class="casAuthors">Slatter, J. G.; Stalker, D. J.; Feenstra, K. L.; Welshman, I. R.; Bruss, J. B.; Sams, J. P.; Johnson, M. G.; Sanders, P. E.; Hauer, M. J.; Fagerness, P. E.; Stryd, R. P.; Peng, G. W.; Shobe, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1136-1145</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The disposition of the oxazolidinone antibiotic linezolid (Zyvox) in human volunteers was detd., after a 500-mg oral dose of [14C]linezolid.  Radioactive linezolid was administered as a single dose or at steady-state on day 4 of a 10-day, 500-mg twice-daily regimen of unlabeled linezolid.  Mean recovery of radioactivity in excreta was 93.8%, of which 83.9% was in urine and 9.9% was in feces.  There was no major difference in rate or route of excretion of radioactivity caused by the dose regimen.  Linezolid was excreted primarily intact and as two inactive, morpholine-ring-oxidized metabolites, PNU-142586 and PNU-142300.  Other minor metabolites were characterized by HPLC-atm. pressure chem. ionization-mass spectrometry and [19F]NMR spectroscopy.  After the single radioactive dose, linezolid was the major circulating drug-related material, accounting for about 78% (in males) and 93% (in females) of the radioactivity area under the curve (AUC).  PNU-142586 (Tmax of 3-5 h) accounted for about 26% (males) and 9% (females) of the radioactivity AUC.  PNU-142300 (Tmax of 2-3 h) accounted for about 7% (males) and 4% (females) of the radioactivity AUC.  Overall, mean linezolid and PNU-142586 exposures at steady-state were similar in both sexes.  In conclusion, linezolid circulates in plasma mainly as parent drug.  Linezolid and two major, inactive metabolites account for the major portion of linezolid disposition, with urinary excretion representing the major elimination route.  Formation of PNU-142586 was the rate-limiting step in the clearance of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGrHg0Kl2fu7Vg90H21EOLACvtfcHk0ljVNGNqOfadYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVChtb8%253D&md5=9291be327bfc7dca0dfd5266def6613a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSlatter%26aufirst%3DJ.%2BG.%26aulast%3DStalker%26aufirst%3DD.%2BJ.%26aulast%3DFeenstra%26aufirst%3DK.%2BL.%26aulast%3DWelshman%26aufirst%3DI.%2BR.%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26aulast%3DSams%26aufirst%3DJ.%2BP.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DSanders%26aufirst%3DP.%2BE.%26aulast%3DHauer%26aufirst%3DM.%2BJ.%26aulast%3DFagerness%26aufirst%3DP.%2BE.%26aulast%3DStryd%26aufirst%3DR.%2BP.%26aulast%3DPeng%26aufirst%3DG.%2BW.%26aulast%3DShobe%26aufirst%3DE.%2BM.%26atitle%3DPharmacokinetics%252C%2520metabolism%252C%2520and%2520excretion%2520of%2520linezolid%2520following%2520an%2520oral%2520dose%2520of%2520%255B%252814%2529C%255Dlinezolid%2520to%2520healthy%2520human%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1136%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Linezolid: a review of safety and tolerability</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">S59</span>– <span class="NLM_lpage">S74</span>, <span class="refDoi"> DOI: 10.1016/S0163-4453(09)60009-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0163-4453%2809%2960009-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19766891" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=S59-S74&issue=Suppl+1&author=D.+C.+Vinhauthor=E.+Rubinstein&title=Linezolid%3A+a+review+of+safety+and+tolerability&doi=10.1016%2FS0163-4453%2809%2960009-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0163-4453%2809%2960009-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-4453%252809%252960009-8%26sid%3Dliteratum%253Aachs%26aulast%3DVinh%26aufirst%3DD.%2BC.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DLinezolid%253A%2520a%2520review%2520of%2520safety%2520and%2520tolerability%26jtitle%3DJ.%2520Infect.%26date%3D2009%26volume%3D59%26issue%3DSuppl%25201%26spage%3DS59%26epage%3DS74%26doi%3D10.1016%2FS0163-4453%2809%2960009-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottagnoud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottagnoud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neftel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Täuber, M. G.</span></span> <span> </span><span class="NLM_article-title">Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1093/jac/46.6.981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2F46.6.981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11102418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlKg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2000&pages=981-985&author=P.+Cottagnoudauthor=C.+M.+Gerberauthor=F.+Acostaauthor=M.+Cottagnoudauthor=K.+Neftelauthor=M.+G.+T%C3%A4uber&title=Linezolid+against+penicillin-sensitive+and+-resistant+pneumococci+in+the+rabbit+meningitis+model&doi=10.1093%2Fjac%2F46.6.981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model</span></div><div class="casAuthors">Cottagnoud, Philippe; Gerber, Cynthia M.; Acosta, F.; Cottagnoud, Marianne; Neftel, Klaus; Tauber, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">981-985</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Linezolid, a new oxazolidinone antibiotic, showed good penetration (38±4%) into the meninges of rabbits with levels in the CSF ranging from 9.5 to 1.8 mg/L after two i.v. injections (20 mg/kg).  Linezolid was clearly less effective than ceftriaxone against a penicillin-sensitive pneumococcal strain.  Against a penicillin-resistant strain, linezolid had slightly inferior killing rates compared with the std. regimen (ceftriaxone combined with vancomycin).  In vitro, linezolid was marginally bactericidal at concns. above the MIC (5 × and 10 × MIC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbuuKNSlUJw7Vg90H21EOLACvtfcHk0ljcrGjT5y95CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlKg&md5=6d53664f489aec9c8faa68ff1ab4119f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F46.6.981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F46.6.981%26sid%3Dliteratum%253Aachs%26aulast%3DCottagnoud%26aufirst%3DP.%26aulast%3DGerber%26aufirst%3DC.%2BM.%26aulast%3DAcosta%26aufirst%3DF.%26aulast%3DCottagnoud%26aufirst%3DM.%26aulast%3DNeftel%26aufirst%3DK.%26aulast%3DT%25C3%25A4uber%26aufirst%3DM.%2BG.%26atitle%3DLinezolid%2520against%2520penicillin-sensitive%2520and%2520-resistant%2520pneumococci%2520in%2520the%2520rabbit%2520meningitis%2520model%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2000%26volume%3D46%26spage%3D981%26epage%3D985%26doi%3D10.1093%2Fjac%2F46.6.981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodo, F.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds</span>. <i>Infez. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16220032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BD2s3gsV2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=112-119&author=S.+Sabbataniauthor=R.+Manfrediauthor=G.+Frankauthor=F.+Chiodo&title=Linezolid+in+the+treatment+of+severe+central+nervous+system+infections+resistant+to+recommended+antimicrobial+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds</span></div><div class="casAuthors">Sabbatani Sergio; Manfredi Roberto; Frank Giorgio; Chiodo Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Le infezioni in medicina</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-9</span>
        ISSN:<span class="NLM_cas:issn">1124-9390</span>.
    </div><div class="casAbstract">The progressive emergence of antimicrobial-resistant Gram-positive cocci especially in the setting of surgery and intensive care, recommends particular attention in making sound therapeutic choices to overcome both microbial resistances and haemato-encephalic barriers to effective local drug penetration.  As in other Western countries, the occurrence of methicillin-resistant Staphylococcus aureus is particularly high also in Italy, especially when high-risk patients and/or settings are involved.  In treating post-neurosurgical central nervous system infections (cerebral abscess and meningitis), a key issue is represented by the low cerebrospinal fluid concentration of the two available glycopeptide antibiotics (vancomycin and teicoplanin), usually recommended as first-line therapy of resistant Gram-positive cocci.  Recent findings have focused on the possible role of linezolid, an oxazolidinone antibiotic, as a suitable candidate for the treatment of severe brain infection (abscesses) and post-neurosurgical infection, where treatment options and efficacy are significantly limited by the low glycopeptide transfer and the spread of glycopeptide-resistant bacterial strains.  Three representative case reports (two brain abscesses and one post-surgical meningitis) are presented and discussed in light of the current literature: in all these cases, salvage linezolid treatment proved resolutory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpTvkkPn9Qpcve_zCu79I8fW6udTcc2eaZA7RrtQtLvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3gsV2muw%253D%253D&md5=9c20b3f2144c5318ae017ef77de25829</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatani%26aufirst%3DS.%26aulast%3DManfredi%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DG.%26aulast%3DChiodo%26aufirst%3DF.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520severe%2520central%2520nervous%2520system%2520infections%2520resistant%2520to%2520recommended%2520antimicrobial%2520compounds%26jtitle%3DInfez.%2520Med.%26date%3D2005%26volume%3D13%26spage%3D112%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frasca, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M. G.</span></span> <span> </span><span class="NLM_article-title">Vancomycin-resistant enterococcal meningitis in an autologous stem cell transplant recipient cured with linezolid</span>. <i>Transpl. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">E1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1111/tid.12032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Ftid.12032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23173835" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=E1-4&author=K.+L.+Frascaauthor=M.+G.+Schuster&title=Vancomycin-resistant+enterococcal+meningitis+in+an+autologous+stem+cell+transplant+recipient+cured+with+linezolid&doi=10.1111%2Ftid.12032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Ftid.12032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftid.12032%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DK.%2BL.%26aulast%3DSchuster%26aufirst%3DM.%2BG.%26atitle%3DVancomycin-resistant%2520enterococcal%2520meningitis%2520in%2520an%2520autologous%2520stem%2520cell%2520transplant%2520recipient%2520cured%2520with%2520linezolid%26jtitle%3DTranspl.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D15%26spage%3DE1%26epage%3D4%26doi%3D10.1111%2Ftid.12032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tunkel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheld, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span> <span> </span><span class="NLM_article-title">Practice guidelines for the management of bacterial meningitis</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1267</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1086/425368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F425368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15494903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BD2critlKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=1267-1284&author=A.+R.+Tunkelauthor=B.+J.+Hartmanauthor=S.+L.+Kaplanauthor=B.+A.+Kaufmanauthor=K.+L.+Roosauthor=W.+M.+Scheldauthor=R.+J.+Whitley&title=Practice+guidelines+for+the+management+of+bacterial+meningitis&doi=10.1086%2F425368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Practice guidelines for the management of bacterial meningitis</span></div><div class="casAuthors">Tunkel Allan R; Hartman Barry J; Kaplan Sheldon L; Kaufman Bruce A; Roos Karen L; Scheld W Michael; Whitley Richard J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1267-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwp7OdL6G4pjEwO064Z95rfW6udTcc2ear6iz43xQ0d7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2critlKqtQ%253D%253D&md5=7a01220adf4e15b09c271e0a35251469</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1086%2F425368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F425368%26sid%3Dliteratum%253Aachs%26aulast%3DTunkel%26aufirst%3DA.%2BR.%26aulast%3DHartman%26aufirst%3DB.%2BJ.%26aulast%3DKaplan%26aufirst%3DS.%2BL.%26aulast%3DKaufman%26aufirst%3DB.%2BA.%26aulast%3DRoos%26aufirst%3DK.%2BL.%26aulast%3DScheld%26aufirst%3DW.%2BM.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26atitle%3DPractice%2520guidelines%2520for%2520the%2520management%2520of%2520bacterial%2520meningitis%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2004%26volume%3D39%26spage%3D1267%26epage%3D1284%26doi%3D10.1086%2F425368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3239</span>, <span class="refDoi"> DOI: 10.1128/AAC.00228-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00228-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19528279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3236-3239&author=R.+Schaadtauthor=D.+Sweeneyauthor=D.+Shinabargerauthor=G.+Zurenko&title=In+vitro+activity+of+TR-700%2C+the+active+ingredient+of+the+antibacterial+prodrug+TR-701%2C+a+novel+oxazolidinone+antibacterial+agent&doi=10.1128%2FAAC.00228-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent</span></div><div class="casAuthors">Schaadt, Ronda; Sweeney, Debora; Shinabarger, Dean; Zurenko, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3236-3239</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TR-701 is the prodrug of the microbiol. active mol. TR-700, a novel orally and i.v. administered oxazolidinone antibacterial agent.  The in vitro activity of TR-700 was evaluated against 1,063 bacterial clin. isolates including staphylococci, enterococci, streptococci, Moraxella catarrhalis, Haemophilus influenzae, and a variety of anaerobic bacterial species.  The test strains were recent (2005 to 2008) clin. isolates from diverse U.S. (80%) and non-U.S. (20%) sites.  MIC assays were conducted using ref. broth microdilution and agar diln. methods with the principal comparators linezolid and vancomycin.  TR-700 was four- to eightfold more potent than linezolid against staphylococci and generally fourfold more potent against enterococci and streptococci.  TR-700 was less active against M. catarrhalis and H. influenzae but was twofold more active than linezolid.  Against anaerobic species, the activity of TR-700 was equiv. to or up to fourfold higher than that of linezolid.  These results indicate that TR-700 is a promising new oxazolidinone antibacterial agent with greater in vitro potency than linezolid against clin. important gram-pos. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa6xQcw37Y9rVg90H21EOLACvtfcHk0lhtvXYIiYhSlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1yhtb0%253D&md5=512aa87f81fa9d85d49a376f4fdf561b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.00228-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00228-09%26sid%3Dliteratum%253Aachs%26aulast%3DSchaadt%26aufirst%3DR.%26aulast%3DSweeney%26aufirst%3DD.%26aulast%3DShinabarger%26aufirst%3DD.%26aulast%3DZurenko%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520activity%2520of%2520TR-700%252C%2520the%2520active%2520ingredient%2520of%2520the%2520antibacterial%2520prodrug%2520TR-701%252C%2520a%2520novel%2520oxazolidinone%2520antibacterial%2520agent%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3236%26epage%3D3239%26doi%3D10.1128%2FAAC.00228-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Anda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span> <span> </span><span class="NLM_article-title">Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial</span>. <i>Jama</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1001%2Fjama.2013.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23403680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2013&pages=559-569&author=P.+Prokocimerauthor=C.+De+Andaauthor=E.+Fangauthor=P.+Mehraauthor=A.+Das&title=Tedizolid+phosphate+vs+linezolid+for+treatment+of+acute+bacterial+skin+and+skin+structure+infections%3A+the+ESTABLISH-1+randomized+trial&doi=10.1001%2Fjama.2013.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. The ESTABLISH-1 randomized trial</span></div><div class="casAuthors">Prokocimer, Philippe; De Anda, Carisa; Fang, Edward; Mehra, Purvi; Das, Anita</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-569</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance. Acute bacterial skin and skin structure infections (ABSSSIs), including cellulitis or erysipelas, major cutaneous abscesses, and wound infections, can be life-threatening and may require surgery and hospitalization.  Increasingly, ABSSSIs are assocd. with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use.  Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs.  Objectives. To establish the noninferiority of tedizolid phosphate vs linezolid in treating ABSSSIs and compare the safety of the 2 agents.  Design, Setting, and Patients. The Efficacy and Safety of 6-day Oral Tedizolid in Acute Bacterial Skin and Skin Structure Infections vs 10-day Oral Linezolid Therapy (ESTABLISH-1) was a phase 3, randomized, double-blind, noninferiority trial that was conducted from August 2010 through Sept. 2011 at 81 study centers in North America, Latin America, and Europe.  The intent-to-treat anal. set consisted of data from 667 adults aged 18 years or older with ABSSSIs treated with tedizolid phosphate (n=332) or linezolid (n=335).  Interventions A 200 mg once daily dose of oral tedizolid phosphate for 6 days or 600 mg of oral linezolid every 12 h for 10 days.  Main Outcome Measures The primary efficacy outcome was early clin. response at the 48- to 72-h assessment (no increase in lesion surface area from baseline and oral temp. of <37.6°C, confirmed by a second temp. measurement within 24 h).  A 10% noninferiority margin was predefined.  Results in the intent-to-treat anal. set, the early clin. treatment response rates were 79.5% (95% Cl, 74.8% to 83.7%) of 332 patients in the tedizolid phosphate group and 79.4% (95% Cl, 74.7% to 83.6%) of 335 patients in the linezolid group (a treatment difference of 0.1 % [95% Cl, -6.1% to 6.2%]).  The sustained clin. treatment response rates at the end of treatment (day 11) were 69.3% (95% Cl, 64.0% to 74.2%) in the tedizolid phosphate group and 71.9% (95% Cl, 66.8% to 76.7%) in the linezolid group (a treatment difference of -2.6% [95% Cl, -9.6% to 4.2%]).  Results of investigator-assessed clin. treatment success rates at a posttherapy evaluation visit (1-2 wk after the end-of-treatment visit) were 85.5% (95% Cl, 81.3% to 89.1%) in the tedizolid phosphate group and 86.0% (95% Cl, 81.8% to 89.5%) in the linezolid group (a treatment difference of -0.5% [95% Cl, -5.8% to 4.9%]), and were similar for 178 patients with methicillin-resistant Staphylococcus aureus isolated from the primary lesion.  Conclusions and Relevance Tedizolid phosphate was a statistically noninferior treatment to linezolid in early clin. response at 48 to 72 h after initiating therapy for an ABSSSI.  Tedizolid phosphate may be a reasonable alternative to linezolid for treating ABSSSI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0d40tRm55KbVg90H21EOLACvtfcHk0lhtvXYIiYhSlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVSiurg%253D&md5=160a3d512213dc797931e20314436553</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.241%26sid%3Dliteratum%253Aachs%26aulast%3DProkocimer%26aufirst%3DP.%26aulast%3DDe%2BAnda%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DMehra%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DTedizolid%2520phosphate%2520vs%2520linezolid%2520for%2520treatment%2520of%2520acute%2520bacterial%2520skin%2520and%2520skin%2520structure%2520infections%253A%2520the%2520ESTABLISH-1%2520randomized%2520trial%26jtitle%3DJama%26date%3D2013%26volume%3D309%26spage%3D559%26epage%3D569%26doi%3D10.1001%2Fjama.2013.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moran, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Anda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P.</span></span> <span> </span><span class="NLM_article-title">Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(14)70737-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS1473-3099%2814%2970737-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=24909499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=696-705&author=G.+J.+Moranauthor=E.+Fangauthor=G.+R.+Coreyauthor=A.+F.+Dasauthor=C.+De+Andaauthor=P.+Prokocimer&title=Tedizolid+for+6+days+versus+linezolid+for+10+days+for+acute+bacterial+skin+and+skin-structure+infections+%28ESTABLISH-2%29%3A+a+randomised%2C+double-blind%2C+phase+3%2C+non-inferiority+trial&doi=10.1016%2FS1473-3099%2814%2970737-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial</span></div><div class="casAuthors">Moran, Gregory J.; Fang, Edward; Corey, G. Ralph; Das, Anita F.; De Anda, Carisa; Prokocimer, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">696-705</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New antibiotics are needed to treat infections caused by drug-resistant bacteria.  Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against Gram-pos. pathogens.  We aimed to assess the efficacy and safety of i.v. to oral tedizolid for treatment of patients with acute bacterial skin and skin-structure infections.  ESTABLISH-2 was a randomised, double-blind, phase 3, non-inferiority trial done between Sept 28, 2011, and Jan 10, 2013, at 58 centers in nine countries.  Patients (aged ≥12 years) with acute bacterial skin and skin-structure infections (cellulitis or erysipelas, major cutaneous abscess, or wound infection) that had a min. lesion area of 75 cm2 and were suspected or documented to be assocd. with a Gram-pos. pathogen, were randomly assigned (1:1), via an interactive voice-response system with block randomisation, to receive i.v. once-daily tedizolid (200 mg for 6 days) or twice-daily linezolid (600 mg for 10 days), with optional oral step-down.  Randomisation was stratified by geog. region and type of acute bacterial skin and skin-structure infection.  The primary endpoint was early clin. response (≥20% redn. in lesion area at 48-72 h compared with baseline), with a non-inferiority margin of -10%.  Anal. was by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT01421511.666 patients were randomly assigned to receive tedizolid (n=332) or linezolid (n=334). 283 (85%) patients in the tedizolid group and 276 (83%) in the linezolid group achieved early clin. response (difference 2·6%, 95% CI -3·0 to 8·2), meeting the prespecified non-inferiority margin.  Gastrointestinal adverse events were less frequent with tedizolid than linezolid, taking place in 52 (16%) of 331 patients and 67 (20%) of 327 patients in the safety population.  Treatment-emergent adverse events leading to discontinuation of study drug were reported by one (<1%) patient in the tedizolid group and four (1%) patients in the linezolid group.  I.v. to oral once-daily tedizolid 200 mg for 6 days was non-inferior to twice-daily linezolid 600 mg for 10 days for treatment of patients with acute bacterial skin and skin-structure infections.  Tedizolid could become a useful option for the treatment of acute bacterial skin and skin-structure infections in the hospital and outpatient settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejt1Zi_NmlrVg90H21EOLACvtfcHk0li0jbrdhfPYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrs7bK&md5=70ead6ed25db678eeec65a6d7e00f151</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2814%2970737-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252814%252970737-6%26sid%3Dliteratum%253Aachs%26aulast%3DMoran%26aufirst%3DG.%2BJ.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DCorey%26aufirst%3DG.%2BR.%26aulast%3DDas%26aufirst%3DA.%2BF.%26aulast%3DDe%2BAnda%26aufirst%3DC.%26aulast%3DProkocimer%26aufirst%3DP.%26atitle%3DTedizolid%2520for%25206%2520days%2520versus%2520linezolid%2520for%252010%2520days%2520for%2520acute%2520bacterial%2520skin%2520and%2520skin-structure%2520infections%2520%2528ESTABLISH-2%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520phase%25203%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2014%26volume%3D14%26spage%3D696%26epage%3D705%26doi%3D10.1016%2FS1473-3099%2814%2970737-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barber, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkv302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26476277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Ohu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=152-155&author=K.+E.+Barberauthor=J.+R.+Smithauthor=A.+Rautauthor=M.+J.+Rybak&title=Evaluation+of+tedizolid+against+Staphylococcus+aureus+and+enterococci+with+reduced+susceptibility+to+vancomycin%2C+daptomycin+or+linezolid&doi=10.1093%2Fjac%2Fdkv302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid</span></div><div class="casAuthors">Barber, Katie E.; Smith, Jordan R.; Raut, Animesh; Rybak, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">152-155</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tedizolid displays potent activity against Gram-pos. pathogens.  In vitro studies against clin. isolates of Staphylococcus aureus and enterococci demonstrated improved tedizolid activity over linezolid.  However, this is not well characterized against a large collection of resistant isolates, including vancomycin-intermediate S. aureus (VISA), heterogeneous VISA (hVISA), daptomycin-non-susceptible (DNS) S. aureus, linezolid-resistant (LR) S. aureus and VRE.  Therefore, the objective here was to det. tedizolid activity vs. other agents, against MRSA and VRE with various resistance phenotypes.  Some 302 MRSA (75 DNS, 100 VISA, 120 hVISA and 7 LR) and 220 VRE [100 Enterococcus faecalis (all susceptible to daptomycin and linezolid) and 120 E. faecium (25 DNS and 10 LR)] were evaluated.  LR isolates were analyzed for the cfr gene.  MICs of tedizolid, linezolid, ampicillin, clindamycin, daptomycin, gentamicin, levofloxacin, oxacillin, tigecycline, trimethoprim/sulfamethoxazole and vancomycin were detd. in accordance with CLSI guidelines.  Results Tedizolid MIC90 values for hVISA, VISA and DNS were 0.5 mg/L (vs. 4, 4 and 2 mg/L, resp., for linezolid).  The tedizolid MIC range for LR MRSA was 0.063-1 mg/L.  Two LR MRSA possessed the cfr gene with tedizolid MICs of 0.125 and 0.25 mg/L (linezolid MICs of 16 and 8 mg/L).  The tedizolid MIC90 for vancomycin-resistant E. faecalis and E. faecium was 0.25 and 1 mg/L, resp.; three dilns. lower for E. faecalis and two dilns. lower for E. faecium compared with linezolid.  Conclusions Tedizolid MICs demonstrate activity against isolates with decreased susceptibility to alternative agents, including linezolid.  Tedizolid may be a viable treatment option in clin. situations with MDR Gram-pos. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CA-Tb0nnr7Vg90H21EOLACvtfcHk0li0jbrdhfPYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Ohu70%253D&md5=971f236b5406ab480be91418039e72b2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv302%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DK.%2BE.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DRaut%26aufirst%3DA.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520tedizolid%2520against%2520Staphylococcus%2520aureus%2520and%2520enterococci%2520with%2520reduced%2520susceptibility%2520to%2520vancomycin%252C%2520daptomycin%2520or%2520linezolid%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D152%26epage%3D155%26doi%3D10.1093%2Fjac%2Fdkv302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bien, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1002/phar.1337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fphar.1337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23926058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=240-250&author=S.+D.+Flanaganauthor=P.+A.+Bienauthor=K.+A.+Mu%C3%B1ozauthor=S.+L.+Minassianauthor=P.+G.+Prokocimer&title=Pharmacokinetics+of+tedizolid+following+oral+administration%3A+single+and+multiple+dose%2C+effect+of+food%2C+and+comparison+of+two+solid+forms+of+the+prodrug&doi=10.1002%2Fphar.1337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug</span></div><div class="casAuthors">Flanagan, Shawn D.; Bien, Paul A.; Munoz, Kelly A.; Minassian, Sonia L.; Prokocimer, Philippe G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-250</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : The single- and multiple-dose pharmacokinetics (PK) of tedizolid were examd. after oral administration of tedizolid phosphate disodium (TPD), including the effect of food on PK.  The relative bioavailability of TPD to the free acid tedizolid phosphate was detd. to bridge the results of these and other studies to the solid form of the prodrug selected for further development.  Design : Randomized placebo-controlled, double-blind single- and multiple-ascending dose studies and randomized open-label, crossover food effect and relative bioavailability studies.  Setting : Clin. Research Units.  Participants : Healthy subjects.  Intervention : Study TR701-101 enrolled 40 subjects in single-ascending dose (200-1200 mg TPD or placebo) and 40 subjects in 21-day multiple-ascending dose (200, 300, or 400 mg TPD once/day; 600 mg linezolid twice/day; or placebo) arms.  Study TR701-103 was a food-effect study in 12 subjects administered 600 mg TPD.  Study TR701-108 was a relative bioavailability study in 12 subjects administered 150-mg tedizolid equiv. as TPD or tedizolid phosphate.  Measurements and Main Results : Plasma concns. of the prodrug tedizolid phosphate, its active moiety tedizolid, and/or linezolid were collected.  After administration of 200 to 600 mg TPD, tedizolid values increased approx. dose proportionally in area under the concn.-time curve (AUC) and max. plasma concn. (Cmax).  Tedizolid half-life values were approx. 2-fold greater compared with linezolid.  TPD administration with food delayed tedizolid absorption and reduced Cmax relative to the fasted state but did not alter AUC.  Minimal accumulation was predicted and obsd. for tedizolid, whereas obsd. accumulation of linezolid exceeded predictions based on single-dose PK.  Comparable PK of tedizolid was obsd. following oral administration of either TPD or tedizolid phosphate.  In the multiple-ascending dose study, 3 of 24 tedizolid subjects were withdrawn under prespecified stopping rules (one each of elevated alanine aminotransferase, low reticulocyte count, or low white blood cell count), as was 1 of 8 linezolid subjects (low reticulocyte count).  Conclusions : Overall, tedizolid has a favorable PK profile, a half-life that supports once daily administration, and no nonlinearities at steady state.  Tedizolid phosphate can be administered without regard to food.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEt2jPHQozibVg90H21EOLACvtfcHk0li0jbrdhfPYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOrs7Y%253D&md5=5e58664eaad2cf534f354f0d83c5131f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fphar.1337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1337%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DS.%2BD.%26aulast%3DBien%26aufirst%3DP.%2BA.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DK.%2BA.%26aulast%3DMinassian%26aufirst%3DS.%2BL.%26aulast%3DProkocimer%26aufirst%3DP.%2BG.%26atitle%3DPharmacokinetics%2520of%2520tedizolid%2520following%2520oral%2520administration%253A%2520single%2520and%2520multiple%2520dose%252C%2520effect%2520of%2520food%252C%2520and%2520comparison%2520of%2520two%2520solid%2520forms%2520of%2520the%2520prodrug%26jtitle%3DPharmacotherapy%26date%3D2014%26volume%3D34%26spage%3D240%26epage%3D250%26doi%3D10.1002%2Fphar.1337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traczewski, M. M.</span></span> <span> </span><span class="NLM_article-title">Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2063</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1128/AAC.01569-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01569-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20231392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFelsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2063-2069&author=S.+D.+Brownauthor=M.+M.+Traczewski&title=Comparative+in+vitro+antimicrobial+activities+of+torezolid+%28TR-700%29%2C+the+active+moiety+of+a+new+oxazolidinone%2C+torezolid+phosphate+%28TR-701%29%2C+determination+of+tentative+disk+diffusion+interpretive+criteria%2C+and+quality+control+ranges&doi=10.1128%2FAAC.01569-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges</span></div><div class="casAuthors">Brown, Steven D.; Traczewski, Maria M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2063-2069</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the spectrum of activity of torezolid (TR-700), the active moiety of torezolid phosphate (TR-701), and proposes tentative MIC and disk diffusion breakpoints as well as quality control ranges.  The in vitro susceptibilities of 1,096 bacterial isolates, representing 23 different species or phenotypic groups, were detd. for torezolid, linezolid, cefotaxime, and levofloxacin using Clin. and Lab. Stds. Institute (CLSI) broth microdilution MICs, min. bactericidal concns. (MBCs), agar diln., and disk diffusion testing methods.  Torezolid was very active against the majority of Gram-pos. strains, including methicillin-susceptible and -resistant Staphylococcus aureus (MIC50 = 0.25 μg/mL, MIC90 ≤ 0.5 μg/mL), coagulase-neg. staphylococci (CNS; MIC50 = 0.25 μg/mL, MIC90 ≤ 0.5 μg/mL), enterococci (MIC50 and MIC90 ≤ 0.5 μg/mL), and streptococci (MIC50 and MIC90 ≤ 0.25 μg/mL).  Based upon MIC90s, torezolid was 4-fold more active than linezolid against S. aureus, coagulase-neg. staphylococci, and the enterococci and 8-fold more active than linezolid against the streptococci.  With the use of tentative MIC breakpoints of ≤2 μg/mL for susceptibility, torezolid disk diffusion zone diam. breakpoints are proposed using a 20-μg disk.  In addn., MIC quality control ranges of torezolid were detd. for three CLSI-recognized std. ATCC ref. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtSdmaewiLfbVg90H21EOLACvtfcHk0li0jbrdhfPYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFelsb4%253D&md5=f0b8c732ccf75ef1df16e0ed7eb92dcc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.01569-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01569-09%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BD.%26aulast%3DTraczewski%26aufirst%3DM.%2BM.%26atitle%3DComparative%2520in%2520vitro%2520antimicrobial%2520activities%2520of%2520torezolid%2520%2528TR-700%2529%252C%2520the%2520active%2520moiety%2520of%2520a%2520new%2520oxazolidinone%252C%2520torezolid%2520phosphate%2520%2528TR-701%2529%252C%2520determination%2520of%2520tentative%2520disk%2520diffusion%2520interpretive%2520criteria%252C%2520and%2520quality%2520control%2520ranges%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2063%26epage%3D2069%26doi%3D10.1128%2FAAC.01569-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0liYdVDL9C-OtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michalska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpiuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Król, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyski, S.</span></span> <span> </span><span class="NLM_article-title">Recent development of potent analogues of oxazolidinone antibacterial agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2012.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23273607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2rs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=577-591&author=K.+Michalskaauthor=I.+Karpiukauthor=M.+Kr%C3%B3lauthor=S.+Tyski&title=Recent+development+of+potent+analogues+of+oxazolidinone+antibacterial+agents&doi=10.1016%2Fj.bmc.2012.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Recent development of potent analogues of oxazolidinone antibacterial agents</span></div><div class="casAuthors">Michalska, Katarzyna; Karpiuk, Izabela; Krol, Marek; Tyski, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The oxazolidinones are a new and potent class of antimicrobial agents with activity mainly against Gram-pos. strains.  The com. success of linezolid, the only FDA-approved oxazolidinone, has prompted many pharmaceutical companies to devote resources to this area of investigation.  Until now, four types of chem. modifications of linezolid and oxazolidinone-type antibacterial agents, including modification on each of the A-(oxazolidinone), B-(phenyl), and C-(morpholine) rings as well as the C-5 side chain of the A-ring substructure, have been described.  Division into sections according to side chain modification or the type of ring will be used throughout this review, although the process of synthesis usually involves the simultaneous modification of several elements of the linezolid substructure; therefore, assignment into the appropriate section depends on the structure-activity relationships (SAR) studies.This review makes an attempt to summarise the work carried out in the period from 2006 until mid-2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniajnzuluNLVg90H21EOLACvtfcHk0liYdVDL9C-OtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2rs73L&md5=5b9cb116db7782b19161503490c8f3e3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DMichalska%26aufirst%3DK.%26aulast%3DKarpiuk%26aufirst%3DI.%26aulast%3DKr%25C3%25B3l%26aufirst%3DM.%26aulast%3DTyski%26aufirst%3DS.%26atitle%3DRecent%2520development%2520of%2520potent%2520analogues%2520of%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D577%26epage%3D591%26doi%3D10.1016%2Fj.bmc.2012.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locke, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahawi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">G. C., K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picazo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5343</span>, <span class="refDoi"> DOI: 10.1128/AAC.00663-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00663-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20837751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5337-5343&author=J.+B.+Lockeauthor=J.+Finnauthor=M.+Hilgersauthor=G.+Moralesauthor=S.+Rahawiauthor=K.+G.+C.author=J.+J.+Picazoauthor=W.+Imauthor=K.+J.+Shawauthor=J.+L.+Stein&title=Structure-activity+relationships+of+diverse+oxazolidinones+for+linezolid-resistant+Staphylococcus+aureus+strains+possessing+the+cfr+methyltransferase+gene+or+ribosomal+mutations&doi=10.1128%2FAAC.00663-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations</span></div><div class="casAuthors">Locke, Jeffrey B.; Finn, John; Hilgers, Mark; Morales, Gracia; Rahawi, Shahad; Kedar, G. C.; Picazo, Juan Jose; Im, Weonbin; Shaw, Karen Joy; Stein, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5337-5343</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcal resistance to linezolid (LZD) is mediated through ribosomal mutations (23S rRNA or ribosomal proteins L3 and L4) or through methylation of 23S rRNA by the horizontally transferred Cfr methyltransferase.  To investigate the structural basis for oxazolidinone activity against LZD-resistant (LZDr) strains, the authors compared structurally diverse, clin. relevant oxazolidinones, including LZD, radezolid (RX-1741), TR-700 (torezolid), and a set of TR-700 analogs (including novel CD-rings and various A-ring C-5 substituents), against a panel of lab.-derived and clin. LZDr Staphylococcus aureus strains possessing a variety of resistance mechanisms.  Potency against all strains was correlated with optimization of C- and D-rings, which interact with more highly conserved regions of the peptidyl transferase center binding site.  Activity against cfr strains was retained with either hydroxymethyl or 1,2,3-triazole C-5 groups but was reduced by 2- to 8-fold in compds. with acetamide substituents.  LZD, which possesses a C-5 acetamide group and lacks a D-ring substituent, demonstrated the lowest potency against all strains tested, particularly against cfr strains.  These data reveal key features contributing to oxazolidinone activity and highlight structural tradeoffs between potency against susceptible strains and potency against strains with various resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxEGhnaI3eNbVg90H21EOLACvtfcHk0liYdVDL9C-OtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FN&md5=32a36e1dcfffd0c1b4e97e69b486804e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.00663-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00663-10%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DJ.%2BB.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DHilgers%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DG.%26aulast%3DRahawi%26aufirst%3DS.%26aulast%3DG.%2BC.%26aufirst%3DK.%26aulast%3DPicazo%26aufirst%3DJ.%2BJ.%26aulast%3DIm%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3DStein%26aufirst%3DJ.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520diverse%2520oxazolidinones%2520for%2520linezolid-resistant%2520Staphylococcus%2520aureus%2520strains%2520possessing%2520the%2520cfr%2520methyltransferase%2520gene%2520or%2520ribosomal%2520mutations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5337%26epage%3D5343%26doi%3D10.1128%2FAAC.00663-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sader, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortridge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamm, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, R. E.</span></span> <span> </span><span class="NLM_article-title">Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)</span>. <i>J. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1080/1120009X.2019.1609740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1080%2F1120009X.2019.1609740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31079589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Cju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=188-194&author=M.+A.+Pfallerauthor=H.+S.+Saderauthor=D.+Shortridgeauthor=M.+Castanheiraauthor=R.+K.+Flammauthor=R.+E.+Mendes&title=Activity+of+tedizolid+against+gram-positive+clinical+isolates+causing+infections+in+Europe+and+surrounding+areas+%282014%E2%80%932015%29&doi=10.1080%2F1120009X.2019.1609740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015)</span></div><div class="casAuthors">Pfaller, Michael A.; Sader, Helio S.; Shortridge, Dee; Castanheira, Mariana; Flamm, Robert K.; Mendes, Rodrigo E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemotherapy (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">JCHEEU</span>;
        ISSN:<span class="NLM_cas:issn">1120-009X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Activities of tedizolid and comparators were evaluated against gram-pos. isolates responsible for skin and skin structure infections, pneumonia, and bloodstream infections.  Non-duplicate gram-pos. isolates (8011) were collected from 20 European countries/regions.  Tedizolid (0.12 mg/L) showed similar results of min. inhibitory concn. required to inhibit the growth of 50% of organisms (MIC50) regardless of pathogen/group or infection type, except for coagulase-neg. staphylococci, Enterococcus faecalis, and viridans group streptococci (VGS), against which tedizolid had MIC50 values of 0.06, 0.25, and 0.06 mg/L, resp.  Similar results of tedizolid MIC50 and min. inhibitory concn. required to inhibit the growth of 90% of organisms (MIC90) (MIC50/90, 0.12/0.12 mg/L) were obtained against methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.  Tedizolid, linezolid, and daptomycin were active against enterococci.  Tedizolid (MIC90, 0.12-0.25 mg/L), ceftaroline (MIC90, 0.12 mg/L), and vancomycin (MIC90, 0.25-0.5 mg/L) had the lowest MIC90 values against Streptococcus pneumoniae and VGS, whereas ceftaroline (MIC90, ≤ 0.015 mg/L), penicillin (MIC90, ≤ 0.06 mg/L), ceftriaxone (MIC90, ≤ 0.06-0.12 mg/L), and tedizolid (MIC90, 0.12 mg/L) were the most potent against β-haemolytic streptococci.  Tedizolid displayed potent activity against gram-pos. isolates from Euinfection rope, regardless of infection type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSub50YcDJVrVg90H21EOLACvtfcHk0lh-dlDLUHfBVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Cju7w%253D&md5=71806280be82315e1bdeb38ee7d7177c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F1120009X.2019.1609740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1120009X.2019.1609740%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DSader%26aufirst%3DH.%2BS.%26aulast%3DShortridge%26aufirst%3DD.%26aulast%3DCastanheira%26aufirst%3DM.%26aulast%3DFlamm%26aufirst%3DR.%2BK.%26aulast%3DMendes%26aufirst%3DR.%2BE.%26atitle%3DActivity%2520of%2520tedizolid%2520against%2520gram-positive%2520clinical%2520isolates%2520causing%2520infections%2520in%2520Europe%2520and%2520surrounding%2520areas%2520%25282014%25E2%2580%25932015%2529%26jtitle%3DJ.%2520Chemother.%26date%3D2019%26volume%3D31%26spage%3D188%26epage%3D194%26doi%3D10.1080%2F1120009X.2019.1609740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiodras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliopoulos, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennersten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, M. J.</span></span> <span> </span><span class="NLM_article-title">Linezolid resistance in a clinical isolate of Staphylococcus aureus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(01)05410-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2801%2905410-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11476839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=207-208&author=S.+Tsiodrasauthor=H.+S.+Goldauthor=G.+Sakoulasauthor=G.+M.+Eliopoulosauthor=C.+Wennerstenauthor=L.+Venkataramanauthor=R.+C.+Moelleringauthor=M.+J.+Ferraro&title=Linezolid+resistance+in+a+clinical+isolate+of+Staphylococcus+aureus&doi=10.1016%2FS0140-6736%2801%2905410-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid resistance in a clinical isolate of Staphylococcus aureus</span></div><div class="casAuthors">Tsiodras, S.; Gold, H. S.; Sakoulas, G.; Eliopoulos, G. M.; Wennersten, C.; Venkataraman, L.; Moellering, R. C.; Ferraro, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">9277</span>),
    <span class="NLM_cas:pages">207-208</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various Gram-pos. bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).  Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clin. isolates of S aureus.  The authors have characterized an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-assocd. peritonitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRryTK5F9tc7Vg90H21EOLACvtfcHk0lh-dlDLUHfBVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlymsr8%253D&md5=d8574bd50d0f1129cbc8d5dae0ac8127</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2905410-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252905410-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsiodras%26aufirst%3DS.%26aulast%3DGold%26aufirst%3DH.%2BS.%26aulast%3DSakoulas%26aufirst%3DG.%26aulast%3DEliopoulos%26aufirst%3DG.%2BM.%26aulast%3DWennersten%26aufirst%3DC.%26aulast%3DVenkataraman%26aufirst%3DL.%26aulast%3DMoellering%26aufirst%3DR.%2BC.%26aulast%3DFerraro%26aufirst%3DM.%2BJ.%26atitle%3DLinezolid%2520resistance%2520in%2520a%2520clinical%2520isolate%2520of%2520Staphylococcus%2520aureus%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D207%26epage%3D208%26doi%3D10.1016%2FS0140-6736%2801%2905410-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreckenberger, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DenBesten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. P.</span></span> <span> </span><span class="NLM_article-title">Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1179</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)04376-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2800%2904376-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11323048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=1179&author=R.+D.+Gonzalesauthor=P.+C.+Schreckenbergerauthor=M.+B.+Grahamauthor=S.+Kelkarauthor=K.+DenBestenauthor=J.+P.+Quinn&title=Infections+due+to+vancomycin-resistant+Enterococcus+faecium+resistant+to+linezolid&doi=10.1016%2FS0140-6736%2800%2904376-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid</span></div><div class="casAuthors">Gonzales, R. D.; Schreckenberger, P. C.; Graham, M. B.; Kelkar, S.; DenBesten, K.; Quinn, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">9263</span>),
    <span class="NLM_cas:pages">1179</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Linezolid is a new oxazolidinone antibiotic used to treat infections caused by vancomycin-resistant enterococci (VRE).  In early clin. trials, emergence of resistance occurred rarely.  The authors report clin. details and antibiotic susceptibility from 5 patients treated with linezolid for VRE infections who had resistant organisms isolated during therapy.  Four were transplant patients receiving protracted courses of the drug; 3 cases were assocd. with treatment failure.  One of 45 linezolid-treated patients developed resistance during therapy.  Susceptibility testing should be done in all cases on starting therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdnzIal5XYyLVg90H21EOLACvtfcHk0lh-dlDLUHfBVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFaqsb0%253D&md5=accd02388931411eaa373b9b69a01347</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2904376-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252904376-2%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DR.%2BD.%26aulast%3DSchreckenberger%26aufirst%3DP.%2BC.%26aulast%3DGraham%26aufirst%3DM.%2BB.%26aulast%3DKelkar%26aufirst%3DS.%26aulast%3DDenBesten%26aufirst%3DK.%26aulast%3DQuinn%26aufirst%3DJ.%2BP.%26atitle%3DInfections%2520due%2520to%2520vancomycin-resistant%2520Enterococcus%2520faecium%2520resistant%2520to%2520linezolid%26jtitle%3DLancet%26date%3D2001%26volume%3D357%26spage%3D1179%26doi%3D10.1016%2FS0140-6736%2800%2904376-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0ljtIshoI-ZdiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrby, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid--a review of the first oxazolidinone</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1517/14656566.2.2.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1517%2F14656566.2.2.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11336587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=293-302&author=R.+Norrby&title=Linezolid%2D%2Da+review+of+the+first+oxazolidinone&doi=10.1517%2F14656566.2.2.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid - a review of the first oxazolidinone</span></div><div class="casAuthors">Norrby, Ragnar</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review with 48 refs.  Linezolid is the first of a truly new class of antibiotics, the oxazolidinones.  It acts as an inhibitor of bacterial protein synthesis by blocking the formation of the 70S ribosomal initiation complex.  Its activity is bacteriostatic against some species (e.g., enterococci) and bactericidal against others (e.g., pneumococci).  The antibacterial spectrum of linezolid includes Gram-pos. pathogens and some Gram-neg. anaerobic species but not Gram-neg. aerobes.  Importantly, multi-drug resistant organisms such as methicillin-resistant staphylococci, staphylococci with reduced susceptibility to vancomycin, penicillin- and macrolide-resistant pneumococci and vancomycin-resistant enterococci are fully susceptible to linezolid.  Linezolid has almost 100% bioavailability and the area under the plasma concn. curve is identical after oral and iv. administration.  This enables initial oral administration of linezolid in those patients who can absorb the drug normally and also an early step-down therapy from iv. to oral.  Controlled, clin. studies have documented efficacy and safety of linezolid in hospital- and community-acquired pneumonia, uncomplicated and complicated skin and soft tissue infections and infections caused by vancomycin-resistant enterococci.  The safety and tolerability of linezolid are advantageous.  Linezolid is a weak and reversible monoamine oxidase (MAO) inhibitor and although no increased frequency of adrenergic or serotonergic adverse events has been reported, it is recommended that linezolid is used with caution in patients treated with other MAO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppV7eFYLHXfLVg90H21EOLACvtfcHk0ljtIshoI-ZdiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFKjs7g%253D&md5=98cd0338a3aaa5aa174226e869647ddc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1517%2F14656566.2.2.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2.2.293%26sid%3Dliteratum%253Aachs%26aulast%3DNorrby%26aufirst%3DR.%26atitle%3DLinezolid--a%2520review%2520of%2520the%2520first%2520oxazolidinone%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2001%26volume%3D2%26spage%3D293%26epage%3D302%26doi%3D10.1517%2F14656566.2.2.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taglialegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A. E.</span></span> <span> </span><span class="NLM_article-title">Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1093/jac/dkz418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkz418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31617901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSrsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=126-134&author=M.+Rochauthor=M.+C.+Varelaauthor=A.+Taglialegnaauthor=A.+E.+Rosato&title=Tedizolid+is+a+promising+antimicrobial+option+for+the+treatment+of+Staphylococcus+aureus+infections+in+cystic+fibrosis+patients&doi=10.1093%2Fjac%2Fdkz418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients</span></div><div class="casAuthors">Roch, Melanie; Varela, Maria Celeste; Taglialegna, Agustina; Rosato, Adriana E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">126-134</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To evaluate the in vitro and in vivo activity of tedizolid and predict the likelihood of tedizolid resistance selection in CF-background Staphylococcus aureus strains.  Methods: A collection of 330 S. aureus strains (from adult and paediatric patients), either of normal or small colony variant (SCV) phenotypes, gathered at three CF centers in the USA was used.  Tedizolid activity was assessed by broth microdilution, Etest and time-kill anal.  In vivo tedizolid efficacy was tested in a murine pneumonia model.  Tedizolid in vitro mutants were obtained by 40 days of exposure and progressive passages.  Whole genome sequencing of clin. S. aureus strains with reduced susceptibility to tedizolid was performed.  Results: MRSA strain MIC90s were tedizolid 0.12-0.25 mg/L and linezolid 1-2 mg/L; for MSSA strains, MIC90s were tedizolid 0.12 mg/L and linezolid 1-2 mg/L.  Two strains, WIS 441 and Seattle 106, with tedizolid MICs of 2 mg/L and 1 mg/L, resp., had MICs above the FDA tedizolid breakpoint (0.5 mg/L).  Tedizolid at free serum concns. exhibited a bacteriostatic effect.  Mean bacterial burdens in lungs (log10 cfu/g) for WIS 423-infected mice were: control, 11.2±0.5; tedizolid-treated (10 mg/kg), 3.40±1.87; linezolid-treated (40 mg/kg), 4.51±2.1; and vancomycin-treated (30 mg/kg), 5.21±1.93.  For WIS 441-infected mice the (log10 cfu/g) values were: control, 9.66±0.8; tedizolid-treated, 3.18±1.35; linezolid-treated 5.94±2.19; and vancomycin-treated, 4.35±1.7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgw4oAHmW32rVg90H21EOLACvtfcHk0ljtIshoI-ZdiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSrsr3F&md5=f4fc681b46e7d6f219b98c834931f017</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkz418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkz418%26sid%3Dliteratum%253Aachs%26aulast%3DRoch%26aufirst%3DM.%26aulast%3DVarela%26aufirst%3DM.%2BC.%26aulast%3DTaglialegna%26aufirst%3DA.%26aulast%3DRosato%26aufirst%3DA.%2BE.%26atitle%3DTedizolid%2520is%2520a%2520promising%2520antimicrobial%2520option%2520for%2520the%2520treatment%2520of%2520Staphylococcus%2520aureus%2520infections%2520in%2520cystic%2520fibrosis%2520patients%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2020%26volume%3D75%26spage%3D126%26epage%3D134%26doi%3D10.1093%2Fjac%2Fdkz418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span> <span> </span><span class="NLM_article-title">Relative Potency of TR-700, the Active Moiety of Prodrug TR-701, against Selected Bacterial Pathogens and Provisional Disk Test</span>. In  <i>Infectious Diseases Society of America 2008 Annual Meeting</i>, October 27, <span class="NLM_year">2008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Brown&title=Relative+Potency+of+TR-700%2C+the+Active+Moiety+of+Prodrug+TR-701%2C+against+Selected+Bacterial+Pathogens+and+Provisional+Disk+Test"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%26atitle%3DRelative%2520Potency%2520of%2520TR-700%252C%2520the%2520Active%2520Moiety%2520of%2520Prodrug%2520TR-701%252C%2520against%2520Selected%2520Bacterial%2520Pathogens%2520and%2520Provisional%2520Disk%2520Test%26jtitle%3DInfectious%2520Diseases%2520Society%2520of%2520America%25202008%2520Annual%2520Meeting%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. N.</span>; <span class="NLM_string-name">Fritsche, T. R.</span>; <span class="NLM_string-name">Sader, H. S.</span></span> <span> </span><span class="NLM_article-title">TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms</span>. In  <i>ICAAC/IDSA 2008</i>, <span class="NLM_publisher-loc">Washington, DC</span>, October 25–28, <span class="NLM_year">2000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=R.+N.+Jones&author=T.+R.+Fritsche&author=H.+S.+Sader&title=TR-700%2C+a+Novel+Oxazolidinone%2C+Tested+Against+Linezolid-Resistant+Gram-positive+Species+with+Well-Characterized+Resistance+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BN.%26atitle%3DTR-700%252C%2520a%2520Novel%2520Oxazolidinone%252C%2520Tested%2520Against%2520Linezolid-Resistant%2520Gram-positive%2520Species%2520with%2520Well-Characterized%2520Resistance%2520Mechanisms%26jtitle%3DICAAC%252FIDSA%25202008%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoellman, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ednie, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, P. C.</span></span> <span> </span><span class="NLM_article-title">Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.3.1148-1150.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.47.3.1148-1150.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12604559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslWiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=1148-1150&author=D.+B.+Hoellmanauthor=G.+Linauthor=L.+M.+Ednieauthor=A.+Rattanauthor=M.+R.+Jacobsauthor=P.+C.+Appelbaum&title=Antipneumococcal+and+antistaphylococcal+activities+of+ranbezolid+%28RBX+7644%29%2C+a+new+oxazolidinone%2C+compared+to+those+of+other+agents&doi=10.1128%2FAAC.47.3.1148-1150.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents</span></div><div class="casAuthors">Hoellman, Dianne B.; Lin, Gengrong; Ednie, Lois M.; Rattan, Ashok; Jacobs, Michael R.; Appelbaum, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1148-1150</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from ≤0.06 to 4 μg/mL.  The MICs for pneumococci were similar irresp. of the strains' β-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-neg. staphylococci were lower than those for Staphylococcus aureus.  Ranbezolid was bacteriostatic against pneumococci.  Ranbezolid MICs were similar to or lower than those of linezolid.  Vancomycin and quinupristin-dalfopristin were also very active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNExvSGSvqLVg90H21EOLACvtfcHk0lhZweEJlCVklA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslWiur4%253D&md5=ba1c9e14ba2e139e88bb011f35b69b44</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.3.1148-1150.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.3.1148-1150.2003%26sid%3Dliteratum%253Aachs%26aulast%3DHoellman%26aufirst%3DD.%2BB.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DEdnie%26aufirst%3DL.%2BM.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DM.%2BR.%26aulast%3DAppelbaum%26aufirst%3DP.%2BC.%26atitle%3DAntipneumococcal%2520and%2520antistaphylococcal%2520activities%2520of%2520ranbezolid%2520%2528RBX%25207644%2529%252C%2520a%2520new%2520oxazolidinone%252C%2520compared%2520to%2520those%2520of%2520other%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D1148%26epage%3D1150%26doi%3D10.1128%2FAAC.47.3.1148-1150.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyal, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmlund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonath, A.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Linezolid Binding Site Rearrangement in the Staphylococcus aureus Ribosome</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1128/mBio.00395-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FmBio.00395-17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8&author=M.+J.+Belousoffauthor=Z.+Eyalauthor=M.+Radjainiaauthor=T.+Ahmedauthor=R.+S.+Bamertauthor=D.+Matzovauthor=A.+Bashanauthor=E.+Zimmermanauthor=S.+Mishraauthor=D.+Cameronauthor=H.+Elmlundauthor=A.+Y.+Pelegauthor=S.+Bhushanauthor=T.+Lithgowauthor=A.+Yonath&title=Structural+Basis+for+Linezolid+Binding+Site+Rearrangement+in+the+Staphylococcus+aureus+Ribosome&doi=10.1128%2FmBio.00395-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FmBio.00395-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00395-17%26sid%3Dliteratum%253Aachs%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DEyal%26aufirst%3DZ.%26aulast%3DRadjainia%26aufirst%3DM.%26aulast%3DAhmed%26aufirst%3DT.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DMatzov%26aufirst%3DD.%26aulast%3DBashan%26aufirst%3DA.%26aulast%3DZimmerman%26aufirst%3DE.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DElmlund%26aufirst%3DH.%26aulast%3DPeleg%26aufirst%3DA.%2BY.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DLithgow%26aufirst%3DT.%26aulast%3DYonath%26aufirst%3DA.%26atitle%3DStructural%2520Basis%2520for%2520Linezolid%2520Binding%2520Site%2520Rearrangement%2520in%2520the%2520Staphylococcus%2520aureus%2520Ribosome%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26spage%3D8%26doi%3D10.1128%2FmBio.00395-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years</span>. <i>Helicobacter</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">e12373</span>, <span class="refDoi"> DOI: 10.1111/hel.12373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fhel.12373" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=e12373&author=L.+Liauthor=Y.+Keauthor=C.+Yuauthor=G.+Liauthor=N.+Yangauthor=J.+Zhangauthor=Y.+Li&title=Antibiotic+resistance+of+Helicobacter+pylori+in+Chinese+children%3A+A+multicenter+retrospective+study+over+7+years&doi=10.1111%2Fhel.12373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fhel.12373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhel.12373%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKe%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DAntibiotic%2520resistance%2520of%2520Helicobacter%2520pylori%2520in%2520Chinese%2520children%253A%2520A%2520multicenter%2520retrospective%2520study%2520over%25207%2520years%26jtitle%3DHelicobacter%26date%3D2017%26volume%3D22%26spage%3De12373%26doi%3D10.1111%2Fhel.12373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of oxazolidinone derivatives containing nitro heteroaromatic moiety</span>. <i>Chem. Res. Chin. Univ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1007/s40242-018-7302-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs40242-018-7302-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=51-56&author=B.+Xuauthor=X.+Dingauthor=Y.+Wuauthor=L.+Cuiauthor=P.+Qianauthor=D.+Wangauthor=Y.+Zhao&title=Synthesis+and+antibacterial+activity+of+oxazolidinone+derivatives+containing+nitro+heteroaromatic+moiety&doi=10.1007%2Fs40242-018-7302-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of oxazolidinone derivatives containing nitro heteroaromatic moiety</span></div><div class="casAuthors">Xu, Boxuan; Ding, Xiudong; Wu, Yachuang; Cui, Lei; Qian, Ping; Wang, Di; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Chinese Universities</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">CRCUED</span>;
        ISSN:<span class="NLM_cas:issn">1005-9040</span>.
    
            (<span class="NLM_cas:orgname">Jilin University</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone derivs. contg. nitro heteroarom. moiety I (R = 1-methyl-5-nitro-1H-imidazol-2-yl, 5-nitrofuran-2-yl, 2-O2NC6H4, etc.) was synthesized and evaluated for their in vitro antibacterial activities against S. aureus ATCC 29213, methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) by min. inhibitory concn. (MIC) assay.  Most of them exhibited antibacterial activity against S. aureus ATCC 29213, MRSA and VRE.  Among them, compds. I (R = 5-nitrofuran-2-yl, 5-nitrothiophen-2-yl) displayed better activity than the control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryB4jCFahUl7Vg90H21EOLACvtfcHk0ljHTSaryoBz9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlSitQ%253D%253D&md5=b8ea04ee2d7eea2f707af716b7ca3755</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40242-018-7302-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40242-018-7302-3%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520oxazolidinone%2520derivatives%2520containing%2520nitro%2520heteroaromatic%2520moiety%26jtitle%3DChem.%2520Res.%2520Chin.%2520Univ.%26date%3D2018%26volume%3D34%26spage%3D51%26epage%3D56%26doi%3D10.1007%2Fs40242-018-7302-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhateja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4261</span>– <span class="NLM_lpage">4267</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2005.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16054358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4261-4267&author=B.+Dasauthor=S.+Rudraauthor=A.+Yadavauthor=A.+Rayauthor=A.+V.+Raoauthor=A.+S.+Srinivasauthor=A.+Soniauthor=S.+Sainiauthor=S.+Shuklaauthor=M.+Pandyaauthor=P.+Bhatejaauthor=S.+Malhotraauthor=T.+Mathurauthor=S.+K.+Aroraauthor=A.+Rattanauthor=A.+Mehta&title=Synthesis+and+SAR+of+novel+oxazolidinones%3A+discovery+of+ranbezolid&doi=10.1016%2Fj.bmcl.2005.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid</span></div><div class="casAuthors">Das, Biswajit; Rudra, Sonali; Yadav, Ajay; Ray, Abhijit; Rao, A. V. S. Raja; Srinivas, A. S. S. V.; Soni, Ajay; Saini, Suman; Shukla, Shalini; Pandya, Manisha; Bhateja, Pragya; Malhotra, Sunita; Mathur, Tarun; Arora, S. K.; Rattan, Ashok; Mehta, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4261-4267</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel oxazolidinones, e.g. I (R = H, CHO, CO2H, HON:CH, CN, Cl, etc.), contg. a no. of substituted five-membered heterocycles attached to the piperazinyl-phenyl-oxazolidinone core of eperezolid, were synthesized.  Further, the piperazine ring of the core was replaced by other diamino-heterocycles.  These modifications led to several compds. with potent activity against a spectrum of resistant and susceptible Gram-pos. organisms, along with the identification of ranbezolid I (R = O2N) (RBx 7644) as a clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUDv4PtgEefrVg90H21EOLACvtfcHk0ljHTSaryoBz9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WnsL8%253D&md5=8c1cbf4f9d288699b3d49e966ee7f9a8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DA.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DA.%2BV.%26aulast%3DSrinivas%26aufirst%3DA.%2BS.%26aulast%3DSoni%26aufirst%3DA.%26aulast%3DSaini%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DPandya%26aufirst%3DM.%26aulast%3DBhateja%26aufirst%3DP.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DT.%26aulast%3DArora%26aufirst%3DS.%2BK.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%2520oxazolidinones%253A%2520discovery%2520of%2520ranbezolid%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4261%26epage%3D4267%26doi%3D10.1016%2Fj.bmcl.2005.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126746</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2019.126746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31676225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOgsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126746&author=Y.+Houauthor=Y.+Dongauthor=T.+Yeauthor=J.+Jiangauthor=L.+Dingauthor=M.+Qinauthor=X.+Dingauthor=Y.+Zhao&title=Synthesis+and+antibacterial+evaluation+of+novel+oxazolidinone+derivatives+containing+a+piperidinyl+moiety&doi=10.1016%2Fj.bmcl.2019.126746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety</span></div><div class="casAuthors">Hou, Yunlei; Dong, Yuhong; Ye, Tianyu; Jiang, Jia; Ding, Liang; Qin, Mingze; Ding, Xiudong; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">126746</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this article, a series of novel oxazolidinone derivs. contg. a piperidinyl moiety was designed and synthesized.  Their antibacterial activities were measured against S. aureus, MRSA, MSSA, LREF and VRE by MIC assay.  Most of them exhibited potent activity against Gram-pos. pathogens comparable to linezolid.  Among them, compd. I exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metab. in human liver microsome.  The most promising compd. I, which showed remarkable antibacterial activity against S. aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.25-1μg/mL, was an interesting candidate for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRe-N1n1cn7Vg90H21EOLACvtfcHk0ljHTSaryoBz9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOgsr3E&md5=00ea5ebc085852aa7aea03c9e4a685b3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126746%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520novel%2520oxazolidinone%2520derivatives%2520containing%2520a%2520piperidinyl%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126746%26doi%3D10.1016%2Fj.bmcl.2019.126746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6389</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+Teraryl+Oxazolidinone+Compound+%28S%29-N-%28%283-%283-Fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+Phosphate+as+a+Novel+Antimicrobial+Agent+with+Enhanced+Safety+Profile+and+Efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0lhLEuQn1Y4dIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Teraryl%2520Oxazolidinone%2520Compound%2520%2528S%2529-N-%2528%25283-%25283-Fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520Phosphate%2520as%2520a%2520Novel%2520Antimicrobial%2520Agent%2520with%2520Enhanced%2520Safety%2520Profile%2520and%2520Efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubenrauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, T.</span></span> <span> </span><span class="NLM_article-title">cryoEM-Guided Development of Antibiotics for Drug-Resistant Bacteria</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fcmdc.201900042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=30667174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislKqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=527-531&author=M.+J.+Belousoffauthor=H.+Venugopalauthor=A.+Wrightauthor=S.+Seonerauthor=I.+Stuartauthor=C.+Stubenrauchauthor=R.+S.+Bamertauthor=D.+W.+Luptonauthor=T.+Lithgow&title=cryoEM-Guided+Development+of+Antibiotics+for+Drug-Resistant+Bacteria&doi=10.1002%2Fcmdc.201900042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">cryoEM-Guided Development of Antibiotics for Drug-Resistant Bacteria</span></div><div class="casAuthors">Belousoff, Matthew J.; Venugopal, Hari; Wright, Alexander; Seoner, Samuel; Stuart, Isabella; Stubenrauch, Chris; Bamert, Rebecca S.; Lupton, David W.; Lithgow, Trevor</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">527-531</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">While the ribosome is a common target for antibiotics, challenges with crystallog. can impede the development of new bioactives using structure-based drug design approaches.  We exploit common structural features present in linezolid-resistant forms of both methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) to redesign the antibiotic.  Enabled by rapid and facile cryoEM structures, this process has identified (S)-2,2-dichloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (LZD-5) and (S)-2-chloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl) acetamide (LZD-6), which inhibit the ribosomal function and growth of linezolid-resistant MRSA and VRE.  The strategy discussed highlights the potential for cryoEM to facilitate the development of novel bioactive materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1INvrja-_irVg90H21EOLACvtfcHk0lhLEuQn1Y4dIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislKqs74%253D&md5=1e9a0855ace9e04fa8371b35448851e5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900042%26sid%3Dliteratum%253Aachs%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DVenugopal%26aufirst%3DH.%26aulast%3DWright%26aufirst%3DA.%26aulast%3DSeoner%26aufirst%3DS.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DStubenrauch%26aufirst%3DC.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DLupton%26aufirst%3DD.%2BW.%26aulast%3DLithgow%26aufirst%3DT.%26atitle%3DcryoEM-Guided%2520Development%2520of%2520Antibiotics%2520for%2520Drug-Resistant%2520Bacteria%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D527%26epage%3D531%26doi%3D10.1002%2Fcmdc.201900042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, J.</span></span> <span> </span><span class="NLM_article-title">Ultrasound Assisted Synthesis, Characterization and Antimicrobial Evaluation of Novel Oxazolidinone- Biphenyl Chalcone Hybrid Derivatives</span>. <i>Indian J. Pharm. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">286</span>, <span class="refDoi"> DOI: 10.5530/ijper.53.2.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.5530%2Fijper.53.2.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVegu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=286&author=N.+Panigrahiauthor=S.+Gangulyauthor=J.+Panda&title=Ultrasound+Assisted+Synthesis%2C+Characterization+and+Antimicrobial+Evaluation+of+Novel+Oxazolidinone-+Biphenyl+Chalcone+Hybrid+Derivatives&doi=10.5530%2Fijper.53.2.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrasound assisted synthesis, characterization and antimicrobial evaluation of novel oxazolidinonebiphenyl chalcone hybrid derivatives</span></div><div class="casAuthors">Panigrahi, Naresh; Ganguly, Swastika; Panda, Jagadeesh</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Education and Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-300</span>CODEN:
                <span class="NLM_cas:coden">IJPEB3</span>;
        ISSN:<span class="NLM_cas:issn">0019-5464</span>.
    
            (<span class="NLM_cas:orgname">Indian Journal of Pharmaceutical Education and Research</span>)
        </div><div class="casAbstract">Objective: The main objective of our present study, is to potentiate the antibacterial activity of biphenyl chalcones and oxazolidinones, thus in order to achieve the potent antibacterial agents, we coupled both derivs. by using green chem. approach for Buchwald's protocol under ultrasound irradn.  Methodol.: Ultrasonication technique was used to couple a series of 24 novel bromo-biphenyl-chalcone derivs. and 5-chloromethyl-oxazolidinone in the presence of copper iodide (CuI) (10 mol %) for the amidation of chalcones and (±)-trans-1,2-diaminocyclohexane was used to solubilize CuI and potassium carbonate (K2CO3) as base, which provided the products in good yields after short reaction times under mild conditions.  Results and Discussion: Herewith we report the synthesis of 24 novel oxazolidinone-biphenyl chalcone hybrid derivs. (7a-7x).  All the synthesized compds. were characterized by spectral data and evaluated for in vitro antibacterial and antifungal activities.  Antibacterial and antifungal activities were tested using the serial diln. method.  From the screening studies it was obsd. that compds. 7c to 7g have shown significant antibacterial activities against the both the strains of gram-pos. and gram-neg. bacteria at 3.125 μg/mL when compared to the std. drugs ciprofloxacin and linezolid and were as other compds. showed moderate to weak activities.  In case of antifungal studies the compds. 7e-7g showed moderate activities at 12.5 μg/mL compared to std. fluconazole and whereas other compds. showed weak activities.  Conclusion: We have developed an exptl. simple, efficient, short time and high yielding CuI-mediated N-arylation of oxazolidinones under ultrasound irradn. with a simple set up at room temp.  This approach would be a worthwhile in the development of green chem. protocols.  Compds. 7c to 7g have shown significant antibacterial activities against the both the strains of gram-pos. and gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7bGkQchM-LVg90H21EOLACvtfcHk0lhLEuQn1Y4dIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVegu77F&md5=e1cd14a89ca969a2e16e475efd91ae38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.5530%2Fijper.53.2.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5530%252Fijper.53.2.37%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahi%26aufirst%3DN.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DPanda%26aufirst%3DJ.%26atitle%3DUltrasound%2520Assisted%2520Synthesis%252C%2520Characterization%2520and%2520Antimicrobial%2520Evaluation%2520of%2520Novel%2520Oxazolidinone-%2520Biphenyl%2520Chalcone%2520Hybrid%2520Derivatives%26jtitle%3DIndian%2520J.%2520Pharm.%2520Educ.%26date%3D2019%26volume%3D53%26spage%3D286%26doi%3D10.5530%2Fijper.53.2.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (−)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28%E2%88%92%29-PNU-286607+by+asymmetric+cyclization+of+alkylidene+barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0lhQb0H00WVAKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528%25E2%2588%2592%2529-PNU-286607%2520by%2520asymmetric%2520cyclization%2520of%2520alkylidene%2520barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.+S.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones%3A+Benzisoxazole+Fusion+with+N-Linked+Oxazolidinone+Substituents+Leading+to+a+Clinical+Candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lhQb0H00WVAKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Novel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%253A%2520Benzisoxazole%2520Fusion%2520with%2520N-Linked%2520Oxazolidinone%2520Substituents%2520Leading%2520to%2520a%2520Clinical%2520Candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattigeri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Spiropyrimidinetriones Oxazolidinone Derivatives as Antibacterial Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1198</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2018.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=29525219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1198&author=A.+Siddiquiauthor=J.+Sattigeriauthor=K.+Javedauthor=S.+Shafiauthor=M.+Shamimauthor=S.+Singhalauthor=M.+Malik&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Spiropyrimidinetriones+Oxazolidinone+Derivatives+as+Antibacterial+Agents&doi=10.1016%2Fj.bmcl.2018.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of spiropyrimidinetriones oxazolidinone derivatives as antibacterial agents</span></div><div class="casAuthors">Siddiqui, Asher M.; Sattigeri, Jitendra A.; Javed, Kalim; Shafi, Syed; Shamim, M.; Singhal, Smita; Malik, Zubbair M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1198-1206</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gram-pos. bacteria are among the most common human pathogens assocd. with clin. infections which range from mild skin infections to sepsis.  Resistance towards existing class of drugs by Gram-pos. bacteria including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE) and vancomycin resistant enterococci (VRE) is a growing concern.  There is an urgent need to discover new antibiotics which are active against resistant strains of Gram pos. bacteria.  We report herein a novel class of spiropyrimidinetrione oxazolidinone derivs. as novel antibacterial agents.  Key step towards the synthesis of title compds. involved the use of tert-amino reaction with [1,5]-hydride shift leading to the new C-C bond formation.  Compd. 30n (I) has demonstrated potent antibacterial activity against a panel of Gram-pos. microbial strains including MRSA, MRSE, and LNZ and vancomycin resistant strains of E. faecalis.  Further, mol. docking studies suggest that 30n has binding mode similar to that of LNZ in 50S RNA ribosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVS5ztoVXm4bVg90H21EOLACvtfcHk0lhQb0H00WVAKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOjsrw%253D&md5=35791eb66d0773b322c147e63fb85710</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DSattigeri%26aufirst%3DJ.%26aulast%3DJaved%26aufirst%3DK.%26aulast%3DShafi%26aufirst%3DS.%26aulast%3DShamim%26aufirst%3DM.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Spiropyrimidinetriones%2520Oxazolidinone%2520Derivatives%2520as%2520Antibacterial%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1198%26doi%3D10.1016%2Fj.bmcl.2018.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelletty, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aeschlimann, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaatz, G. W.</span></span> <span> </span><span class="NLM_article-title">Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.3.721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.42.3.721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9517963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXhvV2kurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=721-724&author=M.+J.+Rybakauthor=D.+M.+Cappellettyauthor=T.+Moldovanauthor=J.+R.+Aeschlimannauthor=G.+W.+Kaatz&title=Comparative+in+vitro+activities+and+postantibiotic+effects+of+the+oxazolidinone+compounds+eperezolid+%28PNU-100592%29+and+linezolid+%28PNU-100766%29+versus+vancomycin+against+Staphylococcus+aureus%2C+coagulase-negative+staphylococci%2C+Enterococcus+faecalis%2C+and+Enterococcus+faecium&doi=10.1128%2FAAC.42.3.721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium</span></div><div class="casAuthors">Rybak, Michael J.; Cappelletty, Diane M.; Moldovan, Tabitha; Aeschlimann, Jeffrey R.; Kaatz, Glenn W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">721-724</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clin. isolates of methicillin-susceptible and -resistant Staphylococcus aureus (n = 200), coagulase-neg. staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium (n = 50).  Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 μg/mL) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 μg/mL).  In time-kill studies, eperezolid and linezolid were bacteriostatic in action.  A postantibiotic effect of 0.8 ± 0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPlbr1PFg7pbVg90H21EOLACvtfcHk0liTxnyQ9pCFtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhvV2kurk%253D&md5=039df71b1c2f19a0e929a190b118056c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.3.721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.3.721%26sid%3Dliteratum%253Aachs%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26aulast%3DCappelletty%26aufirst%3DD.%2BM.%26aulast%3DMoldovan%26aufirst%3DT.%26aulast%3DAeschlimann%26aufirst%3DJ.%2BR.%26aulast%3DKaatz%26aufirst%3DG.%2BW.%26atitle%3DComparative%2520in%2520vitro%2520activities%2520and%2520postantibiotic%2520effects%2520of%2520the%2520oxazolidinone%2520compounds%2520eperezolid%2520%2528PNU-100592%2529%2520and%2520linezolid%2520%2528PNU-100766%2529%2520versus%2520vancomycin%2520against%2520Staphylococcus%2520aureus%252C%2520coagulase-negative%2520staphylococci%252C%2520Enterococcus%2520faecalis%252C%2520and%2520Enterococcus%2520faecium%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D721%26epage%3D724%26doi%3D10.1128%2FAAC.42.3.721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dresser, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span> <span> </span><span class="NLM_article-title">The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1998.tb03109.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fj.1875-9114.1998.tb03109.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Kjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=456-462&issue=3&author=L.+D.+Dresserauthor=M.+J.+Rybak&title=The+pharmacologic+and+bacteriologic+properties+of+oxazolidinones%2C+a+new+class+of+synthetic+antimicrobials&doi=10.1002%2Fj.1875-9114.1998.tb03109.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacologic and bacteriological properties of oxazolidinones, a new class of synthetic antimicrobials</span></div><div class="casAuthors">Dresser, Linda D.; Rybak, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">456-462</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review with 20 refs.  The oxazolidinones are a new synthetic class of antimicrobials structurally unrelated to any agent presently marketed.  Data pertaining to these compds., with respect to their pharmacol., pharmacokinetics, pharmacodynamics, mechanism of action, and bacteriol. activity, focusing on the analogs linezolid (PNU 100766) and eperezolid (PNU 100592), were retrieved by MEDLINE search and review of relevant abstrs. presented at recent clin. conferences.  Since the drugs are still investigational, we obtained in vitro and animal data as well as available human studies.  The oxazolidinones have bacteriostatic activity against a no. of important pathogens including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci.  They appear to be efficacious and well tolerated both orally and parenterally.  Their role remains to be elucidated by clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUs8uzO0PB9rVg90H21EOLACvtfcHk0liTxnyQ9pCFtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Kjt7s%253D&md5=305ebe4863c4360fb80552da747e2029</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1998.tb03109.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1998.tb03109.x%26sid%3Dliteratum%253Aachs%26aulast%3DDresser%26aufirst%3DL.%2BD.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520pharmacologic%2520and%2520bacteriologic%2520properties%2520of%2520oxazolidinones%252C%2520a%2520new%2520class%2520of%2520synthetic%2520antimicrobials%26jtitle%3DPharmacotherapy%26date%3D1998%26volume%3D18%26issue%3D3%26spage%3D456%26epage%3D462%26doi%3D10.1002%2Fj.1875-9114.1998.tb03109.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasukata, T.</span></span> <span> </span><span class="NLM_article-title">Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2013.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23584544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFantrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=811-825&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=N.+Fukuharaauthor=T.+Iwakiauthor=T.+Yasukata&title=Antibacterial+oxazolidinone+analogues+having+a+N-hydroxyacetyl-substituted+seven-membered+%5B1%2C2%2C5%5Dtriazepane+or+%5B1%2C2%2C5%5Doxadiazepane+C-ring+unit&doi=10.1016%2Fj.ejmech.2013.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fukuhara, Norio; Iwaki, Tsutomu; Yasukata, Tatsuro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">811-825</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We synthesized a series of oxazolidinone analogs bearing a N-hydroxyacetyl-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit as homologues of an earlier drug candidate, eperezolid.  Several of these compds. exhibited potent in vitro antibacterial activities towards not only Gram-pos., but also Gram-neg. and linezolid-resistant pathogens.  Compds. I (X = H or F), bearing a thiocarbamate side chain, showed high in vivo activity against methicillin-resistant Staphylococcus aureus SR3637, together with a promising safety profile in terms of weak inhibition of monoamine oxidase and cytochrome P 450 isoenzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AEBvSKxIsbVg90H21EOLACvtfcHk0liTxnyQ9pCFtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFantrw%253D&md5=ee01b3bba0262eba541c7c55552d334e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFukuhara%26aufirst%3DN.%26aulast%3DIwaki%26aufirst%3DT.%26aulast%3DYasukata%26aufirst%3DT.%26atitle%3DAntibacterial%2520oxazolidinone%2520analogues%2520having%2520a%2520N-hydroxyacetyl-substituted%2520seven-membered%2520%255B1%252C2%252C5%255Dtriazepane%2520or%2520%255B1%252C2%252C5%255Doxadiazepane%2520C-ring%2520unit%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D811%26epage%3D825%26doi%3D10.1016%2Fj.ejmech.2013.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhardwaj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, K. R.</span></span> <span> </span><span class="NLM_article-title">Organoiodine (III) mediated synthesis of 3-aryl/hetryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines as antibacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2004.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2004.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15571869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCqsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=1073-1077&author=O.+Prakashauthor=V.+Bhardwajauthor=R.+Kumarauthor=P.+Tyagiauthor=K.+R.+Aneja&title=Organoiodine+%28III%29+mediated+synthesis+of+3-aryl%2Fhetryl-5%2C7-dimethyl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyrimidines+as+antibacterial+agents&doi=10.1016%2Fj.ejmech.2004.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Organoiodine(III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines as antibacterial agents</span></div><div class="casAuthors">Prakash, Om; Bhardwaj, Vikas; Kumar, Ravi; Tyagi, Parikshit; Aneja, Kamal R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1073-1077</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Synthesis of some 3-aryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines, e.g., I, has been accomplished by the oxidn. of 4,6-dimethyl-2-pyrimidinylhydrazones, derived from various aldehydes, with iodobenzene diacetate in dichloromethane.  Some of the compds. were tested in vitro for their antibacterial activity.  Two compds., namely 3-(4'-pyridyl)-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidine and I, were assocd. with substantially higher antibacterial activity than some com. antibiotics against Bacillus subtilis, Escherichia coli, Staphylococcus aureus and Salmonella typhi at MIC (min. inhibitory concn.) i.e. 10 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_29EClD4FMbVg90H21EOLACvtfcHk0lgyL3uPU48w9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCqsr3K&md5=e8b4c4087a5f0e0fc5b60c562f523828</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2004.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2004.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DAneja%26aufirst%3DK.%2BR.%26atitle%3DOrganoiodine%2520%2528III%2529%2520mediated%2520synthesis%2520of%25203-aryl%252Fhetryl-5%252C7-dimethyl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyrimidines%2520as%2520antibacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2004%26volume%3D39%26spage%3D1073%26epage%3D1077%26doi%3D10.1016%2Fj.ejmech.2004.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhiman, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Organoiodine (III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2260</span>– <span class="NLM_lpage">2264</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2008.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18657340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsl2gsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2260-2264&author=R.+Kumarauthor=R.+R.+Nairauthor=S.+S.+Dhimanauthor=J.+Sharmaauthor=O.+Prakash&title=Organoiodine+%28III%29-mediated+synthesis+of+3-aryl%2Fheteroaryl-5%2C7-dimethyl-1%2C2%2C4-triazolo%5B4%2C3-c%5Dpyrimidines+as+antibacterial+agents&doi=10.1016%2Fj.ejmech.2008.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Organoiodine(III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents</span></div><div class="casAuthors">Kumar, Ravi; Nair, Reshmi R.; Dhiman, Saurabh Sudha; Sharma, Jitender; Prakash, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2260-2264</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of 12 new 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines has been accomplished by the oxidn. of pyrimidinylhydrazones of various aryl/heteroaryl aldehydes using 1.1 equiv. of iodobenzene diacetate (IBD) in dichloromethane.  All the compds. were tested in vitro for their antibacterial activity against two Gram-pos. bacteria namely, Bacillus subtilis, Bacillus stearothermophilus and two Gram-neg. bacteria Pseudomonas putida, Escherichia coli.  3-(2,4-Dichlorophenyl)-5,7-dimethyl-1,2,4-triazolo [4,3-c]pyrimidine and 3-(4-hydroxy-2-methoxyphenyl)-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidine were found to be equipotent or more potent than the com. available antibiotics (chloramphenicol and streptomycin).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9i95v2I1op7Vg90H21EOLACvtfcHk0lgyL3uPU48w9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsl2gsLk%253D&md5=f7649aaa54f55d619b57bdc874a33b0b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DNair%26aufirst%3DR.%2BR.%26aulast%3DDhiman%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DOrganoiodine%2520%2528III%2529-mediated%2520synthesis%2520of%25203-aryl%252Fheteroaryl-5%252C7-dimethyl-1%252C2%252C4-triazolo%255B4%252C3-c%255Dpyrimidines%2520as%2520antibacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2260%26epage%3D2264%26doi%3D10.1016%2Fj.ejmech.2008.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khera, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cliffe, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2887</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2011.03.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21507643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2887-2889&author=M.+K.+Kheraauthor=I.+A.+Cliffeauthor=T.+Mathurauthor=O.+Prakash&title=Synthesis+and+in+vitro+activity+of+novel+1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyrimidine+oxazolidinone+antibacterial+agents&doi=10.1016%2Fj.bmcl.2011.03.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents</span></div><div class="casAuthors">Khera, Manoj K.; Cliffe, Ian A.; Mathur, Tarun; Prakash, Om</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2887-2889</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and antibacterial activity of 3-(4-([1,2,4]triazolo[4,3-a]pyrimidin-3-yl)phenyl)oxazolidin-2-ones is reported.  Thiocarbonyl derivs. were found to be potent inhibitors of Gram-pos. pathogens and compd. I was two to fourfold more potent than Linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYa1HhZQpvbVg90H21EOLACvtfcHk0lgyL3uPU48w9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmt7k%253D&md5=56305846a67b3bb8a8019a485d535011</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.075%26sid%3Dliteratum%253Aachs%26aulast%3DKhera%26aufirst%3DM.%2BK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26aulast%3DMathur%26aufirst%3DT.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520activity%2520of%2520novel%25201%252C2%252C4-triazolo%255B4%252C3-a%255Dpyrimidine%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2887%26epage%3D2889%26doi%3D10.1016%2Fj.bmcl.2011.03.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span> <span> </span><span class="NLM_article-title">Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1021/ml400280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1074-1078&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=T.+Fujimuraauthor=M.+Tsujiauthor=I.+Katoauthor=T.+Aokiauthor=A.+Inoauthor=T.+Iwaki&title=Potent+oxazolidinone+antibacterials+with+heteroaromatic+C-ring+substructure&doi=10.1021%2Fml400280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Oxazolidinone Antibacterials with Heteroaromatic C-Ring Substructure</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fujimura, Takaji; Tsuji, Masakatsu; Kato, Issei; Aoki, Toshiaki; Ino, Akira; Iwaki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1074-1078</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel oxazolidinone analogs bearing a condensed heteroarom. ring as the C-ring substructure were synthesized as candidate antibacterial agents.  Analogs 16 and 21 bearing imidazo-[1,2-a]-pyridine and 18 and 23 bearing [1,2,4]-triazolo-[1,5-a]-pyridine as the C-ring had excellent in vitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP).  They also showed promising therapeutic effects in a mouse model of lethal infection.  Preliminary safety data (inhibitory effects on cytochrome P 450 isoforms and monoamine oxidases) were satisfactory.  Further evaluation of 18 and 23 is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBYb1cLJtZI7Vg90H21EOLACvtfcHk0liD9_1ZTNiQVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM&md5=6f39a539a41ec53b3ce04733a74850d1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fml400280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400280z%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DIno%26aufirst%3DA.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DPotent%2520oxazolidinone%2520antibacterials%2520with%2520heteroaromatic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1074%26epage%3D1078%26doi%3D10.1021%2Fml400280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1153-1158&author=M.+S.+Deshmukhauthor=N.+Jain&title=Design%2C+Synthesis%2C+and+Antibacterial+Evaluation+of+Oxazolidinones+with+Fused+Heterocyclic+C-Ring+Substructure&doi=10.1021%2Facsmedchemlett.7b00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span></div><div class="casAuthors">Deshmukh, Mahesh S.; Jain, Nidhi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1158</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone antibacterials with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities were designed and synthesized.  The compd. with benzoxazinone C-ring substructure (I) exhibited superior activity compared to linezolid against a panel of Gram-pos. and Gram-neg. bacteria.  Structural modifications at C5-side chain of I resulted in identification of several potent compds.  Selected compds. I and II showed very good microsomal stability and no CYP450 liability, thus clearing preliminary safety hurdles.  A docking model of II binding to 23S rRNA suggested that the increased potency of II is due to addnl. ligand-receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsos1yjPmoN7Vg90H21EOLACvtfcHk0liD9_1ZTNiQVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL&md5=5edbae88df65af2bd8264ff4755a0498</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00263%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DM.%2BS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antibacterial%2520Evaluation%2520of%2520Oxazolidinones%2520with%2520Fused%2520Heterocyclic%2520C-Ring%2520Substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1153%26epage%3D1158%26doi%3D10.1021%2Facsmedchemlett.7b00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/ardp.200800233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.200800233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19544480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2009&pages=377-385&author=X.+J.+Wangauthor=N.+Wuauthor=G.+J.+Duauthor=S.+Q.+Zhaoauthor=M.+Yanauthor=L.+Q.+Gu&title=Synthesis+and+antibacterial+activities+of+eperezolid+analogs+with+glycinyl+substitutions&doi=10.1002%2Fardp.200800233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Activities of Eperezolid Analogs with Glycinyl Substitutions</span></div><div class="casAuthors">Wang, Xiao-Jun; Wu, Ning; Du, Guang-Jian; Zhao, Shuang-Qi; Yan, Ming; Gu, Lian-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of eperezolid analogs with glycinyl substitutions were prepd. and their antibacterial activities were studied against a panel of susceptible and resistant Gram-pos. bacteria.  The compds. with N-arylacyl or N-heteroarylacyl glycinyl structural units showed good antibacterial activities.  The compds. 11b, 11c, and 11e were twofold more active than linezolid against Staphylococcus epidermidis and Enterococcus faecalis.  Several pyridine analogs were also prepd. and found to have poor antibacterial activity against most of the tested Gram-pos. bacteria, however, one of the compds. 12e showed very high activity against Enterococcus faecalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAe3f_ZJgFXbVg90H21EOLACvtfcHk0lhqI18Ls0ewcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCnu70%253D&md5=e99e1e9cedc16ba8842f8cc7a570203a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800233%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DG.%2BJ.%26aulast%3DZhao%26aufirst%3DS.%2BQ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520eperezolid%2520analogs%2520with%2520glycinyl%2520substitutions%26jtitle%3DArch.%2520Pharm.%26date%3D2009%26volume%3D342%26spage%3D377%26epage%3D385%26doi%3D10.1002%2Fardp.200800233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1128/AAC.01383-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01383-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18316525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=1653-1662&author=L.+Lawrenceauthor=P.+Daneseauthor=J.+DeVitoauthor=F.+Franceschiauthor=J.+Sutcliffe&title=In+vitro+activities+of+the+Rx-01+oxazolidinones+against+hospital+and+community+pathogens&doi=10.1128%2FAAC.01383-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens</span></div><div class="casAuthors">Lawrence, Laura; Danese, Paul; DeVito, Joe; Franceschi, Francois; Sutcliffe, Joyce</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1653-1662</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Rx-01_423 and Rx-01_667 are 2 members of the family of oxazolidinones that were designed using a combination of computational and medicinal chem. and conventional biol. techniques.  The compds. have a 2 - to 8 fold-improved potency over linezolid against serious gram-pos. pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci.  This enhanced potency extends to the coverage of linezolid-resistant gram-pos. microbes, esp. multidrug-resistant enterococci and pneumococci.  Compds. from this series expand the spectrum compared with linezolid to include fastidious gram-neg. organisms like Haemophilus influenzae and Moraxella catarrhalis.  Like linezolid, the Rx-01 compds. are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCqcmJGV8nrVg90H21EOLACvtfcHk0lhqI18Ls0ewcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajtbg%253D&md5=463c37891700f9165d77eed05e407add</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1128%2FAAC.01383-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01383-07%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DL.%26aulast%3DDanese%26aufirst%3DP.%26aulast%3DDeVito%26aufirst%3DJ.%26aulast%3DFranceschi%26aufirst%3DF.%26aulast%3DSutcliffe%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520activities%2520of%2520the%2520Rx-01%2520oxazolidinones%2520against%2520hospital%2520and%2520community%2520pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D1653%26epage%3D1662%26doi%3D10.1128%2FAAC.01383-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown-Driver, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4442</span>– <span class="NLM_lpage">4447</span>, <span class="refDoi"> DOI: 10.1128/AAC.00859-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00859-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18838596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2mu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=4442-4447&author=K.+J.+Shawauthor=S.+Poppeauthor=R.+Schaadtauthor=V.+Brown-Driverauthor=J.+Finnauthor=C.+M.+Pillarauthor=D.+Shinabargerauthor=G.+Zurenko&title=In+vitro+activity+of+TR-700%2C+the+antibacterial+moiety+of+the+prodrug+TR-701%2C+against+linezolid-resistant+strains&doi=10.1128%2FAAC.00859-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains</span></div><div class="casAuthors">Shaw, K. J.; Poppe, S.; Schaadt, R.; Brown-Driver, V.; Finn, J.; Pillar, C. M.; Shinabarger, D.; Zurenko, G.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4442-4447</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four- to eightfold-greater activity than linezolid (LZD) against Staphylococcus and Enterococcus spp.  In this study evaluating the in vitro sensitivity of LZD-resistant isolates, TR-700 demonstrated 8- to 16-fold-greater potency than LZD against all strains tested, including methicillin-resistant Staphylococcus aureus (MRSA), strains of MRSA carrying the mobile cfr methyltransferase gene, and vancomycin-resistant enterococci.  The MIC90 for TR-700 against LZD-resistant S. aureus was 2 μg/mL, demonstrating the utility of TR-700 against LZD-resistant strains.  A model of TR-700 binding to 23S rRNA suggests that the increased potency of TR-700 is due to addnl. target site interactions and that TR-700 binding is less reliant on target residues assocd. with resistance to LZD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-PvHNUp7EBbVg90H21EOLACvtfcHk0lhqI18Ls0ewcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2mu77F&md5=f9ff1cf68056ec69f0b70d49c4522f69</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FAAC.00859-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00859-08%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3DPoppe%26aufirst%3DS.%26aulast%3DSchaadt%26aufirst%3DR.%26aulast%3DBrown-Driver%26aufirst%3DV.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DPillar%26aufirst%3DC.%2BM.%26aulast%3DShinabarger%26aufirst%3DD.%26aulast%3DZurenko%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520activity%2520of%2520TR-700%252C%2520the%2520antibacterial%2520moiety%2520of%2520the%2520prodrug%2520TR-701%252C%2520against%2520linezolid-resistant%2520strains%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D4442%26epage%3D4447%26doi%3D10.1128%2FAAC.00859-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4113</span>– <span class="NLM_lpage">4123</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.03.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2005.03.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15911326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4113-4123&author=O.+A.+Phillipsauthor=E.+E.+Udoauthor=A.+A.+Aliauthor=S.+M.+Samuel&title=Synthesis+and+antibacterial+activity+of+new+N-linked+5-triazolylmethyl+oxazolidinones&doi=10.1016%2Fj.bmc.2005.03.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones</span></div><div class="casAuthors">Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4113-4123</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new series of N-linked 5-triazolylmethyl oxazolidinones with varying substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates.  Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms.  One of the compds. showed enhanced antibacterial activity against Moraxella catarrhalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn3GyicMxM77Vg90H21EOLACvtfcHk0ljP7iaeenRyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gjs7w%253D&md5=b8cace1f3aaf0614c774c2301ba45a5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.03.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.03.036%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DUdo%26aufirst%3DE.%2BE.%26aulast%3DAli%26aufirst%3DA.%2BA.%26aulast%3DSamuel%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520new%2520N-linked%25205-triazolylmethyl%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4113%26epage%3D4123%26doi%3D10.1016%2Fj.bmc.2005.03.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hamid, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2013.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23811087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=246-257&author=O.+A.+Phillipsauthor=E.+E.+Udoauthor=M.+E.+Abdel-Hamidauthor=R.+Varghese&title=Synthesis+and+antibacterial+activities+of+N-substituted-glycinyl+1H-1%2C2%2C3-triazolyl+oxazolidinones&doi=10.1016%2Fj.ejmech.2013.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones</span></div><div class="casAuthors">Phillips, Oludotun A.; Udo, Edet E.; Abdel-Hamid, Mohammed E.; Varghese, Reny</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">246-257</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1H-1,2,3-triazolyl piperazino oxazolidinone analogs with optionally varied glycinyl substitutions were synthesized and their antibacterial activity assessed against a panel of susceptible and resistant Gram-pos. and selected Gram-neg. bacteria including clin. isolates.  The N-aroyl- and N-heteroaroyl-glycinyl (MIC: 0.06-4 μg/mL) derivs. were more potent than the N-acylglycinyl (2-8 μg/mL) derivs. against all Gram-pos. bacteria tested.  Nitro substitution on aryl and heteroaryl rings significantly enhanced activity against Gram-pos. bacteria, as noted with the 3,5-dinitrobenzoyl (I, R = H, Me) and 5-nitro-2-furoyl (II, R = H, Me) derivs. with MIC ranges of and 0.25-0.5 and 0.06-0.5 μg/mL, resp.  These nitro analogs also showed more potent extended activity against Moraxella catarrhalis, with MICs ranges of 0.25-1 μg/mL, compared to linezolid (MIC: 8 μg/mL).  Hence, the presence of the N-aroyl and/or N-heteroaroyl glycinyl structural motifs as spacer groups could significantly enhance the antibacterial activities of 1H-1,2,3-triazolyl oxazolidinone class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryeCCv-YLmMrVg90H21EOLACvtfcHk0ljP7iaeenRyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SktLzE&md5=c12a45b3cb05e9a053f5cd03f81356ae</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DUdo%26aufirst%3DE.%2BE.%26aulast%3DAbdel-Hamid%26aufirst%3DM.%2BE.%26aulast%3DVarghese%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520N-substituted-glycinyl%25201H-1%252C2%252C3-triazolyl%2520oxazolidinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D246%26epage%3D257%26doi%3D10.1016%2Fj.ejmech.2013.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of novel Ligustrazine derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3315</span>– <span class="NLM_lpage">3320</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2007.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=17383884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvFOmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3315-3320&author=X.+C.+Chengauthor=X.+Y.+Liuauthor=W.+F.+Xuauthor=X.+L.+Guoauthor=Y.+Ou&title=Design%2C+synthesis%2C+and+biological+activities+of+novel+Ligustrazine+derivatives&doi=10.1016%2Fj.bmc.2007.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological activities of novel Ligustrazine derivatives</span></div><div class="casAuthors">Cheng, Xian-Chao; Liu, Xin-Yong; Xu, Wen-Fang; Guo, Xiu-Li; Ou, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3315-3320</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of novel Ligustrazine derivs. was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities.  The results showed that most Ligustrazine derivs. exhibited lower EC50 values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine.  And some Ligustrazine derivs. presented better antiplatelet aggregation activities than Ligustrazine. The derivs. contg. the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency.  Compd. 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compd. 7c was found to be the most active antiplatelet aggregation agent.  Structure-activity relationships were briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYvrWZfPyMOrVg90H21EOLACvtfcHk0ljP7iaeenRyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvFOmurg%253D&md5=d8c65234f7d1c16ae731965061d89028</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%2BC.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DW.%2BF.%26aulast%3DGuo%26aufirst%3DX.%2BL.%26aulast%3DOu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520novel%2520Ligustrazine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3315%26epage%3D3320%26doi%3D10.1016%2Fj.bmc.2007.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. B.</span></span> <span> </span><span class="NLM_article-title">Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.jns.2012.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23140983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2013&pages=94-99&author=J.+Z.+Huauthor=J.+H.+Huangauthor=Z.+M.+Xiaoauthor=J.+H.+Liauthor=X.+M.+Liauthor=H.+B.+Lu&title=Tetramethylpyrazine+accelerates+the+function+recovery+of+traumatic+spinal+cord+in+rat+model+by+attenuating+inflammation&doi=10.1016%2Fj.jns.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation</span></div><div class="casAuthors">Hu, Jian-Zhong; Huang, Jiang-Hu; Xiao, Zhi-Man; Li, Jun-Hao; Li, Xiao-Ming; Lu, Hong-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, we explored the effects of tetramethylpyrazine (TMP), an alkaloid extd. from the Chinese herbal medicine Ligusticum wallichii Franchat (chuanxiong), on a rat model of contusion spinal cord injury (SCI).  The contusion SCI model was induced in rats by a modified Allen's wt.-drop method with a severity of 5 g × 50 mm impacting on the T10 segment.  In the TMP treatment group, rats were injected i.p. (i.p.) with TMP (200 mg/kg), every 24 h for 5 days, starting half an hour after contusion SCI.  The control group was treated with saline.  Compared with the control group, the TMP group significantly ameliorated the recovery of hindlimb function of rats.  TMP treatment significantly reduced the expression of macrophage migration inhibitory factor, nuclear factor κappa B, pro-inflammatory cytokine interleukin-18 and neutrophil infiltration.  On the other hand, TMP enhanced the expression of inhibitor κappa B and anti-inflammation cytokine interleukin-10.  In conclusion, our results demonstrate that TMP inhibits the development of inflammation and tissue injury assocd. with spinal cord contusion in rats which may improve the rats' hindlimb function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRROEOzCOySrVg90H21EOLACvtfcHk0ljTVgNOqntAaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqtb7L&md5=bac34f7562bae80c8f1d1ff383c0c1a2</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%2BZ.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DXiao%26aufirst%3DZ.%2BM.%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DLu%26aufirst%3DH.%2BB.%26atitle%3DTetramethylpyrazine%2520accelerates%2520the%2520function%2520recovery%2520of%2520traumatic%2520spinal%2520cord%2520in%2520rat%2520model%2520by%2520attenuating%2520inflammation%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2013%26volume%3D324%26spage%3D94%26epage%3D99%26doi%3D10.1016%2Fj.jns.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kao, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. J.</span></span> <span> </span><span class="NLM_article-title">Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2013.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.expneurol.2013.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23644042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1KgsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=2013&pages=188-201&author=T.+K.+Kaoauthor=C.+Y.+Changauthor=Y.+C.+Ouauthor=W.+Y.+Chenauthor=Y.+H.+Kuanauthor=H.+C.+Panauthor=S.+L.+Liaoauthor=G.+Z.+Liauthor=C.+J.+Chen&title=Tetramethylpyrazine+reduces+cellular+inflammatory+response+following+permanent+focal+cerebral+ischemia+in+rats&doi=10.1016%2Fj.expneurol.2013.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats</span></div><div class="casAuthors">Kao, Tsung-Kuei; Chang, Cheng-Yi; Ou, Yen-Chuan; Chen, Wen-Ying; Kuan, Yu-Hsiang; Pan, Hung-Chuan; Liao, Su-Lan; Li, Guo-Zhang; Chen, Chun-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188-201</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tetramethylpyrazine (TMP) has been used to treat ischemic stroke.  However, scientific evidence related to its effectiveness or precise modes of neuroprotective action is largely unclear.  This study provides evidence of an alternative target for TMP and sheds light on the mechanism of its physiol. benefits.  We report a global inhibitory effect of TMP on intracerebral cellular inflammatory response in a rat model of permanent cerebral ischemia.  TMP exhibited a neuroprotective effect against ischemic deficits by redn. of behavioral disturbance, brain infarction, and edema.  The results of immunohistochem., enzymic assay, Western blot, real-time reverse transcriptase-polymerase chain reaction (RT-PCR), and flow cytometric anal. revealed that TMP reduced the percentages of activated macrophages/microglia and infiltrative lymphocytes, neutrophils, and macrophages and pro-inflammatory cytokine expression after cerebral ischemia.  In parallel with these immunosuppressive phenomena, TMP also attenuated the activities of ischemia-induced inflammation-assocd. signaling mols. and transcription factors.  Another finding in this study was that the anti-inflammatory and neuroprotective effects of TMP were accompanied by a further elevated expression of NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in ipsilateral neurons and macrophages/microglia after cerebral ischemia.  Taken together, our results suggest that both the promotion of endogenous defense capacity and the attenuation of the extent and compn. percentage of the major cellular inflammatory responses via targeting of macrophages/microglia by elevating Nrf2/HO-1 expression might actively contribute to TMP-mediated neuroprotection against cerebral ischemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4UACzRMskarVg90H21EOLACvtfcHk0ljTVgNOqntAaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1KgsLjK&md5=b046158bce4b881a30122c60faf8534b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2013.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2013.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKao%26aufirst%3DT.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DOu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DW.%2BY.%26aulast%3DKuan%26aufirst%3DY.%2BH.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DLiao%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BZ.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26atitle%3DTetramethylpyrazine%2520reduces%2520cellular%2520inflammatory%2520response%2520following%2520permanent%2520focal%2520cerebral%2520ischemia%2520in%2520rats%26jtitle%3DExp.%2520Neurol.%26date%3D2013%26volume%3D247%26spage%3D188%26epage%3D201%26doi%3D10.1016%2Fj.expneurol.2013.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, Y.</span></span> <span> </span><span class="NLM_article-title">Antiinflammatory effect of tetramethylpyrazine and ferulic acid</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1248/cpb.40.954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1248%2Fcpb.40.954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1525949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1Sit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1992&pages=954-956&author=Y.+Ozaki&title=Antiinflammatory+effect+of+tetramethylpyrazine+and+ferulic+acid&doi=10.1248%2Fcpb.40.954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effect of tetramethylpyrazine and ferulic acid</span></div><div class="casAuthors">Ozaki, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">954-6</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Tetramethylpyrazine (TMP) is one of the alkaloids contained in Ligusticum wallichii.  Ferulic acid (FA) is a phenolic compd. contained in L. wallichii and Angelica sinensis.  The present study was carried out to examine the anti-inflammatory effect and to elucidate the mode of the effect of TMP and FA.  Both compds. significantly inhibited the edema induced by carrageenin, the increase of the dye leakage induced by acetic acid and the granuloma formation induced by cotton pellet.  And also, TMP and FA inhibited the no. of writhes induced by acetic acid.  From these results, it is suggested that both compds. have the anti-inflammatory effect and the analgesic effect, and both compds. exert an anti-inflammatory effect at the early and the late stages of processes in the inflammatory pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kf6LkFA1JrVg90H21EOLACvtfcHk0ljTVgNOqntAaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1Sit7k%253D&md5=b1d0bedf38da89af176d3f64337b66b6</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1248%2Fcpb.40.954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.40.954%26sid%3Dliteratum%253Aachs%26aulast%3DOzaki%26aufirst%3DY.%26atitle%3DAntiinflammatory%2520effect%2520of%2520tetramethylpyrazine%2520and%2520ferulic%2520acid%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1992%26volume%3D40%26spage%3D954%26epage%3D956%26doi%3D10.1248%2Fcpb.40.954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. B.</span></span> <span> </span><span class="NLM_article-title">Protective effects of ligustrazine on TNF-α-induced endothelial dysfunction</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>674</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.10.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejphar.2011.10.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22094067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1KmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=674&publication_year=2012&pages=365-369&author=H.+J.+Wuauthor=J.+Haoauthor=S.+Q.+Wangauthor=B.+L.+Jinauthor=X.+B.+Chen&title=Protective+effects+of+ligustrazine+on+TNF-%CE%B1-induced+endothelial+dysfunction&doi=10.1016%2Fj.ejphar.2011.10.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of ligustrazine on TNF-α-induced endothelial dysfunction</span></div><div class="casAuthors">Wu, Hong-Jin; Hao, Jing; Wang, Sheng-Qi; Jin, Bi-Lian; Chen, Xian-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">674</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">365-369</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To investigate the effects of Ligustrazine, a compd. derived from chuanxiong, on tumor necrosis factor-α (TNF-α) stimulated endothelial cells.  Human umbilical vein endothelial cells (HUVECs) were stimulated with TNF-α in vitro.  Nitric oxide (NO) was measured as a std. of endothelial dysfunction.  Two important indicators of autoimmunity, intracellular adhesion mol.-1 (ICAM-1) and heat shock protein 60 (HSP60), were selected to evaluate the influence of Ligustrazine on HUVECs.  Ligustrazine (40 μg/mL) significantly reversed the decrease in NO prodn. induced by TNF-α (5 ng/mL) in HUVECs.  The expressions of ICAM-1 and HSP60 were increased by TNF-α treatment, but dramatically inhibited by treatment with ligustrazine in TNF-α-stimulated cells.  Ligustrazine increased the prodn. of NO in HUVECs and had an immunomodulatory effect on HUVECs stimulated with TNF-α by down-regulating the expression of ICAM-1 and HSP60.  These results suggest that ligustrazine protects the endothelium via inhibition of immunol. reactions, preventing atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCAUE9kl-JrVg90H21EOLACvtfcHk0liZQtSVXGUAgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1KmsQ%253D%253D&md5=31939a4eab87b96fb37cfd00f96f0d03</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.10.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.10.046%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DJin%26aufirst%3DB.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BB.%26atitle%3DProtective%2520effects%2520of%2520ligustrazine%2520on%2520TNF-%25CE%25B1-induced%2520endothelial%2520dysfunction%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D674%26spage%3D365%26epage%3D369%26doi%3D10.1016%2Fj.ejphar.2011.10.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, F.</span></span> <span> </span><span class="NLM_article-title">Effect of tetramethylpyrazine on primary afferent transmission mediated by P2 × 3 receptor in neuropathic pain states</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2008.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.brainresbull.2008.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18639742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=27-32&author=Y.+Gaoauthor=C.+Xuauthor=S.+Liangauthor=A.+Zhangauthor=S.+Muauthor=Y.+Wangauthor=F.+Wan&title=Effect+of+tetramethylpyrazine+on+primary+afferent+transmission+mediated+by+P2+%C3%97+3+receptor+in+neuropathic+pain+states&doi=10.1016%2Fj.brainresbull.2008.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X3 receptor in neuropathic pain states</span></div><div class="casAuthors">Gao, Yun; Xu, Changshui; Liang, Shangdong; Zhang, Aixia; Mu, Songniu; Wang, Yunxia; Wan, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-32</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Neuropathic pain is the most difficult type of pain to treat.  The P2X3 receptors play a crucial role in facilitating pain transmission at peripheral and spinal sites.  The present research investigated the effects of tetramethylpyrazine (TMP) on the primary afferent transmission induced by P2X3 receptor in neuropathic pain states.  Chronic constriction injury (CCI) model was adopted.  Sprague-Dawley male rats (n = 30) had been randomly divided into normal saline (sham + NS) group (I), TMP group (II), sham group (III), CCI + TMP group (IV), and CCI group (V).  Mech. withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were measured and P2X3 immunoreactivity in L4/L5 dorsal root ganglion (DRG) and spinal cord was detected by immunohistochem.  The mech. withdrawal threshold and thermal withdrawal latency in group V were lower than those in groups I-III or IV (p < 0.05), while P2X3 receptor expression of L4/L5 DRG and spinal cord in group V was higher than those in groups I-III (p < 0.01) or group IV (p < 0.05).  The mech. withdrawal threshold, thermal withdrawal latency and P2X3 immunoreactivity of L4/L5 DRG and spinal cord in group IV showed no significant difference compared with those in groups I, II or III (p > 0.05).  The amplitudes of the currents in group V (CCI) were much larger than those obtained in other groups after application of same concn. ATP disodium (ATP) (p < 0.01). α,β-Methylene-ATP (α,β-meATP)-activated currents in DRG neurons of CCI rats were more obvious than those obtained in other group rats (p < 0.01).  The results showed that TMP may inhibit the primary afferent transmission of neuropathic pain induced by P2X3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5uaZHQkmC7Vg90H21EOLACvtfcHk0liZQtSVXGUAgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGrs7s%253D&md5=0b0698904231ccd13bb845a59fd10a4d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2008.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2008.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DF.%26atitle%3DEffect%2520of%2520tetramethylpyrazine%2520on%2520primary%2520afferent%2520transmission%2520mediated%2520by%2520P2%2520%25C3%2597%25203%2520receptor%2520in%2520neuropathic%2520pain%2520states%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2008%26volume%3D77%26spage%3D27%26epage%3D32%26doi%3D10.1016%2Fj.brainresbull.2008.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo</span>. <i>BMC Complementary Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">233</span>, <span class="refDoi"> DOI: 10.1186/s12906-017-1739-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1186%2Fs12906-017-1739-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28449676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=233&author=L.+Chenauthor=T.+Liuauthor=Q.+Wangauthor=J.+Liu&title=Anti-inflammatory+effect+of+combined+tetramethylpyrazine%2C+resveratrol+and+curcumin+in+vivo&doi=10.1186%2Fs12906-017-1739-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo</span></div><div class="casAuthors">Chen, Long; Liu, Tianjun; Wang, Qiangsong; Liu, Juan</div><div class="citationInfo"><span class="NLM_cas:title">BMC Complementary and Alternative Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233/1-233/10</span>CODEN:
                <span class="NLM_cas:coden">BCAMCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6882</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Resveratrol and curcumin, as natural flavones products, have good therapeutic effect in acute and chronic inflammation; on the other hand, tetramethylpyrazine (TMP) has angiogenesis and vessel protection effect as well as anti-inflammatory function.  In this paper, the anti-inflammatory effect of the tetramethylpyrazine, resveratrol and curcumin (TRC) combination in acute and chronic inflammation was reported in vivo.  Methods: The dose of the combined three natural products was optimized based on the acute paw swelling mouse model with a Uniform Design methodol.  The therapeutic effect of TRC combination on chronic inflammation was investigated by using the collagen-induced arthritis (CIA) rat model based upon the following indexes: the vol. of paw swelling, arthritis score, serum mediators and histol. examn. as well as immunohistochem. staining.  The levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) in serum were measured and the pathol. sections of liver and kidney were analyzed.  LD50 was measured based on the acute oral toxicity (AOT) std. method.  Results: The best formulation was the three components combined at the same mass proportion revealed by the Uniform Design methodol.  This combination could significantly reduce the paw swelling in acute paw swelling mouse model, could reduce paw swelling and alleviate the damage in joint structural of ankle, cartilages and fibrous tissue in CIA rat model.  The dose relationship was clear in both cases.  Immunohistochem. staining of ankle tissue revealed that TRC combination was able to inhibit the expression of NF-κB p65 and TNF-α which were closely related to the inflammatory process.  Anal. of serum mediators revealed TRC combination could inhibit the prodn. of TNF-α, IL-1β, and IL-6 in the serum.  Toxic study revealed this formulation was low toxic, LD50 was larger than 5 g/kg, both the level of ALT and AST and histopathol. in the liver and kidney exhibited no distinctions between the TRC combination and the blank group, no mortality occurred at the administered doses of 5 g/kg.  Conclusions: The results showed this formulation could provide a novel potent treatment for acute and chronic inflammation (RA) without side effect like gastric injury occurring in NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAiJiTlLXCxbVg90H21EOLACvtfcHk0liZQtSVXGUAgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitL%252FK&md5=4aaa59353f7d43541331c7e8fe776cc7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1186%2Fs12906-017-1739-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12906-017-1739-7%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DAnti-inflammatory%2520effect%2520of%2520combined%2520tetramethylpyrazine%252C%2520resveratrol%2520and%2520curcumin%2520in%2520vivo%26jtitle%3DBMC%2520Complementary%2520Altern.%2520Med.%26date%3D2017%26volume%3D17%26spage%3D233%26doi%3D10.1186%2Fs12906-017-1739-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huangfu, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. M.</span></span> <span> </span><span class="NLM_article-title">Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fcbdd.12537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25677093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKnsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=682-690&author=Y.+Chenauthor=Z.+X.+Ruanauthor=F.+Wangauthor=D.+S.+Huangfuauthor=P.+H.+Sunauthor=J.+Linauthor=W.+M.+Chen&title=Novel+Oxazolidinone+Antibacterial+Analogues+with+a+Substituted+Ligustrazine+C-ring+Unit&doi=10.1111%2Fcbdd.12537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit</span></div><div class="casAuthors">Chen, Yan; Ruan, Zhi-Xiong; Wang, Fang; Huangfu, De-Sheng; Sun, Ping-Hua; Lin, Jing; Chen, Wei-Min</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone compds. with a substituted ligustrazine C-ring unit and different substituted groups at the C-5 side chain were designed and synthesized using linezolid as a lead and based on a scaffold hopping strategy.  Their antibacterial and anti-inflammatory activities were evaluated.  The results of in vitro antibacterial assays showed that all fourteen target compds. displayed potent activity against Gram-pos. pathogens, particularly I, II and 4 other compds.  Moreover, I and II exhibited significant inhibitory activities on the prodn. of inflammatory mediators, including nitric oxide, interleukin-6, and tumor necrosis factor-alpha.  Thus, these derivs. could serve as valuable candidates to develop anti-infective agents for the treatment of chronic wounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs5x0cVc4ABbVg90H21EOLACvtfcHk0lgcokbE7HHOxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKnsL3F&md5=304dc66cd8436863eda3ea916881abb1</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12537%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRuan%26aufirst%3DZ.%2BX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuangfu%26aufirst%3DD.%2BS.%26aulast%3DSun%26aufirst%3DP.%2BH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%2BM.%26atitle%3DNovel%2520Oxazolidinone%2520Antibacterial%2520Analogues%2520with%2520a%2520Substituted%2520Ligustrazine%2520C-ring%2520Unit%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D682%26epage%3D690%26doi%3D10.1111%2Fcbdd.12537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seetharamsingh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dange, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khairnar, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeraraghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalanka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1105-1110&author=B.+Seetharamsinghauthor=R.+Rameshauthor=S.+S.+Dangeauthor=P.+V.+Khairnarauthor=S.+Singhalauthor=D.+Upadhyayauthor=S.+Veeraraghavanauthor=S.+Viswanadhaauthor=S.+Vakkalankaauthor=D.+S.+Reddy&title=Design%2C+Synthesis%2C+and+Identification+of+Silicon+Incorporated+Oxazolidinone+Antibiotics+with+Improved+Brain+Exposure&doi=10.1021%2Facsmedchemlett.5b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure</span></div><div class="casAuthors">Seetharamsingh, B.; Ramesh, Remya; Dange, Santoshkumar S.; Khairnar, Pankaj V.; Singhal, Smita; Upadhyay, Dilip; Veeraraghavan, Sridhar; Viswanadha, Srikant; Vakkalanka, Swaroop; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1105-1110</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapeutic options for brain infections caused by pathogens with a reduced sensitivity to drugs are limited.  Recent reports on the potential use of linezolid in treating brain infections prompted us to design novel compds. around this scaffold.  Herein, we describe the design and synthesis of various oxazolidinone antibiotics with the incorporation of silicon.  Our findings in preclin. species suggest that silicon incorporation is highly useful in improving brain exposures.  Interestingly, three compds. from this series demonstrated up to a 30-fold higher brain/plasma ratio when compared to linezolid thereby indicating their therapeutic potential in brain assocd. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbe8J69irIubVg90H21EOLACvtfcHk0lgcokbE7HHOxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWlt7rN&md5=46c49403d18d279226b5cdc8d1a94418</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00213%26sid%3Dliteratum%253Aachs%26aulast%3DSeetharamsingh%26aufirst%3DB.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DDange%26aufirst%3DS.%2BS.%26aulast%3DKhairnar%26aufirst%3DP.%2BV.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DUpadhyay%26aufirst%3DD.%26aulast%3DVeeraraghavan%26aufirst%3DS.%26aulast%3DViswanadha%26aufirst%3DS.%26aulast%3DVakkalanka%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Identification%2520of%2520Silicon%2520Incorporated%2520Oxazolidinone%2520Antibiotics%2520with%2520Improved%2520Brain%2520Exposure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1105%26epage%3D1110%26doi%3D10.1021%2Facsmedchemlett.5b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0lgcokbE7HHOxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manninen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allwine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovasz, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00194-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0960-894X%2898%2900194-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9871741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXjsVyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1231-1236&author=D.+M.+Gleaveauthor=S.+J.+Bricknerauthor=P.+R.+Manninenauthor=D.+A.+Allwineauthor=K.+D.+Lovaszauthor=D.+C.+Rohrerauthor=J.+A.+Tuckerauthor=G.+E.+Zurenkoauthor=C.+W.+Ford&title=Synthesis+and+antibacterial+activity+of+%5B6%2C5%2C5%5D+and+%5B6%2C6%2C5%5D+tricyclic+fused+oxazolidinones&doi=10.1016%2FS0960-894X%2898%2900194-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones</span></div><div class="casAuthors">Gleave, D. Mark; Brickner, Steven J.; Manninen, Peter R.; Allwine, Debra A.; Lovasz, Kristine D.; Rohrer, Douglas C.; Tucker, John A.; Zurenko, Gary E.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1231-1236</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of conformationally restricted, [6,5,5] and [6,6,5] tricyclic fused oxazolidinones were synthesized and tested for antibacterial activity.  Several compds., e.g. I, in the trans-[6,5,5] series demonstrated potent in vitro and in vivo activity.  This work provides valuable information regarding the preferred conformational orientation of the oxazolidinones at the binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUIYes0rBV7Vg90H21EOLACvtfcHk0ljMAOxeH0aFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsVyit7k%253D&md5=309a6e1105f09d7e03887c04abef86b4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900194-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900194-2%26sid%3Dliteratum%253Aachs%26aulast%3DGleave%26aufirst%3DD.%2BM.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DAllwine%26aufirst%3DD.%2BA.%26aulast%3DLovasz%26aufirst%3DK.%2BD.%26aulast%3DRohrer%26aufirst%3DD.%2BC.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520%255B6%252C5%252C5%255D%2520and%2520%255B6%252C6%252C5%255D%2520tricyclic%2520fused%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D1231%26epage%3D1236%26doi%3D10.1016%2FS0960-894X%2898%2900194-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone Antibacterial Agents. An Enantioselective Synthesis of the [6,5,5] Tricyclic Fused Oxazolidinone Ring System and Application to the Synthesis of a Rigid DuP 721 Analogue</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6470</span>– <span class="NLM_lpage">6474</span>, <span class="refDoi"> DOI: 10.1021/jo960945s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo960945s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XltVWksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=6470-6474&author=D.+M.+Gleaveauthor=S.+J.+Brickner&title=Oxazolidinone+Antibacterial+Agents.+An+Enantioselective+Synthesis+of+the+%5B6%2C5%2C5%5D+Tricyclic+Fused+Oxazolidinone+Ring+System+and+Application+to+the+Synthesis+of+a+Rigid+DuP+721+Analogue&doi=10.1021%2Fjo960945s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antibacterial agents. An enantioselective synthesis of the [6,5,5] tricyclic fused oxazolidinone ring system and application to the synthesis of a rigid DuP 721 analog</span></div><div class="casAuthors">Gleave, D. Mark; Brickner, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6470-6474</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An asym. synthesis of the parent tricyclic fused oxazolidinone I (R = H) was reported.  This compd. is a useful intermediate for the synthesis of oxazolidinone antibacterial agents.  A key step in the synthesis of I was an intramol. aryl N-lithio carbamate-epoxide cyclization which led to the formation of both five-membered rings, with complete regiochem. control.  Good enantioselectivity was achieved through the use of an asym. Sharpless epoxidn., which furnishes the epoxide product in ≥95% ee.  Oxazolidinone I was readily converted into I (R = acetyl), a tricyclic analog of the known antibacterial agent DuP 721.  Oxazolidinone I (R = acetyl) is a potent antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9KaPUXd4heLVg90H21EOLACvtfcHk0ljMAOxeH0aFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltVWksbg%253D&md5=31fcf031e4c0f9d91bb30a2078c1d907</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjo960945s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo960945s%26sid%3Dliteratum%253Aachs%26aulast%3DGleave%26aufirst%3DD.%2BM.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26atitle%3DOxazolidinone%2520Antibacterial%2520Agents.%2520An%2520Enantioselective%2520Synthesis%2520of%2520the%2520%255B6%252C5%252C5%255D%2520Tricyclic%2520Fused%2520Oxazolidinone%2520Ring%2520System%2520and%2520Application%2520to%2520the%2520Synthesis%2520of%2520a%2520Rigid%2520DuP%2520721%2520Analogue%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D6470%26epage%3D6474%26doi%3D10.1021%2Fjo960945s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, R.</span></span> <span> </span><span class="NLM_article-title">Stereocontrolled Synthesis of Tricyclic Fused Oxazolidinone as Antibacterial Agent</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570430438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fjhet.5570430438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD28XosFCru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=1071-1075&author=Y.+Cuiauthor=Y.+Dangauthor=Y.+Yangauthor=R.+Ji&title=Stereocontrolled+Synthesis+of+Tricyclic+Fused+Oxazolidinone+as+Antibacterial+Agent&doi=10.1002%2Fjhet.5570430438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Stereocontrolled synthesis of tricyclic fused oxazolidinone as antibacterial agent</span></div><div class="casAuthors">Cui, Yingjie; Dang, Yaxian; Yang, Yushe; Ji, Ruyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1071-1075</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">Tricyclic fused oxazolidinones (shown as I; R = H, Br) were synthesized as antibacterial agents in 12 and 11 steps resp.  The key intermediates (3R,3aS)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]-3a,4-dihydro-3H-[1,3]oxazolo[4,3-c][1,4]benzoxazin-1-one and (3R,3aS)-7-bromo-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]-3a,4-dihydro-3H-[1,3]oxazolo[4,3-c][1,4]benzoxazin-1-one were developed via opening of epoxides benzyl [2-[[(2R,3S)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]oxiran-2-yl]methoxy]phenyl]carbamate and benzyl [4-bromo-2-[[(2R,3S)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]oxiran-2-yl]methoxy]phenyl]carbamate and cyclization by the resulting oxygen anion attack.  The antibacterial activity of I was weak.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoltshfwhsCV7Vg90H21EOLACvtfcHk0ljMAOxeH0aFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosFCru7o%253D&md5=5982244c015d713e550cb5034926f75e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430438%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DR.%26atitle%3DStereocontrolled%2520Synthesis%2520of%2520Tricyclic%2520Fused%2520Oxazolidinone%2520as%2520Antibacterial%2520Agent%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D1071%26epage%3D1075%26doi%3D10.1002%2Fjhet.5570430438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0ljMAOxeH0aFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0lilumRLAVzLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyermann, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravestock, M. B.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1021/jm0400810</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0400810" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslKj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=499-506&author=F.+Reckauthor=F.+Zhouauthor=M.+Girardotauthor=G.+Kernauthor=C.+J.+Eyermannauthor=N.+J.+Halesauthor=R.+R.+Ramsayauthor=M.+B.+Gravestock&title=Identification+of+4-substituted+1%2C2%2C3-triazoles+as+novel+oxazolidinone+antibacterial+agents+with+reduced+activity+against+monoamine+oxidase+A&doi=10.1021%2Fjm0400810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A</span></div><div class="casAuthors">Reck, Folkert; Zhou, Fei; Girardot, Marc; Kern, Gunther; Eyermann, Charles J.; Hales, Neil J.; Ramsay, Rona R.; Gravestock, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones represent a new and promising class of antibacterial agents.  Current research in this area is mainly concd. on improving the safety profile and the antibacterial spectrum.  Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.  Recently, it was found that the 1,2,3-triazole is a good replacement for the conventional acetamide functionality found in oxazolidinones.  The authors now disclose the finding that 1,2,3-triazoles bearing a substituent like Me, small substituted Me, bromo, or a linear (sp-hybridized) group at the 4 position are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A.  The results are esp. promising for the development of oxazolidinones with an improved safety profile.  The MAO-A SAR can be rationalized on the basis of docking studies to a MAO-A/MAO-B homol. model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDPr2eh7f0ArVg90H21EOLACvtfcHk0lilumRLAVzLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslKj&md5=350b152fd789697c92694e1a747827de</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm0400810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0400810%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGirardot%26aufirst%3DM.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DEyermann%26aufirst%3DC.%2BJ.%26aulast%3DHales%26aufirst%3DN.%2BJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DGravestock%26aufirst%3DM.%2BB.%26atitle%3DIdentification%2520of%25204-substituted%25201%252C2%252C3-triazoles%2520as%2520novel%2520oxazolidinone%2520antibacterial%2520agents%2520with%2520reduced%2520activity%2520against%2520monoamine%2520oxidase%2520A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D499%26epage%3D506%26doi%3D10.1021%2Fjm0400810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brieland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brideau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dority, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadwood, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongliang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulavik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, J. V.</span></span> <span> </span><span class="NLM_article-title">Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5886</span>– <span class="NLM_lpage">5889</span>, <span class="refDoi"> DOI: 10.1021/jm070708p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070708p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12gs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5886-5889&author=T.+J.+Poelauthor=R.+C.+Thomasauthor=W.+J.+Adamsauthor=P.+A.+Aristoffauthor=M.+R.+Barbachynauthor=F.+E.+Boyerauthor=J.+Brielandauthor=R.+Brideauauthor=J.+Brodfuehrerauthor=A.+P.+Brownauthor=A.+L.+Choyauthor=M.+Dermyerauthor=M.+Dorityauthor=C.+W.+Fordauthor=R.+C.+Gadwoodauthor=D.+Hannaauthor=C.+Hongliangauthor=M.+D.+Hubandauthor=C.+Huberauthor=R.+Kellyauthor=J.+Y.+Kimauthor=J.+P.+Martinauthor=P.+J.+Paganoauthor=D.+Rossauthor=L.+Skerlosauthor=M.+C.+Sulavikauthor=T.+Zhuauthor=G.+E.+Zurenkoauthor=J.+V.+Prasad&title=Antibacterial+oxazolidinones+possessing+a+novel+C-5+side+chain.+%285R%29-trans-3-%5B3-Fluoro-4-+%281-oxotetrahydrothiopyran-4-yl%29phenyl%5D-2-+oxooxazolidine-5-carboxylic+acid+amide+%28PF-00422602%29%2C+a+new+lead+compound&doi=10.1021%2Fjm070708p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial Oxazolidinones Possessing a Novel C-5 Side Chain. (5R)-trans-3-[3-Fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxylic Acid Amide (PF-00422602), a New Lead Compound</span></div><div class="casAuthors">Poel, Toni-Jo; Thomas, Richard C.; Adams, Wade J.; Aristoff, Paul A.; Barbachyn, Michael R.; Boyer, Frederick E.; Brieland, Joan; Brideau, Roger; Brodfuehrer, Joanne; Brown, Alan P.; Choy, Allison L.; Dermyer, Michael; Dority, Michael; Ford, Charles W.; Gadwood, Robert C.; Hanna, Debra; Cai, Hongliang; Huband, Michael D.; Huber, Christopher; Kelly, Rose; Kim, Ji-Young; Martin, Joseph P., Jr.; Pagano, Paul J.; Ross, Daniel; Skerlos, Laura; Sulavik, Mark C.; Zhu, Tong; Zurenko, Gary E.; Prasad, J. V. N. Vara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5886-5889</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones possessing a C-5 carboxamide functionality (reverse amides) represent a new series of compds. that block bacterial protein synthesis.  These reverse amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus possess less potential for the side effects assocd. with MAO inhibition.  The title compd. (14) showed reduced in vivo myelotoxicity compared to linezolid in a 14-day safety study in rats, potent in vivo efficacy in murine systemic infection models, and excellent pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcqvXBXhlyY7Vg90H21EOLACvtfcHk0lhHX8YJXFNJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12gs7%252FM&md5=4444deb21162db7f82e60259a85f07d1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm070708p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070708p%26sid%3Dliteratum%253Aachs%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DBoyer%26aufirst%3DF.%2BE.%26aulast%3DBrieland%26aufirst%3DJ.%26aulast%3DBrideau%26aufirst%3DR.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BP.%26aulast%3DChoy%26aufirst%3DA.%2BL.%26aulast%3DDermyer%26aufirst%3DM.%26aulast%3DDority%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DGadwood%26aufirst%3DR.%2BC.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DHongliang%26aufirst%3DC.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DMartin%26aufirst%3DJ.%2BP.%26aulast%3DPagano%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DD.%26aulast%3DSkerlos%26aufirst%3DL.%26aulast%3DSulavik%26aufirst%3DM.%2BC.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DPrasad%26aufirst%3DJ.%2BV.%26atitle%3DAntibacterial%2520oxazolidinones%2520possessing%2520a%2520novel%2520C-5%2520side%2520chain.%2520%25285R%2529-trans-3-%255B3-Fluoro-4-%2520%25281-oxotetrahydrothiopyran-4-yl%2529phenyl%255D-2-%2520oxooxazolidine-5-carboxylic%2520acid%2520amide%2520%2528PF-00422602%2529%252C%2520a%2520new%2520lead%2520compound%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5886%26epage%3D5889%26doi%3D10.1021%2Fjm070708p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3697</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23721807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3697-3699&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+biological+evaluation+of+novel+benzoxazinyl-oxazolidinones+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3697-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of benzoxazinyl-oxazolidinones bearing 3-triazolylmethyl or 3-carboxamide side chain were designed and synthesized with the aim to develop antibacterial agents with improved properties.  In vitro antibacterial activities of these novel compds. were evaluated against a panel of resistant and susceptible Gram-pos. bacteria.  Most analogs bearing 3-triazolylmethyl showed good to moderate antibacterial activities.  Compd. I exhibited a fourfold increase in activity compared with linezolid against all the tested strains, which was identified to be a promising antibacterial agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGOMF4mbAZWbVg90H21EOLACvtfcHk0lhHX8YJXFNJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D&md5=6b94ab65a6988a6456e66f526f871ef4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzoxazinyl-oxazolidinones%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3697%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2203</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2015.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25838143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2203-2210&author=T.+Xueauthor=S.+Dingauthor=B.+Guoauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+structure-activity+relationship+studies+of+novel+%5B6%2C6%2C5%5D+tricyclic+oxazolidinone+derivatives+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2015.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents</span></div><div class="casAuthors">Xue, Tao; Ding, Shi; Guo, Bin; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2203-2210</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our previous Letter, we reported the discovery of a novel benzoxazinyl-oxazolidinone antibacterial candidate I.  In order to identify a potential backup compd., extensive modifications on the B/C ring and C3 side chain were undertaken.  A series of novel [6,6,5] tricyclic analogs were synthesized and their in vitro antibacterial activities were tested against a panel of susceptible and resistant Gram-pos. pathogens.  Among of them, benzothiazinyl-oxazolidinones with acetamide or thioamide as C3 side chains exhibited moderate to good antibacterial activity, such as compds. II and III.  In vitro liver microsomal stability was further evaluated and the results manifested that compds. II and III were both metabolically stable in rat and human liver microsomes.  Addnl., insights gained from this investigation should provide directions for the further research of new oxazolidinone antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWKeyGmADQbVg90H21EOLACvtfcHk0lhHX8YJXFNJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOjt7w%253D&md5=d3062900e23c28723128541924869aba</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%2520%255B6%252C6%252C5%255D%2520tricyclic%2520oxazolidinone%2520derivatives%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2203%26epage%3D2210%26doi%3D10.1016%2Fj.bmcl.2015.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+Fluorine-Containing+Benzoxazinyl-oxazolidinones+for+the+Treatment+of+Multidrug+Resistant+Tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0liy1pgLQDPkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Fluorine-Containing%2520Benzoxazinyl-oxazolidinones%2520for%2520the%2520Treatment%2520of%2520Multidrug%2520Resistant%2520Tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+Conformationally+Constrained+Oxazolidinone+with+Improved+Safety+and+Efficacy+Profiles+for+the+Treatment+of+Multidrug-Resistant+Tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0liy1pgLQDPkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Conformationally%2520Constrained%2520Oxazolidinone%2520with%2520Improved%2520Safety%2520and%2520Efficacy%2520Profiles%2520for%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3234</span>– <span class="NLM_lpage">3248</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c02153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmtVOktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=3234-3248&author=Y.+Wuauthor=B.+Wangauthor=H.+Luauthor=H.+Zhaoauthor=B.+Yangauthor=L.+Liauthor=Y.+Luauthor=D.+Zhangauthor=N.+Sunauthor=H.+Huang&title=Identification+of+Novel+Tricyclic+Benzo%5B1%2C3%5Doxazinyloxazolidinones+as+Potent+Antibacterial+Agents+with+Excellent+Pharmacokinetic+Profiles+against+Drug-Resistant+Pathogens&doi=10.1021%2Facs.jmedchem.0c02153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens</span></div><div class="casAuthors">Wu, Yongqi; Wang, Bin; Lu, Haijia; Zhao, Hongyi; Yang, Beibei; Li, Li; Lu, Yu; Zhang, Dongfeng; Sun, Ning; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3234-3248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-pos. bacteria, and Gram-neg. bacteria.  The studies identified a new compd. 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL).  Compd. 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase.  Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concn. (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%).  The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh8_qQMEyOLbVg90H21EOLACvtfcHk0liy1pgLQDPkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmtVOktr8%253D&md5=e42709b515626613fd559330cc8d0373</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02153%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Novel%2520Tricyclic%2520Benzo%255B1%252C3%255Doxazinyloxazolidinones%2520as%2520Potent%2520Antibacterial%2520Agents%2520with%2520Excellent%2520Pharmacokinetic%2520Profiles%2520against%2520Drug-Resistant%2520Pathogens%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D3234%26epage%3D3248%26doi%3D10.1021%2Facs.jmedchem.0c02153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baruah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzari, A.</span></span> <span> </span><span class="NLM_article-title">(S)□4□(4□aminobenzyl)□2□oxazolidinone based 2□azetidinones for antimicrobial application and luminescent sensing of divalent metal cations</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2511</span>, <span class="refDoi"> DOI: 10.1002/jhet.3965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fjhet.3965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslKnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=2498-2511&author=S.+Baruahauthor=M.+Aierauthor=A.+Puzari&title=%28S%29%E2%96%A14%E2%96%A1%284%E2%96%A1aminobenzyl%29%E2%96%A12%E2%96%A1oxazolidinone+based+2%E2%96%A1azetidinones+for+antimicrobial+application+and+luminescent+sensing+of+divalent+metal+cations&doi=10.1002%2Fjhet.3965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-4-(4-Aminobenzyl)-2-oxazolidinone based 2-azetidinones for antimicrobial application and luminescent sensing of divalent metal cations</span></div><div class="casAuthors">Baruah, Shyamal; Aier, Merangmenla; Puzari, Amrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2498-2511</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Design and synthesis of a new series of (S)-4-(4-aminobenzyl)-2-oxazolidinone based multifunctional azetidinones I (R = C6H5, 2,4-(Cl)2C6H3, 3,4-(OCH3)2C6H3, 3,4-(Cl)2C6H3) were accomplished.  Synthesis of the scaffolds was performed through a multi-step reaction process involving protection of amine functional group, conversion of protected (S)-4-(4-aminobenzyl)-2-oxazolidinone to its acetic acid deriv. II and then to acid chloride III, and finally coupled with different substituted arom. imines (E)-RCH=NR1 (R1 = (CH2)2CH3, C6H5) under mild reaction conditions in presence of an appropriate base.  The compds. I and II were screened for their antimicrobial activity against gram-pos. and gram-neg. bacteria and found to possess better and promising antimicrobial property than some of the reported antimicrobial drugs like disulfonamide and tetracycline.  Addnl., the scaffolds also exhibit prominent sensing property for divalent metal cations like Cu2+, Zn2+, and Ni2+, through fluorescence quenching effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2NnNYVnwoqrVg90H21EOLACvtfcHk0ljY9gcC0vEPqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslKnt7Y%253D&md5=ab14b69efaa12e57b698b31ab12d18e3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fjhet.3965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.3965%26sid%3Dliteratum%253Aachs%26aulast%3DBaruah%26aufirst%3DS.%26aulast%3DAier%26aufirst%3DM.%26aulast%3DPuzari%26aufirst%3DA.%26atitle%3D%2528S%2529%25E2%2596%25A14%25E2%2596%25A1%25284%25E2%2596%25A1aminobenzyl%2529%25E2%2596%25A12%25E2%2596%25A1oxazolidinone%2520based%25202%25E2%2596%25A1azetidinones%2520for%2520antimicrobial%2520application%2520and%2520luminescent%2520sensing%2520of%2520divalent%2520metal%2520cations%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2020%26volume%3D57%26spage%3D2498%26epage%3D2511%26doi%3D10.1002%2Fjhet.3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adil Zainel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapkaç, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaca Gençer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilgın, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaduman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaküçük-İyidoǧan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oruç-Emre, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koçyiǧit-Kaymakçıoǧlu, B.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of biological activities of 1,3-oxazolidinone derivatives bearing amide, sulfonamide, and thiourea moieties</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>, <span class="NLM_elocation-id">1800057</span> <span class="refDoi"> DOI: 10.1002/ardp.201800057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.201800057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&author=N.+Karamanauthor=R.+Adil+Zainelauthor=H.+A.+Kapka%C3%A7author=H.+Karaca+Gen%C3%A7erauthor=S.+Ilg%C4%B1nauthor=A.+B.+Karadumanauthor=A.+Karak%C3%BC%C3%A7%C3%BCk-%C4%B0yido%C7%A7anauthor=E.+E.+Oru%C3%A7-Emreauthor=B.+Ko%C3%A7yi%C7%A7it-Kaymak%C3%A7%C4%B1o%C7%A7lu&title=Design+and+evaluation+of+biological+activities+of+1%2C3-oxazolidinone+derivatives+bearing+amide%2C+sulfonamide%2C+and+thiourea+moieties&doi=10.1002%2Fardp.201800057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fardp.201800057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201800057%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DN.%26aulast%3DAdil%2BZainel%26aufirst%3DR.%26aulast%3DKapka%25C3%25A7%26aufirst%3DH.%2BA.%26aulast%3DKaraca%2BGen%25C3%25A7er%26aufirst%3DH.%26aulast%3DIlg%25C4%25B1n%26aufirst%3DS.%26aulast%3DKaraduman%26aufirst%3DA.%2BB.%26aulast%3DKarak%25C3%25BC%25C3%25A7%25C3%25BCk-%25C4%25B0yido%25C7%25A7an%26aufirst%3DA.%26aulast%3DOru%25C3%25A7-Emre%26aufirst%3DE.%2BE.%26aulast%3DKo%25C3%25A7yi%25C7%25A7it-Kaymak%25C3%25A7%25C4%25B1o%25C7%25A7lu%26aufirst%3DB.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520biological%2520activities%2520of%25201%252C3-oxazolidinone%2520derivatives%2520bearing%2520amide%252C%2520sulfonamide%252C%2520and%2520thiourea%2520moieties%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26doi%3D10.1002%2Fardp.201800057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrère-Kremer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">7-chloroquinoline-isatin conjugates: antimalarial, antitubercular, and cytotoxic evaluation</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fcbdd.12273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=24341638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=622-629&author=R.+Rajauthor=C.+Biotauthor=S.+Carr%C3%A8re-Kremerauthor=L.+Kremerauthor=Y.+Gu%C3%A9rardelauthor=J.+Gutauthor=P.+J.+Rosenthalauthor=D.+Forgeauthor=V.+Kumar&title=7-chloroquinoline-isatin+conjugates%3A+antimalarial%2C+antitubercular%2C+and+cytotoxic+evaluation&doi=10.1111%2Fcbdd.12273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloroquinoline-isatin Conjugates: Antimalarial, Antitubercular, and Cytotoxic Evaluation</span></div><div class="casAuthors">Raj, Raghu; Biot, Christophe; Carrere-Kremer, Severine; Kremer, Laurent; Guerardel, Yann; Gut, Jiri; Rosenthal, Philip J.; Forge, Delphine; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of twenty piperazine-tethered 7-chloroquinoline-isatin hybrids have been synthesized via either direct nucleophilic substitution or Cu(Ι)Cl-mediated Mannich reaction.  These new conjugates were evaluated for their antimalarial and antitubercular efficacy against a chloroquine-resistant strain of Plasmodium falciparum and Mycobacterium tuberculosis, resp., while the cytotoxic profiles were evaluated against 3T6 cell line, a permanent mouse embryonic fibroblast cell line.  The most potent of the test compd. with IC50 of 0.22 μm against W2 strain of P. falciparum and 31.62 μm against the embryonic fibroblast cell line (cytotoxicity) displayed a high selective index of 143.73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyxMsit48IqrVg90H21EOLACvtfcHk0ljY9gcC0vEPqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWmsr0%253D&md5=4ab50cf9a231f0e9782062cdde98d69e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12273%26sid%3Dliteratum%253Aachs%26aulast%3DRaj%26aufirst%3DR.%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DCarr%25C3%25A8re-Kremer%26aufirst%3DS.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DForge%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3D7-chloroquinoline-isatin%2520conjugates%253A%2520antimalarial%252C%2520antitubercular%252C%2520and%2520cytotoxic%2520evaluation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D83%26spage%3D622%26epage%3D629%26doi%3D10.1111%2Fcbdd.12273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shalini</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Variedly connected 1,8-naphthalimide-7-chloroquinoline conjugates: Synthesis, anti-mycobacterial and cytotoxic evaluation</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">103241</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bioorg.2019.103241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31518758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&pages=103241&author=+Shaliniauthor=M.+D.+Johansenauthor=L.+Kremerauthor=V.+Kumar&title=Variedly+connected+1%2C8-naphthalimide-7-chloroquinoline+conjugates%3A+Synthesis%2C+anti-mycobacterial+and+cytotoxic+evaluation&doi=10.1016%2Fj.bioorg.2019.103241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Variedly connected 1,8-naphthalimide-7-chloroquinoline conjugates: Synthesis, anti-mycobacterial and cytotoxic evaluation</span></div><div class="casAuthors">Shalini; Johansen, Matt D.; Kremer, Laurent; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103241</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis, anti-mycobacterial and cytotoxic evaluation of 4-substituted 1,8-naphthalimide-7-chloroquinoline conjugates I [R = Br, piperidin-1-yl, 4-morpholinyl, 4-(2-hydroxyethyl)piperazin-1-yl; n = 2,3,4,6,8] and II connected through varied linkers in order to study their structure-activity relationship was reported.  Simple alkyl chain linked conjugates showed better activity profiles without any cytotoxicity, while the inclusion of amide bond enhanced the cytotoxic tendency.  Copmd. II [R1 = piperidin-1-yl; n = 6] proved to be the most potent and non-cytotoxic with MIC99 of 6.25 μg/mL and selectivity index of > 16.  An interesting behavior of conjugates I and II in terms of activity and cytotoxicity was obsd. via switching over the nature of linker between two pharmacophores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZNc1EinryPbVg90H21EOLACvtfcHk0lhIVfFqVLm98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhurrI&md5=7241f1b29ace5ce285d8cde0f90a5352</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103241%26sid%3Dliteratum%253Aachs%26aulast%3DShalini%26aulast%3DJohansen%26aufirst%3DM.%2BD.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DVariedly%2520connected%25201%252C8-naphthalimide-7-chloroquinoline%2520conjugates%253A%2520Synthesis%252C%2520anti-mycobacterial%2520and%2520cytotoxic%2520evaluation%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26spage%3D103241%26doi%3D10.1016%2Fj.bioorg.2019.103241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaduskar, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkahtani, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almehizia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangshetti, J. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluations and computational studies of N-(3-(−2-(7-Chloroquinolin-2-yl)vinyl) benzylidene)anilines as fungal biofilm inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2018.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=30595445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=623-630&author=F.+A.+K.+Khanauthor=R.+N.+Kaduskarauthor=R.+Patilauthor=R.+H.+Patilauthor=S.+A.+Ansariauthor=H.+M.+Alkahtaniauthor=A.+A.+Almehiziaauthor=D.+B.+Shindeauthor=J.+N.+Sangshetti&title=Synthesis%2C+biological+evaluations+and+computational+studies+of+N-%283-%28%E2%88%922-%287-Chloroquinolin-2-yl%29vinyl%29+benzylidene%29anilines+as+fungal+biofilm+inhibitors&doi=10.1016%2Fj.bmcl.2018.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluations and computational studies of N-(3-(-2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)anilines as fungal biofilm inhibitors</span></div><div class="casAuthors">Khan, Firoz A. Kalam; Kaduskar, Rashmi N.; Patil, Rajesh; Patil, Rajendra H.; Ansari, Siddique Akber; Alkahtani, Hamad M.; Almehizia, Abdulrahman A.; Shinde, Devanand B.; Sangshetti, Jaiprakash N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New chloroquinoline derivs. bearing vinyl benzylidene aniline substituents at 2nd position were synthesized and screed for biofilm inhibitory, antifungal and antibacterial activity.  The result of biofilm inhibition of C. albicans suggested that compds. N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)-4-(trifluoromethyl)aniline (IC50 value = 51.2 μM) and N-(3-(2-(7-chloroquinolin-2-yl)vinyl)benzylidene)-4-chloroaniline (IC50 value = 66.2 μM) possess promising antibiofilm inhibition when compared with the std. antifungal drug fluconazole (IC50 = 40.0 μM).  Two compds. N-(3-(2-(7-chloroquinolin-2-yl)vinyl)benzylidene)-4-chloroaniline (MIC = 94.2 μg/mL) and N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)aniline (MIC = 98.8 μg/mL) also exhibited good antifungal activity comparable to std. drug fluconazole (MIC = 50.0 μg/mL).  The antibacterial screening against four strains of bacteria viz.  E. coli, P. aeruginosa, B. subtilis, and S. aureus suggested their potential antibacterial activity and esp. all the compds. except N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)-2-methylaniline were found more active than the std. drug ciprofloxacin against B. subtilis.  To further gain insights into the possible mechanism of these compds. in biofilm inhibition through the agglutinin like protein (Als), mol. docking and mol. dynamics simulation studies were carried out.  Mol. modeling studies suggested the clear role in inhibition of this protein and the resulting biofilm inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprdXjMPY62I7Vg90H21EOLACvtfcHk0lhIVfFqVLm98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bN&md5=9af94cb65d08198e63f3497c43cabfa9</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DF.%2BA.%2BK.%26aulast%3DKaduskar%26aufirst%3DR.%2BN.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPatil%26aufirst%3DR.%2BH.%26aulast%3DAnsari%26aufirst%3DS.%2BA.%26aulast%3DAlkahtani%26aufirst%3DH.%2BM.%26aulast%3DAlmehizia%26aufirst%3DA.%2BA.%26aulast%3DShinde%26aufirst%3DD.%2BB.%26aulast%3DSangshetti%26aufirst%3DJ.%2BN.%26atitle%3DSynthesis%252C%2520biological%2520evaluations%2520and%2520computational%2520studies%2520of%2520N-%25283-%2528%25E2%2588%25922-%25287-Chloroquinolin-2-yl%2529vinyl%2529%2520benzylidene%2529anilines%2520as%2520fungal%2520biofilm%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D623%26epage%3D630%26doi%3D10.1016%2Fj.bmcl.2018.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of some novel precursors of oxazolidinone analogues of chloroquinoline for their antimicrobial and cytotoxic potential</span>. <i>J. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1007/s12039-013-0492-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs12039-013-0492-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2013&pages=1093-1101&author=K.+Deviauthor=K.+Asmatauthor=M.+Agrawalauthor=S.+Sharmaauthor=J.+Dwivedi&title=Synthesis+and+evaluation+of+some+novel+precursors+of+oxazolidinone+analogues+of+chloroquinoline+for+their+antimicrobial+and+cytotoxic+potential&doi=10.1007%2Fs12039-013-0492-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of some novel precursors of oxazolidinone analogues of chloroquinoline for their antimicrobial and cytotoxic potential</span></div><div class="casAuthors">Devi, Kavita; Asmat, Kavita; Agrawal, Meenakshi; Sharma, Swapnil; Dwivedi, Jaya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Sciences (Bangalore, India)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1093-1101</span>CODEN:
                <span class="NLM_cas:coden">JCSBB5</span>;
        ISSN:<span class="NLM_cas:issn">0974-3626</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Some 3-(3-(7-chloroquinolin-4-ylamino)propyl-2-imino-5-(4-chloro/nitro/methoxybenzylidene)) oxazolidin-4-one and 4-(3-(7-chloroquinolin-4-ylamino) propyl)-2(4-chloro/nitro/methoxybenzylidene)-1,6-dioxo-4,9-diazaspiro[4,4]nonane-3,8-dione derivs. were synthesized using appropriate synthetic route.  The newly prepd. compds. demonstrated inhibitory effects on the growth of a MCF7 (hormone-dependent breast carcinoma cell line), HT29 (colon carcinoma cell line on leukemia).  The MCF7 cell line is very susceptible towards compd. 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-chlorobenzylidene)-1,6-dioxo-4,9-diazaspiro[4,4]nonane-3,8-dione with IC50 values of 16 μg/mL.  Similarly, the HT29 cell line is moderately susceptible towards compds. 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-chlorobenzylidene)-1,6-dion-4,9-diazaspiro[4,4]nonane-3,8-dione and 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-methoxybenzylidene)-1,6-dion-4,9-diazaspiro[4,4]nonane-3,8-dione with IC 50 values of 32 and 49 μg/mL, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN7yJVW7YshbVg90H21EOLACvtfcHk0lhIVfFqVLm98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurjO&md5=d8477fd76bd455ec142fe52af8b1f34f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs12039-013-0492-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12039-013-0492-9%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%26aufirst%3DK.%26aulast%3DAsmat%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDwivedi%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520some%2520novel%2520precursors%2520of%2520oxazolidinone%2520analogues%2520of%2520chloroquinoline%2520for%2520their%2520antimicrobial%2520and%2520cytotoxic%2520potential%26jtitle%3DJ.%2520Chem.%2520Sci.%26date%3D2013%26volume%3D125%26spage%3D1093%26epage%3D1101%26doi%3D10.1007%2Fs12039-013-0492-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, H. R.</span></span> <span> </span><span class="NLM_article-title">Review on Synthetic Chemistry and Antibacterial Importance of Thiazole Derivatives</span>. <i>Curr. Drug Discovery Technol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.2174/1570163814666170911144036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F1570163814666170911144036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28901248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=214-228&author=A.+Kashyapauthor=N.+Adhikariauthor=A.+Dasauthor=A.+Shakyaauthor=S.+K.+Ghoshauthor=U.+P.+Singhauthor=H.+R.+Bhat&title=Review+on+Synthetic+Chemistry+and+Antibacterial+Importance+of+Thiazole+Derivatives&doi=10.2174%2F1570163814666170911144036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Review on Synthetic Chemistry and Antibacterial Importance of Thiazole Derivatives</span></div><div class="casAuthors">Kashyap, Ankita; Adhikari, Nayana; Das, Arpita; Shakya, Anshul; Ghosh, Surajit Kumar; Singh, Udaya Pratap; Bhat, Hans Raj</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-228</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Thiazole is one of the leading heterocyclic five-member ring compds. that contain nitrogen and sulfur atom.  Many natural and/or synthetic compds. contain thiazole as an essential moiety and possess diverse therapeutic activities.  The thiazole ring was modified at different positions to generate new mols. with potent antibacterial activities.  Thus, the present review enumerates the antibacterial importance of thiazole and its derivs.  Method: The mining of literature has been performed using different database which includes only peer-reviewed journals.  The quality of retrieved papers was appraised using std. tools.  Moreover, the significant papers were described in detail to focus on thiazole derivs. showing considerable antibacterial activity.  Result: The present review describes the chem., SAR (Structure Activity Relationship) studies and antibacterial importance of thiazole with different synthetic procedures.  Conclusion: This particular study certainly benefits the researchers interested in exploiting the antibacterial activity of thiazoles in search of novel agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaef4q5BNU7Vg90H21EOLACvtfcHk0liMnLTjIBUdrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsr%252FM&md5=eac1445ad4366e6d03642ddbdeaa6cdc</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F1570163814666170911144036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163814666170911144036%26sid%3Dliteratum%253Aachs%26aulast%3DKashyap%26aufirst%3DA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DShakya%26aufirst%3DA.%26aulast%3DGhosh%26aufirst%3DS.%2BK.%26aulast%3DSingh%26aufirst%3DU.%2BP.%26aulast%3DBhat%26aufirst%3DH.%2BR.%26atitle%3DReview%2520on%2520Synthetic%2520Chemistry%2520and%2520Antibacterial%2520Importance%2520of%2520Thiazole%2520Derivatives%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2018%26volume%3D15%26spage%3D214%26epage%3D228%26doi%3D10.2174%2F1570163814666170911144036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmkshatriya, P. S.</span></span> <span> </span><span class="NLM_article-title">Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160506130731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F1568026616666160506130731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=27150376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWhtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2841-2862&author=M.+T.+Chhabriaauthor=S.+Patelauthor=P.+Modiauthor=P.+S.+Brahmkshatriya&title=Thiazole%3A+A+Review+on+Chemistry%2C+Synthesis+and+Therapeutic+Importance+of+its+Derivatives&doi=10.2174%2F1568026616666160506130731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives</span></div><div class="casAuthors">Chhabria, Mahesh T.; Patel, Shivani; Modi, Palmi; Brahmkshatriya, Pathik S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2841-2862</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Thiazole, a unique heterocycle contg. sulfur and nitrogen atoms, occupies an important place in medicinal chem.  It is an essential core scaffold present in many natural (Vitamin B1- Thiamine) and synthetic medicinally important compds.  The versatility of thiazole nucleus demonstrated by the fact that it is an essential part of penicillin nucleus and some of its derivs. which have shown antimicrobial (sulfazole), antiretroviral (ritonavir), antifungal (abafungin), antihistaminic and antithyroid activities.  The synthetic importance of thiazole derivs., its reduced forms and condensed derivs. have been increased much by their recent applications as anticancer (tiazofurin), anthelmintic, vulcanising accelerators (mercaptobenzothiazole) and photog. sensitizers.  Thiazole chem. has developed steadily after the pioneering work of Hofmann and Hantsch.  Bogert and co-workers made significant contribution to expand this field.  Mills established the importance of thiazole ring in cyanine dyes which is used as photog. sensitizer.  Benzothiazole, a fused deriv. of thiazole have also proved its com. value.  Present review describes chem. and biol. importance of thiazole and its condensed derivs. with an emphasis on recent developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvuNJYino70LVg90H21EOLACvtfcHk0liMnLTjIBUdrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWhtLnJ&md5=68a9bfebbbee523315d49c735fb1d47f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160506130731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160506130731%26sid%3Dliteratum%253Aachs%26aulast%3DChhabria%26aufirst%3DM.%2BT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DP.%26aulast%3DBrahmkshatriya%26aufirst%3DP.%2BS.%26atitle%3DThiazole%253A%2520A%2520Review%2520on%2520Chemistry%252C%2520Synthesis%2520and%2520Therapeutic%2520Importance%2520of%2520its%2520Derivatives%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2841%26epage%3D2862%26doi%3D10.2174%2F1568026616666160506130731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteleone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayhoub, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammac, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seleem, M. N.</span></span> <span> </span><span class="NLM_article-title">Antibacterial Characterization of Novel Synthetic Thiazole Compounds against Methicillin-Resistant Staphylococcus pseudintermedius</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0130385</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0130385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1371%2Fjournal.pone.0130385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26086336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlGmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=H.+Mohammadauthor=P.+V.+Reddyauthor=D.+Monteleoneauthor=A.+S.+Mayhoubauthor=M.+Cushmanauthor=G.+K.+Hammacauthor=M.+N.+Seleem&title=Antibacterial+Characterization+of+Novel+Synthetic+Thiazole+Compounds+against+Methicillin-Resistant+Staphylococcus+pseudintermedius&doi=10.1371%2Fjournal.pone.0130385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial characterization of novel synthetic thiazole compounds against methicillin-resistant Staphylococcus pseudintermedius</span></div><div class="casAuthors">Mohammad, Haroon; Reddy, P. V. Narasimha; Monteleone, Dennis; Mayhoub, Abdelrahman S.; Cushman, Mark; Hammac, G. Kenitra; Seleem, Mohamed N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0130385/1-e0130385/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Staphylococcus pseudintermedius is a commensal organism of companion animals that is a significant source of opportunistic infections in dogs.  With the emergence of clin. isolates of S. pseudintermedius (chiefly methicillin-resistant S. pseudintermedius (MRSP)) exhibiting increased resistance to nearly all antibiotic classes, new antimicrobials and therapeutic strategies are urgently needed.  Thiazole compds. have been previously shown to possess potent antibacterial activity against multidrug-resistant strains of Staphylococcus aureus of human and animal concern.  Given the genetic similarity between S. aureus and S. pseudintermedius, this study explores the potential use of thiazole compds. as novel antibacterial agents against methicillin-sensitive S. pseudintermedius (MSSP) and MRSP.  A broth microdilution assay confirmed these compds. exhibit potent bactericidal activity (at sub-microgram/mL concns.) against both MSSA and MRSP clin. isolates while the MTS assay confirmed three compds. (at 10 μg/mL) were not toxic to mammalian cells.  A time-kill assay revealed two derivs. rapidly kill MRSP within two hours.  However, this rapid bactericidal activity was not due to disruption of the bacterial cell membrane indicating an alternative mechanism of action for these compds. against MRSP.  A multistep resistance selection anal. revealed compds. 4 and 5 exhibited a modest (twofold) shift in activity over ten passages.  Furthermore, all six compds. (at a sub-inhibitory concn.) demonstrated the ability to re-sensitize MRSP to oxacillin, indicating these compds. have potential use for extending the therapeutic utility of β-lactam antibiotics against MRSP.  Metabolic stability anal. with dog liver microsomes revealed compd. 3 exhibited an improved physicochem. profile compared to the lead compd.  In addn. to this, all six thiazole compds. possessed a long post-antibiotic effect (at least 8 h) against MRSP.  Collectively the present study demonstrates these synthetic thiazole compds. possess potent antibacterial activity against both MSSP and MRSP and warrant further investigation into their use as novel antimicrobial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMDR9JEWJ-LVg90H21EOLACvtfcHk0liMnLTjIBUdrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlGmtbw%253D&md5=e5647a577a78937901f4f1ab522b4341</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0130385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0130385%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%26aulast%3DReddy%26aufirst%3DP.%2BV.%26aulast%3DMonteleone%26aufirst%3DD.%26aulast%3DMayhoub%26aufirst%3DA.%2BS.%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DHammac%26aufirst%3DG.%2BK.%26aulast%3DSeleem%26aufirst%3DM.%2BN.%26atitle%3DAntibacterial%2520Characterization%2520of%2520Novel%2520Synthetic%2520Thiazole%2520Compounds%2520against%2520Methicillin-Resistant%2520Staphylococcus%2520pseudintermedius%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0130385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, M. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimicrobial studies of thiazolotriazinones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5039</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2010.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20813429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KrtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=5039-43&author=M.+S.+Karthikeyan&title=Synthesis+and+antimicrobial+studies+of+thiazolotriazinones&doi=10.1016%2Fj.ejmech.2010.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimicrobial studies of thiazolotriazinones</span></div><div class="casAuthors">Karthikeyan, Mari Sithambaram</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5039-5043</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">6-Benzyl-3-phenylthiazolo-1,2,4-triazinones I (R = 4-Cl or 2,4-Cl2; R1 = 4-Cl, 4-Br, 4-MeO, 4-NO2, or 2,4-Cl2-5-F) were obtained by the initial reaction of 6-benzyl-3-mercapto-1,2,4-triazin-5-ones with phenacyl bromides followed by PPA cyclization.  The structures of the newly synthesized compds. were confirmed by IR, 1H NMR, mass and anal. data.  Compds. I (R = 4-Cl, R1 = 4-Cl, 2,4-Cl2-5-F; R = 2,4-Cl2, R1 = 4-Cl, 4-MeO) exhibited good antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMHYoBkEcJbVg90H21EOLACvtfcHk0liMnLTjIBUdrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KrtrjP&md5=9ba386f76da0312dc337b2ae6db4768b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DKarthikeyan%26aufirst%3DM.%2BS.%26atitle%3DSynthesis%2520and%2520antimicrobial%2520studies%2520of%2520thiazolotriazinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D5039%26epage%3D43%26doi%3D10.1016%2Fj.ejmech.2010.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammar, Y. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some new 2-(3-pyridyl)-4,5-disubstituted thiazoles as potent antimicrobial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2012.12.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23357308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=270-279&author=S.+Bondockauthor=T.+Naserauthor=Y.+A.+Ammar&title=Synthesis+of+some+new+2-%283-pyridyl%29-4%2C5-disubstituted+thiazoles+as+potent+antimicrobial+agents&doi=10.1016%2Fj.ejmech.2012.12.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some new 2-(3-pyridyl)-4,5-disubstituted thiazoles as potent antimicrobial agents</span></div><div class="casAuthors">Bondock, Samir; Naser, Tamer; Ammar, Yousry A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270-279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a part of ongoing studies in developing new potent antimicrobial agents, a series of novel 2-(3-pyridyl)-4,5-disubstituted thiazoles was efficiently synthesized and characterized by spectral and elemental analyses.  The newly synthesized compds. were evaluated for their in vitro antimicrobial activity against ten bacterial and five fungal human pathogenic strains using the disk diffusion assay.  Among the synthesized compds., 5-acetyl-4-methyl-2-(3-pyridyl)thiazole exhibited twofold antibacterial activity of ampicillin in inhibiting the growth of Staphylococcus epidermidis (MIC 0.24 μg/mL) and also showed equipotent antifungal activity with amphotricin B against Geotricum candidum (MIC 0.48 μg/mL).  From structure-activity relationship (SAR) point of view, increasing the size of the substitutions either at position 4 or 5 on the thiazole nucleus decreased the antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYF-Kh_rbFPLVg90H21EOLACvtfcHk0lg7_Z8Si6MKgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgsr0%253D&md5=0d2e833c871ffd5d1018273c39b8f860</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.050%26sid%3Dliteratum%253Aachs%26aulast%3DBondock%26aufirst%3DS.%26aulast%3DNaser%26aufirst%3DT.%26aulast%3DAmmar%26aufirst%3DY.%2BA.%26atitle%3DSynthesis%2520of%2520some%2520new%25202-%25283-pyridyl%2529-4%252C5-disubstituted%2520thiazoles%2520as%2520potent%2520antimicrobial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D270%26epage%3D279%26doi%3D10.1016%2Fj.ejmech.2012.12.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karuvalam, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haridas, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru
Row, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishikesan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, N. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2012.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22280817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=172-182&author=R.+P.+Karuvalamauthor=K.+R.+Haridasauthor=S.+K.+Nayakauthor=T.+N.+Guru%0ARowauthor=P.+Rajeeshauthor=R.+Rishikesanauthor=N.+S.+Kumari&title=Design%2C+synthesis+of+some+new+%282-aminothiazol-4-yl%29methylester+derivatives+as+possible+antimicrobial+and+antitubercular+agents&doi=10.1016%2Fj.ejmech.2012.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents</span></div><div class="casAuthors">Karuvalam, Ranjith P.; Haridas, Karickal R.; Nayak, Susanta K.; Guru Row, Tayur N.; Rajeesh, P.; Rishikesan, R.; Kumari, N. Suchetha</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-182</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 20 (2-aminothiazol-4-yl)methylester derivs. were synthesized in good yields and characterized by 1H NMR, 13C NMR, mass spectral and elemental analyses.  The crystal structure of I was detd. and data are referenced.  The compds. were evaluated for their preliminary in vitro antibacterial, antifungal activity and were screened for antitubercular activity against Mycobacterium tuberculosis H37Rv strain.  The synthesized compds. displayed interesting antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6HY93B1NqqrVg90H21EOLACvtfcHk0lg7_Z8Si6MKgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOrsro%253D&md5=7594d0db699b54f406b915a8e224fdf4</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DKaruvalam%26aufirst%3DR.%2BP.%26aulast%3DHaridas%26aufirst%3DK.%2BR.%26aulast%3DNayak%26aufirst%3DS.%2BK.%26aulast%3DGuru%2BRow%26aufirst%3DT.%2BN.%26aulast%3DRajeesh%26aufirst%3DP.%26aulast%3DRishikesan%26aufirst%3DR.%26aulast%3DKumari%26aufirst%3DN.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520of%2520some%2520new%2520%25282-aminothiazol-4-yl%2529methylester%2520derivatives%2520as%2520possible%2520antimicrobial%2520and%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D172%26epage%3D182%26doi%3D10.1016%2Fj.ejmech.2012.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beniwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglan, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some novel oxazolidinone-thiazole hybrids as potential antimicrobial, antioxidant and UV mediated DNA damage protecting agents</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2249</span>, <span class="refDoi"> DOI: 10.1007/s00044-016-1663-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs00044-016-1663-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gis7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=2237-2249&author=K.+Kaurauthor=V.+Kumarauthor=V.+Beniwalauthor=V.+Kumarauthor=N.+Kumarauthor=V.+Sharmaauthor=S.+Jaglan&title=Synthesis+of+some+novel+oxazolidinone-thiazole+hybrids+as+potential+antimicrobial%2C+antioxidant+and+UV+mediated+DNA+damage+protecting+agents&doi=10.1007%2Fs00044-016-1663-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some novel oxazolidinone-thiazole hybrids as potential antimicrobial, antioxidant and UV mediated DNA damage protecting agents</span></div><div class="casAuthors">Kaur, Kamalneet; Kumar, Vinod; Beniwal, Vikas; Kumar, Vikas; Kumar, Neeraj; Sharma, Vishal; Jaglan, Sundeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2237-2249</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In search of a new class of biol. active agents, some novel oxazolidinone-thiazole hybrids 4a-m have been synthesized and characterized on the basis of a combined use of IR, NMR (1H, 13C) spectroscopy, mass spectrometry and elemental anal.  All compds. were evaluated for their antimicrobial, antioxidant and UV mediated DNA damage protective activity.  Among the series, compd. 4i emerged as the most potent antimicrobial agent, particularly, against Bacillus subtilis, Candida albicans and Saccharomyces cerevisiae in comparison to the std. drugs, Ciprofloxacin (antibacterial) and Amphotericin-B (antifungal).  Other promising antimicrobial agents including the compds. 4f-h.  In addn., all compds. 4a-m were found to show very high DNA damage protecting ability under UV irradn.  The antioxidant study revealed that the compds. 4d and 4j were found as the most potent antioxidants as compared to ascorbic acid, a ref. compd. considered in the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQECOF4HJWbVg90H21EOLACvtfcHk0lg7_Z8Si6MKgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gis7zK&md5=a7f031f5e627f67d14191157369c28cb</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs00044-016-1663-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-016-1663-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBeniwal%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DJaglan%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520some%2520novel%2520oxazolidinone-thiazole%2520hybrids%2520as%2520potential%2520antimicrobial%252C%2520antioxidant%2520and%2520UV%2520mediated%2520DNA%2520damage%2520protecting%2520agents%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2016%26volume%3D25%26spage%3D2237%26epage%3D2249%26doi%3D10.1007%2Fs00044-016-1663-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelak, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerckens, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahan, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span> <span> </span><span class="NLM_article-title">Antibacterial agents that inhibit lipid A biosynthesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1126/science.274.5289.980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.274.5289.980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=8875939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XmslKmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=980-982&author=H.+R.+Onishiauthor=B.+A.+Pelakauthor=L.+S.+Gerckensauthor=L.+L.+Silverauthor=F.+M.+Kahanauthor=M.+H.+Chenauthor=A.+A.+Patchettauthor=S.+M.+Gallowayauthor=S.+A.+Hylandauthor=M.+S.+Andersonauthor=C.+R.+Raetz&title=Antibacterial+agents+that+inhibit+lipid+A+biosynthesis&doi=10.1126%2Fscience.274.5289.980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial agents that inhibit lipid A biosynthesis</span></div><div class="casAuthors">Onishi, H. Russell; Pelak, Barbara A.; Gerckens, Lynn S.; Silver, Lynn L.; Kahan, Frederick M.; Chen, Meng-Hsin; Patchett, Arthur A.; Galloway, Susan M.; Hyland, Sheryl A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5289</span>),
    <span class="NLM_cas:pages">980-982</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lipid A constitutes the outer monolayer of the outer membrane of Gram-neg. bacteria and is essential for bacterial growth.  Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis.  The inhibitors are chiral hydroxamic acids bearing certain hydrophobic arom. moieties.  They may bind to a metal in the active site of the deacetylase.  The most potent analog (with an inhibition const. of about 50 nM) displayed a minimal inhibitory concn. of about 1 μg per mL against Escherichia coli, causes three logs of bacterial killing in 4 h, and cured mice infected with a lethal i.p. dose of E. coli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKgUe_5zI9rVg90H21EOLACvtfcHk0lg_i2RP7zz7_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmslKmsLw%253D&md5=d5098756849325110d7f1f4850322cba</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1126%2Fscience.274.5289.980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.274.5289.980%26sid%3Dliteratum%253Aachs%26aulast%3DOnishi%26aufirst%3DH.%2BR.%26aulast%3DPelak%26aufirst%3DB.%2BA.%26aulast%3DGerckens%26aufirst%3DL.%2BS.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DGalloway%26aufirst%3DS.%2BM.%26aulast%3DHyland%26aufirst%3DS.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%2BS.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26atitle%3DAntibacterial%2520agents%2520that%2520inhibit%2520lipid%2520A%2520biosynthesis%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D980%26epage%3D982%26doi%3D10.1126%2Fscience.274.5289.980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2038</span>– <span class="NLM_lpage">2050</span>, <span class="refDoi"> DOI: 10.2174/092986712800167374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F092986712800167374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22414079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2htbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=2038-2050&author=J.+Zhangauthor=L.+Zhangauthor=X.+Liauthor=W.+Xu&title=UDP-3-O-%28R-3-hydroxymyristoyl%29-N-acetylglucosamine+deacetylase+%28LpxC%29+inhibitors%3A+a+new+class+of+antibacterial+agents&doi=10.2174%2F092986712800167374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents</span></div><div class="casAuthors">Zhang, J.; Zhang, L.; Li, X.; Xu, W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2038-2050</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The rapid increase of health-threatening infections by Gram-neg. pathogens along with the emergence of multidrug-resistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets.  One of the promising targets in Gram-neg. bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).  LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A.  Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-neg. bacteria.  In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYTK2EcNm38rVg90H21EOLACvtfcHk0lg_i2RP7zz7_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2htbY%253D&md5=dc02cdeadab2b97151b6453e08301f92</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.2174%2F092986712800167374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712800167374%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DUDP-3-O-%2528R-3-hydroxymyristoyl%2529-N-acetylglucosamine%2520deacetylase%2520%2528LpxC%2529%2520inhibitors%253A%2520a%2520new%2520class%2520of%2520antibacterial%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D2038%26epage%3D2050%26doi%3D10.2174%2F092986712800167374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langsdorf, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malikzay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarr, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daubaras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravec, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozbal, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miesel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, C. A.</span></span> <span> </span><span class="NLM_article-title">Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1177/1087057109355319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1177%2F1087057109355319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20019290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFWmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=52-61&author=E.+F.+Langsdorfauthor=A.+Malikzayauthor=W.+A.+Lamarrauthor=D.+Daubarasauthor=C.+Kravecauthor=R.+Zhangauthor=R.+Hartauthor=F.+Monsmaauthor=T.+Blackauthor=C.+C.+Ozbalauthor=L.+Mieselauthor=C.+A.+Lunn&title=Screening+for+antibacterial+inhibitors+of+the+UDP-3-O-%28R-3-hydroxymyristoyl%29-N-acetylglucosamine+deacetylase+%28LpxC%29+using+a+high-throughput+mass+spectrometry+assay&doi=10.1177%2F1087057109355319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay</span></div><div class="casAuthors">Langsdorf, Erik F.; Malikzay, Asra; Lamarr, William A.; Daubaras, Dayna; Kravec, Cynthia; Zhang, Rumin; Hart, Richard; Monsma, Frederick; Black, Todd; Ozbal, Can C.; Miesel, Lynn; Lunn, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-61</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A high-throughput mass spectrometry assay to measure the catalytic activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, LpxC, is described.  This reaction is essential in the biosynthesis of lipopolysaccharide (LPS) of gram-neg. bacteria and is an attractive target for the development of new antibacterial agents.  The assay uses the RapidFire mass spectrometry platform to measure the native LpxC substrate and the reaction product and thereby generates a ratiometric readout with minimal artifacts due to detection interference.  The assay was robust in a high-throughput screen of a library of more than 700,000 compds. arrayed as orthogonal mixts., with a median Z' factor of 0.74.  Selected novel inhibitors from the screening campaign were confirmed as binding to LpxC by biophys. measurements using a thermal stability shift assay.  Some inhibitors showed whole-cell antimicrobial activity against a sensitive strain of Escherichia coli with reduced LpxC activity (strain D22; min. inhibitory concns. ranging from 0.625-20 μg/mL).  The results show that mass spectrometry-based screening is a valuable high-throughput screening tool for detecting inhibitors of enzymic targets involving difficult to detect reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF4SfcBGLJ7Vg90H21EOLACvtfcHk0lg_i2RP7zz7_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFWmu70%253D&md5=c37066b26757e2909e23c25037ef64b4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1177%2F1087057109355319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109355319%26sid%3Dliteratum%253Aachs%26aulast%3DLangsdorf%26aufirst%3DE.%2BF.%26aulast%3DMalikzay%26aufirst%3DA.%26aulast%3DLamarr%26aufirst%3DW.%2BA.%26aulast%3DDaubaras%26aufirst%3DD.%26aulast%3DKravec%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DR.%26aulast%3DMonsma%26aufirst%3DF.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DOzbal%26aufirst%3DC.%2BC.%26aulast%3DMiesel%26aufirst%3DL.%26aulast%3DLunn%26aufirst%3DC.%2BA.%26atitle%3DScreening%2520for%2520antibacterial%2520inhibitors%2520of%2520the%2520UDP-3-O-%2528R-3-hydroxymyristoyl%2529-N-acetylglucosamine%2520deacetylase%2520%2528LpxC%2529%2520using%2520a%2520high-throughput%2520mass%2520spectrometry%2520assay%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26spage%3D52%26epage%3D61%26doi%3D10.1177%2F1087057109355319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span> <span> </span><span class="NLM_article-title">Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">18433</span>– <span class="NLM_lpage">18438</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709412104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1073%2Fpnas.0709412104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18025458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2ku7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=18433-18438&author=A.+W.+Barbauthor=L.+Jiangauthor=C.+R.+Raetzauthor=P.+Zhou&title=Structure+of+the+deacetylase+LpxC+bound+to+the+antibiotic+CHIR-090%3A+Time-dependent+inhibition+and+specificity+in+ligand+binding&doi=10.1073%2Fpnas.0709412104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding</span></div><div class="casAuthors">Barb, Adam W.; Jiang, Ling; Raetz, Christian R. H.; Zhou, Pei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18433-18438, S18433/1-S18433/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-neg. bacteria and a promising antibiotic target.  CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-neg. pathogens as effectively as ciprofloxacin or tobramycin.  In this study, we report the soln. structure of the LpxC-CHIR-090 complex.  CHIR-090 exploits conserved features of LpxC that are crit. for catalysis, including the hydrophobic passage and essential active-site residues.  CHIR-090 is adjacent to, but does not occupy, the UDP-binding pocket of LpxC, suggesting that a fragment-based approach may facilitate further optimization of LpxC inhibitors.  Addnl., we identified key residues in the Insert II hydrophobic passage that modulate time-dependent inhibition and CHIR-090 resistance.  CHIR-090 shares a similar, although previously unrecognized, chem. scaffold with other small-mol. antibiotics such as L-161,240 targeting LpxC, and provides a template for understanding the binding mode of these inhibitors.  Consistent with this model, we provide evidence that L-161,240 also occupies the hydrophobic passage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWHV0AFZnM7Vg90H21EOLACvtfcHk0ljYdMrCM_QHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2ku7rP&md5=e54a3a1c978536947380f6f1bbdbc4bf</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709412104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709412104%26sid%3Dliteratum%253Aachs%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DZhou%26aufirst%3DP.%26atitle%3DStructure%2520of%2520the%2520deacetylase%2520LpxC%2520bound%2520to%2520the%2520antibiotic%2520CHIR-090%253A%2520Time-dependent%2520inhibition%2520and%2520specificity%2520in%2520ligand%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D18433%26epage%3D18438%26doi%3D10.1073%2Fpnas.0709412104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toone, E. J.</span></span> <span> </span><span class="NLM_article-title">Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21194954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=852-860&author=X.+Liangauthor=C.+J.+Leeauthor=X.+Chenauthor=H.+S.+Chungauthor=D.+Zengauthor=C.+R.+Raetzauthor=Y.+Liauthor=P.+Zhouauthor=E.+J.+Toone&title=Syntheses%2C+structures+and+antibiotic+activities+of+LpxC+inhibitors+based+on+the+diacetylene+scaffold&doi=10.1016%2Fj.bmc.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold</span></div><div class="casAuthors">Liang, Xiaofei; Lee, Chul-Jin; Chen, Xin; Chung, Hak Suk; Zeng, Daina; Raetz, Christian R. H.; Li, Yaoxian; Zhou, Pei; Toone, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compds. inhibiting LpxC in the lipid A biosynthetic pathway are promising leads for novel antibiotics against multidrug-resistant Gram-neg. pathogens.  The authors report the syntheses and structural and biochem. characterizations of LpxC inhibitors based on a diphenyl-diacetylene (1,4-diphenyl-1,3-butadiyne) threonyl-hydroxamate scaffold.  These studies provide a mol. interpretation for the differential antibiotic activities of compds. with a substituted distal Ph ring as well as the abs. stereochem. requirement at the C2, but not C3, position of the threonyl group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWL2QPzfjArLVg90H21EOLACvtfcHk0ljYdMrCM_QHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVCnuw%253D%253D&md5=10326af21364b0785a67692687b21385</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChung%26aufirst%3DH.%2BS.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26atitle%3DSyntheses%252C%2520structures%2520and%2520antibiotic%2520activities%2520of%2520LpxC%2520inhibitors%2520based%2520on%2520the%2520diacetylene%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D852%26epage%3D860%26doi%3D10.1016%2Fj.bmc.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toone, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span> <span> </span><span class="NLM_article-title">Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.chembiol.2010.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21167751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=38-47&author=C.+J.+Leeauthor=X.+Liangauthor=X.+Chenauthor=D.+Zengauthor=S.+H.+Jooauthor=H.+S.+Chungauthor=A.+W.+Barbauthor=S.+M.+Swansonauthor=R.+A.+Nicholasauthor=Y.+Liauthor=E.+J.+Tooneauthor=C.+R.+Raetzauthor=P.+Zhou&title=Species-specific+and+inhibitor-dependent+conformations+of+LpxC%3A+implications+for+antibiotic+design&doi=10.1016%2Fj.chembiol.2010.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design</span></div><div class="casAuthors">Lee, Chul-Jin; Liang, Xiao-Fei; Chen, Xin; Zeng, Dai-Na; Joo, Sang-Hoon; Chung, Hak-Suk; Barb, Adam W.; Swanson, Shauna M.; Nicholas, Robert A.; Li, Yao-Xian; Toone, Eric J.; Raetz, Christian R. H.; Zhou, Pei</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">LpxC is an essential enzyme in the lipid A biosynthetic pathway in gram-neg. bacteria.  Several promising antimicrobial lead compds. targeting LpxC have been reported, though they typically display a large variation in potency against different gram-neg. pathogens.  We report that inhibitors with a diacetylene scaffold effectively overcome the resistance caused by sequence variation in the LpxC substrate-binding passage.  Compd. binding is captured in complex with representative LpxC orthologs, and structural anal. reveals large conformational differences that mostly reflect inherent mol. features of distinct LpxC orthologs, whereas ligand-induced structural adaptations occur at a smaller scale.  These observations highlight the need for a mol. understanding of inherent structural features and conformational plasticity of LpxC enzymes for optimizing LpxC inhibitors as broad-spectrum antibiotics against gram-neg. infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbcwncn731jrVg90H21EOLACvtfcHk0ljYdMrCM_QHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars70%253D&md5=7aa1222210dfec8ad8675194b0b13731</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DJoo%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DH.%2BS.%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DSwanson%26aufirst%3DS.%2BM.%26aulast%3DNicholas%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DZhou%26aufirst%3DP.%26atitle%3DSpecies-specific%2520and%2520inhibitor-dependent%2520conformations%2520of%2520LpxC%253A%2520implications%2520for%2520antibiotic%2520design%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.chembiol.2010.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=623-628&author=H.+Kurasakiauthor=K.+Tsudaauthor=M.+Shinoyamaauthor=N.+Takayaauthor=Y.+Yamaguchiauthor=R.+Kishiiauthor=K.+Iwaseauthor=N.+Andoauthor=M.+Nomuraauthor=Y.+Kohno&title=LpxC+Inhibitors%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Oxazolidinones+as+Gram-negative+Antibacterial+Agents&doi=10.1021%2Facsmedchemlett.6b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents</span></div><div class="casAuthors">Kurasaki, Haruaki; Tsuda, Kosuke; Shinoyama, Mariko; Takaya, Noriko; Yamaguchi, Yuko; Kishii, Ryuta; Iwase, Kazuhiko; Ando, Naoki; Nomura, Masahiro; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-628</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report a scaffold-hopping approach to identify a new scaffold with a zinc binding headgroup.  Structural information was used to give novel oxazolidinone-based LpxC inhibitors.  In particular, the most potent compd., 23j, showed a low efflux ratio, nanomolar potencies against E. coli LpxC enzyme, and excellent antibacterial activity against E. coli and K. pneumoniae.  Computational docking was used to predict the interaction between 23j and E. coli LpxC, suggesting that the interactions with C207 and C63 contribute to the strong activity.  These results provide new insights into the design of next-generation LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRbZ4j4AMLZbVg90H21EOLACvtfcHk0lj5Ihalg81qQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlOmsbY%253D&md5=992199b55365298f2960ffc9ef88b4cd</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00057%26sid%3Dliteratum%253Aachs%26aulast%3DKurasaki%26aufirst%3DH.%26aulast%3DTsuda%26aufirst%3DK.%26aulast%3DShinoyama%26aufirst%3DM.%26aulast%3DTakaya%26aufirst%3DN.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DKishii%26aufirst%3DR.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DAndo%26aufirst%3DN.%26aulast%3DNomura%26aufirst%3DM.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DLpxC%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Oxazolidinones%2520as%2520Gram-negative%2520Antibacterial%2520Agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D623%26epage%3D628%26doi%3D10.1021%2Facsmedchemlett.6b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>352</i></span>, <span class="NLM_elocation-id">1900129</span> <span class="refDoi"> DOI: 10.1002/ardp.201900129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.201900129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ylurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2019&author=S.+Dingauthor=J.+C.+Jiauthor=M.+J.+Zhangauthor=Y.+S.+Yangauthor=R.+Wangauthor=X.+L.+Zhuauthor=L.+H.+Wangauthor=Y.+Zhongauthor=L.+Gaoauthor=M.+Luauthor=J.+Liuauthor=Y.+Chen&title=Exploration+of+the+structure-activity+relationship+and+druggability+of+novel+oxazolidinone-based+compounds+as+Gram-negative+antibacterial+agents&doi=10.1002%2Fardp.201900129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents</span></div><div class="casAuthors">Ding, Shi; Ji, Jing-Chao; Zhang, Ming-Juan; Yang, Yu-She; Wang, Rui; Zhu, Xing-Long; Wang, Li-Hong; Zhong, Yi; Gao, Le; Lu, Man; Liu, Ju; Chen, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1900129</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">To gain further knowledge of the structure-activity relationship and druggability of novel oxazolidinone-based UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) inhibitors as Gram-neg. antibacterial agents, compds. contg. the hydrophobic tails with different lengths and terminal substitutions were synthesized and their antibacterial activities against std. and clin. isolated Gram-neg. strains were evaluated.  We summarized their structure-activity relationships and found that oxazolidinone-based compds. exhibited a narrower antibacterial spectrum compared with threonine-based compds.  Furthermore, we parallelly compared the metabolic stabilities of the compds. with the classic threonine scaffold and the novel oxazolidinone scaffold in liver microsomes.  The results indicated that the druggability of the oxazolidinone scaffold may be inferior to the classic threonine scaffold in the design of LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpguMarKAFN5rVg90H21EOLACvtfcHk0lj5Ihalg81qQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ylurjM&md5=618d8ce37262d6a8d2f2464a028b78b3</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fardp.201900129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201900129%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DJ.%2BC.%26aulast%3DZhang%26aufirst%3DM.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BH.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DExploration%2520of%2520the%2520structure-activity%2520relationship%2520and%2520druggability%2520of%2520novel%2520oxazolidinone-based%2520compounds%2520as%2520Gram-negative%2520antibacterial%2520agents%26jtitle%3DArch.%2520Pharm.%26date%3D2019%26volume%3D352%26doi%3D10.1002%2Fardp.201900129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalia, V. C.</span></span> <span> </span><span class="NLM_article-title">Quorum sensing inhibitors: an overview</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2012.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.biotechadv.2012.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23142623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCntbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=224-245&author=V.+C.+Kalia&title=Quorum+sensing+inhibitors%3A+an+overview&doi=10.1016%2Fj.biotechadv.2012.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Quorum sensing inhibitors: An overview</span></div><div class="casAuthors">Kalia, Vipin Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-245</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Excessive and indiscriminate use of antibiotics to treat bacterial infections has lead to the emergence of multiple drug resistant strains.  Most infectious diseases are caused by bacteria which proliferate within quorum sensing (QS) mediated biofilms.  Efforts to disrupt biofilms have enabled the identification of bioactive mols. produced by prokaryotes and eukaryotes.  These mols. act primarily by quenching the QS system.  The phenomenon is also termed as quorum quenching (QQ).  In addn., synthetic compds. have also been found to be effective in QQ.  This review focuses primarily on natural and synthetic quorum sensing inhibitors (QSIs) with the potential for treating bacterial infections.  It has been opined that the most versatile prokaryotes to produce QSI are likely to be those, which are generally regarded as safe.  Among the eukaryotes, certain legumes and traditional medicinal plants are likely to act as QSIs.  Such findings are likely to lead to efficient treatments with much lower doses of drugs esp. antibiotics than required at present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuSARllnsBRLVg90H21EOLACvtfcHk0lj5Ihalg81qQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCntbjM&md5=c90645da9d9f8404d0042c66364455cf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2012.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2012.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DKalia%26aufirst%3DV.%2BC.%26atitle%3DQuorum%2520sensing%2520inhibitors%253A%2520an%2520overview%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2013%26volume%3D31%26spage%3D224%26epage%3D245%26doi%3D10.1016%2Fj.biotechadv.2012.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingender, J.</span></span> <span> </span><span class="NLM_article-title">The biofilm matrix</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">633</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1038%2Fnrmicro2415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20676145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFWlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=623-633&author=H.+C.+Flemmingauthor=J.+Wingender&title=The+biofilm+matrix&doi=10.1038%2Fnrmicro2415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The biofilm matrix</span></div><div class="casAuthors">Flemming, Hans-Curt; Wingender, Jost</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-633</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The microorganisms in biofilms live in a self-produced matrix of hydrated extracellular polymeric substances (EPS) that form their immediate environment.  EPS are mainly polysaccharides, proteins, nucleic acids and lipids; they provide the mech. stability of biofilms, mediate their adhesion to surfaces and form a cohesive, three-dimensional polymer network that interconnects and transiently immobilizes biofilm cells.  In addn., the biofilm matrix acts as an external digestive system by keeping extracellular enzymes close to the cells, enabling them to metabolize dissolved, colloidal and solid biopolymers.  Here we describe the functions, properties and constituents of the EPS matrix that make biofilms the most successful forms of life on earth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfq7HQglC-L7Vg90H21EOLACvtfcHk0lia0QLymKuHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFWlur4%253D&md5=28ecf529c890b3eb5a906487b654c0e1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2415%26sid%3Dliteratum%253Aachs%26aulast%3DFlemming%26aufirst%3DH.%2BC.%26aulast%3DWingender%26aufirst%3DJ.%26atitle%3DThe%2520biofilm%2520matrix%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2010%26volume%3D8%26spage%3D623%26epage%3D633%26doi%3D10.1038%2Fnrmicro2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isabella, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglewski, B. H.</span></span> <span> </span><span class="NLM_article-title">Analysis of the hierarchy of quorum-sensing regulation in Pseudomonas aeruginosa</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1007/s00216-006-0964-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs00216-006-0964-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=17139483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2007&pages=469-479&author=V.+E.+Wagnerauthor=L.+L.+Liauthor=V.+M.+Isabellaauthor=B.+H.+Iglewski&title=Analysis+of+the+hierarchy+of+quorum-sensing+regulation+in+Pseudomonas+aeruginosa&doi=10.1007%2Fs00216-006-0964-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the hierarchy of quorum sensing regulation in Pseudomonas aeruginosa</span></div><div class="casAuthors">Wagner, Victoria E.; Li, Luen-Luen; Isabella, Vincent M.; Iglewski, Barbara H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">469-479</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Quorum sensing in Pseudomonas aeruginosa is known to regulate several aspects of pathogenesis, including virulence factor prodn., biofilm development, and antimicrobial resistance.  Recent high-throughput anal. has revealed the existence of several layers of regulation within the QS-circuit.  To address this complexity, mutations in genes encoding known or putative transcriptional regulators that were also identified as being regulated by the las and/or rhl QS systems were screened for their contribution in mediating several phenotypes, for example motility, secreted virulence products, and pathogenic capacity in a lettuce leaf model.  These studies have further elucidated the potential contribution to virulence of these genes within the QS regulon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5G4QzlH2qbVg90H21EOLACvtfcHk0lia0QLymKuHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFOnsQ%253D%253D&md5=76367be06596846b05709b391a65b947</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00216-006-0964-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-006-0964-6%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DV.%2BE.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DIsabella%26aufirst%3DV.%2BM.%26aulast%3DIglewski%26aufirst%3DB.%2BH.%26atitle%3DAnalysis%2520of%2520the%2520hierarchy%2520of%2520quorum-sensing%2520regulation%2520in%2520Pseudomonas%2520aeruginosa%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2007%26volume%3D387%26spage%3D469%26epage%3D479%26doi%3D10.1007%2Fs00216-006-0964-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">112252</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2020.112252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=32244097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmt1GgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2020&pages=112252&author=K.+Jiangauthor=X.+Yanauthor=J.+Yuauthor=Z.+Xiaoauthor=H.+Wuauthor=M.+Zhaoauthor=Y.+Yueauthor=X.+Zhouauthor=J.+Xiaoauthor=F.+Lin&title=Design%2C+synthesis%2C+and+biological+evaluation+of+3-amino-2-oxazolidinone+derivatives+as+potent+quorum-sensing+inhibitors+of+Pseudomonas+aeruginosa+PAO1&doi=10.1016%2Fj.ejmech.2020.112252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1</span></div><div class="casAuthors">Jiang, Kai; Yan, Xinlin; Yu, Jiahao; Xiao, Zijian; Wu, Hao; Zhao, Meihua; Yue, Yuandong; Zhou, Xiaoping; Xiao, Junhai; Lin, Feng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112252</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-amino-2-oxazolidinone compds. (I) [R = 4-FC6H4, 4-ClC6H4, 4-NO2C6H4, etc.; X = O, S; n = 1,2,3,4] was designed and synthesized using ZS-12 as the lead compd.  Compds. I were screened for inhibitory activities against QS using C. violaceum CV026 as a reporter strain.  Some of the compds. I showed good activities (IC50 range 3.69-63.58μM) and compd. I [R = 4-BrC6H4; X = O; n = 1] inhibition was the most significant (IC50= 3.686 ± 0.5790μM) against biofilm formation and virulence factors detn. of P. aeruginosa PAO1.  In vitro, compd. I [R = 4-BrC6H4; X = O; n = 1] significantly inhibited the formation of PAO1 biofilm (range 42.98%-17.67%), the prodn. of virulence factors (pyocyanin, elastase, rhamnolipid and protease) and bacterial motility.  Moreover, the combination of compd. I [R = 4-BrC6H4; X = O; n = 1] with an antibiotic (meropenem trihydrate) could significantly improve the antibiotic susceptibility of biofilm P. aeruginosa PAO1 cells.  In vivo, compd. I [R = 4-BrC6H4; X = O; n = 1] significantly prolonged the lifespan of wildtype Caenorhabditis elegans N2 infected by P. aeruginosa PAO1.  In conclusion, compd. I [R = 4-BrC6H4; X = O; n = 1] was a candidate agent for antibiotic-resistant P. aeruginosa PAO1 and provided a method for finding new antibacterial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzK3am2Lm-rVg90H21EOLACvtfcHk0lia0QLymKuHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmt1GgtL4%253D&md5=9207bc5a7e023d9c743200501c2e4791</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112252%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25203-amino-2-oxazolidinone%2520derivatives%2520as%2520potent%2520quorum-sensing%2520inhibitors%2520of%2520Pseudomonas%2520aeruginosa%2520PAO1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D194%26spage%3D112252%26doi%3D10.1016%2Fj.ejmech.2020.112252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyskiel, C.</span></span> <span> </span><span class="NLM_article-title">To be or not to be exclusive: the sutezolid story</span>. <i>Lancet Glob. Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e91</span> <span class="refDoi"> DOI: 10.1016/S2214-109X(15)00283-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS2214-109X%2815%2900283-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26823223" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&author=C.+Wyskiel&title=To+be+or+not+to+be+exclusive%3A+the+sutezolid+story&doi=10.1016%2FS2214-109X%2815%2900283-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2815%2900283-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252815%252900283-1%26sid%3Dliteratum%253Aachs%26aulast%3DWyskiel%26aufirst%3DC.%26atitle%3DTo%2520be%2520or%2520not%2520to%2520be%2520exclusive%253A%2520the%2520sutezolid%2520story%26jtitle%3DLancet%2520Glob.%2520Health%26date%3D2016%26volume%3D4%26doi%3D10.1016%2FS2214-109X%2815%2900283-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1164/rccm.200904-0611OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1164%2Frccm.200904-0611OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19520903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=371-376&author=K.+N.+Williamsauthor=S.+J.+Bricknerauthor=C.+K.+Stoverauthor=T.+Zhuauthor=A.+Ogdenauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+L.+Nuermberger&title=Addition+of+PNU-100480+to+first-line+drugs+shortens+the+time+needed+to+cure+murine+tuberculosis&doi=10.1164%2Frccm.200904-0611OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span></div><div class="casAuthors">Williams, Kathy N.; Brickner, Steven J.; Stover, Charles K.; Zhu, Tong; Ogden, Adam; Tasneen, Rokeya; Tyagi, Sandeep; Grosset, Jacques H.; Nuermberger, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model.  To investigate whether the addn. of PNU-100480 to the std. first-line regimen of rifampin, isoniazid, and pyrazinamide could shorten the duration of treatment necessary to prevent relapse after treatment discontinuation.  Following aerosol infection with Mycobacterium tuberculosis H37Rv and a 13-day incubation period, control mice were treated with the first-line regimen while test mice received the same regimen with PNU-100480 or linezolid added for the first 2 or 4 mo.  Efficacy was assessed on the basis of quant. cultures of lung homogenates performed monthly during treatment and 3 mo after completion of 3, 4, 5, or 6 mo of treatment to det. the relapse rate.  After 2 mo of treatment, mice receiving PNU-100480 in addn. to the first-line regimen had lung CFU counts two orders of magnitude lower than control mice receiving the first-line regimen alone.  Relapse rates after 4 mo of treatment were 90, 35, and 5% when PNU-100480 was added to the first-line regimen for 0, 2, and 4 mo, resp.  When the total treatment duration was 3 mo, relapse rates were 85 and 35 to 45% when mice received PNU-100480 for 2 and 3 mo, resp.; all control mice remained culture pos. at the time of treatment completion with 17 to 72 CFU per lung.  Addn. of linezolid to the first-line regimen had an antagonistic effect resulting in higher CFU counts and failure to render mice culture-neg. in 4 mo of treatment.  Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clin. testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnFWkF1J81fbVg90H21EOLACvtfcHk0liDvfxicBSyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L&md5=c4f5928eaf02b292e40d8b724ade1897</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0611OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0611OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DAddition%2520of%2520PNU-100480%2520to%2520first-line%2520drugs%2520shortens%2520the%2520time%2520needed%2520to%2520cure%2520murine%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D371%26epage%3D376%26doi%3D10.1164%2Frccm.200904-0611OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0liDvfxicBSyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/AAC.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2FAAC.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0lj-4F1Y1Y9Mgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2FAAC.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span>; <span class="NLM_string-name">Brown, D.</span>; <span class="NLM_string-name">Swift, M.</span>; <span class="NLM_string-name">Files, K.</span>; <span class="NLM_string-name">Fikes, S.</span>; <span class="NLM_string-name">Drusano, G. L.</span></span> <span> </span><span class="NLM_article-title">Clinical Doses of PNU-100480 (U, Sutezolid) Plus Rifampin (r) Synergistically Kills <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) while Linezolid (1) Plus R Does Not</span>. In  <i>52nd Interscience Conference of Antimicrobialgents and Chemotherapy (ICAAC)</i>, <span class="NLM_publisher-loc">San Francisco, CA</span>, Sept 9–12, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Louie&author=D.+Brown&author=M.+Swift&author=K.+Files&author=S.+Fikes&author=G.+L.+Drusano&title=Clinical+Doses+of+PNU-100480+%28U%2C+Sutezolid%29+Plus+Rifampin+%28r%29+Synergistically+Kills+Mycobacterium+tuberculosis+%28Mtb%29+while+Linezolid+%281%29+Plus+R+Does+Not"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLouie%26aufirst%3DA.%26atitle%3DClinical%2520Doses%2520of%2520PNU-100480%2520%2528U%252C%2520Sutezolid%2529%2520Plus%2520Rifampin%2520%2528r%2529%2520Synergistically%2520Kills%2520Mycobacterium%2520tuberculosis%2520%2528Mtb%2529%2520while%2520Linezolid%2520%25281%2529%2520Plus%2520R%2520Does%2520Not%26jtitle%3D52nd%2520Interscience%2520Conference%2520of%2520Antimicrobialgents%2520and%2520Chemotherapy%2520%2528ICAAC%2529%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure–activity relationship for linezolid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure–activity relationship for tedizolid phosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy and antibacterial activities of oxazolidinone compounds <b>2a</b>–<b>i</b> (<i>S. aureus</i>, <i>Staphylococcus aureus</i>; MRSA, methicillin-resistant <i>Staphylococcus aureus</i>; VRE, vancomycin-resistant <i>Enterococcus</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design strategy and chemical structures of oxazolidinone compounds <b>3a</b>–<b>m</b> containing piperidinyl moieties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of compounds <b>4a</b>–<b>e</b> and <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Oxazolidinone derivatives modified at the C-5 position of linezolid. (B) Interaction of oxazolidinone antibiotic <b>6d</b> with the residues in the 50S ribosomal subunit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of newly synthesized oxazolidinone-biphenyl chalcone hybrid derivatives (<b>7a</b>–<b>i</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure–activity relationships of the synthesized spiropyrimidinetrione oxazolidinone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design strategy and chemical structures of compounds <b>11</b>–<b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of compounds <b>15a</b>–<b>f</b>, <b>16a</b>–<b>d</b>, <b>17a</b>–<b>d</b>, <b>18a</b>–<b>f</b>, and <b>19a-f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design strategy and chemical structures of compounds <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of compounds <b>24a</b>–<b>d</b> and <b>25a</b>–<b>d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Design strategy and chemical structures of compound <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Design strategy and chemical structures of compounds <b>28</b>–<b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design strategy and chemical structures of compounds <b>32</b>–<b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of compounds <b>36</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of compounds <b>43a</b>–<b>f</b>, <b>44a</b>–<b>f</b>, and <b>45a</b>–<b>f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of compounds <b>47a</b>–<b>c</b> and antibacterial activity, toxicity, and PK of compound <b>47a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of compounds <b>48</b>–<b>65</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Design of oxazolidinone antibiotics based on LpxC inhibitors. (B) Chemical structures of compounds <b>69a–i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of compounds <b>70a</b>–<b>i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/medium/jm1c00480_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of compounds <b>71a–l</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00480/20210714/images/large/jm1c00480_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00480&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 127 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truman, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span> <span> </span><span class="NLM_article-title">Antibiotics: past, present and future</span>. <i>Curr. Opin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.mib.2019.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.mib.2019.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31733401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2msbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=72-80&author=M.+I.+Hutchingsauthor=A.+W.+Trumanauthor=B.+Wilkinson&title=Antibiotics%3A+past%2C+present+and+future&doi=10.1016%2Fj.mib.2019.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics: past, present and future</span></div><div class="casAuthors">Hutchings, Matt; Truman, Andrew; Wilkinson, Barrie</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-80</span>CODEN:
                <span class="NLM_cas:coden">COMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1369-5274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The first antibiotic, salvarsan, was deployed in 1910.  In just over 100 years antibiotics have drastically changed modern medicine and extended the av. human lifespan by 23 years.  The discovery of penicillin in 1928 started the golden age of natural product antibiotic discovery that peaked in the mid-1950s.  Since then, a gradual decline in antibiotic discovery and development and the evolution of drug resistance in many human pathogens has led to the current antimicrobial resistance crisis.  Here we give an overview of the history of antibiotic discovery, the major classes of antibiotics and where they come from.  We argue that the future of antibiotic discovery looks bright as new technologies such as genome mining and editing are deployed to discover new natural products with diverse bioactivities.  We also report on the current state of antibiotic development, with 45 drugs currently going through the clin. trials pipeline, including several new classes with novel modes of action that are in phase 3 clin. trials.  Overall, there are promising signs for antibiotic discovery, but changes in financial models are required to translate scientific advances into clin. approved antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY6ZUsf1XmrVg90H21EOLACvtfcHk0lhic8XPmYM3Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2msbjP&md5=cdb3445303ef36cbe05f5ec1d2a0e37a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.mib.2019.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mib.2019.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutchings%26aufirst%3DM.%2BI.%26aulast%3DTruman%26aufirst%3DA.%2BW.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DAntibiotics%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCurr.%2520Opin.%2520Microbiol.%26date%3D2019%26volume%3D51%26spage%3D72%26epage%3D80%26doi%3D10.1016%2Fj.mib.2019.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasz, A.</span></span> <span> </span><span class="NLM_article-title">Microbiology. Weapons of microbial drug resistance abound in soil flora</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1126/science.1123982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.1123982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16424327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsVWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2006&pages=342-343&author=A.+Tomasz&title=Microbiology.+Weapons+of+microbial+drug+resistance+abound+in+soil+flora&doi=10.1126%2Fscience.1123982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Weapons of Microbial Drug Resistance Abound in Soil Flora</span></div><div class="casAuthors">Tomasz, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5759</span>),
    <span class="NLM_cas:pages">342-343</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Bacteria found in soils show robust resistance to many antibiotics.  These protective mechanisms may offer clues for generating a new arsenal of therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX6Uw3Cb0547Vg90H21EOLACvtfcHk0ljcrCJZEFmNHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsVWrsA%253D%253D&md5=1da4aadf997472af304d48e2dc580bb2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1123982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1123982%26sid%3Dliteratum%253Aachs%26aulast%3DTomasz%26aufirst%3DA.%26atitle%3DMicrobiology.%2520Weapons%2520of%2520microbial%2520drug%2520resistance%2520abound%2520in%2520soil%2520flora%26jtitle%3DScience%26date%3D2006%26volume%3D311%26spage%3D342%26epage%3D343%26doi%3D10.1126%2Fscience.1123982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaston, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presbury, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarkowsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vichinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falletta, J. M.</span></span> <span> </span><span class="NLM_article-title">Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1056/NEJM198606193142501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1056%2FNEJM198606193142501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=3086721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADyaL283jtVOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=1986&pages=1593-1599&author=M.+H.+Gastonauthor=J.+I.+Verterauthor=G.+Woodsauthor=C.+Pegelowauthor=J.+Kelleherauthor=G.+Presburyauthor=H.+Zarkowskyauthor=E.+Vichinskyauthor=R.+Iyerauthor=J.+S.+Lobelauthor=S.+Diamondauthor=C.+T.+Holbrookauthor=F.+M.+Gillauthor=K.+Ritcheyauthor=J.+M.+Falletta&title=Prophylaxis+with+oral+penicillin+in+children+with+sickle+cell+anemia.+A+randomized+trial&doi=10.1056%2FNEJM198606193142501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial</span></div><div class="casAuthors">Gaston M H; Verter J I; Woods G; Pegelow C; Kelleher J; Presbury G; Zarkowsky H; Vichinsky E; Iyer R; Lobel J S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1593-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Children with sickle cell anemia have an increased susceptibility to bacterial infections, especially to those caused by Streptococcus pneumoniae.  We therefore conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial to test whether the regular, daily administration of oral penicillin would reduce the incidence of documented septicemia due to S.pneumoniae in children with sickle cell anemia who were under the age of three years at the time of entry.  The children were randomly assigned to receive either 125 mg of penicillin V potassium (105 children) or placebo (110 children) twice daily.  The trial was terminated 8 months early, after an average of 15 months of follow-up, when an 84 percent reduction in the incidence of infection was observed in the group treated with penicillin, as compared with the group given placebo (13 of 110 patients vs. 2 of 105; P = 0.0025), with no deaths from pneumococcal septicemia occurring in the penicillin group but three deaths from the infection occurring in the placebo group.  On the basis of these results, we conclude that children should be screened in the neonatal period for sickle cell hemoglobinopathy and that those with sickle cell anemia should receive prophylactic therapy with oral penicillin by four months of age to decrease the morbidity and mortality associated with pneumococcal septicemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWPn7gNIRgrrYtC3U5jeOifW6udTcc2eYUp3_p110Carntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL283jtVOhsA%253D%253D&md5=5203a5ab53e9148913fdd83d0c1b2547</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM198606193142501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198606193142501%26sid%3Dliteratum%253Aachs%26aulast%3DGaston%26aufirst%3DM.%2BH.%26aulast%3DVerter%26aufirst%3DJ.%2BI.%26aulast%3DWoods%26aufirst%3DG.%26aulast%3DPegelow%26aufirst%3DC.%26aulast%3DKelleher%26aufirst%3DJ.%26aulast%3DPresbury%26aufirst%3DG.%26aulast%3DZarkowsky%26aufirst%3DH.%26aulast%3DVichinsky%26aufirst%3DE.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLobel%26aufirst%3DJ.%2BS.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DC.%2BT.%26aulast%3DGill%26aufirst%3DF.%2BM.%26aulast%3DRitchey%26aufirst%3DK.%26aulast%3DFalletta%26aufirst%3DJ.%2BM.%26atitle%3DProphylaxis%2520with%2520oral%2520penicillin%2520in%2520children%2520with%2520sickle%2520cell%2520anemia.%2520A%2520randomized%2520trial%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1986%26volume%3D314%26spage%3D1593%26epage%3D1599%26doi%3D10.1056%2FNEJM198606193142501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plésiat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span> <span> </span><span class="NLM_article-title">The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1128/CMR.00117-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FCMR.00117-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25788514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlyhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=337-418&author=X.+Z.+Liauthor=P.+Pl%C3%A9siatauthor=H.+Nikaido&title=The+challenge+of+efflux-mediated+antibiotic+resistance+in+Gram-negative+bacteria&doi=10.1128%2FCMR.00117-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria</span></div><div class="casAuthors">Li, Xian-Zhi; Plesiat, Patrick; Nikaido, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-418</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global emergence of multidrug-resistant Gram-neg. bacteria is a growing threat to antibiotic therapy.  The chromosomally encoded drug efflux mechanisms that are ubiquitous in these bacteria greatly contribute to antibiotic resistance and present a major challenge for antibiotic development.  Multidrug pumps, particularly those represented by the clin. relevant AcrAB-TolC and Mex pumps of the resistance-nodulation-division (RND) superfamily, not only mediate intrinsic and acquired multidrug resistance (MDR) but also are involved in other functions, including the bacterial stress response and pathogenicity.  Addnl., efflux pumps interact synergistically with other resistance mechanisms (e.g., with the outer membrane permeability barrier) to increase resistance levels.  Since the discovery of RND pumps in the early 1990s, remarkable scientific and technol. advances have allowed for an in-depth understanding of the structural and biochem. basis, substrate profiles, mol. regulation, and inhibition of MDR pumps.  However, the development of clin. useful efflux pump inhibitors and/or new antibiotics that can bypass pump effects continues to be a challenge.  Plasmid-borne efflux pump genes (including those for RND pumps) have increasingly been identified.  This article highlights the recent progress obtained for organisms of clin. significance, together with methodol. considerations for the characterization of MDR pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8mBa4pi9DV7Vg90H21EOLACvtfcHk0ljcrCJZEFmNHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlyhs7o%253D&md5=f481bdc9d3813f008c4c69502e9c9639</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FCMR.00117-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00117-14%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BZ.%26aulast%3DPl%25C3%25A9siat%26aufirst%3DP.%26aulast%3DNikaido%26aufirst%3DH.%26atitle%3DThe%2520challenge%2520of%2520efflux-mediated%2520antibiotic%2520resistance%2520in%2520Gram-negative%2520bacteria%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2015%26volume%3D28%26spage%3D337%26epage%3D418%26doi%3D10.1128%2FCMR.00117-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance patterns of Gram-negative and Gram-positive strains isolated from inpatients with nosocomial infections in a tertiary hospital in Beijing, China from 2011 to 2014</span>. <i>J. Chemother. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1080/1120009X.2016.1157946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1080%2F1120009X.2016.1157946" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2017&pages=317-320&author=X.+Zhuauthor=A.+Tongauthor=D.+Wangauthor=H.+Sunauthor=L.+Chenauthor=M.+Dong&title=Antibiotic+resistance+patterns+of+Gram-negative+and+Gram-positive+strains+isolated+from+inpatients+with+nosocomial+infections+in+a+tertiary+hospital+in+Beijing%2C+China+from+2011+to+2014&doi=10.1080%2F1120009X.2016.1157946"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F1120009X.2016.1157946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1120009X.2016.1157946%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DM.%26atitle%3DAntibiotic%2520resistance%2520patterns%2520of%2520Gram-negative%2520and%2520Gram-positive%2520strains%2520isolated%2520from%2520inpatients%2520with%2520nosocomial%2520infections%2520in%2520a%2520tertiary%2520hospital%2520in%2520Beijing%252C%2520China%2520from%25202011%2520to%25202014%26jtitle%3DJ.%2520Chemother.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2017%26volume%3D29%26spage%3D317%26epage%3D320%26doi%3D10.1080%2F1120009X.2016.1157946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neu, H. C.</span></span> <span> </span><span class="NLM_article-title">The crisis in antibiotic resistance</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1126/science.257.5073.1064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.257.5073.1064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1509257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK38Xls1OhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1992&pages=1064-1073&author=H.+C.+Neu&title=The+crisis+in+antibiotic+resistance&doi=10.1126%2Fscience.257.5073.1064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The crisis in antibiotic resistance</span></div><div class="casAuthors">Neu, Harold C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5073</span>),
    <span class="NLM_cas:pages">1064-72</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with >64 refs.  The synthesis of large nos. of antibiotics over the past three decades has caused complacency about the threat of bacterial resistance.  Bacteria have become resistant to antimicrobial agents as a result of chromosomal changes or the exchange of genetic material via plasmids and transposons.  Streptococcus pneumoniae, Streptococcus pyogenes, and staphylococci, organisms that cause respiratory and cutaneous infections, and members of the Enterobacteriaceae and Pseudomonas families, organisms that cause diarrhea, urinary infection, and sepsis, are now resistant to virtually all of the older antibiotics.  The extensive use of antibiotics in the community and hospitals has fueled this crisis.  Mechanisms such as antibiotic control programs, better hygiene, and synthesis of agents with improved antimicrobial activity need to be adopted in order to limit bacterial resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmntDmhDYAKrVg90H21EOLACvtfcHk0liYo4StkuXGWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1OhsbY%253D&md5=02b98676a76f669ffde4dbb1f10a3876</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.257.5073.1064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.257.5073.1064%26sid%3Dliteratum%253Aachs%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DThe%2520crisis%2520in%2520antibiotic%2520resistance%26jtitle%3DScience%26date%3D1992%26volume%3D257%26spage%3D1064%26epage%3D1073%26doi%3D10.1126%2Fscience.257.5073.1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumental, S.</span></span> <span> </span><span class="NLM_article-title">Specialty Grand Challenge In Pediatric Infectious Diseases</span>. <i>Front. pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>, <span class="refDoi"> DOI: 10.3389/fped.2017.00185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.3389%2Ffped.2017.00185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28894730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmvFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=185&author=P.+Lepageauthor=S.+Blumental&title=Specialty+Grand+Challenge+In+Pediatric+Infectious+Diseases&doi=10.3389%2Ffped.2017.00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Specialty Grand Challenge In Pediatric Infectious Diseases</span></div><div class="casAuthors">Lepage Philippe; Blumental Sophie; Lepage Philippe; Blumental Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6GJEjgZePFpNiNltV31zlfW6udTcc2ebblKWlhEyXBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmvFymsg%253D%253D&md5=95c131a56638492dfea30db241a71626</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffped.2017.00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2017.00185%26sid%3Dliteratum%253Aachs%26aulast%3DLepage%26aufirst%3DP.%26aulast%3DBlumental%26aufirst%3DS.%26atitle%3DSpecialty%2520Grand%2520Challenge%2520In%2520Pediatric%2520Infectious%2520Diseases%26jtitle%3DFront.%2520pediatr.%26date%3D2017%26volume%3D5%26spage%3D185%26doi%3D10.3389%2Ffped.2017.00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi
Bialvaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgharzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi Kafil, H.</span></span> <span> </span><span class="NLM_article-title">Linezolid: a promising option in the treatment of Gram-positives</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1093/jac/dkw450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkw450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=27999068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=354-364&author=A.+Zahedi%0ABialvaeiauthor=M.+Rahbarauthor=M.+Yousefiauthor=M.+Asgharzadehauthor=H.+Samadi+Kafil&title=Linezolid%3A+a+promising+option+in+the+treatment+of+Gram-positives&doi=10.1093%2Fjac%2Fdkw450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid: a promising option in the treatment of Gram-positives</span></div><div class="casAuthors">Zahedi Bialvaei Abed; Rahbar Mohammad; Yousefi Mehdi; Asgharzadeh Mohammad; Samadi Kafil Hossein</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antimicrobial chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Linezolid, an oxazolidinone antimicrobial agent that acts by inhibiting protein synthesis in a unique fashion, is used in the treatment of community-acquired pneumonia, skin and soft-tissue infections and other infections caused by Gram-positive bacteria including VRE and methicillin-resistant staphylococci.  Currently, linezolid resistance among these pathogens remains low, commonly <1.0%, although the prevalence of antibiotic resistance is increasing in many countries.  Therefore, the development of resistance by clinical isolates should prompt increased attention of clinical laboratories to routinely perform linezolid susceptibility testing for this important agent and should be taken into account when considering its therapeutic use.  Considering the importance of linezolid in the treatment of infections caused by Gram-positive bacteria, this review was undertaken to optimize the clinical use of this antibiotic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6wL2yu320D2gRQsDqrjW_fW6udTcc2ebblKWlhEyXBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmvFWitQ%253D%253D&md5=7b7621e958610ab9288e0d7cff155b2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkw450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkw450%26sid%3Dliteratum%253Aachs%26aulast%3DZahedi%2BBialvaei%26aufirst%3DA.%26aulast%3DRahbar%26aufirst%3DM.%26aulast%3DYousefi%26aufirst%3DM.%26aulast%3DAsgharzadeh%26aufirst%3DM.%26aulast%3DSamadi%2BKafil%26aufirst%3DH.%26atitle%3DLinezolid%253A%2520a%2520promising%2520option%2520in%2520the%2520treatment%2520of%2520Gram-positives%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2017%26volume%3D72%26spage%3D354%26epage%3D364%26doi%3D10.1093%2Fjac%2Fdkw450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanamori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumaru, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani-Ui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuzaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanehisa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, K.</span></span> <span> </span><span class="NLM_article-title">Whole genome sequencing of meticillin-resistant Staphylococcus aureus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)04403-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2800%2904403-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11418146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvVClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=1225-1240&author=M.+Kurodaauthor=T.+Ohtaauthor=I.+Uchiyamaauthor=T.+Babaauthor=H.+Yuzawaauthor=I.+Kobayashiauthor=L.+Cuiauthor=A.+Oguchiauthor=K.+Aokiauthor=Y.+Nagaiauthor=J.+Lianauthor=T.+Itoauthor=M.+Kanamoriauthor=H.+Matsumaruauthor=A.+Maruyamaauthor=H.+Murakamiauthor=A.+Hosoyamaauthor=Y.+Mizutani-Uiauthor=N.+K.+Takahashiauthor=T.+Sawanoauthor=R.+Inoueauthor=C.+Kaitoauthor=K.+Sekimizuauthor=H.+Hirakawaauthor=S.+Kuharaauthor=S.+Gotoauthor=J.+Yabuzakiauthor=M.+Kanehisaauthor=A.+Yamashitaauthor=K.+Oshimaauthor=K.+Furuyaauthor=C.+Yoshinoauthor=T.+Shibaauthor=M.+Hattoriauthor=N.+Ogasawaraauthor=H.+Hayashiauthor=K.+Hiramatsu&title=Whole+genome+sequencing+of+meticillin-resistant+Staphylococcus+aureus&doi=10.1016%2FS0140-6736%2800%2904403-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Whole genome sequencing of meticillin-resistant Staphylococcus aureus</span></div><div class="casAuthors">Kuroda, Makoto; Ohta, Toshiko; Uchiyama, Ikuo; Baba, Tadashi; Yuzawa, Harumi; Kobayashi, Ichizo; Cui, Longzhu; Oguchi, Akio; Aoki, Ken-ichi; Nagai, Yoshimi; Lian, JianQi; Ito, Teruyo; Kanamori, Mutsumi; Matsumaru, Hiroyuki; Maruyama, Atsushi; Murakami, Hiroyuki; Hosoyama, Akira; Mizutani-Ui, Yoko; Takahashi, Noriko K.; Sawano, Toshihiko; Inoue, Ryu-ichi; Kaito, Chikara; Sekimizu, Kazuhisa; Hirakawa, Hideki; Kuhara, Satoru; Goto, Susumu; Yabuzaki, Junko; Kanehisa, Minoru; Yamashita, Atsushi; Oshima, Kenshiro; Furuya, Keiko; Yoshino, Chie; Shiba, Tadayoshi; Hattori, Masahira; Ogasawara, Naotake; Hayashi, Hideo; Hiramatsu, Keiichi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">9264</span>),
    <span class="NLM_cas:pages">1225-1240</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Staphylococcus aureus is one of the major causes of community-acquired and hospital-acquired infections.  It produces numerous toxins including superantigens that cause unique disease entities such as toxic-shock syndrome and staphylococcal scarlet fever, and has acquired resistance to practically all antibiotics.  Whole genome anal. is a necessary step towards future development of countermeasures against this organism.  Whole genome sequences of two related S aureus strains (N315 and Mu50) were detd. by shot-gun random sequencing.  N315 is a meticillin-resistant S aureus (MRSA) strain isolated in 1982, and Mu50 is an MRSA strain with vancomycin resistance isolated in 1997.  The open reading frames were identified by use of GAMBLER and GLIMMER programs, and annotation of each was done with a BLAST homol. search, motif anal., and protein localization prediction.  The Staphylococcus genome was composed of a complex mixt. of genes, many of which seem to have been acquired by lateral gene transfer.  Most of the antibiotic resistance genes were carried either by plasmids or by mobile genetic elements including a unique resistance island.  Three classes of new pathogenicity islands were identified in the genome: a toxic shock syndrome toxin island family, exotoxin islands, and enterotoxin islands.  In the latter two pathogenicity islands, clusters of exotoxin and enterotoxin genes were found closely linked with other gene clusters encoding putative pathogenic factors.  The anal. also identified 70 candidates for new virulence factors.  The remarkable ability of S aureus to acquire useful genes from various organisms was revealed through the observation of genome complexity and evidence of lateral gene transfer.  Repeated duplication of genes encoding superantigens explains why S aureus is capable of infecting humans of diverse genetic backgrounds, eliciting severe immune reactions.  Investigation of many newly identified gene products, including the 70 putative virulence factors, will greatly improve our understanding of the biol. of staphylococci and the processes of infectious diseases caused by S aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpU6n9OxpCX7Vg90H21EOLACvtfcHk0ljekYViaaq8Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvVClur0%253D&md5=3b46b4b35182e65e5794bd2e689b740b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2904403-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252904403-2%26sid%3Dliteratum%253Aachs%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DI.%26aulast%3DBaba%26aufirst%3DT.%26aulast%3DYuzawa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DI.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DOguchi%26aufirst%3DA.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DLian%26aufirst%3DJ.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKanamori%26aufirst%3DM.%26aulast%3DMatsumaru%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DHosoyama%26aufirst%3DA.%26aulast%3DMizutani-Ui%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%2BK.%26aulast%3DSawano%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DR.%26aulast%3DKaito%26aufirst%3DC.%26aulast%3DSekimizu%26aufirst%3DK.%26aulast%3DHirakawa%26aufirst%3DH.%26aulast%3DKuhara%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DYabuzaki%26aufirst%3DJ.%26aulast%3DKanehisa%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DA.%26aulast%3DOshima%26aufirst%3DK.%26aulast%3DFuruya%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DC.%26aulast%3DShiba%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DM.%26aulast%3DOgasawara%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DHiramatsu%26aufirst%3DK.%26atitle%3DWhole%2520genome%2520sequencing%2520of%2520meticillin-resistant%2520Staphylococcus%2520aureus%26jtitle%3DLancet%26date%3D2001%26volume%3D357%26spage%3D1225%26epage%3D1240%26doi%3D10.1016%2FS0140-6736%2800%2904403-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouts, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mongodin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deboy, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beanan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madupu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiuoli, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haft, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamathevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utterback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hance, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C. M.</span></span> <span> </span><span class="NLM_article-title">Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">2426</span>– <span class="NLM_lpage">2438</span>, <span class="refDoi"> DOI: 10.1128/JB.187.7.2426-2438.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FJB.187.7.2426-2438.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15774886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1Kqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2005&pages=2426-2438&author=S.+R.+Gillauthor=D.+E.+Foutsauthor=G.+L.+Archerauthor=E.+F.+Mongodinauthor=R.+T.+Deboyauthor=J.+Ravelauthor=I.+T.+Paulsenauthor=J.+F.+Kolonayauthor=L.+Brinkacauthor=M.+Beananauthor=R.+J.+Dodsonauthor=S.+C.+Daughertyauthor=R.+Madupuauthor=S.+V.+Angiuoliauthor=A.+S.+Durkinauthor=D.+H.+Haftauthor=J.+Vamathevanauthor=H.+Khouriauthor=T.+Utterbackauthor=C.+Leeauthor=G.+Dimitrovauthor=L.+Jiangauthor=H.+Qinauthor=J.+Weidmanauthor=K.+Tranauthor=K.+Kangauthor=I.+R.+Hanceauthor=K.+E.+Nelsonauthor=C.+M.+Fraser&title=Insights+on+evolution+of+virulence+and+resistance+from+the+complete+genome+analysis+of+an+early+methicillin-resistant+Staphylococcus+aureus+strain+and+a+biofilm-producing+methicillin-resistant+Staphylococcus+epidermidis+strain&doi=10.1128%2FJB.187.7.2426-2438.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Streptococcus epidermidis strain</span></div><div class="casAuthors">Gill, Steven R.; Fouts, Derrick E.; Archer, Gordon L.; Mongodin, Emmanuel F.; DeBoy, Robert T.; Ravel, Jacques; Paulsen, Ian T.; Kolonay, James F.; Brinkac, Lauren; Beanan, Mauren; Dodson, Robert J.; Daugherty, Sean C.; Madupu, Ramana; Angiuoli, Samuel V.; Durkin, A. Scott; Haft, Daniel H.; Vamathevan, Jessica; Khouri, Hoda; Utterback, Terry; Lee, Chris; Dimitrov, George; Jiang, Lingxia; Qin, Haiying; Weidman, Jan; Tran, Kevin; Kang, Kathy; Hance, Ioana R.; Nelson, Karen E.; Fraser, Claire M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2426-2438</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcus aureus is an opportunistic pathogen and the major causative agent of numerous hospital- and community-acquired infections.  Staphylococcus epidermidis has emerged as a causative agent of infections often assocd. with implanted medical devices.  The ∼2.8-Mb genome of S. aureus COL, an early methicillin-resistant isolate, and the ∼2.6-Mb genome of S. epidermidis RP62a, a methicillin-resistant biofilm isolate, were sequenced.  Comparative anal. of these and other staphylococcal genomes was used to explore the evolution of virulence and resistance between these two species.  The S. aureus and S. epidermidis genomes are syntenic throughout their lengths and share a core set of 1681 open reading frames.  Genome islands in nonsyntenic regions are the primary source of variations in pathogenicity and resistance.  Gene transfer between staphylococci and low-GC-content gram-pos. bacteria appears to have shaped their virulence and resistance profiles.  Integrated plasmids in S. epidermidis carry genes encoding resistance to cadmium and species-specific LPXTG surface proteins.  A novel genome island encodes multiple phenol-sol. modulins, a potential S. epidermidis virulence factor.  S. epidermidis contains the cap operon, encoding the polyglutamate capsule, a major virulence factor in Bacillus anthracis.  Addnl. phenotypic differences are likely the result of single nucleotide polymorphisms, which are most numerous in cell envelope proteins.  Overall differences in pathogenicity can be attributed to genome islands in S. aureus which encode enterotoxins, exotoxins, leukocidins, and leukotoxins not found in S. epidermidis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQCOEqBmlu3rVg90H21EOLACvtfcHk0ljekYViaaq8Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1Kqs7s%253D&md5=b4485eb277352166ed70e211eeef47dd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FJB.187.7.2426-2438.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.187.7.2426-2438.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BR.%26aulast%3DFouts%26aufirst%3DD.%2BE.%26aulast%3DArcher%26aufirst%3DG.%2BL.%26aulast%3DMongodin%26aufirst%3DE.%2BF.%26aulast%3DDeboy%26aufirst%3DR.%2BT.%26aulast%3DRavel%26aufirst%3DJ.%26aulast%3DPaulsen%26aufirst%3DI.%2BT.%26aulast%3DKolonay%26aufirst%3DJ.%2BF.%26aulast%3DBrinkac%26aufirst%3DL.%26aulast%3DBeanan%26aufirst%3DM.%26aulast%3DDodson%26aufirst%3DR.%2BJ.%26aulast%3DDaugherty%26aufirst%3DS.%2BC.%26aulast%3DMadupu%26aufirst%3DR.%26aulast%3DAngiuoli%26aufirst%3DS.%2BV.%26aulast%3DDurkin%26aufirst%3DA.%2BS.%26aulast%3DHaft%26aufirst%3DD.%2BH.%26aulast%3DVamathevan%26aufirst%3DJ.%26aulast%3DKhouri%26aufirst%3DH.%26aulast%3DUtterback%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDimitrov%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DWeidman%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DK.%26aulast%3DHance%26aufirst%3DI.%2BR.%26aulast%3DNelson%26aufirst%3DK.%2BE.%26aulast%3DFraser%26aufirst%3DC.%2BM.%26atitle%3DInsights%2520on%2520evolution%2520of%2520virulence%2520and%2520resistance%2520from%2520the%2520complete%2520genome%2520analysis%2520of%2520an%2520early%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520strain%2520and%2520a%2520biofilm-producing%2520methicillin-resistant%2520Staphylococcus%2520epidermidis%2520strain%26jtitle%3DJ.%2520Bacteriol.%26date%3D2005%26volume%3D187%26spage%3D2426%26epage%3D2438%26doi%3D10.1128%2FJB.187.7.2426-2438.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshadri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouts, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidelberg, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettelin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umayam, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beanan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugherty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBoy, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madupu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamathevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utterback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radune, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketchum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C. M.</span></span> <span> </span><span class="NLM_article-title">Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">2071</span>– <span class="NLM_lpage">2074</span>, <span class="refDoi"> DOI: 10.1126/science.1080613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.1080613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12663927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlCisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=2071-2074&author=I.+T.+Paulsenauthor=L.+Banerjeiauthor=G.+S.+Myersauthor=K.+E.+Nelsonauthor=R.+Seshadriauthor=T.+D.+Readauthor=D.+E.+Foutsauthor=J.+A.+Eisenauthor=S.+R.+Gillauthor=J.+F.+Heidelbergauthor=H.+Tettelinauthor=R.+J.+Dodsonauthor=L.+Umayamauthor=L.+Brinkacauthor=M.+Beananauthor=S.+Daughertyauthor=R.+T.+DeBoyauthor=S.+Durkinauthor=J.+Kolonayauthor=R.+Madupuauthor=W.+Nelsonauthor=J.+Vamathevanauthor=B.+Tranauthor=J.+Uptonauthor=T.+Hansenauthor=J.+Shettyauthor=H.+Khouriauthor=T.+Utterbackauthor=D.+Raduneauthor=K.+A.+Ketchumauthor=B.+A.+Doughertyauthor=C.+M.+Fraser&title=Role+of+mobile+DNA+in+the+evolution+of+vancomycin-resistant+Enterococcus+faecalis&doi=10.1126%2Fscience.1080613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis</span></div><div class="casAuthors">Paulsen, I. T.; Banerjei, L.; Myers, G. S. A.; Nelson, K. E.; Seshadri, R.; Read, T. D.; Fouts, D. E.; Eisen, J. A.; Gill, S. R.; Heidelberg, J. F.; Tettelin, H.; Dodson, R. J.; Umayam, L.; Brinkac, L.; Beanan, M.; Daugherty, S.; DeBoy, R. T.; Durkin, S.; Kolonay, J.; Madupu, R.; Nelson, W.; Vamathevan, J.; Tran, B.; Upton, J.; Hansen, T.; Shetty, J.; Khouri, H.; Utterback, T.; Radune, D.; Ketchum, K. A.; Dougherty, B. A.; Fraser, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5615</span>),
    <span class="NLM_cas:pages">2071-2074</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The complete genome sequence of Enterococcus faecalis V583, a vancomycin-resistant clin. isolate, revealed that more than a quarter of the genome consists of probable mobile or foreign DNA.  One of the predicted mobile elements is a previously unknown vanB vancomycin-resistance conjugative transposon.  Three plasmids were identified, including two pheromone-sensing conjugative plasmids, one encoding a previously undescribed pheromone inhibitor.  The apparent propensity for the incorporation of mobile elements probably contributed to the rapid acquisition and dissemination of drug resistance in the enterococci.  The genome sequence is deposited in GenBank/EMBL/DDBJ under accession no. AE016830 and in the RefSeq database under accession no. NC_004668.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX6y7SjuOTKbVg90H21EOLACvtfcHk0liX2jGRELAiQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlCisLw%253D&md5=ca314c76de2ea22cb758ed8c431f42fd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1080613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1080613%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DI.%2BT.%26aulast%3DBanerjei%26aufirst%3DL.%26aulast%3DMyers%26aufirst%3DG.%2BS.%26aulast%3DNelson%26aufirst%3DK.%2BE.%26aulast%3DSeshadri%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DT.%2BD.%26aulast%3DFouts%26aufirst%3DD.%2BE.%26aulast%3DEisen%26aufirst%3DJ.%2BA.%26aulast%3DGill%26aufirst%3DS.%2BR.%26aulast%3DHeidelberg%26aufirst%3DJ.%2BF.%26aulast%3DTettelin%26aufirst%3DH.%26aulast%3DDodson%26aufirst%3DR.%2BJ.%26aulast%3DUmayam%26aufirst%3DL.%26aulast%3DBrinkac%26aufirst%3DL.%26aulast%3DBeanan%26aufirst%3DM.%26aulast%3DDaugherty%26aufirst%3DS.%26aulast%3DDeBoy%26aufirst%3DR.%2BT.%26aulast%3DDurkin%26aufirst%3DS.%26aulast%3DKolonay%26aufirst%3DJ.%26aulast%3DMadupu%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DW.%26aulast%3DVamathevan%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DB.%26aulast%3DUpton%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DShetty%26aufirst%3DJ.%26aulast%3DKhouri%26aufirst%3DH.%26aulast%3DUtterback%26aufirst%3DT.%26aulast%3DRadune%26aufirst%3DD.%26aulast%3DKetchum%26aufirst%3DK.%2BA.%26aulast%3DDougherty%26aufirst%3DB.%2BA.%26aulast%3DFraser%26aufirst%3DC.%2BM.%26atitle%3DRole%2520of%2520mobile%2520DNA%2520in%2520the%2520evolution%2520of%2520vancomycin-resistant%2520Enterococcus%2520faecalis%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D2071%26epage%3D2074%26doi%3D10.1126%2Fscience.1080613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.4.839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.40.4.839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=8849237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XitVWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=839-845&author=G.+E.+Zurenkoauthor=B.+H.+Yagiauthor=R.+D.+Schaadtauthor=J.+W.+Allisonauthor=J.+O.+Kilburnauthor=S.+E.+Glickmanauthor=D.+K.+Hutchinsonauthor=M.+R.+Barbachynauthor=S.+J.+Brickner&title=In+vitro+activities+of+U-100592+and+U-100766%2C+novel+oxazolidinone+antibacterial+agents&doi=10.1128%2FAAC.40.4.839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents</span></div><div class="casAuthors">Zurenko, Gary E.; Yagi, Betty H.; Schaadt, Ronda D.; Allison, John W.; Kilburn, James O.; Glickman, Suzanne E.; Hutchinson, Douglas K.; Barbachyn, Michael R.; Brickner, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">839-45</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition.  U-100592 {(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} and U-100766 {(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} are novel oxazolidinone analogs from a directed chem. modification program.  MICs were detd. for a variety of bacterial clin. isolates; the resp. MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 μg/mL; methicillin-resistant S. aureus, 4 and 4 μg/mL; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 μg/mL; methicillin-resistant S. epidermidis, 1 and 2 μg/mL; Enterococcus faecalis, 2 and 4 μg/mL; Enterococcus faecium, 2 and 4 μg/mL; Streptococcus pyogenes, 1 and 2 μg/mL; Streptococcus pneumoniae, 0.50 and 1 μg/mL; Corynebacterium spp., 0.50 and 0.50 μg/mL; Moraxella catarrhalis, 4 and 4 μg/mL; Listeria monocytogenes, 8 and 2 μg/mL; and Bacteroides fragilis, 16 and 4 μg/mL.  Most strains of Mycobacterium tuberculosis and the gram-pos. anaerobes were inhibited in the range of 0.50 to 2 μg/mL.  Enterococcal strains resistant to vancomycin (VanA, VanB, and VanC resistance phenotypes), pneumococcal strains resistant to penicillin, and M. tuberculosis strains resistant to common antitubercular agents (isoniazid, streptomycin, rifampin, ethionamide, and ethambutol) were not cross-resistant to the oxazolidinones.  The presence of 10, 20, and 40% pooled human serum did not affect the antibacterial activities of the oxazolidinones.  Time-kill studies demonstrated a bacteriostatic effect of the analogs against staphylococci and enterococci but a bactericidal effect against streptococci.  The spontaneous mutation frequencies of S. aureus ATCC 29213 were <3.8 × 10-10 and <8 × 10-11 for U-100592 and U-100766, resp.  Serial transfer of three staphylococcal and two enterococcal strains on drug gradient plates produced no evidence of rapid resistance development.  Thus, these new oxazolidinone analogs demonstrated in vitro antibacterial activities against a variety of clin. important human pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnq8VHb5v2UrVg90H21EOLACvtfcHk0liX2jGRELAiQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVWqs74%253D&md5=772cd4103720083e338e250db8ba9458</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.4.839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.4.839%26sid%3Dliteratum%253Aachs%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DYagi%26aufirst%3DB.%2BH.%26aulast%3DSchaadt%26aufirst%3DR.%2BD.%26aulast%3DAllison%26aufirst%3DJ.%2BW.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26atitle%3DIn%2520vitro%2520activities%2520of%2520U-100592%2520and%2520U-100766%252C%2520novel%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D839%26epage%3D845%26doi%3D10.1128%2FAAC.40.4.839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boger, W. P.</span></span> <span> </span><span class="NLM_article-title">Sulfaphenazol (orisul), a long-acting antibacterial sulfonamide</span>. <i>J. Am. Geriatr. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1111/j.1532-5415.1959.tb01072.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fj.1532-5415.1959.tb01072.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=13640890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaF3cXmvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1959&pages=314-321&author=W.+P.+Boger&title=Sulfaphenazol+%28orisul%29%2C+a+long-acting+antibacterial+sulfonamide&doi=10.1111%2Fj.1532-5415.1959.tb01072.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfaphenazol, a long-acting antibacterial sulfonamide</span></div><div class="casAuthors">Boger, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314-21</span>CODEN:
                <span class="NLM_cas:coden">JAGSAF</span>;
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    </div><div class="casAbstract">In 9 subjects a single oral dose of 2.0 g. N1-(phenylpyrazolyl)sulfanilamide gave peak plasma levels (free + conjugated) of 17.2 mg./100 ml. at 6 hrs.  After similar doses of sulfamethoxypyridazine and sulfisoxazole max. concns. of 23.9 and 20.4, resp., were reached at 4 hrs.  Ranges of the conjugated form of the 3 drugs in plasma were 12-16, 8-20, and 13-34%, resp.  In 38 patients receiving the 1st compd., no evidence was found that it diffused into cerebrospinal fluid, despite high blood concns.  Approx. 21% of the administered dose was recovered in urine within 8 hrs. and 30% of it in the conjugated form.  For the other 2 drugs 8-hr. urinary excretions were 10 and 53%, with 50 and 24%, resp., being in the conjugated form.  The av. clearance of free sulfaphenazol was between 1.03 and 1.79 ml./min.  It did not show any evidence of toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIpWGok55p17Vg90H21EOLACvtfcHk0liX2jGRELAiQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXmvFyisQ%253D%253D&md5=cfe85fdc228e74bab824d2ffe16529f5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1532-5415.1959.tb01072.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1532-5415.1959.tb01072.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoger%26aufirst%3DW.%2BP.%26atitle%3DSulfaphenazol%2520%2528orisul%2529%252C%2520a%2520long-acting%2520antibacterial%2520sulfonamide%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D1959%26volume%3D7%26spage%3D314%26epage%3D321%26doi%3D10.1111%2Fj.1532-5415.1959.tb01072.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of novel oxazolidinone analogs and 13 conventional antimicrobial agents against clinical isolates of Staphylococcus aureus in Beijing, China</span>. <i>Jpn. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.7883/yoken.67.402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.7883%2Fyoken.67.402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25241696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVynt7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=402-404&author=H.+Leiauthor=Y.+Jiangauthor=D.+Wangauthor=P.+Gongauthor=Y.+Liauthor=Y.+Dongauthor=M.+Dong&title=In+vitro+activity+of+novel+oxazolidinone+analogs+and+13+conventional+antimicrobial+agents+against+clinical+isolates+of+Staphylococcus+aureus+in+Beijing%2C+China&doi=10.7883%2Fyoken.67.402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of novel oxazolidinone analogs and 13 conventional antimicrobial agents against clinical isolates of Staphylococcus aureus in Beijing, China</span></div><div class="casAuthors">Lei, Hong; Jiang, Ying; Wang, Di; Gong, Ping; Li, Yanyan; Dong, Yueming; Dong, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">402-404</span>CODEN:
                <span class="NLM_cas:coden">JJIDFE</span>;
        ISSN:<span class="NLM_cas:issn">1344-6304</span>.
    
            (<span class="NLM_cas:orgname">National Institute of Infectious Diseases</span>)
        </div><div class="casAbstract">Methicillin-resistant Staphylococcus aureus (MRSA) has been a public health concern since it was first identified in the United Kingdom in 1961.  In this study, we investigated the prevalence of MRSA in the PLA 309 Hospital located in Beijing, China, and we detd. the susceptibility of S. aureus to novel oxazolidinone analogs and 13 conventional antimicrobial agents.  It was shown that drug resistant patterns were severe among the clin. isolates, and the av. rate of MRSA among the S. aureus strains was 56.3z.  All the S. aureus strains tested were completely susceptible to linezolid, but the min. inhibitory concn. distribution drifted upwards.  Among the novel oxazolidinone analogs, sy142 exhibited more potent antimicrobial activity than linezolid against both the std. and clin. S. aureus strains.  This observation provides an impetus for the development of potential novel agents based on sy142 in the near future to combat MRSA and linezolid-resistant S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnCTecrk8YtrVg90H21EOLACvtfcHk0lhZPMD9fE7OjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVynt7jE&md5=adc9f1f9f3d764c1f1379c78b09ba7cc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.7883%2Fyoken.67.402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7883%252Fyoken.67.402%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520activity%2520of%2520novel%2520oxazolidinone%2520analogs%2520and%252013%2520conventional%2520antimicrobial%2520agents%2520against%2520clinical%2520isolates%2520of%2520Staphylococcus%2520aureus%2520in%2520Beijing%252C%2520China%26jtitle%3DJpn.%2520J.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D67%26spage%3D402%26epage%3D404%26doi%3D10.7883%2Fyoken.67.402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidmar, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1128/AAC.41.10.2127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.41.10.2127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9333036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Snsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=2127-2131&author=A.+H.+Linauthor=R.+W.+Murrayauthor=T.+J.+Vidmarauthor=K.+R.+Marotti&title=The+oxazolidinone+eperezolid+binds+to+the+50S+ribosomal+subunit+and+competes+with+binding+of+chloramphenicol+and+lincomycin&doi=10.1128%2FAAC.41.10.2127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin</span></div><div class="casAuthors">Lin, Alice H.; Murray, Robert W.; Vidmar, Thomas J.; Marotti, Keith R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2131</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones are a novel class of antibiotics that act by inhibiting protein synthesis.  It as been reported that the drug exerts its primary activity on the initiation phase of translation.  In order to study the possibility of direct interaction between the drug and the ribosome, the authors have developed a binding assay using 14C-labeled eperezolid (PNU-100592; formerly U-100592).  Eperezolid binds specifically to the 50S ribosomal subunit of Escherichia coli.  The specific binding of eperezolid is dose dependent and is proportional to the ribosome concns.  Scatchard anal. of the binding data reveals that the dissocn. const. (Kd) is about 20 μM.  The binding of eperezolid to the ribosome is competitively inhibited by chloramphenicol and lincomycin.  However, unlike chloramphenicol and lincomycin, eperezolid does not inhibit the puromycin reaction, indicating that the oxazolidinones have no effect on peptidyl transferase.  In addn., whereas lincomycin and, to some extent, chloramphenicol inhibit translation termination, eperezolid has no effect.  Therefore, it is concluded that the oxazolidinones inhibit protein synthesis by binding to the 50S ribosomal subunit at a site close to the site(s) to which chloramphenicol and lincomycin bind but that the oxazolidinones are mechanistically distinct from these two antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdNVfxAmkfbVg90H21EOLACvtfcHk0lhZPMD9fE7OjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Snsr8%253D&md5=d1018ceacedb23aa1c7110743d348bf9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.41.10.2127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.41.10.2127%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DA.%2BH.%26aulast%3DMurray%26aufirst%3DR.%2BW.%26aulast%3DVidmar%26aufirst%3DT.%2BJ.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26atitle%3DThe%2520oxazolidinone%2520eperezolid%2520binds%2520to%2520the%252050S%2520ribosomal%2520subunit%2520and%2520competes%2520with%2520binding%2520of%2520chloramphenicol%2520and%2520lincomycin%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D2127%26epage%3D2131%26doi%3D10.1128%2FAAC.41.10.2127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganoza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D. L.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3251</span>– <span class="NLM_lpage">3255</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.12.3251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.42.12.3251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9835522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3251-3255&author=S.+M.+Swaneyauthor=H.+Aokiauthor=M.+C.+Ganozaauthor=D.+L.+Shinabarger&title=The+oxazolidinone+linezolid+inhibits+initiation+of+protein+synthesis+in+bacteria&doi=10.1128%2FAAC.42.12.3251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria</span></div><div class="casAuthors">Swaney, Steve M.; Aoki, Hiroyuki; Ganoza, M. Clelia; Shinabarger, Dean L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3251-3255</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones represent a new class of antimicrobial agents which are active against multidrug-resistant staphylococci, streptococci, and enterococci.  Previous studies have demonstrated that oxazolidinones inhibit bacterial translation in vitro at a step preceding elongation but after the charging of N-formylmethionine to the initiator tRNA mol.  The event that occurs between these two steps is termed initiation.  Initiation of protein synthesis requires the simultaneous presence of N-formylmethionine-tRNA, the 30S ribosomal subunit, mRNA, GTP, and the initiation factors IF1, IF2, and IF3.  An initiation complex assay measuring the binding of [3H]N-formylmethionyl-tRNA to ribosomes in response to mRNA binding was used in order to investigate the mechanism of oxazolidinone action.  Linezolid inhibited initiation complex formation with either the 30S or the 70S ribosomal subunits from Escherichia coli.  In addn., complex formation with Staphylococcus aureus 70S tight-couple ribosomes was inhibited by linezolid.  Linezolid did not inhibit the independent binding of either mRNA or N-formylmethionyl-tRNA to E. coli 30S ribosomal subunits, nor did it prevent the formation of the IF2-N-formylmethionyl-tRNA binary complex.  The results demonstrate that oxazolidinones inhibit the formation of the initiation complex in bacterial translation systems by preventing formation of the N-formylmethionyl-tRNA-ribosome-mRNA ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7APXXFOUkbVg90H21EOLACvtfcHk0lhZPMD9fE7OjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOqt7c%253D&md5=f5d7848e6074f7a178cda7b54eded6f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.12.3251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.12.3251%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DAoki%26aufirst%3DH.%26aulast%3DGanoza%26aufirst%3DM.%2BC.%26aulast%3DShinabarger%26aufirst%3DD.%2BL.%26atitle%3DThe%2520oxazolidinone%2520linezolid%2520inhibits%2520initiation%2520of%2520protein%2520synthesis%2520in%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3251%26epage%3D3255%26doi%3D10.1128%2FAAC.42.12.3251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockman, B. J.</span></span> <span> </span><span class="NLM_article-title">1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.3.625-629.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.46.3.625-629.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11850240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVKht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=625-629&author=C.+C.+Zhouauthor=S.+M.+Swaneyauthor=D.+L.+Shinabargerauthor=B.+J.+Stockman&title=1H+nuclear+magnetic+resonance+study+of+oxazolidinone+binding+to+bacterial+ribosomes&doi=10.1128%2FAAC.46.3.625-629.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes</span></div><div class="casAuthors">Zhou, Casey Chun; Swaney, Steven M.; Shinabarger, Dean L.; Stockman, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-629</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The oxazolidinones are a novel class of antibiotics that inhibit initiation of protein synthesis in bacteria.  In order to investigate their novel mechanism of action, the interactions of several oxazolidinones with bacterial 70S ribosomes, 50S subunits, and 30S subunits have been characterized by 1H NMR line-broadening analyses and transferred nuclear Overhauser enhancement (TRNOE) expts.  PNU-177553 and PNU-100592 (eperezolid) and their corresponding enantiomers, PNU-184414 and PNU-107112, were studied.  The dissocn. consts. were detd. to be 94±44 μM and 195±40 μM for PNU-177553 and eperezolid, resp.  There was a ∼4-fold decrease in affinity for their corresponding enantiomers.  The NMR-derived dissocn. consts. are consistent with their antibacterial activity.  PNU-177553 and eperezolid were found to bind only to the 50S subunit, with similar affinity as to the 70S ribosome, and to have no affinity for the 30S subunit.  Specific binding of PNU-177553 was further confirmed in TRNOE expts. in which pos. NOEs obsd. for the small mol. alone were changed to neg. NOEs in the presence of bacterial 70S ribosomes.  The obsd. NOEs indicated that PNU-177553 did not adopt a significantly different conformation when bound to the 70S ribosome, compared to the extended conformation that exists when free in soln.  Since this is likeliest the case for each of the four compds. included in this study, the A ring C5 side chain may be positioned in the proper orientation for antibacterial activity in PNU-177553 and eperezolid but not in their inactive enantiomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBSW3ou9t1P7Vg90H21EOLACvtfcHk0lhZ6tpaXumyZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVKht7g%253D&md5=39813208b8dfc2597741d7e8324bcba8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.3.625-629.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.3.625-629.2002%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DShinabarger%26aufirst%3DD.%2BL.%26aulast%3DStockman%26aufirst%3DB.%2BJ.%26atitle%3D1H%2520nuclear%2520magnetic%2520resonance%2520study%2520of%2520oxazolidinone%2520binding%2520to%2520bacterial%2520ribosomes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D625%26epage%3D629%26doi%3D10.1128%2FAAC.46.3.625-629.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M. H.</span></span> <span> </span><span class="NLM_article-title">Update on linezolid: the first oxazolidinone antibiotic</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1517/14656566.6.13.2315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1517%2F14656566.6.13.2315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16218891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2315-26&author=M.+H.+Wilcox&title=Update+on+linezolid%3A+the+first+oxazolidinone+antibiotic&doi=10.1517%2F14656566.6.13.2315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Update on linezolid: the first oxazolidinone antibiotic</span></div><div class="casAuthors">Wilcox, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2315-2326</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Linezolid is the first of an entirely new class of antibiotics, the oxazolidinones, in decades.  It has a spectrum of activity against virtually all important Gram-pos. pathogens.  The unique mechanism of action of linezolid makes cross-resistance with other antimicrobial agents unlikely.  Linezolid has both i.v. and oral formulations and the latter is 100% bioavailable.  Since its first approval and marketing in Mar. 2000 in the US, linezolid has gained approval for use in many other countries for the treatment of community-acquired and nosocomial pneumonia, complicated and uncomplicated skin and soft-tissue infections, and infections caused by methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, including cases with concurrent bacteremia.  Several earlier comprehensive reviews summarised the chem., mechanism of action, pharmacokinetics, clin. efficacy and safety profile of linezolid.  The present review provides an update on the latest data regarding the antimicrobial activity of linezolid vs. other commonly used agents, the clin. and health-economic outcomes of linezolid vs. vancomycin and teicoplanin, and safety issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS883zstYuHrVg90H21EOLACvtfcHk0lhZ6tpaXumyZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbvI&md5=aad1b478428b9c22bf04ac18845f74b7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.13.2315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.13.2315%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DM.%2BH.%26atitle%3DUpdate%2520on%2520linezolid%253A%2520the%2520first%2520oxazolidinone%2520antibiotic%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2315%26epage%3D26%26doi%3D10.1517%2F14656566.6.13.2315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampiris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batts, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, B.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1086/340353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F340353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12015695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFamtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=1481-1490&author=D.+L.+Stevensauthor=D.+Herrauthor=H.+Lampirisauthor=J.+L.+Huntauthor=D.+H.+Battsauthor=B.+Hafkin&title=Linezolid+versus+vancomycin+for+the+treatment+of+methicillin-resistant+Staphylococcus+aureus+infections&doi=10.1086%2F340353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections</span></div><div class="casAuthors">Stevens, Dennis L.; Herr, Daniel; Lampiris, Harry; Hunt, John Lee; Batts, Donald H.; Hafkin, Barry</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-1490</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-pos. bacteria, including drug-resistant strains.  In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n = 240) or vancomycin (1 g twice daily; n = 220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA.  Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection.  At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clin. cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiol. success rates (58.9% in the linezolid group and 63.2% in the vancomycin group).  Both regimens were well tolerated, with similar rates of adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IbjTJICYhbVg90H21EOLACvtfcHk0lhZ6tpaXumyZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFamtrk%253D&md5=eac34e7cb0bc1598026918055d68bd02</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1086%2F340353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F340353%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DD.%2BL.%26aulast%3DHerr%26aufirst%3DD.%26aulast%3DLampiris%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DJ.%2BL.%26aulast%3DBatts%26aufirst%3DD.%2BH.%26aulast%3DHafkin%26aufirst%3DB.%26atitle%3DLinezolid%2520versus%2520vancomycin%2520for%2520the%2520treatment%2520of%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520infections%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2002%26volume%3D34%26spage%3D1481%26epage%3D1490%26doi%3D10.1086%2F340353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. J.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus vancomycin for skin and soft tissue infections</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">CD008056</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD008056.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2F14651858.CD008056.pub3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26758498" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=CD008056&author=J.+Yueauthor=B.+R.+Dongauthor=M.+Yangauthor=X.+Chenauthor=T.+Wuauthor=G.+J.+Liu&title=Linezolid+versus+vancomycin+for+skin+and+soft+tissue+infections&doi=10.1002%2F14651858.CD008056.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD008056.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD008056.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DB.%2BR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DG.%2BJ.%26atitle%3DLinezolid%2520versus%2520vancomycin%2520for%2520skin%2520and%2520soft%2520tissue%2520infections%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26spage%3DCD008056%26doi%3D10.1002%2F14651858.CD008056.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliphant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderink, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1086/318486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F318486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11170948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Whur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=402-412&author=E.+Rubinsteinauthor=S.+Cammarataauthor=T.+Oliphantauthor=R.+Wunderink&title=Linezolid+%28PNU-100766%29+versus+vancomycin+in+the+treatment+of+hospitalized+patients+with+nosocomial+pneumonia%3A+a+randomized%2C+double-blind%2C+multicenter+study&doi=10.1086%2F318486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study</span></div><div class="casAuthors">Rubinstein, Ethan; Cammarata, Sue K.; Oliphant, Thomas H.; Wunderink, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-412</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Linezolid, the first oxazolidinone, is active against gram-pos. bacteria, including multidrug-resistant strains.  This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia.  A total of 203 patients received i.v. linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g i.v. twice daily, plus aztreonam for 7-21 days.  Clin. and microbiol. outcomes were evaluated at test of cure 12-28 days after treatment.  Clin. cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiol. success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, resp.) for evaluable patients were equiv. between treatment groups.  Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups.  Resistance to either treatment was not detected.  Linezolid is a well-tolerated, effective treatment for adults with gram-pos. nosocomial pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9r4oDwHfyM7Vg90H21EOLACvtfcHk0lgvNp1mbMVQHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Whur0%253D&md5=87c2552d05e938a67225778f4908073b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1086%2F318486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F318486%26sid%3Dliteratum%253Aachs%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DCammarata%26aufirst%3DS.%26aulast%3DOliphant%26aufirst%3DT.%26aulast%3DWunderink%26aufirst%3DR.%26atitle%3DLinezolid%2520%2528PNU-100766%2529%2520versus%2520vancomycin%2520in%2520the%2520treatment%2520of%2520hospitalized%2520patients%2520with%2520nosocomial%2520pneumonia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520multicenter%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D32%26spage%3D402%26epage%3D412%26doi%3D10.1086%2F318486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D. J.</span></span> <span> </span><span class="NLM_article-title">Hematologic effects of linezolid: summary of clinical experience</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2723</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.8.2723-2726.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.46.8.2723-2726.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12121967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFGiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=2723-2726&author=S.+L.+Gersonauthor=S.+L.+Kaplanauthor=J.+B.+Brussauthor=V.+Leauthor=F.+M.+Arellanoauthor=B.+Hafkinauthor=D.+J.+Kuter&title=Hematologic+effects+of+linezolid%3A+summary+of+clinical+experience&doi=10.1128%2FAAC.46.8.2723-2726.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Hematologic effects of linezolid: summary of clinical experience</span></div><div class="casAuthors">Gerson, Stanton L.; Kaplan, Sheldon L.; Bruss, Jon B.; Le, Vu; Arellano, Felix M.; Hafkin, Barry; Kuter, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2723-2726</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Linezolid has been assocd. with reversible myelosuppression.  Clin. trial data were evaluated for anemia, thrombocytopenia, and neutropenia.  Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 wk of linezolid treatment.  Hematol. abnormalities were consistent with mild, reversible, duration-dependent myelosuppression.  Appropriate monitoring is warranted with linezolid use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnT1YIKN07e7Vg90H21EOLACvtfcHk0lgvNp1mbMVQHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFGiu70%253D&md5=4b0a0b10715d1feb8287fb8f4789b8c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.8.2723-2726.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.8.2723-2726.2002%26sid%3Dliteratum%253Aachs%26aulast%3DGerson%26aufirst%3DS.%2BL.%26aulast%3DKaplan%26aufirst%3DS.%2BL.%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DArellano%26aufirst%3DF.%2BM.%26aulast%3DHafkin%26aufirst%3DB.%26aulast%3DKuter%26aufirst%3DD.%2BJ.%26atitle%3DHematologic%2520effects%2520of%2520linezolid%253A%2520summary%2520of%2520clinical%2520experience%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D2723%26epage%3D2726%26doi%3D10.1128%2FAAC.46.8.2723-2726.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, G.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of linezolid</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">Suppl 2</span>), <span class="NLM_elocation-id">45ii</span> <span class="refDoi"> DOI: 10.1093/jac/dkg253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkg253" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&issue=Suppl+2&author=G.+French&title=Safety+and+tolerability+of+linezolid&doi=10.1093%2Fjac%2Fdkg253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg253%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DG.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520linezolid%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3DSuppl%25202%26doi%3D10.1093%2Fjac%2Fdkg253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manninen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulanowicz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmon, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1021/jm9509556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9509556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=673-679&author=S.+J.+Bricknerauthor=D.+K.+Hutchinsonauthor=M.+R.+Barbachynauthor=P.+R.+Manninenauthor=D.+A.+Ulanowiczauthor=S.+A.+Garmonauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Synthesis+and+antibacterial+activity+of+U-100592+and+U-100766%2C+two+oxazolidinone+antibacterial+agents+for+the+potential+treatment+of+multidrug-resistant+gram-positive+bacterial+infections&doi=10.1021%2Fjm9509556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections</span></div><div class="casAuthors">Brickner, Steven J.; Hutchinson, Douglas K.; Barbachyn, Michael R.; Manninen, Peter R.; Ulanowicz, Debra A.; Garmon, Stuart A.; Grega, Kevin C.; Hendges, Susan K.; Toops, Dana S.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bacterial resistance development has become a very serious clin. problem for many classes of antibiotics.  The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis.  Two potent, synthetic oxazolidinones, U-100592 [i.e., (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] and U-100766 [i.e., (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] were prepd., which are currently in clin. development for the treatment of serious multidrug-resistant Gram-pos. bacterial infections caused by strains of staphylococci, streptococci, and enterococci.  The in vitro and in vivo (po and i.v.) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin.  U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis.  A novel and practical asym. synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones was developed and was employed for the synthesis of U-100592 and U-100766.  This involved the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMNrR9x9ErrVg90H21EOLACvtfcHk0ljaC7V3pQauxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisA%253D%253D&md5=fe1733b71f4953ec67853fe4284a33ac</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm9509556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9509556%26sid%3Dliteratum%253Aachs%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DUlanowicz%26aufirst%3DD.%2BA.%26aulast%3DGarmon%26aufirst%3DS.%2BA.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520U-100592%2520and%2520U-100766%252C%2520two%2520oxazolidinone%2520antibacterial%2520agents%2520for%2520the%2520potential%2520treatment%2520of%2520multidrug-resistant%2520gram-positive%2520bacterial%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D673%26epage%3D679%26doi%3D10.1021%2Fjm9509556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madaras-Kelly, K.</span></span> <span> </span><span class="NLM_article-title">A review of linezolid: the first oxazolidinone antibiotic</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1586/14787210.2.1.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1586%2F14787210.2.1.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15482171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=51-59&author=D.+L.+Stevensauthor=B.+Dotterauthor=K.+Madaras-Kelly&title=A+review+of+linezolid%3A+the+first+oxazolidinone+antibiotic&doi=10.1586%2F14787210.2.1.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A review of linezolid: the first oxazolidinone antibiotic</span></div><div class="casAuthors">Stevens, Dennis L.; Dotter, Brian; Madaras-Kelly, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Resistance of Gram-pos. bacterial pathogens, such as Staphylococcus aureus and Enterococcus faecium, to existing antibiotics continues to increase, and new antibiotics with activity against these pathogens are in demand.  Linezolid (Zyvox, Pharmacia and Upjohn) is the first agent of a new class of antibiotics called the oxazolidinones.  Linezolid possesses excellent microbial activity against a wide variety of Gram-pos. pathogens including those resistant to methicillin and vancomycin (Vancocin, Eli Lilly).  Linezolid is available for i.v. and oral administration and possesses excellent bioavailability.  It exhibits good penetration into pulmonary, as well as skin and related structure tissues, and does not require dosage adjustment in hepatic or renal dysfunction.  Linezolid is generally well-tolerated, with the predominant adverse effect manifesting as a duration dependent, reversible thrombocytopenia.  Linezolid possesses monoamine oxidase inhibitor activity and caution is warranted with coadministration of adrenergic or serotonergic medications.  Clin. trials conducted with linezolid in skin and structure infections, lower respiratory tract infections and vancomycin-resistant enterococcal infections demonstrate that linezolid is an effective therapy.  Recent data suggest that linezolid may be superior to vancomycin for the treatment of infections caused by methicillin-resistant S. aureus.  Linezolid is an excellent and promising new antibiotic for the treatment of resistant Gram-pos. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7oEdTlj5Q3rVg90H21EOLACvtfcHk0ljaC7V3pQauxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFCqsbw%253D&md5=985d26f3e42a6143858b0b902db649cc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2F14787210.2.1.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.2.1.51%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DD.%2BL.%26aulast%3DDotter%26aufirst%3DB.%26aulast%3DMadaras-Kelly%26aufirst%3DK.%26atitle%3DA%2520review%2520of%2520linezolid%253A%2520the%2520first%2520oxazolidinone%2520antibiotic%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2004%26volume%3D2%26spage%3D51%26epage%3D59%26doi%3D10.1586%2F14787210.2.1.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, K.</span></span> <span> </span><span class="NLM_article-title">Clinical update on linezolid in the treatment of Gram-positive bacterial infections</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.2147/IDR.S25890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2147%2FIDR.S25890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22787406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVakurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=87-102&author=S.+Agerauthor=K.+Gould&title=Clinical+update+on+linezolid+in+the+treatment+of+Gram-positive+bacterial+infections&doi=10.2147%2FIDR.S25890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical update on linezolid in the treatment of Gram-positive bacterial infections</span></div><div class="casAuthors">Ager, Sally; Gould, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87-102</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Gram-pos. pathogens are a significant cause of morbidity and mortality in both community and health care settings.  Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-pos. pathogens but there are problems with their use, including the emergence of glycopeptide-resistant strains, tissue penetration and achieving and monitoring adequate serum levels.  Newer antibiotics such as linezolid, a synthetic oxazolidinone, are available for the treatment of resistant Gram-pos. bacteria.  Linezolid is active against a wide range of Gram-pos. bacteria and has been generally available for the treatment of Gram-pos. infections since 2000.  There are potential problems with linezolid use, including its bacteriostatic action and the relatively high incidence of reported adverse effects, particularly with long-term use.  Long-term use may also be complicated by the development of resistance.  However, linezolid has been shown to be clin. useful in the treatment of several serious infections where traditionally bacteriocidal agents have been required and many of its adverse effects are reversible on cessation.  It has also been shown to be a cost-effective treatment option in several studies, with its high oral bioavailability allowing an early change from i.v. to oral formulations with consequent earlier patient discharge and lower inpatient costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gZNul36oJ7Vg90H21EOLACvtfcHk0ljaC7V3pQauxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVakurzE&md5=a8209a0f4421280292d2cd1762857577</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2147%2FIDR.S25890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S25890%26sid%3Dliteratum%253Aachs%26aulast%3DAger%26aufirst%3DS.%26aulast%3DGould%26aufirst%3DK.%26atitle%3DClinical%2520update%2520on%2520linezolid%2520in%2520the%2520treatment%2520of%2520Gram-positive%2520bacterial%2520infections%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2012%26volume%3D5%26spage%3D87%26epage%3D102%26doi%3D10.2147%2FIDR.S25890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howden, B. P.</span></span> <span> </span><span class="NLM_article-title">What’s new in the treatment of serious MRSA infection?</span>. <i>Curr. Opin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1097/QCO.0000000000000101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1097%2FQCO.0000000000000101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25211361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=471-478&author=N.+E.+Holmesauthor=B.+P.+Howden&title=What%E2%80%99s+new+in+the+treatment+of+serious+MRSA+infection%3F&doi=10.1097%2FQCO.0000000000000101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">What's new in the treatment of serious MRSA infection?</span></div><div class="casAuthors">Holmes, Natasha E.; Howden, Benjamin P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">471-478</span>CODEN:
                <span class="NLM_cas:coden">COIDE5</span>;
        ISSN:<span class="NLM_cas:issn">0951-7375</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections.  This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance.  Recent findings: Elevations in the vancomycin min. inhibitory concn. within the susceptible range are assocd. with treatment failure and mortality in the treatment of MRSA infections.  Ceftaroline and ceftobiprole are anti-MRSA cephalosporins and are noninferior to comparator agents in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia.  Tedizolid is more potent than linezolid, has improved pharmacokinetics and reduced toxicity and is active against cfr-contg. S. aureus.  Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. aureus bacteremia.  Dalbavancin and oritavancin are administered once weekly and are noninferior to comparators for acute bacterial skin and skin structure infections.  Resistance has emerged against many new anti-MRSA antimicrobials including ceftaroline.  Combination therapy of β-lactams with vancomycin or daptomycin is increasing.  Summary: Several new MRSA-active agents are now approved for use, although much of the data is derived from treatment of acute bacterial skin and skin structure infections or pneumonia.  Further studies are required for more invasive infections, such as bacteremia and endocarditis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXib3GRCQHqbVg90H21EOLACvtfcHk0lgX2C9ZsXkFfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsL3N&md5=5e89d932f3618b2055c55abaf2b531d3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FQCO.0000000000000101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0000000000000101%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DN.%2BE.%26aulast%3DHowden%26aufirst%3DB.%2BP.%26atitle%3DWhat%25E2%2580%2599s%2520new%2520in%2520the%2520treatment%2520of%2520serious%2520MRSA%2520infection%253F%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D27%26spage%3D471%26epage%3D478%26doi%3D10.1097%2FQCO.0000000000000101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slatter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feenstra, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welshman, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagerness, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryd, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shobe, E. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11454733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVChtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1136-1145&author=J.+G.+Slatterauthor=D.+J.+Stalkerauthor=K.+L.+Feenstraauthor=I.+R.+Welshmanauthor=J.+B.+Brussauthor=J.+P.+Samsauthor=M.+G.+Johnsonauthor=P.+E.+Sandersauthor=M.+J.+Hauerauthor=P.+E.+Fagernessauthor=R.+P.+Strydauthor=G.+W.+Pengauthor=E.+M.+Shobe&title=Pharmacokinetics%2C+metabolism%2C+and+excretion+of+linezolid+following+an+oral+dose+of+%5B%2814%29C%5Dlinezolid+to+healthy+human+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects</span></div><div class="casAuthors">Slatter, J. G.; Stalker, D. J.; Feenstra, K. L.; Welshman, I. R.; Bruss, J. B.; Sams, J. P.; Johnson, M. G.; Sanders, P. E.; Hauer, M. J.; Fagerness, P. E.; Stryd, R. P.; Peng, G. W.; Shobe, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1136-1145</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The disposition of the oxazolidinone antibiotic linezolid (Zyvox) in human volunteers was detd., after a 500-mg oral dose of [14C]linezolid.  Radioactive linezolid was administered as a single dose or at steady-state on day 4 of a 10-day, 500-mg twice-daily regimen of unlabeled linezolid.  Mean recovery of radioactivity in excreta was 93.8%, of which 83.9% was in urine and 9.9% was in feces.  There was no major difference in rate or route of excretion of radioactivity caused by the dose regimen.  Linezolid was excreted primarily intact and as two inactive, morpholine-ring-oxidized metabolites, PNU-142586 and PNU-142300.  Other minor metabolites were characterized by HPLC-atm. pressure chem. ionization-mass spectrometry and [19F]NMR spectroscopy.  After the single radioactive dose, linezolid was the major circulating drug-related material, accounting for about 78% (in males) and 93% (in females) of the radioactivity area under the curve (AUC).  PNU-142586 (Tmax of 3-5 h) accounted for about 26% (males) and 9% (females) of the radioactivity AUC.  PNU-142300 (Tmax of 2-3 h) accounted for about 7% (males) and 4% (females) of the radioactivity AUC.  Overall, mean linezolid and PNU-142586 exposures at steady-state were similar in both sexes.  In conclusion, linezolid circulates in plasma mainly as parent drug.  Linezolid and two major, inactive metabolites account for the major portion of linezolid disposition, with urinary excretion representing the major elimination route.  Formation of PNU-142586 was the rate-limiting step in the clearance of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGrHg0Kl2fu7Vg90H21EOLACvtfcHk0lgX2C9ZsXkFfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVChtb8%253D&md5=9291be327bfc7dca0dfd5266def6613a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSlatter%26aufirst%3DJ.%2BG.%26aulast%3DStalker%26aufirst%3DD.%2BJ.%26aulast%3DFeenstra%26aufirst%3DK.%2BL.%26aulast%3DWelshman%26aufirst%3DI.%2BR.%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26aulast%3DSams%26aufirst%3DJ.%2BP.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DSanders%26aufirst%3DP.%2BE.%26aulast%3DHauer%26aufirst%3DM.%2BJ.%26aulast%3DFagerness%26aufirst%3DP.%2BE.%26aulast%3DStryd%26aufirst%3DR.%2BP.%26aulast%3DPeng%26aufirst%3DG.%2BW.%26aulast%3DShobe%26aufirst%3DE.%2BM.%26atitle%3DPharmacokinetics%252C%2520metabolism%252C%2520and%2520excretion%2520of%2520linezolid%2520following%2520an%2520oral%2520dose%2520of%2520%255B%252814%2529C%255Dlinezolid%2520to%2520healthy%2520human%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1136%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Linezolid: a review of safety and tolerability</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">S59</span>– <span class="NLM_lpage">S74</span>, <span class="refDoi"> DOI: 10.1016/S0163-4453(09)60009-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0163-4453%2809%2960009-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19766891" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=S59-S74&issue=Suppl+1&author=D.+C.+Vinhauthor=E.+Rubinstein&title=Linezolid%3A+a+review+of+safety+and+tolerability&doi=10.1016%2FS0163-4453%2809%2960009-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0163-4453%2809%2960009-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-4453%252809%252960009-8%26sid%3Dliteratum%253Aachs%26aulast%3DVinh%26aufirst%3DD.%2BC.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DLinezolid%253A%2520a%2520review%2520of%2520safety%2520and%2520tolerability%26jtitle%3DJ.%2520Infect.%26date%3D2009%26volume%3D59%26issue%3DSuppl%25201%26spage%3DS59%26epage%3DS74%26doi%3D10.1016%2FS0163-4453%2809%2960009-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottagnoud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottagnoud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neftel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Täuber, M. G.</span></span> <span> </span><span class="NLM_article-title">Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1093/jac/46.6.981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2F46.6.981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11102418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlKg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2000&pages=981-985&author=P.+Cottagnoudauthor=C.+M.+Gerberauthor=F.+Acostaauthor=M.+Cottagnoudauthor=K.+Neftelauthor=M.+G.+T%C3%A4uber&title=Linezolid+against+penicillin-sensitive+and+-resistant+pneumococci+in+the+rabbit+meningitis+model&doi=10.1093%2Fjac%2F46.6.981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model</span></div><div class="casAuthors">Cottagnoud, Philippe; Gerber, Cynthia M.; Acosta, F.; Cottagnoud, Marianne; Neftel, Klaus; Tauber, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">981-985</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Linezolid, a new oxazolidinone antibiotic, showed good penetration (38±4%) into the meninges of rabbits with levels in the CSF ranging from 9.5 to 1.8 mg/L after two i.v. injections (20 mg/kg).  Linezolid was clearly less effective than ceftriaxone against a penicillin-sensitive pneumococcal strain.  Against a penicillin-resistant strain, linezolid had slightly inferior killing rates compared with the std. regimen (ceftriaxone combined with vancomycin).  In vitro, linezolid was marginally bactericidal at concns. above the MIC (5 × and 10 × MIC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbuuKNSlUJw7Vg90H21EOLACvtfcHk0lgX2C9ZsXkFfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlKg&md5=6d53664f489aec9c8faa68ff1ab4119f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F46.6.981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F46.6.981%26sid%3Dliteratum%253Aachs%26aulast%3DCottagnoud%26aufirst%3DP.%26aulast%3DGerber%26aufirst%3DC.%2BM.%26aulast%3DAcosta%26aufirst%3DF.%26aulast%3DCottagnoud%26aufirst%3DM.%26aulast%3DNeftel%26aufirst%3DK.%26aulast%3DT%25C3%25A4uber%26aufirst%3DM.%2BG.%26atitle%3DLinezolid%2520against%2520penicillin-sensitive%2520and%2520-resistant%2520pneumococci%2520in%2520the%2520rabbit%2520meningitis%2520model%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2000%26volume%3D46%26spage%3D981%26epage%3D985%26doi%3D10.1093%2Fjac%2F46.6.981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodo, F.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds</span>. <i>Infez. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16220032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BD2s3gsV2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=112-119&author=S.+Sabbataniauthor=R.+Manfrediauthor=G.+Frankauthor=F.+Chiodo&title=Linezolid+in+the+treatment+of+severe+central+nervous+system+infections+resistant+to+recommended+antimicrobial+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds</span></div><div class="casAuthors">Sabbatani Sergio; Manfredi Roberto; Frank Giorgio; Chiodo Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Le infezioni in medicina</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-9</span>
        ISSN:<span class="NLM_cas:issn">1124-9390</span>.
    </div><div class="casAbstract">The progressive emergence of antimicrobial-resistant Gram-positive cocci especially in the setting of surgery and intensive care, recommends particular attention in making sound therapeutic choices to overcome both microbial resistances and haemato-encephalic barriers to effective local drug penetration.  As in other Western countries, the occurrence of methicillin-resistant Staphylococcus aureus is particularly high also in Italy, especially when high-risk patients and/or settings are involved.  In treating post-neurosurgical central nervous system infections (cerebral abscess and meningitis), a key issue is represented by the low cerebrospinal fluid concentration of the two available glycopeptide antibiotics (vancomycin and teicoplanin), usually recommended as first-line therapy of resistant Gram-positive cocci.  Recent findings have focused on the possible role of linezolid, an oxazolidinone antibiotic, as a suitable candidate for the treatment of severe brain infection (abscesses) and post-neurosurgical infection, where treatment options and efficacy are significantly limited by the low glycopeptide transfer and the spread of glycopeptide-resistant bacterial strains.  Three representative case reports (two brain abscesses and one post-surgical meningitis) are presented and discussed in light of the current literature: in all these cases, salvage linezolid treatment proved resolutory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpTvkkPn9Qpcve_zCu79I8fW6udTcc2ebJ8cU8UoUbabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3gsV2muw%253D%253D&md5=9c20b3f2144c5318ae017ef77de25829</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatani%26aufirst%3DS.%26aulast%3DManfredi%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DG.%26aulast%3DChiodo%26aufirst%3DF.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520severe%2520central%2520nervous%2520system%2520infections%2520resistant%2520to%2520recommended%2520antimicrobial%2520compounds%26jtitle%3DInfez.%2520Med.%26date%3D2005%26volume%3D13%26spage%3D112%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frasca, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M. G.</span></span> <span> </span><span class="NLM_article-title">Vancomycin-resistant enterococcal meningitis in an autologous stem cell transplant recipient cured with linezolid</span>. <i>Transpl. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">E1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1111/tid.12032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Ftid.12032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23173835" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=E1-4&author=K.+L.+Frascaauthor=M.+G.+Schuster&title=Vancomycin-resistant+enterococcal+meningitis+in+an+autologous+stem+cell+transplant+recipient+cured+with+linezolid&doi=10.1111%2Ftid.12032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Ftid.12032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftid.12032%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DK.%2BL.%26aulast%3DSchuster%26aufirst%3DM.%2BG.%26atitle%3DVancomycin-resistant%2520enterococcal%2520meningitis%2520in%2520an%2520autologous%2520stem%2520cell%2520transplant%2520recipient%2520cured%2520with%2520linezolid%26jtitle%3DTranspl.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D15%26spage%3DE1%26epage%3D4%26doi%3D10.1111%2Ftid.12032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tunkel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheld, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span> <span> </span><span class="NLM_article-title">Practice guidelines for the management of bacterial meningitis</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1267</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1086/425368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F425368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15494903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A280%3ADC%252BD2critlKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=1267-1284&author=A.+R.+Tunkelauthor=B.+J.+Hartmanauthor=S.+L.+Kaplanauthor=B.+A.+Kaufmanauthor=K.+L.+Roosauthor=W.+M.+Scheldauthor=R.+J.+Whitley&title=Practice+guidelines+for+the+management+of+bacterial+meningitis&doi=10.1086%2F425368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Practice guidelines for the management of bacterial meningitis</span></div><div class="casAuthors">Tunkel Allan R; Hartman Barry J; Kaplan Sheldon L; Kaufman Bruce A; Roos Karen L; Scheld W Michael; Whitley Richard J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1267-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwp7OdL6G4pjEwO064Z95rfW6udTcc2ebJ8cU8UoUbabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2critlKqtQ%253D%253D&md5=7a01220adf4e15b09c271e0a35251469</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1086%2F425368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F425368%26sid%3Dliteratum%253Aachs%26aulast%3DTunkel%26aufirst%3DA.%2BR.%26aulast%3DHartman%26aufirst%3DB.%2BJ.%26aulast%3DKaplan%26aufirst%3DS.%2BL.%26aulast%3DKaufman%26aufirst%3DB.%2BA.%26aulast%3DRoos%26aufirst%3DK.%2BL.%26aulast%3DScheld%26aufirst%3DW.%2BM.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26atitle%3DPractice%2520guidelines%2520for%2520the%2520management%2520of%2520bacterial%2520meningitis%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2004%26volume%3D39%26spage%3D1267%26epage%3D1284%26doi%3D10.1086%2F425368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3239</span>, <span class="refDoi"> DOI: 10.1128/AAC.00228-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00228-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19528279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3236-3239&author=R.+Schaadtauthor=D.+Sweeneyauthor=D.+Shinabargerauthor=G.+Zurenko&title=In+vitro+activity+of+TR-700%2C+the+active+ingredient+of+the+antibacterial+prodrug+TR-701%2C+a+novel+oxazolidinone+antibacterial+agent&doi=10.1128%2FAAC.00228-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent</span></div><div class="casAuthors">Schaadt, Ronda; Sweeney, Debora; Shinabarger, Dean; Zurenko, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3236-3239</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TR-701 is the prodrug of the microbiol. active mol. TR-700, a novel orally and i.v. administered oxazolidinone antibacterial agent.  The in vitro activity of TR-700 was evaluated against 1,063 bacterial clin. isolates including staphylococci, enterococci, streptococci, Moraxella catarrhalis, Haemophilus influenzae, and a variety of anaerobic bacterial species.  The test strains were recent (2005 to 2008) clin. isolates from diverse U.S. (80%) and non-U.S. (20%) sites.  MIC assays were conducted using ref. broth microdilution and agar diln. methods with the principal comparators linezolid and vancomycin.  TR-700 was four- to eightfold more potent than linezolid against staphylococci and generally fourfold more potent against enterococci and streptococci.  TR-700 was less active against M. catarrhalis and H. influenzae but was twofold more active than linezolid.  Against anaerobic species, the activity of TR-700 was equiv. to or up to fourfold higher than that of linezolid.  These results indicate that TR-700 is a promising new oxazolidinone antibacterial agent with greater in vitro potency than linezolid against clin. important gram-pos. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa6xQcw37Y9rVg90H21EOLACvtfcHk0lhYeOlqdTk0PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1yhtb0%253D&md5=512aa87f81fa9d85d49a376f4fdf561b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.00228-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00228-09%26sid%3Dliteratum%253Aachs%26aulast%3DSchaadt%26aufirst%3DR.%26aulast%3DSweeney%26aufirst%3DD.%26aulast%3DShinabarger%26aufirst%3DD.%26aulast%3DZurenko%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520activity%2520of%2520TR-700%252C%2520the%2520active%2520ingredient%2520of%2520the%2520antibacterial%2520prodrug%2520TR-701%252C%2520a%2520novel%2520oxazolidinone%2520antibacterial%2520agent%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3236%26epage%3D3239%26doi%3D10.1128%2FAAC.00228-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Anda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span> <span> </span><span class="NLM_article-title">Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial</span>. <i>Jama</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1001%2Fjama.2013.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23403680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2013&pages=559-569&author=P.+Prokocimerauthor=C.+De+Andaauthor=E.+Fangauthor=P.+Mehraauthor=A.+Das&title=Tedizolid+phosphate+vs+linezolid+for+treatment+of+acute+bacterial+skin+and+skin+structure+infections%3A+the+ESTABLISH-1+randomized+trial&doi=10.1001%2Fjama.2013.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. The ESTABLISH-1 randomized trial</span></div><div class="casAuthors">Prokocimer, Philippe; De Anda, Carisa; Fang, Edward; Mehra, Purvi; Das, Anita</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-569</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance. Acute bacterial skin and skin structure infections (ABSSSIs), including cellulitis or erysipelas, major cutaneous abscesses, and wound infections, can be life-threatening and may require surgery and hospitalization.  Increasingly, ABSSSIs are assocd. with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use.  Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs.  Objectives. To establish the noninferiority of tedizolid phosphate vs linezolid in treating ABSSSIs and compare the safety of the 2 agents.  Design, Setting, and Patients. The Efficacy and Safety of 6-day Oral Tedizolid in Acute Bacterial Skin and Skin Structure Infections vs 10-day Oral Linezolid Therapy (ESTABLISH-1) was a phase 3, randomized, double-blind, noninferiority trial that was conducted from August 2010 through Sept. 2011 at 81 study centers in North America, Latin America, and Europe.  The intent-to-treat anal. set consisted of data from 667 adults aged 18 years or older with ABSSSIs treated with tedizolid phosphate (n=332) or linezolid (n=335).  Interventions A 200 mg once daily dose of oral tedizolid phosphate for 6 days or 600 mg of oral linezolid every 12 h for 10 days.  Main Outcome Measures The primary efficacy outcome was early clin. response at the 48- to 72-h assessment (no increase in lesion surface area from baseline and oral temp. of <37.6°C, confirmed by a second temp. measurement within 24 h).  A 10% noninferiority margin was predefined.  Results in the intent-to-treat anal. set, the early clin. treatment response rates were 79.5% (95% Cl, 74.8% to 83.7%) of 332 patients in the tedizolid phosphate group and 79.4% (95% Cl, 74.7% to 83.6%) of 335 patients in the linezolid group (a treatment difference of 0.1 % [95% Cl, -6.1% to 6.2%]).  The sustained clin. treatment response rates at the end of treatment (day 11) were 69.3% (95% Cl, 64.0% to 74.2%) in the tedizolid phosphate group and 71.9% (95% Cl, 66.8% to 76.7%) in the linezolid group (a treatment difference of -2.6% [95% Cl, -9.6% to 4.2%]).  Results of investigator-assessed clin. treatment success rates at a posttherapy evaluation visit (1-2 wk after the end-of-treatment visit) were 85.5% (95% Cl, 81.3% to 89.1%) in the tedizolid phosphate group and 86.0% (95% Cl, 81.8% to 89.5%) in the linezolid group (a treatment difference of -0.5% [95% Cl, -5.8% to 4.9%]), and were similar for 178 patients with methicillin-resistant Staphylococcus aureus isolated from the primary lesion.  Conclusions and Relevance Tedizolid phosphate was a statistically noninferior treatment to linezolid in early clin. response at 48 to 72 h after initiating therapy for an ABSSSI.  Tedizolid phosphate may be a reasonable alternative to linezolid for treating ABSSSI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0d40tRm55KbVg90H21EOLACvtfcHk0lhYeOlqdTk0PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVSiurg%253D&md5=160a3d512213dc797931e20314436553</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.241%26sid%3Dliteratum%253Aachs%26aulast%3DProkocimer%26aufirst%3DP.%26aulast%3DDe%2BAnda%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DMehra%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DTedizolid%2520phosphate%2520vs%2520linezolid%2520for%2520treatment%2520of%2520acute%2520bacterial%2520skin%2520and%2520skin%2520structure%2520infections%253A%2520the%2520ESTABLISH-1%2520randomized%2520trial%26jtitle%3DJama%26date%3D2013%26volume%3D309%26spage%3D559%26epage%3D569%26doi%3D10.1001%2Fjama.2013.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moran, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Anda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P.</span></span> <span> </span><span class="NLM_article-title">Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(14)70737-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS1473-3099%2814%2970737-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=24909499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=696-705&author=G.+J.+Moranauthor=E.+Fangauthor=G.+R.+Coreyauthor=A.+F.+Dasauthor=C.+De+Andaauthor=P.+Prokocimer&title=Tedizolid+for+6+days+versus+linezolid+for+10+days+for+acute+bacterial+skin+and+skin-structure+infections+%28ESTABLISH-2%29%3A+a+randomised%2C+double-blind%2C+phase+3%2C+non-inferiority+trial&doi=10.1016%2FS1473-3099%2814%2970737-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial</span></div><div class="casAuthors">Moran, Gregory J.; Fang, Edward; Corey, G. Ralph; Das, Anita F.; De Anda, Carisa; Prokocimer, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">696-705</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New antibiotics are needed to treat infections caused by drug-resistant bacteria.  Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against Gram-pos. pathogens.  We aimed to assess the efficacy and safety of i.v. to oral tedizolid for treatment of patients with acute bacterial skin and skin-structure infections.  ESTABLISH-2 was a randomised, double-blind, phase 3, non-inferiority trial done between Sept 28, 2011, and Jan 10, 2013, at 58 centers in nine countries.  Patients (aged ≥12 years) with acute bacterial skin and skin-structure infections (cellulitis or erysipelas, major cutaneous abscess, or wound infection) that had a min. lesion area of 75 cm2 and were suspected or documented to be assocd. with a Gram-pos. pathogen, were randomly assigned (1:1), via an interactive voice-response system with block randomisation, to receive i.v. once-daily tedizolid (200 mg for 6 days) or twice-daily linezolid (600 mg for 10 days), with optional oral step-down.  Randomisation was stratified by geog. region and type of acute bacterial skin and skin-structure infection.  The primary endpoint was early clin. response (≥20% redn. in lesion area at 48-72 h compared with baseline), with a non-inferiority margin of -10%.  Anal. was by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT01421511.666 patients were randomly assigned to receive tedizolid (n=332) or linezolid (n=334). 283 (85%) patients in the tedizolid group and 276 (83%) in the linezolid group achieved early clin. response (difference 2·6%, 95% CI -3·0 to 8·2), meeting the prespecified non-inferiority margin.  Gastrointestinal adverse events were less frequent with tedizolid than linezolid, taking place in 52 (16%) of 331 patients and 67 (20%) of 327 patients in the safety population.  Treatment-emergent adverse events leading to discontinuation of study drug were reported by one (<1%) patient in the tedizolid group and four (1%) patients in the linezolid group.  I.v. to oral once-daily tedizolid 200 mg for 6 days was non-inferior to twice-daily linezolid 600 mg for 10 days for treatment of patients with acute bacterial skin and skin-structure infections.  Tedizolid could become a useful option for the treatment of acute bacterial skin and skin-structure infections in the hospital and outpatient settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejt1Zi_NmlrVg90H21EOLACvtfcHk0lhYeOlqdTk0PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrs7bK&md5=70ead6ed25db678eeec65a6d7e00f151</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2814%2970737-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252814%252970737-6%26sid%3Dliteratum%253Aachs%26aulast%3DMoran%26aufirst%3DG.%2BJ.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DCorey%26aufirst%3DG.%2BR.%26aulast%3DDas%26aufirst%3DA.%2BF.%26aulast%3DDe%2BAnda%26aufirst%3DC.%26aulast%3DProkocimer%26aufirst%3DP.%26atitle%3DTedizolid%2520for%25206%2520days%2520versus%2520linezolid%2520for%252010%2520days%2520for%2520acute%2520bacterial%2520skin%2520and%2520skin-structure%2520infections%2520%2528ESTABLISH-2%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520phase%25203%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2014%26volume%3D14%26spage%3D696%26epage%3D705%26doi%3D10.1016%2FS1473-3099%2814%2970737-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barber, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkv302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26476277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Ohu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=152-155&author=K.+E.+Barberauthor=J.+R.+Smithauthor=A.+Rautauthor=M.+J.+Rybak&title=Evaluation+of+tedizolid+against+Staphylococcus+aureus+and+enterococci+with+reduced+susceptibility+to+vancomycin%2C+daptomycin+or+linezolid&doi=10.1093%2Fjac%2Fdkv302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid</span></div><div class="casAuthors">Barber, Katie E.; Smith, Jordan R.; Raut, Animesh; Rybak, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">152-155</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tedizolid displays potent activity against Gram-pos. pathogens.  In vitro studies against clin. isolates of Staphylococcus aureus and enterococci demonstrated improved tedizolid activity over linezolid.  However, this is not well characterized against a large collection of resistant isolates, including vancomycin-intermediate S. aureus (VISA), heterogeneous VISA (hVISA), daptomycin-non-susceptible (DNS) S. aureus, linezolid-resistant (LR) S. aureus and VRE.  Therefore, the objective here was to det. tedizolid activity vs. other agents, against MRSA and VRE with various resistance phenotypes.  Some 302 MRSA (75 DNS, 100 VISA, 120 hVISA and 7 LR) and 220 VRE [100 Enterococcus faecalis (all susceptible to daptomycin and linezolid) and 120 E. faecium (25 DNS and 10 LR)] were evaluated.  LR isolates were analyzed for the cfr gene.  MICs of tedizolid, linezolid, ampicillin, clindamycin, daptomycin, gentamicin, levofloxacin, oxacillin, tigecycline, trimethoprim/sulfamethoxazole and vancomycin were detd. in accordance with CLSI guidelines.  Results Tedizolid MIC90 values for hVISA, VISA and DNS were 0.5 mg/L (vs. 4, 4 and 2 mg/L, resp., for linezolid).  The tedizolid MIC range for LR MRSA was 0.063-1 mg/L.  Two LR MRSA possessed the cfr gene with tedizolid MICs of 0.125 and 0.25 mg/L (linezolid MICs of 16 and 8 mg/L).  The tedizolid MIC90 for vancomycin-resistant E. faecalis and E. faecium was 0.25 and 1 mg/L, resp.; three dilns. lower for E. faecalis and two dilns. lower for E. faecium compared with linezolid.  Conclusions Tedizolid MICs demonstrate activity against isolates with decreased susceptibility to alternative agents, including linezolid.  Tedizolid may be a viable treatment option in clin. situations with MDR Gram-pos. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CA-Tb0nnr7Vg90H21EOLACvtfcHk0ljpFhSptoH7nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Ohu70%253D&md5=971f236b5406ab480be91418039e72b2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv302%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DK.%2BE.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DRaut%26aufirst%3DA.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520tedizolid%2520against%2520Staphylococcus%2520aureus%2520and%2520enterococci%2520with%2520reduced%2520susceptibility%2520to%2520vancomycin%252C%2520daptomycin%2520or%2520linezolid%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D152%26epage%3D155%26doi%3D10.1093%2Fjac%2Fdkv302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bien, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokocimer, P. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1002/phar.1337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fphar.1337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23926058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=240-250&author=S.+D.+Flanaganauthor=P.+A.+Bienauthor=K.+A.+Mu%C3%B1ozauthor=S.+L.+Minassianauthor=P.+G.+Prokocimer&title=Pharmacokinetics+of+tedizolid+following+oral+administration%3A+single+and+multiple+dose%2C+effect+of+food%2C+and+comparison+of+two+solid+forms+of+the+prodrug&doi=10.1002%2Fphar.1337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug</span></div><div class="casAuthors">Flanagan, Shawn D.; Bien, Paul A.; Munoz, Kelly A.; Minassian, Sonia L.; Prokocimer, Philippe G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-250</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : The single- and multiple-dose pharmacokinetics (PK) of tedizolid were examd. after oral administration of tedizolid phosphate disodium (TPD), including the effect of food on PK.  The relative bioavailability of TPD to the free acid tedizolid phosphate was detd. to bridge the results of these and other studies to the solid form of the prodrug selected for further development.  Design : Randomized placebo-controlled, double-blind single- and multiple-ascending dose studies and randomized open-label, crossover food effect and relative bioavailability studies.  Setting : Clin. Research Units.  Participants : Healthy subjects.  Intervention : Study TR701-101 enrolled 40 subjects in single-ascending dose (200-1200 mg TPD or placebo) and 40 subjects in 21-day multiple-ascending dose (200, 300, or 400 mg TPD once/day; 600 mg linezolid twice/day; or placebo) arms.  Study TR701-103 was a food-effect study in 12 subjects administered 600 mg TPD.  Study TR701-108 was a relative bioavailability study in 12 subjects administered 150-mg tedizolid equiv. as TPD or tedizolid phosphate.  Measurements and Main Results : Plasma concns. of the prodrug tedizolid phosphate, its active moiety tedizolid, and/or linezolid were collected.  After administration of 200 to 600 mg TPD, tedizolid values increased approx. dose proportionally in area under the concn.-time curve (AUC) and max. plasma concn. (Cmax).  Tedizolid half-life values were approx. 2-fold greater compared with linezolid.  TPD administration with food delayed tedizolid absorption and reduced Cmax relative to the fasted state but did not alter AUC.  Minimal accumulation was predicted and obsd. for tedizolid, whereas obsd. accumulation of linezolid exceeded predictions based on single-dose PK.  Comparable PK of tedizolid was obsd. following oral administration of either TPD or tedizolid phosphate.  In the multiple-ascending dose study, 3 of 24 tedizolid subjects were withdrawn under prespecified stopping rules (one each of elevated alanine aminotransferase, low reticulocyte count, or low white blood cell count), as was 1 of 8 linezolid subjects (low reticulocyte count).  Conclusions : Overall, tedizolid has a favorable PK profile, a half-life that supports once daily administration, and no nonlinearities at steady state.  Tedizolid phosphate can be administered without regard to food.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEt2jPHQozibVg90H21EOLACvtfcHk0ljpFhSptoH7nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOrs7Y%253D&md5=5e58664eaad2cf534f354f0d83c5131f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fphar.1337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1337%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DS.%2BD.%26aulast%3DBien%26aufirst%3DP.%2BA.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DK.%2BA.%26aulast%3DMinassian%26aufirst%3DS.%2BL.%26aulast%3DProkocimer%26aufirst%3DP.%2BG.%26atitle%3DPharmacokinetics%2520of%2520tedizolid%2520following%2520oral%2520administration%253A%2520single%2520and%2520multiple%2520dose%252C%2520effect%2520of%2520food%252C%2520and%2520comparison%2520of%2520two%2520solid%2520forms%2520of%2520the%2520prodrug%26jtitle%3DPharmacotherapy%26date%3D2014%26volume%3D34%26spage%3D240%26epage%3D250%26doi%3D10.1002%2Fphar.1337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traczewski, M. M.</span></span> <span> </span><span class="NLM_article-title">Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2063</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1128/AAC.01569-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01569-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20231392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFelsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2063-2069&author=S.+D.+Brownauthor=M.+M.+Traczewski&title=Comparative+in+vitro+antimicrobial+activities+of+torezolid+%28TR-700%29%2C+the+active+moiety+of+a+new+oxazolidinone%2C+torezolid+phosphate+%28TR-701%29%2C+determination+of+tentative+disk+diffusion+interpretive+criteria%2C+and+quality+control+ranges&doi=10.1128%2FAAC.01569-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges</span></div><div class="casAuthors">Brown, Steven D.; Traczewski, Maria M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2063-2069</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the spectrum of activity of torezolid (TR-700), the active moiety of torezolid phosphate (TR-701), and proposes tentative MIC and disk diffusion breakpoints as well as quality control ranges.  The in vitro susceptibilities of 1,096 bacterial isolates, representing 23 different species or phenotypic groups, were detd. for torezolid, linezolid, cefotaxime, and levofloxacin using Clin. and Lab. Stds. Institute (CLSI) broth microdilution MICs, min. bactericidal concns. (MBCs), agar diln., and disk diffusion testing methods.  Torezolid was very active against the majority of Gram-pos. strains, including methicillin-susceptible and -resistant Staphylococcus aureus (MIC50 = 0.25 μg/mL, MIC90 ≤ 0.5 μg/mL), coagulase-neg. staphylococci (CNS; MIC50 = 0.25 μg/mL, MIC90 ≤ 0.5 μg/mL), enterococci (MIC50 and MIC90 ≤ 0.5 μg/mL), and streptococci (MIC50 and MIC90 ≤ 0.25 μg/mL).  Based upon MIC90s, torezolid was 4-fold more active than linezolid against S. aureus, coagulase-neg. staphylococci, and the enterococci and 8-fold more active than linezolid against the streptococci.  With the use of tentative MIC breakpoints of ≤2 μg/mL for susceptibility, torezolid disk diffusion zone diam. breakpoints are proposed using a 20-μg disk.  In addn., MIC quality control ranges of torezolid were detd. for three CLSI-recognized std. ATCC ref. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtSdmaewiLfbVg90H21EOLACvtfcHk0licGPEfA98wqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFelsb4%253D&md5=f0b8c732ccf75ef1df16e0ed7eb92dcc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.01569-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01569-09%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BD.%26aulast%3DTraczewski%26aufirst%3DM.%2BM.%26atitle%3DComparative%2520in%2520vitro%2520antimicrobial%2520activities%2520of%2520torezolid%2520%2528TR-700%2529%252C%2520the%2520active%2520moiety%2520of%2520a%2520new%2520oxazolidinone%252C%2520torezolid%2520phosphate%2520%2528TR-701%2529%252C%2520determination%2520of%2520tentative%2520disk%2520diffusion%2520interpretive%2520criteria%252C%2520and%2520quality%2520control%2520ranges%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2063%26epage%3D2069%26doi%3D10.1128%2FAAC.01569-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0licGPEfA98wqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michalska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpiuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Król, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyski, S.</span></span> <span> </span><span class="NLM_article-title">Recent development of potent analogues of oxazolidinone antibacterial agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2012.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23273607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2rs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=577-591&author=K.+Michalskaauthor=I.+Karpiukauthor=M.+Kr%C3%B3lauthor=S.+Tyski&title=Recent+development+of+potent+analogues+of+oxazolidinone+antibacterial+agents&doi=10.1016%2Fj.bmc.2012.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Recent development of potent analogues of oxazolidinone antibacterial agents</span></div><div class="casAuthors">Michalska, Katarzyna; Karpiuk, Izabela; Krol, Marek; Tyski, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The oxazolidinones are a new and potent class of antimicrobial agents with activity mainly against Gram-pos. strains.  The com. success of linezolid, the only FDA-approved oxazolidinone, has prompted many pharmaceutical companies to devote resources to this area of investigation.  Until now, four types of chem. modifications of linezolid and oxazolidinone-type antibacterial agents, including modification on each of the A-(oxazolidinone), B-(phenyl), and C-(morpholine) rings as well as the C-5 side chain of the A-ring substructure, have been described.  Division into sections according to side chain modification or the type of ring will be used throughout this review, although the process of synthesis usually involves the simultaneous modification of several elements of the linezolid substructure; therefore, assignment into the appropriate section depends on the structure-activity relationships (SAR) studies.This review makes an attempt to summarise the work carried out in the period from 2006 until mid-2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniajnzuluNLVg90H21EOLACvtfcHk0licGPEfA98wqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2rs73L&md5=5b9cb116db7782b19161503490c8f3e3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DMichalska%26aufirst%3DK.%26aulast%3DKarpiuk%26aufirst%3DI.%26aulast%3DKr%25C3%25B3l%26aufirst%3DM.%26aulast%3DTyski%26aufirst%3DS.%26atitle%3DRecent%2520development%2520of%2520potent%2520analogues%2520of%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D577%26epage%3D591%26doi%3D10.1016%2Fj.bmc.2012.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locke, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahawi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">G. C., K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picazo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5343</span>, <span class="refDoi"> DOI: 10.1128/AAC.00663-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00663-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20837751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5337-5343&author=J.+B.+Lockeauthor=J.+Finnauthor=M.+Hilgersauthor=G.+Moralesauthor=S.+Rahawiauthor=K.+G.+C.author=J.+J.+Picazoauthor=W.+Imauthor=K.+J.+Shawauthor=J.+L.+Stein&title=Structure-activity+relationships+of+diverse+oxazolidinones+for+linezolid-resistant+Staphylococcus+aureus+strains+possessing+the+cfr+methyltransferase+gene+or+ribosomal+mutations&doi=10.1128%2FAAC.00663-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations</span></div><div class="casAuthors">Locke, Jeffrey B.; Finn, John; Hilgers, Mark; Morales, Gracia; Rahawi, Shahad; Kedar, G. C.; Picazo, Juan Jose; Im, Weonbin; Shaw, Karen Joy; Stein, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5337-5343</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcal resistance to linezolid (LZD) is mediated through ribosomal mutations (23S rRNA or ribosomal proteins L3 and L4) or through methylation of 23S rRNA by the horizontally transferred Cfr methyltransferase.  To investigate the structural basis for oxazolidinone activity against LZD-resistant (LZDr) strains, the authors compared structurally diverse, clin. relevant oxazolidinones, including LZD, radezolid (RX-1741), TR-700 (torezolid), and a set of TR-700 analogs (including novel CD-rings and various A-ring C-5 substituents), against a panel of lab.-derived and clin. LZDr Staphylococcus aureus strains possessing a variety of resistance mechanisms.  Potency against all strains was correlated with optimization of C- and D-rings, which interact with more highly conserved regions of the peptidyl transferase center binding site.  Activity against cfr strains was retained with either hydroxymethyl or 1,2,3-triazole C-5 groups but was reduced by 2- to 8-fold in compds. with acetamide substituents.  LZD, which possesses a C-5 acetamide group and lacks a D-ring substituent, demonstrated the lowest potency against all strains tested, particularly against cfr strains.  These data reveal key features contributing to oxazolidinone activity and highlight structural tradeoffs between potency against susceptible strains and potency against strains with various resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxEGhnaI3eNbVg90H21EOLACvtfcHk0lh8pFQc8EiV3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FN&md5=32a36e1dcfffd0c1b4e97e69b486804e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.00663-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00663-10%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DJ.%2BB.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DHilgers%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DG.%26aulast%3DRahawi%26aufirst%3DS.%26aulast%3DG.%2BC.%26aufirst%3DK.%26aulast%3DPicazo%26aufirst%3DJ.%2BJ.%26aulast%3DIm%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3DStein%26aufirst%3DJ.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520diverse%2520oxazolidinones%2520for%2520linezolid-resistant%2520Staphylococcus%2520aureus%2520strains%2520possessing%2520the%2520cfr%2520methyltransferase%2520gene%2520or%2520ribosomal%2520mutations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5337%26epage%3D5343%26doi%3D10.1128%2FAAC.00663-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sader, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortridge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamm, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, R. E.</span></span> <span> </span><span class="NLM_article-title">Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)</span>. <i>J. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1080/1120009X.2019.1609740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1080%2F1120009X.2019.1609740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31079589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Cju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=188-194&author=M.+A.+Pfallerauthor=H.+S.+Saderauthor=D.+Shortridgeauthor=M.+Castanheiraauthor=R.+K.+Flammauthor=R.+E.+Mendes&title=Activity+of+tedizolid+against+gram-positive+clinical+isolates+causing+infections+in+Europe+and+surrounding+areas+%282014%E2%80%932015%29&doi=10.1080%2F1120009X.2019.1609740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015)</span></div><div class="casAuthors">Pfaller, Michael A.; Sader, Helio S.; Shortridge, Dee; Castanheira, Mariana; Flamm, Robert K.; Mendes, Rodrigo E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemotherapy (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">JCHEEU</span>;
        ISSN:<span class="NLM_cas:issn">1120-009X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Activities of tedizolid and comparators were evaluated against gram-pos. isolates responsible for skin and skin structure infections, pneumonia, and bloodstream infections.  Non-duplicate gram-pos. isolates (8011) were collected from 20 European countries/regions.  Tedizolid (0.12 mg/L) showed similar results of min. inhibitory concn. required to inhibit the growth of 50% of organisms (MIC50) regardless of pathogen/group or infection type, except for coagulase-neg. staphylococci, Enterococcus faecalis, and viridans group streptococci (VGS), against which tedizolid had MIC50 values of 0.06, 0.25, and 0.06 mg/L, resp.  Similar results of tedizolid MIC50 and min. inhibitory concn. required to inhibit the growth of 90% of organisms (MIC90) (MIC50/90, 0.12/0.12 mg/L) were obtained against methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.  Tedizolid, linezolid, and daptomycin were active against enterococci.  Tedizolid (MIC90, 0.12-0.25 mg/L), ceftaroline (MIC90, 0.12 mg/L), and vancomycin (MIC90, 0.25-0.5 mg/L) had the lowest MIC90 values against Streptococcus pneumoniae and VGS, whereas ceftaroline (MIC90, ≤ 0.015 mg/L), penicillin (MIC90, ≤ 0.06 mg/L), ceftriaxone (MIC90, ≤ 0.06-0.12 mg/L), and tedizolid (MIC90, 0.12 mg/L) were the most potent against β-haemolytic streptococci.  Tedizolid displayed potent activity against gram-pos. isolates from Euinfection rope, regardless of infection type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSub50YcDJVrVg90H21EOLACvtfcHk0lh8pFQc8EiV3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Cju7w%253D&md5=71806280be82315e1bdeb38ee7d7177c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F1120009X.2019.1609740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1120009X.2019.1609740%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DSader%26aufirst%3DH.%2BS.%26aulast%3DShortridge%26aufirst%3DD.%26aulast%3DCastanheira%26aufirst%3DM.%26aulast%3DFlamm%26aufirst%3DR.%2BK.%26aulast%3DMendes%26aufirst%3DR.%2BE.%26atitle%3DActivity%2520of%2520tedizolid%2520against%2520gram-positive%2520clinical%2520isolates%2520causing%2520infections%2520in%2520Europe%2520and%2520surrounding%2520areas%2520%25282014%25E2%2580%25932015%2529%26jtitle%3DJ.%2520Chemother.%26date%3D2019%26volume%3D31%26spage%3D188%26epage%3D194%26doi%3D10.1080%2F1120009X.2019.1609740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiodras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliopoulos, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennersten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, M. J.</span></span> <span> </span><span class="NLM_article-title">Linezolid resistance in a clinical isolate of Staphylococcus aureus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(01)05410-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2801%2905410-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11476839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=207-208&author=S.+Tsiodrasauthor=H.+S.+Goldauthor=G.+Sakoulasauthor=G.+M.+Eliopoulosauthor=C.+Wennerstenauthor=L.+Venkataramanauthor=R.+C.+Moelleringauthor=M.+J.+Ferraro&title=Linezolid+resistance+in+a+clinical+isolate+of+Staphylococcus+aureus&doi=10.1016%2FS0140-6736%2801%2905410-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid resistance in a clinical isolate of Staphylococcus aureus</span></div><div class="casAuthors">Tsiodras, S.; Gold, H. S.; Sakoulas, G.; Eliopoulos, G. M.; Wennersten, C.; Venkataraman, L.; Moellering, R. C.; Ferraro, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">9277</span>),
    <span class="NLM_cas:pages">207-208</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various Gram-pos. bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).  Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clin. isolates of S aureus.  The authors have characterized an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-assocd. peritonitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRryTK5F9tc7Vg90H21EOLACvtfcHk0lh8pFQc8EiV3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlymsr8%253D&md5=d8574bd50d0f1129cbc8d5dae0ac8127</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2905410-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252905410-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsiodras%26aufirst%3DS.%26aulast%3DGold%26aufirst%3DH.%2BS.%26aulast%3DSakoulas%26aufirst%3DG.%26aulast%3DEliopoulos%26aufirst%3DG.%2BM.%26aulast%3DWennersten%26aufirst%3DC.%26aulast%3DVenkataraman%26aufirst%3DL.%26aulast%3DMoellering%26aufirst%3DR.%2BC.%26aulast%3DFerraro%26aufirst%3DM.%2BJ.%26atitle%3DLinezolid%2520resistance%2520in%2520a%2520clinical%2520isolate%2520of%2520Staphylococcus%2520aureus%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D207%26epage%3D208%26doi%3D10.1016%2FS0140-6736%2801%2905410-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreckenberger, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DenBesten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. P.</span></span> <span> </span><span class="NLM_article-title">Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1179</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)04376-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0140-6736%2800%2904376-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11323048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=1179&author=R.+D.+Gonzalesauthor=P.+C.+Schreckenbergerauthor=M.+B.+Grahamauthor=S.+Kelkarauthor=K.+DenBestenauthor=J.+P.+Quinn&title=Infections+due+to+vancomycin-resistant+Enterococcus+faecium+resistant+to+linezolid&doi=10.1016%2FS0140-6736%2800%2904376-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid</span></div><div class="casAuthors">Gonzales, R. D.; Schreckenberger, P. C.; Graham, M. B.; Kelkar, S.; DenBesten, K.; Quinn, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">9263</span>),
    <span class="NLM_cas:pages">1179</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Linezolid is a new oxazolidinone antibiotic used to treat infections caused by vancomycin-resistant enterococci (VRE).  In early clin. trials, emergence of resistance occurred rarely.  The authors report clin. details and antibiotic susceptibility from 5 patients treated with linezolid for VRE infections who had resistant organisms isolated during therapy.  Four were transplant patients receiving protracted courses of the drug; 3 cases were assocd. with treatment failure.  One of 45 linezolid-treated patients developed resistance during therapy.  Susceptibility testing should be done in all cases on starting therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdnzIal5XYyLVg90H21EOLACvtfcHk0lh8pFQc8EiV3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFaqsb0%253D&md5=accd02388931411eaa373b9b69a01347</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2904376-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252904376-2%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DR.%2BD.%26aulast%3DSchreckenberger%26aufirst%3DP.%2BC.%26aulast%3DGraham%26aufirst%3DM.%2BB.%26aulast%3DKelkar%26aufirst%3DS.%26aulast%3DDenBesten%26aufirst%3DK.%26aulast%3DQuinn%26aufirst%3DJ.%2BP.%26atitle%3DInfections%2520due%2520to%2520vancomycin-resistant%2520Enterococcus%2520faecium%2520resistant%2520to%2520linezolid%26jtitle%3DLancet%26date%3D2001%26volume%3D357%26spage%3D1179%26doi%3D10.1016%2FS0140-6736%2800%2904376-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0lh7PQaDstTHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrby, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid--a review of the first oxazolidinone</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1517/14656566.2.2.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1517%2F14656566.2.2.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=11336587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=293-302&author=R.+Norrby&title=Linezolid%2D%2Da+review+of+the+first+oxazolidinone&doi=10.1517%2F14656566.2.2.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid - a review of the first oxazolidinone</span></div><div class="casAuthors">Norrby, Ragnar</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review with 48 refs.  Linezolid is the first of a truly new class of antibiotics, the oxazolidinones.  It acts as an inhibitor of bacterial protein synthesis by blocking the formation of the 70S ribosomal initiation complex.  Its activity is bacteriostatic against some species (e.g., enterococci) and bactericidal against others (e.g., pneumococci).  The antibacterial spectrum of linezolid includes Gram-pos. pathogens and some Gram-neg. anaerobic species but not Gram-neg. aerobes.  Importantly, multi-drug resistant organisms such as methicillin-resistant staphylococci, staphylococci with reduced susceptibility to vancomycin, penicillin- and macrolide-resistant pneumococci and vancomycin-resistant enterococci are fully susceptible to linezolid.  Linezolid has almost 100% bioavailability and the area under the plasma concn. curve is identical after oral and iv. administration.  This enables initial oral administration of linezolid in those patients who can absorb the drug normally and also an early step-down therapy from iv. to oral.  Controlled, clin. studies have documented efficacy and safety of linezolid in hospital- and community-acquired pneumonia, uncomplicated and complicated skin and soft tissue infections and infections caused by vancomycin-resistant enterococci.  The safety and tolerability of linezolid are advantageous.  Linezolid is a weak and reversible monoamine oxidase (MAO) inhibitor and although no increased frequency of adrenergic or serotonergic adverse events has been reported, it is recommended that linezolid is used with caution in patients treated with other MAO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppV7eFYLHXfLVg90H21EOLACvtfcHk0lh7PQaDstTHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFKjs7g%253D&md5=98cd0338a3aaa5aa174226e869647ddc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1517%2F14656566.2.2.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2.2.293%26sid%3Dliteratum%253Aachs%26aulast%3DNorrby%26aufirst%3DR.%26atitle%3DLinezolid--a%2520review%2520of%2520the%2520first%2520oxazolidinone%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2001%26volume%3D2%26spage%3D293%26epage%3D302%26doi%3D10.1517%2F14656566.2.2.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taglialegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A. E.</span></span> <span> </span><span class="NLM_article-title">Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1093/jac/dkz418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1093%2Fjac%2Fdkz418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31617901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSrsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=126-134&author=M.+Rochauthor=M.+C.+Varelaauthor=A.+Taglialegnaauthor=A.+E.+Rosato&title=Tedizolid+is+a+promising+antimicrobial+option+for+the+treatment+of+Staphylococcus+aureus+infections+in+cystic+fibrosis+patients&doi=10.1093%2Fjac%2Fdkz418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients</span></div><div class="casAuthors">Roch, Melanie; Varela, Maria Celeste; Taglialegna, Agustina; Rosato, Adriana E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">126-134</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To evaluate the in vitro and in vivo activity of tedizolid and predict the likelihood of tedizolid resistance selection in CF-background Staphylococcus aureus strains.  Methods: A collection of 330 S. aureus strains (from adult and paediatric patients), either of normal or small colony variant (SCV) phenotypes, gathered at three CF centers in the USA was used.  Tedizolid activity was assessed by broth microdilution, Etest and time-kill anal.  In vivo tedizolid efficacy was tested in a murine pneumonia model.  Tedizolid in vitro mutants were obtained by 40 days of exposure and progressive passages.  Whole genome sequencing of clin. S. aureus strains with reduced susceptibility to tedizolid was performed.  Results: MRSA strain MIC90s were tedizolid 0.12-0.25 mg/L and linezolid 1-2 mg/L; for MSSA strains, MIC90s were tedizolid 0.12 mg/L and linezolid 1-2 mg/L.  Two strains, WIS 441 and Seattle 106, with tedizolid MICs of 2 mg/L and 1 mg/L, resp., had MICs above the FDA tedizolid breakpoint (0.5 mg/L).  Tedizolid at free serum concns. exhibited a bacteriostatic effect.  Mean bacterial burdens in lungs (log10 cfu/g) for WIS 423-infected mice were: control, 11.2±0.5; tedizolid-treated (10 mg/kg), 3.40±1.87; linezolid-treated (40 mg/kg), 4.51±2.1; and vancomycin-treated (30 mg/kg), 5.21±1.93.  For WIS 441-infected mice the (log10 cfu/g) values were: control, 9.66±0.8; tedizolid-treated, 3.18±1.35; linezolid-treated 5.94±2.19; and vancomycin-treated, 4.35±1.7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgw4oAHmW32rVg90H21EOLACvtfcHk0lh7PQaDstTHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSrsr3F&md5=f4fc681b46e7d6f219b98c834931f017</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkz418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkz418%26sid%3Dliteratum%253Aachs%26aulast%3DRoch%26aufirst%3DM.%26aulast%3DVarela%26aufirst%3DM.%2BC.%26aulast%3DTaglialegna%26aufirst%3DA.%26aulast%3DRosato%26aufirst%3DA.%2BE.%26atitle%3DTedizolid%2520is%2520a%2520promising%2520antimicrobial%2520option%2520for%2520the%2520treatment%2520of%2520Staphylococcus%2520aureus%2520infections%2520in%2520cystic%2520fibrosis%2520patients%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2020%26volume%3D75%26spage%3D126%26epage%3D134%26doi%3D10.1093%2Fjac%2Fdkz418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span> <span> </span><span class="NLM_article-title">Relative Potency of TR-700, the Active Moiety of Prodrug TR-701, against Selected Bacterial Pathogens and Provisional Disk Test</span>. In  <i>Infectious Diseases Society of America 2008 Annual Meeting</i>, October 27, <span class="NLM_year">2008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Brown&title=Relative+Potency+of+TR-700%2C+the+Active+Moiety+of+Prodrug+TR-701%2C+against+Selected+Bacterial+Pathogens+and+Provisional+Disk+Test"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%26atitle%3DRelative%2520Potency%2520of%2520TR-700%252C%2520the%2520Active%2520Moiety%2520of%2520Prodrug%2520TR-701%252C%2520against%2520Selected%2520Bacterial%2520Pathogens%2520and%2520Provisional%2520Disk%2520Test%26jtitle%3DInfectious%2520Diseases%2520Society%2520of%2520America%25202008%2520Annual%2520Meeting%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. N.</span>; <span class="NLM_string-name">Fritsche, T. R.</span>; <span class="NLM_string-name">Sader, H. S.</span></span> <span> </span><span class="NLM_article-title">TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms</span>. In  <i>ICAAC/IDSA 2008</i>, <span class="NLM_publisher-loc">Washington, DC</span>, October 25–28, <span class="NLM_year">2000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=R.+N.+Jones&author=T.+R.+Fritsche&author=H.+S.+Sader&title=TR-700%2C+a+Novel+Oxazolidinone%2C+Tested+Against+Linezolid-Resistant+Gram-positive+Species+with+Well-Characterized+Resistance+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BN.%26atitle%3DTR-700%252C%2520a%2520Novel%2520Oxazolidinone%252C%2520Tested%2520Against%2520Linezolid-Resistant%2520Gram-positive%2520Species%2520with%2520Well-Characterized%2520Resistance%2520Mechanisms%26jtitle%3DICAAC%252FIDSA%25202008%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoellman, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ednie, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, P. C.</span></span> <span> </span><span class="NLM_article-title">Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.3.1148-1150.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.47.3.1148-1150.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=12604559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslWiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=1148-1150&author=D.+B.+Hoellmanauthor=G.+Linauthor=L.+M.+Ednieauthor=A.+Rattanauthor=M.+R.+Jacobsauthor=P.+C.+Appelbaum&title=Antipneumococcal+and+antistaphylococcal+activities+of+ranbezolid+%28RBX+7644%29%2C+a+new+oxazolidinone%2C+compared+to+those+of+other+agents&doi=10.1128%2FAAC.47.3.1148-1150.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents</span></div><div class="casAuthors">Hoellman, Dianne B.; Lin, Gengrong; Ednie, Lois M.; Rattan, Ashok; Jacobs, Michael R.; Appelbaum, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1148-1150</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from ≤0.06 to 4 μg/mL.  The MICs for pneumococci were similar irresp. of the strains' β-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-neg. staphylococci were lower than those for Staphylococcus aureus.  Ranbezolid was bacteriostatic against pneumococci.  Ranbezolid MICs were similar to or lower than those of linezolid.  Vancomycin and quinupristin-dalfopristin were also very active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNExvSGSvqLVg90H21EOLACvtfcHk0ljTRbt_hi3-Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslWiur4%253D&md5=ba1c9e14ba2e139e88bb011f35b69b44</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.3.1148-1150.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.3.1148-1150.2003%26sid%3Dliteratum%253Aachs%26aulast%3DHoellman%26aufirst%3DD.%2BB.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DEdnie%26aufirst%3DL.%2BM.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DM.%2BR.%26aulast%3DAppelbaum%26aufirst%3DP.%2BC.%26atitle%3DAntipneumococcal%2520and%2520antistaphylococcal%2520activities%2520of%2520ranbezolid%2520%2528RBX%25207644%2529%252C%2520a%2520new%2520oxazolidinone%252C%2520compared%2520to%2520those%2520of%2520other%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D1148%26epage%3D1150%26doi%3D10.1128%2FAAC.47.3.1148-1150.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyal, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmlund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonath, A.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Linezolid Binding Site Rearrangement in the Staphylococcus aureus Ribosome</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1128/mBio.00395-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FmBio.00395-17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8&author=M.+J.+Belousoffauthor=Z.+Eyalauthor=M.+Radjainiaauthor=T.+Ahmedauthor=R.+S.+Bamertauthor=D.+Matzovauthor=A.+Bashanauthor=E.+Zimmermanauthor=S.+Mishraauthor=D.+Cameronauthor=H.+Elmlundauthor=A.+Y.+Pelegauthor=S.+Bhushanauthor=T.+Lithgowauthor=A.+Yonath&title=Structural+Basis+for+Linezolid+Binding+Site+Rearrangement+in+the+Staphylococcus+aureus+Ribosome&doi=10.1128%2FmBio.00395-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FmBio.00395-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00395-17%26sid%3Dliteratum%253Aachs%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DEyal%26aufirst%3DZ.%26aulast%3DRadjainia%26aufirst%3DM.%26aulast%3DAhmed%26aufirst%3DT.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DMatzov%26aufirst%3DD.%26aulast%3DBashan%26aufirst%3DA.%26aulast%3DZimmerman%26aufirst%3DE.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DElmlund%26aufirst%3DH.%26aulast%3DPeleg%26aufirst%3DA.%2BY.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DLithgow%26aufirst%3DT.%26aulast%3DYonath%26aufirst%3DA.%26atitle%3DStructural%2520Basis%2520for%2520Linezolid%2520Binding%2520Site%2520Rearrangement%2520in%2520the%2520Staphylococcus%2520aureus%2520Ribosome%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26spage%3D8%26doi%3D10.1128%2FmBio.00395-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years</span>. <i>Helicobacter</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">e12373</span>, <span class="refDoi"> DOI: 10.1111/hel.12373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fhel.12373" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=e12373&author=L.+Liauthor=Y.+Keauthor=C.+Yuauthor=G.+Liauthor=N.+Yangauthor=J.+Zhangauthor=Y.+Li&title=Antibiotic+resistance+of+Helicobacter+pylori+in+Chinese+children%3A+A+multicenter+retrospective+study+over+7+years&doi=10.1111%2Fhel.12373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fhel.12373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhel.12373%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKe%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DAntibiotic%2520resistance%2520of%2520Helicobacter%2520pylori%2520in%2520Chinese%2520children%253A%2520A%2520multicenter%2520retrospective%2520study%2520over%25207%2520years%26jtitle%3DHelicobacter%26date%3D2017%26volume%3D22%26spage%3De12373%26doi%3D10.1111%2Fhel.12373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of oxazolidinone derivatives containing nitro heteroaromatic moiety</span>. <i>Chem. Res. Chin. Univ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1007/s40242-018-7302-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs40242-018-7302-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=51-56&author=B.+Xuauthor=X.+Dingauthor=Y.+Wuauthor=L.+Cuiauthor=P.+Qianauthor=D.+Wangauthor=Y.+Zhao&title=Synthesis+and+antibacterial+activity+of+oxazolidinone+derivatives+containing+nitro+heteroaromatic+moiety&doi=10.1007%2Fs40242-018-7302-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of oxazolidinone derivatives containing nitro heteroaromatic moiety</span></div><div class="casAuthors">Xu, Boxuan; Ding, Xiudong; Wu, Yachuang; Cui, Lei; Qian, Ping; Wang, Di; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Chinese Universities</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">CRCUED</span>;
        ISSN:<span class="NLM_cas:issn">1005-9040</span>.
    
            (<span class="NLM_cas:orgname">Jilin University</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone derivs. contg. nitro heteroarom. moiety I (R = 1-methyl-5-nitro-1H-imidazol-2-yl, 5-nitrofuran-2-yl, 2-O2NC6H4, etc.) was synthesized and evaluated for their in vitro antibacterial activities against S. aureus ATCC 29213, methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) by min. inhibitory concn. (MIC) assay.  Most of them exhibited antibacterial activity against S. aureus ATCC 29213, MRSA and VRE.  Among them, compds. I (R = 5-nitrofuran-2-yl, 5-nitrothiophen-2-yl) displayed better activity than the control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryB4jCFahUl7Vg90H21EOLACvtfcHk0liPkS0TKTQ7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlSitQ%253D%253D&md5=b8ea04ee2d7eea2f707af716b7ca3755</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40242-018-7302-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40242-018-7302-3%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520oxazolidinone%2520derivatives%2520containing%2520nitro%2520heteroaromatic%2520moiety%26jtitle%3DChem.%2520Res.%2520Chin.%2520Univ.%26date%3D2018%26volume%3D34%26spage%3D51%26epage%3D56%26doi%3D10.1007%2Fs40242-018-7302-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhateja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4261</span>– <span class="NLM_lpage">4267</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2005.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=16054358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4261-4267&author=B.+Dasauthor=S.+Rudraauthor=A.+Yadavauthor=A.+Rayauthor=A.+V.+Raoauthor=A.+S.+Srinivasauthor=A.+Soniauthor=S.+Sainiauthor=S.+Shuklaauthor=M.+Pandyaauthor=P.+Bhatejaauthor=S.+Malhotraauthor=T.+Mathurauthor=S.+K.+Aroraauthor=A.+Rattanauthor=A.+Mehta&title=Synthesis+and+SAR+of+novel+oxazolidinones%3A+discovery+of+ranbezolid&doi=10.1016%2Fj.bmcl.2005.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid</span></div><div class="casAuthors">Das, Biswajit; Rudra, Sonali; Yadav, Ajay; Ray, Abhijit; Rao, A. V. S. Raja; Srinivas, A. S. S. V.; Soni, Ajay; Saini, Suman; Shukla, Shalini; Pandya, Manisha; Bhateja, Pragya; Malhotra, Sunita; Mathur, Tarun; Arora, S. K.; Rattan, Ashok; Mehta, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4261-4267</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel oxazolidinones, e.g. I (R = H, CHO, CO2H, HON:CH, CN, Cl, etc.), contg. a no. of substituted five-membered heterocycles attached to the piperazinyl-phenyl-oxazolidinone core of eperezolid, were synthesized.  Further, the piperazine ring of the core was replaced by other diamino-heterocycles.  These modifications led to several compds. with potent activity against a spectrum of resistant and susceptible Gram-pos. organisms, along with the identification of ranbezolid I (R = O2N) (RBx 7644) as a clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUDv4PtgEefrVg90H21EOLACvtfcHk0liPkS0TKTQ7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WnsL8%253D&md5=8c1cbf4f9d288699b3d49e966ee7f9a8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DA.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DA.%2BV.%26aulast%3DSrinivas%26aufirst%3DA.%2BS.%26aulast%3DSoni%26aufirst%3DA.%26aulast%3DSaini%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DPandya%26aufirst%3DM.%26aulast%3DBhateja%26aufirst%3DP.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DT.%26aulast%3DArora%26aufirst%3DS.%2BK.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520novel%2520oxazolidinones%253A%2520discovery%2520of%2520ranbezolid%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4261%26epage%3D4267%26doi%3D10.1016%2Fj.bmcl.2005.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126746</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2019.126746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31676225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOgsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126746&author=Y.+Houauthor=Y.+Dongauthor=T.+Yeauthor=J.+Jiangauthor=L.+Dingauthor=M.+Qinauthor=X.+Dingauthor=Y.+Zhao&title=Synthesis+and+antibacterial+evaluation+of+novel+oxazolidinone+derivatives+containing+a+piperidinyl+moiety&doi=10.1016%2Fj.bmcl.2019.126746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety</span></div><div class="casAuthors">Hou, Yunlei; Dong, Yuhong; Ye, Tianyu; Jiang, Jia; Ding, Liang; Qin, Mingze; Ding, Xiudong; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">126746</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this article, a series of novel oxazolidinone derivs. contg. a piperidinyl moiety was designed and synthesized.  Their antibacterial activities were measured against S. aureus, MRSA, MSSA, LREF and VRE by MIC assay.  Most of them exhibited potent activity against Gram-pos. pathogens comparable to linezolid.  Among them, compd. I exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metab. in human liver microsome.  The most promising compd. I, which showed remarkable antibacterial activity against S. aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.25-1μg/mL, was an interesting candidate for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRe-N1n1cn7Vg90H21EOLACvtfcHk0liPkS0TKTQ7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOgsr3E&md5=00ea5ebc085852aa7aea03c9e4a685b3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126746%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520novel%2520oxazolidinone%2520derivatives%2520containing%2520a%2520piperidinyl%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126746%26doi%3D10.1016%2Fj.bmcl.2019.126746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6389</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+Teraryl+Oxazolidinone+Compound+%28S%29-N-%28%283-%283-Fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+Phosphate+as+a+Novel+Antimicrobial+Agent+with+Enhanced+Safety+Profile+and+Efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0lhnhVm8ojutTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Teraryl%2520Oxazolidinone%2520Compound%2520%2528S%2529-N-%2528%25283-%25283-Fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520Phosphate%2520as%2520a%2520Novel%2520Antimicrobial%2520Agent%2520with%2520Enhanced%2520Safety%2520Profile%2520and%2520Efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubenrauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, T.</span></span> <span> </span><span class="NLM_article-title">cryoEM-Guided Development of Antibiotics for Drug-Resistant Bacteria</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fcmdc.201900042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=30667174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislKqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=527-531&author=M.+J.+Belousoffauthor=H.+Venugopalauthor=A.+Wrightauthor=S.+Seonerauthor=I.+Stuartauthor=C.+Stubenrauchauthor=R.+S.+Bamertauthor=D.+W.+Luptonauthor=T.+Lithgow&title=cryoEM-Guided+Development+of+Antibiotics+for+Drug-Resistant+Bacteria&doi=10.1002%2Fcmdc.201900042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">cryoEM-Guided Development of Antibiotics for Drug-Resistant Bacteria</span></div><div class="casAuthors">Belousoff, Matthew J.; Venugopal, Hari; Wright, Alexander; Seoner, Samuel; Stuart, Isabella; Stubenrauch, Chris; Bamert, Rebecca S.; Lupton, David W.; Lithgow, Trevor</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">527-531</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">While the ribosome is a common target for antibiotics, challenges with crystallog. can impede the development of new bioactives using structure-based drug design approaches.  We exploit common structural features present in linezolid-resistant forms of both methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) to redesign the antibiotic.  Enabled by rapid and facile cryoEM structures, this process has identified (S)-2,2-dichloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (LZD-5) and (S)-2-chloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl) acetamide (LZD-6), which inhibit the ribosomal function and growth of linezolid-resistant MRSA and VRE.  The strategy discussed highlights the potential for cryoEM to facilitate the development of novel bioactive materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1INvrja-_irVg90H21EOLACvtfcHk0lhnhVm8ojutTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislKqs74%253D&md5=1e9a0855ace9e04fa8371b35448851e5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900042%26sid%3Dliteratum%253Aachs%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DVenugopal%26aufirst%3DH.%26aulast%3DWright%26aufirst%3DA.%26aulast%3DSeoner%26aufirst%3DS.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DStubenrauch%26aufirst%3DC.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DLupton%26aufirst%3DD.%2BW.%26aulast%3DLithgow%26aufirst%3DT.%26atitle%3DcryoEM-Guided%2520Development%2520of%2520Antibiotics%2520for%2520Drug-Resistant%2520Bacteria%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D527%26epage%3D531%26doi%3D10.1002%2Fcmdc.201900042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, J.</span></span> <span> </span><span class="NLM_article-title">Ultrasound Assisted Synthesis, Characterization and Antimicrobial Evaluation of Novel Oxazolidinone- Biphenyl Chalcone Hybrid Derivatives</span>. <i>Indian J. Pharm. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">286</span>, <span class="refDoi"> DOI: 10.5530/ijper.53.2.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.5530%2Fijper.53.2.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVegu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=286&author=N.+Panigrahiauthor=S.+Gangulyauthor=J.+Panda&title=Ultrasound+Assisted+Synthesis%2C+Characterization+and+Antimicrobial+Evaluation+of+Novel+Oxazolidinone-+Biphenyl+Chalcone+Hybrid+Derivatives&doi=10.5530%2Fijper.53.2.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrasound assisted synthesis, characterization and antimicrobial evaluation of novel oxazolidinonebiphenyl chalcone hybrid derivatives</span></div><div class="casAuthors">Panigrahi, Naresh; Ganguly, Swastika; Panda, Jagadeesh</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Pharmaceutical Education and Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-300</span>CODEN:
                <span class="NLM_cas:coden">IJPEB3</span>;
        ISSN:<span class="NLM_cas:issn">0019-5464</span>.
    
            (<span class="NLM_cas:orgname">Indian Journal of Pharmaceutical Education and Research</span>)
        </div><div class="casAbstract">Objective: The main objective of our present study, is to potentiate the antibacterial activity of biphenyl chalcones and oxazolidinones, thus in order to achieve the potent antibacterial agents, we coupled both derivs. by using green chem. approach for Buchwald's protocol under ultrasound irradn.  Methodol.: Ultrasonication technique was used to couple a series of 24 novel bromo-biphenyl-chalcone derivs. and 5-chloromethyl-oxazolidinone in the presence of copper iodide (CuI) (10 mol %) for the amidation of chalcones and (±)-trans-1,2-diaminocyclohexane was used to solubilize CuI and potassium carbonate (K2CO3) as base, which provided the products in good yields after short reaction times under mild conditions.  Results and Discussion: Herewith we report the synthesis of 24 novel oxazolidinone-biphenyl chalcone hybrid derivs. (7a-7x).  All the synthesized compds. were characterized by spectral data and evaluated for in vitro antibacterial and antifungal activities.  Antibacterial and antifungal activities were tested using the serial diln. method.  From the screening studies it was obsd. that compds. 7c to 7g have shown significant antibacterial activities against the both the strains of gram-pos. and gram-neg. bacteria at 3.125 μg/mL when compared to the std. drugs ciprofloxacin and linezolid and were as other compds. showed moderate to weak activities.  In case of antifungal studies the compds. 7e-7g showed moderate activities at 12.5 μg/mL compared to std. fluconazole and whereas other compds. showed weak activities.  Conclusion: We have developed an exptl. simple, efficient, short time and high yielding CuI-mediated N-arylation of oxazolidinones under ultrasound irradn. with a simple set up at room temp.  This approach would be a worthwhile in the development of green chem. protocols.  Compds. 7c to 7g have shown significant antibacterial activities against the both the strains of gram-pos. and gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7bGkQchM-LVg90H21EOLACvtfcHk0lh8FU0E5Zv3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVegu77F&md5=e1cd14a89ca969a2e16e475efd91ae38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.5530%2Fijper.53.2.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5530%252Fijper.53.2.37%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahi%26aufirst%3DN.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DPanda%26aufirst%3DJ.%26atitle%3DUltrasound%2520Assisted%2520Synthesis%252C%2520Characterization%2520and%2520Antimicrobial%2520Evaluation%2520of%2520Novel%2520Oxazolidinone-%2520Biphenyl%2520Chalcone%2520Hybrid%2520Derivatives%26jtitle%3DIndian%2520J.%2520Pharm.%2520Educ.%26date%3D2019%26volume%3D53%26spage%3D286%26doi%3D10.5530%2Fijper.53.2.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (−)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28%E2%88%92%29-PNU-286607+by+asymmetric+cyclization+of+alkylidene+barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0lh8FU0E5Zv3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528%25E2%2588%2592%2529-PNU-286607%2520by%2520asymmetric%2520cyclization%2520of%2520alkylidene%2520barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.+S.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones%3A+Benzisoxazole+Fusion+with+N-Linked+Oxazolidinone+Substituents+Leading+to+a+Clinical+Candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lh8FU0E5Zv3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Novel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%253A%2520Benzisoxazole%2520Fusion%2520with%2520N-Linked%2520Oxazolidinone%2520Substituents%2520Leading%2520to%2520a%2520Clinical%2520Candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattigeri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Spiropyrimidinetriones Oxazolidinone Derivatives as Antibacterial Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1198</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2018.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=29525219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1198&author=A.+Siddiquiauthor=J.+Sattigeriauthor=K.+Javedauthor=S.+Shafiauthor=M.+Shamimauthor=S.+Singhalauthor=M.+Malik&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Spiropyrimidinetriones+Oxazolidinone+Derivatives+as+Antibacterial+Agents&doi=10.1016%2Fj.bmcl.2018.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of spiropyrimidinetriones oxazolidinone derivatives as antibacterial agents</span></div><div class="casAuthors">Siddiqui, Asher M.; Sattigeri, Jitendra A.; Javed, Kalim; Shafi, Syed; Shamim, M.; Singhal, Smita; Malik, Zubbair M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1198-1206</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gram-pos. bacteria are among the most common human pathogens assocd. with clin. infections which range from mild skin infections to sepsis.  Resistance towards existing class of drugs by Gram-pos. bacteria including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE) and vancomycin resistant enterococci (VRE) is a growing concern.  There is an urgent need to discover new antibiotics which are active against resistant strains of Gram pos. bacteria.  We report herein a novel class of spiropyrimidinetrione oxazolidinone derivs. as novel antibacterial agents.  Key step towards the synthesis of title compds. involved the use of tert-amino reaction with [1,5]-hydride shift leading to the new C-C bond formation.  Compd. 30n (I) has demonstrated potent antibacterial activity against a panel of Gram-pos. microbial strains including MRSA, MRSE, and LNZ and vancomycin resistant strains of E. faecalis.  Further, mol. docking studies suggest that 30n has binding mode similar to that of LNZ in 50S RNA ribosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVS5ztoVXm4bVg90H21EOLACvtfcHk0lj4ctkfAKZtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOjsrw%253D&md5=35791eb66d0773b322c147e63fb85710</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DSattigeri%26aufirst%3DJ.%26aulast%3DJaved%26aufirst%3DK.%26aulast%3DShafi%26aufirst%3DS.%26aulast%3DShamim%26aufirst%3DM.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Spiropyrimidinetriones%2520Oxazolidinone%2520Derivatives%2520as%2520Antibacterial%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1198%26doi%3D10.1016%2Fj.bmcl.2018.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelletty, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aeschlimann, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaatz, G. W.</span></span> <span> </span><span class="NLM_article-title">Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.3.721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.42.3.721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9517963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXhvV2kurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=721-724&author=M.+J.+Rybakauthor=D.+M.+Cappellettyauthor=T.+Moldovanauthor=J.+R.+Aeschlimannauthor=G.+W.+Kaatz&title=Comparative+in+vitro+activities+and+postantibiotic+effects+of+the+oxazolidinone+compounds+eperezolid+%28PNU-100592%29+and+linezolid+%28PNU-100766%29+versus+vancomycin+against+Staphylococcus+aureus%2C+coagulase-negative+staphylococci%2C+Enterococcus+faecalis%2C+and+Enterococcus+faecium&doi=10.1128%2FAAC.42.3.721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium</span></div><div class="casAuthors">Rybak, Michael J.; Cappelletty, Diane M.; Moldovan, Tabitha; Aeschlimann, Jeffrey R.; Kaatz, Glenn W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">721-724</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clin. isolates of methicillin-susceptible and -resistant Staphylococcus aureus (n = 200), coagulase-neg. staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium (n = 50).  Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 μg/mL) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 μg/mL).  In time-kill studies, eperezolid and linezolid were bacteriostatic in action.  A postantibiotic effect of 0.8 ± 0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPlbr1PFg7pbVg90H21EOLACvtfcHk0lj4ctkfAKZtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhvV2kurk%253D&md5=039df71b1c2f19a0e929a190b118056c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.3.721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.3.721%26sid%3Dliteratum%253Aachs%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26aulast%3DCappelletty%26aufirst%3DD.%2BM.%26aulast%3DMoldovan%26aufirst%3DT.%26aulast%3DAeschlimann%26aufirst%3DJ.%2BR.%26aulast%3DKaatz%26aufirst%3DG.%2BW.%26atitle%3DComparative%2520in%2520vitro%2520activities%2520and%2520postantibiotic%2520effects%2520of%2520the%2520oxazolidinone%2520compounds%2520eperezolid%2520%2528PNU-100592%2529%2520and%2520linezolid%2520%2528PNU-100766%2529%2520versus%2520vancomycin%2520against%2520Staphylococcus%2520aureus%252C%2520coagulase-negative%2520staphylococci%252C%2520Enterococcus%2520faecalis%252C%2520and%2520Enterococcus%2520faecium%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D721%26epage%3D724%26doi%3D10.1128%2FAAC.42.3.721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dresser, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, M. J.</span></span> <span> </span><span class="NLM_article-title">The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1998.tb03109.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fj.1875-9114.1998.tb03109.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Kjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=456-462&issue=3&author=L.+D.+Dresserauthor=M.+J.+Rybak&title=The+pharmacologic+and+bacteriologic+properties+of+oxazolidinones%2C+a+new+class+of+synthetic+antimicrobials&doi=10.1002%2Fj.1875-9114.1998.tb03109.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacologic and bacteriological properties of oxazolidinones, a new class of synthetic antimicrobials</span></div><div class="casAuthors">Dresser, Linda D.; Rybak, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">456-462</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review with 20 refs.  The oxazolidinones are a new synthetic class of antimicrobials structurally unrelated to any agent presently marketed.  Data pertaining to these compds., with respect to their pharmacol., pharmacokinetics, pharmacodynamics, mechanism of action, and bacteriol. activity, focusing on the analogs linezolid (PNU 100766) and eperezolid (PNU 100592), were retrieved by MEDLINE search and review of relevant abstrs. presented at recent clin. conferences.  Since the drugs are still investigational, we obtained in vitro and animal data as well as available human studies.  The oxazolidinones have bacteriostatic activity against a no. of important pathogens including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci.  They appear to be efficacious and well tolerated both orally and parenterally.  Their role remains to be elucidated by clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUs8uzO0PB9rVg90H21EOLACvtfcHk0lj4ctkfAKZtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Kjt7s%253D&md5=305ebe4863c4360fb80552da747e2029</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1998.tb03109.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1998.tb03109.x%26sid%3Dliteratum%253Aachs%26aulast%3DDresser%26aufirst%3DL.%2BD.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520pharmacologic%2520and%2520bacteriologic%2520properties%2520of%2520oxazolidinones%252C%2520a%2520new%2520class%2520of%2520synthetic%2520antimicrobials%26jtitle%3DPharmacotherapy%26date%3D1998%26volume%3D18%26issue%3D3%26spage%3D456%26epage%3D462%26doi%3D10.1002%2Fj.1875-9114.1998.tb03109.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasukata, T.</span></span> <span> </span><span class="NLM_article-title">Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2013.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23584544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFantrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=811-825&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=N.+Fukuharaauthor=T.+Iwakiauthor=T.+Yasukata&title=Antibacterial+oxazolidinone+analogues+having+a+N-hydroxyacetyl-substituted+seven-membered+%5B1%2C2%2C5%5Dtriazepane+or+%5B1%2C2%2C5%5Doxadiazepane+C-ring+unit&doi=10.1016%2Fj.ejmech.2013.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fukuhara, Norio; Iwaki, Tsutomu; Yasukata, Tatsuro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">811-825</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We synthesized a series of oxazolidinone analogs bearing a N-hydroxyacetyl-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit as homologues of an earlier drug candidate, eperezolid.  Several of these compds. exhibited potent in vitro antibacterial activities towards not only Gram-pos., but also Gram-neg. and linezolid-resistant pathogens.  Compds. I (X = H or F), bearing a thiocarbamate side chain, showed high in vivo activity against methicillin-resistant Staphylococcus aureus SR3637, together with a promising safety profile in terms of weak inhibition of monoamine oxidase and cytochrome P 450 isoenzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AEBvSKxIsbVg90H21EOLACvtfcHk0lhJk5xNeo0FGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFantrw%253D&md5=ee01b3bba0262eba541c7c55552d334e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFukuhara%26aufirst%3DN.%26aulast%3DIwaki%26aufirst%3DT.%26aulast%3DYasukata%26aufirst%3DT.%26atitle%3DAntibacterial%2520oxazolidinone%2520analogues%2520having%2520a%2520N-hydroxyacetyl-substituted%2520seven-membered%2520%255B1%252C2%252C5%255Dtriazepane%2520or%2520%255B1%252C2%252C5%255Doxadiazepane%2520C-ring%2520unit%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D811%26epage%3D825%26doi%3D10.1016%2Fj.ejmech.2013.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhardwaj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, K. R.</span></span> <span> </span><span class="NLM_article-title">Organoiodine (III) mediated synthesis of 3-aryl/hetryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines as antibacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2004.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2004.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15571869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCqsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=1073-1077&author=O.+Prakashauthor=V.+Bhardwajauthor=R.+Kumarauthor=P.+Tyagiauthor=K.+R.+Aneja&title=Organoiodine+%28III%29+mediated+synthesis+of+3-aryl%2Fhetryl-5%2C7-dimethyl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyrimidines+as+antibacterial+agents&doi=10.1016%2Fj.ejmech.2004.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Organoiodine(III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines as antibacterial agents</span></div><div class="casAuthors">Prakash, Om; Bhardwaj, Vikas; Kumar, Ravi; Tyagi, Parikshit; Aneja, Kamal R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1073-1077</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Synthesis of some 3-aryl-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidines, e.g., I, has been accomplished by the oxidn. of 4,6-dimethyl-2-pyrimidinylhydrazones, derived from various aldehydes, with iodobenzene diacetate in dichloromethane.  Some of the compds. were tested in vitro for their antibacterial activity.  Two compds., namely 3-(4'-pyridyl)-5,7-dimethyl-1,2,4-triazolo[4,3-a]pyrimidine and I, were assocd. with substantially higher antibacterial activity than some com. antibiotics against Bacillus subtilis, Escherichia coli, Staphylococcus aureus and Salmonella typhi at MIC (min. inhibitory concn.) i.e. 10 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_29EClD4FMbVg90H21EOLACvtfcHk0lhJk5xNeo0FGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCqsr3K&md5=e8b4c4087a5f0e0fc5b60c562f523828</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2004.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2004.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DAneja%26aufirst%3DK.%2BR.%26atitle%3DOrganoiodine%2520%2528III%2529%2520mediated%2520synthesis%2520of%25203-aryl%252Fhetryl-5%252C7-dimethyl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyrimidines%2520as%2520antibacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2004%26volume%3D39%26spage%3D1073%26epage%3D1077%26doi%3D10.1016%2Fj.ejmech.2004.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhiman, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Organoiodine (III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2260</span>– <span class="NLM_lpage">2264</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2008.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18657340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsl2gsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2260-2264&author=R.+Kumarauthor=R.+R.+Nairauthor=S.+S.+Dhimanauthor=J.+Sharmaauthor=O.+Prakash&title=Organoiodine+%28III%29-mediated+synthesis+of+3-aryl%2Fheteroaryl-5%2C7-dimethyl-1%2C2%2C4-triazolo%5B4%2C3-c%5Dpyrimidines+as+antibacterial+agents&doi=10.1016%2Fj.ejmech.2008.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Organoiodine(III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents</span></div><div class="casAuthors">Kumar, Ravi; Nair, Reshmi R.; Dhiman, Saurabh Sudha; Sharma, Jitender; Prakash, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2260-2264</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of 12 new 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines has been accomplished by the oxidn. of pyrimidinylhydrazones of various aryl/heteroaryl aldehydes using 1.1 equiv. of iodobenzene diacetate (IBD) in dichloromethane.  All the compds. were tested in vitro for their antibacterial activity against two Gram-pos. bacteria namely, Bacillus subtilis, Bacillus stearothermophilus and two Gram-neg. bacteria Pseudomonas putida, Escherichia coli.  3-(2,4-Dichlorophenyl)-5,7-dimethyl-1,2,4-triazolo [4,3-c]pyrimidine and 3-(4-hydroxy-2-methoxyphenyl)-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidine were found to be equipotent or more potent than the com. available antibiotics (chloramphenicol and streptomycin).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9i95v2I1op7Vg90H21EOLACvtfcHk0lhJk5xNeo0FGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsl2gsLk%253D&md5=f7649aaa54f55d619b57bdc874a33b0b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DNair%26aufirst%3DR.%2BR.%26aulast%3DDhiman%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DOrganoiodine%2520%2528III%2529-mediated%2520synthesis%2520of%25203-aryl%252Fheteroaryl-5%252C7-dimethyl-1%252C2%252C4-triazolo%255B4%252C3-c%255Dpyrimidines%2520as%2520antibacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2260%26epage%3D2264%26doi%3D10.1016%2Fj.ejmech.2008.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khera, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cliffe, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2887</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2011.03.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21507643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2887-2889&author=M.+K.+Kheraauthor=I.+A.+Cliffeauthor=T.+Mathurauthor=O.+Prakash&title=Synthesis+and+in+vitro+activity+of+novel+1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyrimidine+oxazolidinone+antibacterial+agents&doi=10.1016%2Fj.bmcl.2011.03.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents</span></div><div class="casAuthors">Khera, Manoj K.; Cliffe, Ian A.; Mathur, Tarun; Prakash, Om</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2887-2889</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and antibacterial activity of 3-(4-([1,2,4]triazolo[4,3-a]pyrimidin-3-yl)phenyl)oxazolidin-2-ones is reported.  Thiocarbonyl derivs. were found to be potent inhibitors of Gram-pos. pathogens and compd. I was two to fourfold more potent than Linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYa1HhZQpvbVg90H21EOLACvtfcHk0lj2y-2VBkgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmt7k%253D&md5=56305846a67b3bb8a8019a485d535011</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.075%26sid%3Dliteratum%253Aachs%26aulast%3DKhera%26aufirst%3DM.%2BK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26aulast%3DMathur%26aufirst%3DT.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520activity%2520of%2520novel%25201%252C2%252C4-triazolo%255B4%252C3-a%255Dpyrimidine%2520oxazolidinone%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2887%26epage%3D2889%26doi%3D10.1016%2Fj.bmcl.2011.03.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsunomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, T.</span></span> <span> </span><span class="NLM_article-title">Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1021/ml400280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1074-1078&author=H.+Suzukiauthor=I.+Utsunomiyaauthor=K.+Shudoauthor=T.+Fujimuraauthor=M.+Tsujiauthor=I.+Katoauthor=T.+Aokiauthor=A.+Inoauthor=T.+Iwaki&title=Potent+oxazolidinone+antibacterials+with+heteroaromatic+C-ring+substructure&doi=10.1021%2Fml400280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Oxazolidinone Antibacterials with Heteroaromatic C-Ring Substructure</span></div><div class="casAuthors">Suzuki, Hideyuki; Utsunomiya, Iwao; Shudo, Koichi; Fujimura, Takaji; Tsuji, Masakatsu; Kato, Issei; Aoki, Toshiaki; Ino, Akira; Iwaki, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1074-1078</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel oxazolidinone analogs bearing a condensed heteroarom. ring as the C-ring substructure were synthesized as candidate antibacterial agents.  Analogs 16 and 21 bearing imidazo-[1,2-a]-pyridine and 18 and 23 bearing [1,2,4]-triazolo-[1,5-a]-pyridine as the C-ring had excellent in vitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP).  They also showed promising therapeutic effects in a mouse model of lethal infection.  Preliminary safety data (inhibitory effects on cytochrome P 450 isoforms and monoamine oxidases) were satisfactory.  Further evaluation of 18 and 23 is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBYb1cLJtZI7Vg90H21EOLACvtfcHk0lj2y-2VBkgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrtb%252FM&md5=6f39a539a41ec53b3ce04733a74850d1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fml400280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400280z%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DUtsunomiya%26aufirst%3DI.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DIno%26aufirst%3DA.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DPotent%2520oxazolidinone%2520antibacterials%2520with%2520heteroaromatic%2520C-ring%2520substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1074%26epage%3D1078%26doi%3D10.1021%2Fml400280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1153-1158&author=M.+S.+Deshmukhauthor=N.+Jain&title=Design%2C+Synthesis%2C+and+Antibacterial+Evaluation+of+Oxazolidinones+with+Fused+Heterocyclic+C-Ring+Substructure&doi=10.1021%2Facsmedchemlett.7b00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure</span></div><div class="casAuthors">Deshmukh, Mahesh S.; Jain, Nidhi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1158</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone antibacterials with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities were designed and synthesized.  The compd. with benzoxazinone C-ring substructure (I) exhibited superior activity compared to linezolid against a panel of Gram-pos. and Gram-neg. bacteria.  Structural modifications at C5-side chain of I resulted in identification of several potent compds.  Selected compds. I and II showed very good microsomal stability and no CYP450 liability, thus clearing preliminary safety hurdles.  A docking model of II binding to 23S rRNA suggested that the increased potency of II is due to addnl. ligand-receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsos1yjPmoN7Vg90H21EOLACvtfcHk0lj2y-2VBkgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtbfL&md5=5edbae88df65af2bd8264ff4755a0498</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00263%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DM.%2BS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antibacterial%2520Evaluation%2520of%2520Oxazolidinones%2520with%2520Fused%2520Heterocyclic%2520C-Ring%2520Substructure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1153%26epage%3D1158%26doi%3D10.1021%2Facsmedchemlett.7b00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/ardp.200800233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.200800233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19544480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2009&pages=377-385&author=X.+J.+Wangauthor=N.+Wuauthor=G.+J.+Duauthor=S.+Q.+Zhaoauthor=M.+Yanauthor=L.+Q.+Gu&title=Synthesis+and+antibacterial+activities+of+eperezolid+analogs+with+glycinyl+substitutions&doi=10.1002%2Fardp.200800233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Activities of Eperezolid Analogs with Glycinyl Substitutions</span></div><div class="casAuthors">Wang, Xiao-Jun; Wu, Ning; Du, Guang-Jian; Zhao, Shuang-Qi; Yan, Ming; Gu, Lian-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of eperezolid analogs with glycinyl substitutions were prepd. and their antibacterial activities were studied against a panel of susceptible and resistant Gram-pos. bacteria.  The compds. with N-arylacyl or N-heteroarylacyl glycinyl structural units showed good antibacterial activities.  The compds. 11b, 11c, and 11e were twofold more active than linezolid against Staphylococcus epidermidis and Enterococcus faecalis.  Several pyridine analogs were also prepd. and found to have poor antibacterial activity against most of the tested Gram-pos. bacteria, however, one of the compds. 12e showed very high activity against Enterococcus faecalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAe3f_ZJgFXbVg90H21EOLACvtfcHk0lj2y-2VBkgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCnu70%253D&md5=e99e1e9cedc16ba8842f8cc7a570203a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800233%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DG.%2BJ.%26aulast%3DZhao%26aufirst%3DS.%2BQ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520eperezolid%2520analogs%2520with%2520glycinyl%2520substitutions%26jtitle%3DArch.%2520Pharm.%26date%3D2009%26volume%3D342%26spage%3D377%26epage%3D385%26doi%3D10.1002%2Fardp.200800233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1128/AAC.01383-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01383-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18316525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=1653-1662&author=L.+Lawrenceauthor=P.+Daneseauthor=J.+DeVitoauthor=F.+Franceschiauthor=J.+Sutcliffe&title=In+vitro+activities+of+the+Rx-01+oxazolidinones+against+hospital+and+community+pathogens&doi=10.1128%2FAAC.01383-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens</span></div><div class="casAuthors">Lawrence, Laura; Danese, Paul; DeVito, Joe; Franceschi, Francois; Sutcliffe, Joyce</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1653-1662</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Rx-01_423 and Rx-01_667 are 2 members of the family of oxazolidinones that were designed using a combination of computational and medicinal chem. and conventional biol. techniques.  The compds. have a 2 - to 8 fold-improved potency over linezolid against serious gram-pos. pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci.  This enhanced potency extends to the coverage of linezolid-resistant gram-pos. microbes, esp. multidrug-resistant enterococci and pneumococci.  Compds. from this series expand the spectrum compared with linezolid to include fastidious gram-neg. organisms like Haemophilus influenzae and Moraxella catarrhalis.  Like linezolid, the Rx-01 compds. are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCqcmJGV8nrVg90H21EOLACvtfcHk0ljFmrRJJPpQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajtbg%253D&md5=463c37891700f9165d77eed05e407add</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1128%2FAAC.01383-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01383-07%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DL.%26aulast%3DDanese%26aufirst%3DP.%26aulast%3DDeVito%26aufirst%3DJ.%26aulast%3DFranceschi%26aufirst%3DF.%26aulast%3DSutcliffe%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520activities%2520of%2520the%2520Rx-01%2520oxazolidinones%2520against%2520hospital%2520and%2520community%2520pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D1653%26epage%3D1662%26doi%3D10.1128%2FAAC.01383-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaadt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown-Driver, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillar, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinabarger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4442</span>– <span class="NLM_lpage">4447</span>, <span class="refDoi"> DOI: 10.1128/AAC.00859-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.00859-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18838596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2mu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=4442-4447&author=K.+J.+Shawauthor=S.+Poppeauthor=R.+Schaadtauthor=V.+Brown-Driverauthor=J.+Finnauthor=C.+M.+Pillarauthor=D.+Shinabargerauthor=G.+Zurenko&title=In+vitro+activity+of+TR-700%2C+the+antibacterial+moiety+of+the+prodrug+TR-701%2C+against+linezolid-resistant+strains&doi=10.1128%2FAAC.00859-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains</span></div><div class="casAuthors">Shaw, K. J.; Poppe, S.; Schaadt, R.; Brown-Driver, V.; Finn, J.; Pillar, C. M.; Shinabarger, D.; Zurenko, G.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4442-4447</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four- to eightfold-greater activity than linezolid (LZD) against Staphylococcus and Enterococcus spp.  In this study evaluating the in vitro sensitivity of LZD-resistant isolates, TR-700 demonstrated 8- to 16-fold-greater potency than LZD against all strains tested, including methicillin-resistant Staphylococcus aureus (MRSA), strains of MRSA carrying the mobile cfr methyltransferase gene, and vancomycin-resistant enterococci.  The MIC90 for TR-700 against LZD-resistant S. aureus was 2 μg/mL, demonstrating the utility of TR-700 against LZD-resistant strains.  A model of TR-700 binding to 23S rRNA suggests that the increased potency of TR-700 is due to addnl. target site interactions and that TR-700 binding is less reliant on target residues assocd. with resistance to LZD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-PvHNUp7EBbVg90H21EOLACvtfcHk0ljFmrRJJPpQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2mu77F&md5=f9ff1cf68056ec69f0b70d49c4522f69</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FAAC.00859-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00859-08%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3DPoppe%26aufirst%3DS.%26aulast%3DSchaadt%26aufirst%3DR.%26aulast%3DBrown-Driver%26aufirst%3DV.%26aulast%3DFinn%26aufirst%3DJ.%26aulast%3DPillar%26aufirst%3DC.%2BM.%26aulast%3DShinabarger%26aufirst%3DD.%26aulast%3DZurenko%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520activity%2520of%2520TR-700%252C%2520the%2520antibacterial%2520moiety%2520of%2520the%2520prodrug%2520TR-701%252C%2520against%2520linezolid-resistant%2520strains%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D4442%26epage%3D4447%26doi%3D10.1128%2FAAC.00859-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4113</span>– <span class="NLM_lpage">4123</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.03.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2005.03.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=15911326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4113-4123&author=O.+A.+Phillipsauthor=E.+E.+Udoauthor=A.+A.+Aliauthor=S.+M.+Samuel&title=Synthesis+and+antibacterial+activity+of+new+N-linked+5-triazolylmethyl+oxazolidinones&doi=10.1016%2Fj.bmc.2005.03.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones</span></div><div class="casAuthors">Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4113-4123</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new series of N-linked 5-triazolylmethyl oxazolidinones with varying substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates.  Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms.  One of the compds. showed enhanced antibacterial activity against Moraxella catarrhalis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn3GyicMxM77Vg90H21EOLACvtfcHk0ljFmrRJJPpQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gjs7w%253D&md5=b8cace1f3aaf0614c774c2301ba45a5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.03.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.03.036%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DUdo%26aufirst%3DE.%2BE.%26aulast%3DAli%26aufirst%3DA.%2BA.%26aulast%3DSamuel%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520new%2520N-linked%25205-triazolylmethyl%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4113%26epage%3D4123%26doi%3D10.1016%2Fj.bmc.2005.03.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hamid, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2013.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23811087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=246-257&author=O.+A.+Phillipsauthor=E.+E.+Udoauthor=M.+E.+Abdel-Hamidauthor=R.+Varghese&title=Synthesis+and+antibacterial+activities+of+N-substituted-glycinyl+1H-1%2C2%2C3-triazolyl+oxazolidinones&doi=10.1016%2Fj.ejmech.2013.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones</span></div><div class="casAuthors">Phillips, Oludotun A.; Udo, Edet E.; Abdel-Hamid, Mohammed E.; Varghese, Reny</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">246-257</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1H-1,2,3-triazolyl piperazino oxazolidinone analogs with optionally varied glycinyl substitutions were synthesized and their antibacterial activity assessed against a panel of susceptible and resistant Gram-pos. and selected Gram-neg. bacteria including clin. isolates.  The N-aroyl- and N-heteroaroyl-glycinyl (MIC: 0.06-4 μg/mL) derivs. were more potent than the N-acylglycinyl (2-8 μg/mL) derivs. against all Gram-pos. bacteria tested.  Nitro substitution on aryl and heteroaryl rings significantly enhanced activity against Gram-pos. bacteria, as noted with the 3,5-dinitrobenzoyl (I, R = H, Me) and 5-nitro-2-furoyl (II, R = H, Me) derivs. with MIC ranges of and 0.25-0.5 and 0.06-0.5 μg/mL, resp.  These nitro analogs also showed more potent extended activity against Moraxella catarrhalis, with MICs ranges of 0.25-1 μg/mL, compared to linezolid (MIC: 8 μg/mL).  Hence, the presence of the N-aroyl and/or N-heteroaroyl glycinyl structural motifs as spacer groups could significantly enhance the antibacterial activities of 1H-1,2,3-triazolyl oxazolidinone class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryeCCv-YLmMrVg90H21EOLACvtfcHk0lgJ_OIBS1lN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SktLzE&md5=c12a45b3cb05e9a053f5cd03f81356ae</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DUdo%26aufirst%3DE.%2BE.%26aulast%3DAbdel-Hamid%26aufirst%3DM.%2BE.%26aulast%3DVarghese%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520N-substituted-glycinyl%25201H-1%252C2%252C3-triazolyl%2520oxazolidinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D246%26epage%3D257%26doi%3D10.1016%2Fj.ejmech.2013.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activities of novel Ligustrazine derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3315</span>– <span class="NLM_lpage">3320</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2007.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=17383884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvFOmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3315-3320&author=X.+C.+Chengauthor=X.+Y.+Liuauthor=W.+F.+Xuauthor=X.+L.+Guoauthor=Y.+Ou&title=Design%2C+synthesis%2C+and+biological+activities+of+novel+Ligustrazine+derivatives&doi=10.1016%2Fj.bmc.2007.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological activities of novel Ligustrazine derivatives</span></div><div class="casAuthors">Cheng, Xian-Chao; Liu, Xin-Yong; Xu, Wen-Fang; Guo, Xiu-Li; Ou, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3315-3320</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of novel Ligustrazine derivs. was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities.  The results showed that most Ligustrazine derivs. exhibited lower EC50 values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine.  And some Ligustrazine derivs. presented better antiplatelet aggregation activities than Ligustrazine. The derivs. contg. the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency.  Compd. 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compd. 7c was found to be the most active antiplatelet aggregation agent.  Structure-activity relationships were briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYvrWZfPyMOrVg90H21EOLACvtfcHk0lgJ_OIBS1lN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvFOmurg%253D&md5=d8c65234f7d1c16ae731965061d89028</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%2BC.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DW.%2BF.%26aulast%3DGuo%26aufirst%3DX.%2BL.%26aulast%3DOu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520novel%2520Ligustrazine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3315%26epage%3D3320%26doi%3D10.1016%2Fj.bmc.2007.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. B.</span></span> <span> </span><span class="NLM_article-title">Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.jns.2012.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23140983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2013&pages=94-99&author=J.+Z.+Huauthor=J.+H.+Huangauthor=Z.+M.+Xiaoauthor=J.+H.+Liauthor=X.+M.+Liauthor=H.+B.+Lu&title=Tetramethylpyrazine+accelerates+the+function+recovery+of+traumatic+spinal+cord+in+rat+model+by+attenuating+inflammation&doi=10.1016%2Fj.jns.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation</span></div><div class="casAuthors">Hu, Jian-Zhong; Huang, Jiang-Hu; Xiao, Zhi-Man; Li, Jun-Hao; Li, Xiao-Ming; Lu, Hong-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, we explored the effects of tetramethylpyrazine (TMP), an alkaloid extd. from the Chinese herbal medicine Ligusticum wallichii Franchat (chuanxiong), on a rat model of contusion spinal cord injury (SCI).  The contusion SCI model was induced in rats by a modified Allen's wt.-drop method with a severity of 5 g × 50 mm impacting on the T10 segment.  In the TMP treatment group, rats were injected i.p. (i.p.) with TMP (200 mg/kg), every 24 h for 5 days, starting half an hour after contusion SCI.  The control group was treated with saline.  Compared with the control group, the TMP group significantly ameliorated the recovery of hindlimb function of rats.  TMP treatment significantly reduced the expression of macrophage migration inhibitory factor, nuclear factor κappa B, pro-inflammatory cytokine interleukin-18 and neutrophil infiltration.  On the other hand, TMP enhanced the expression of inhibitor κappa B and anti-inflammation cytokine interleukin-10.  In conclusion, our results demonstrate that TMP inhibits the development of inflammation and tissue injury assocd. with spinal cord contusion in rats which may improve the rats' hindlimb function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRROEOzCOySrVg90H21EOLACvtfcHk0lgJ_OIBS1lN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqtb7L&md5=bac34f7562bae80c8f1d1ff383c0c1a2</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%2BZ.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DXiao%26aufirst%3DZ.%2BM.%26aulast%3DLi%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DLu%26aufirst%3DH.%2BB.%26atitle%3DTetramethylpyrazine%2520accelerates%2520the%2520function%2520recovery%2520of%2520traumatic%2520spinal%2520cord%2520in%2520rat%2520model%2520by%2520attenuating%2520inflammation%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2013%26volume%3D324%26spage%3D94%26epage%3D99%26doi%3D10.1016%2Fj.jns.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kao, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. J.</span></span> <span> </span><span class="NLM_article-title">Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2013.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.expneurol.2013.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23644042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1KgsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=2013&pages=188-201&author=T.+K.+Kaoauthor=C.+Y.+Changauthor=Y.+C.+Ouauthor=W.+Y.+Chenauthor=Y.+H.+Kuanauthor=H.+C.+Panauthor=S.+L.+Liaoauthor=G.+Z.+Liauthor=C.+J.+Chen&title=Tetramethylpyrazine+reduces+cellular+inflammatory+response+following+permanent+focal+cerebral+ischemia+in+rats&doi=10.1016%2Fj.expneurol.2013.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats</span></div><div class="casAuthors">Kao, Tsung-Kuei; Chang, Cheng-Yi; Ou, Yen-Chuan; Chen, Wen-Ying; Kuan, Yu-Hsiang; Pan, Hung-Chuan; Liao, Su-Lan; Li, Guo-Zhang; Chen, Chun-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188-201</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tetramethylpyrazine (TMP) has been used to treat ischemic stroke.  However, scientific evidence related to its effectiveness or precise modes of neuroprotective action is largely unclear.  This study provides evidence of an alternative target for TMP and sheds light on the mechanism of its physiol. benefits.  We report a global inhibitory effect of TMP on intracerebral cellular inflammatory response in a rat model of permanent cerebral ischemia.  TMP exhibited a neuroprotective effect against ischemic deficits by redn. of behavioral disturbance, brain infarction, and edema.  The results of immunohistochem., enzymic assay, Western blot, real-time reverse transcriptase-polymerase chain reaction (RT-PCR), and flow cytometric anal. revealed that TMP reduced the percentages of activated macrophages/microglia and infiltrative lymphocytes, neutrophils, and macrophages and pro-inflammatory cytokine expression after cerebral ischemia.  In parallel with these immunosuppressive phenomena, TMP also attenuated the activities of ischemia-induced inflammation-assocd. signaling mols. and transcription factors.  Another finding in this study was that the anti-inflammatory and neuroprotective effects of TMP were accompanied by a further elevated expression of NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in ipsilateral neurons and macrophages/microglia after cerebral ischemia.  Taken together, our results suggest that both the promotion of endogenous defense capacity and the attenuation of the extent and compn. percentage of the major cellular inflammatory responses via targeting of macrophages/microglia by elevating Nrf2/HO-1 expression might actively contribute to TMP-mediated neuroprotection against cerebral ischemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4UACzRMskarVg90H21EOLACvtfcHk0liKoFpoRiER9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1KgsLjK&md5=b046158bce4b881a30122c60faf8534b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2013.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2013.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKao%26aufirst%3DT.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DOu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DW.%2BY.%26aulast%3DKuan%26aufirst%3DY.%2BH.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DLiao%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BZ.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26atitle%3DTetramethylpyrazine%2520reduces%2520cellular%2520inflammatory%2520response%2520following%2520permanent%2520focal%2520cerebral%2520ischemia%2520in%2520rats%26jtitle%3DExp.%2520Neurol.%26date%3D2013%26volume%3D247%26spage%3D188%26epage%3D201%26doi%3D10.1016%2Fj.expneurol.2013.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, Y.</span></span> <span> </span><span class="NLM_article-title">Antiinflammatory effect of tetramethylpyrazine and ferulic acid</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1248/cpb.40.954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1248%2Fcpb.40.954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1525949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1Sit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1992&pages=954-956&author=Y.+Ozaki&title=Antiinflammatory+effect+of+tetramethylpyrazine+and+ferulic+acid&doi=10.1248%2Fcpb.40.954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effect of tetramethylpyrazine and ferulic acid</span></div><div class="casAuthors">Ozaki, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">954-6</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Tetramethylpyrazine (TMP) is one of the alkaloids contained in Ligusticum wallichii.  Ferulic acid (FA) is a phenolic compd. contained in L. wallichii and Angelica sinensis.  The present study was carried out to examine the anti-inflammatory effect and to elucidate the mode of the effect of TMP and FA.  Both compds. significantly inhibited the edema induced by carrageenin, the increase of the dye leakage induced by acetic acid and the granuloma formation induced by cotton pellet.  And also, TMP and FA inhibited the no. of writhes induced by acetic acid.  From these results, it is suggested that both compds. have the anti-inflammatory effect and the analgesic effect, and both compds. exert an anti-inflammatory effect at the early and the late stages of processes in the inflammatory pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kf6LkFA1JrVg90H21EOLACvtfcHk0liKoFpoRiER9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1Sit7k%253D&md5=b1d0bedf38da89af176d3f64337b66b6</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1248%2Fcpb.40.954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.40.954%26sid%3Dliteratum%253Aachs%26aulast%3DOzaki%26aufirst%3DY.%26atitle%3DAntiinflammatory%2520effect%2520of%2520tetramethylpyrazine%2520and%2520ferulic%2520acid%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1992%26volume%3D40%26spage%3D954%26epage%3D956%26doi%3D10.1248%2Fcpb.40.954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. B.</span></span> <span> </span><span class="NLM_article-title">Protective effects of ligustrazine on TNF-α-induced endothelial dysfunction</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>674</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.10.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejphar.2011.10.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22094067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1KmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=674&publication_year=2012&pages=365-369&author=H.+J.+Wuauthor=J.+Haoauthor=S.+Q.+Wangauthor=B.+L.+Jinauthor=X.+B.+Chen&title=Protective+effects+of+ligustrazine+on+TNF-%CE%B1-induced+endothelial+dysfunction&doi=10.1016%2Fj.ejphar.2011.10.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of ligustrazine on TNF-α-induced endothelial dysfunction</span></div><div class="casAuthors">Wu, Hong-Jin; Hao, Jing; Wang, Sheng-Qi; Jin, Bi-Lian; Chen, Xian-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">674</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">365-369</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To investigate the effects of Ligustrazine, a compd. derived from chuanxiong, on tumor necrosis factor-α (TNF-α) stimulated endothelial cells.  Human umbilical vein endothelial cells (HUVECs) were stimulated with TNF-α in vitro.  Nitric oxide (NO) was measured as a std. of endothelial dysfunction.  Two important indicators of autoimmunity, intracellular adhesion mol.-1 (ICAM-1) and heat shock protein 60 (HSP60), were selected to evaluate the influence of Ligustrazine on HUVECs.  Ligustrazine (40 μg/mL) significantly reversed the decrease in NO prodn. induced by TNF-α (5 ng/mL) in HUVECs.  The expressions of ICAM-1 and HSP60 were increased by TNF-α treatment, but dramatically inhibited by treatment with ligustrazine in TNF-α-stimulated cells.  Ligustrazine increased the prodn. of NO in HUVECs and had an immunomodulatory effect on HUVECs stimulated with TNF-α by down-regulating the expression of ICAM-1 and HSP60.  These results suggest that ligustrazine protects the endothelium via inhibition of immunol. reactions, preventing atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCAUE9kl-JrVg90H21EOLACvtfcHk0liKoFpoRiER9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1KmsQ%253D%253D&md5=31939a4eab87b96fb37cfd00f96f0d03</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.10.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.10.046%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DJin%26aufirst%3DB.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BB.%26atitle%3DProtective%2520effects%2520of%2520ligustrazine%2520on%2520TNF-%25CE%25B1-induced%2520endothelial%2520dysfunction%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D674%26spage%3D365%26epage%3D369%26doi%3D10.1016%2Fj.ejphar.2011.10.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, F.</span></span> <span> </span><span class="NLM_article-title">Effect of tetramethylpyrazine on primary afferent transmission mediated by P2 × 3 receptor in neuropathic pain states</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2008.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.brainresbull.2008.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18639742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=27-32&author=Y.+Gaoauthor=C.+Xuauthor=S.+Liangauthor=A.+Zhangauthor=S.+Muauthor=Y.+Wangauthor=F.+Wan&title=Effect+of+tetramethylpyrazine+on+primary+afferent+transmission+mediated+by+P2+%C3%97+3+receptor+in+neuropathic+pain+states&doi=10.1016%2Fj.brainresbull.2008.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X3 receptor in neuropathic pain states</span></div><div class="casAuthors">Gao, Yun; Xu, Changshui; Liang, Shangdong; Zhang, Aixia; Mu, Songniu; Wang, Yunxia; Wan, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-32</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Neuropathic pain is the most difficult type of pain to treat.  The P2X3 receptors play a crucial role in facilitating pain transmission at peripheral and spinal sites.  The present research investigated the effects of tetramethylpyrazine (TMP) on the primary afferent transmission induced by P2X3 receptor in neuropathic pain states.  Chronic constriction injury (CCI) model was adopted.  Sprague-Dawley male rats (n = 30) had been randomly divided into normal saline (sham + NS) group (I), TMP group (II), sham group (III), CCI + TMP group (IV), and CCI group (V).  Mech. withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were measured and P2X3 immunoreactivity in L4/L5 dorsal root ganglion (DRG) and spinal cord was detected by immunohistochem.  The mech. withdrawal threshold and thermal withdrawal latency in group V were lower than those in groups I-III or IV (p < 0.05), while P2X3 receptor expression of L4/L5 DRG and spinal cord in group V was higher than those in groups I-III (p < 0.01) or group IV (p < 0.05).  The mech. withdrawal threshold, thermal withdrawal latency and P2X3 immunoreactivity of L4/L5 DRG and spinal cord in group IV showed no significant difference compared with those in groups I, II or III (p > 0.05).  The amplitudes of the currents in group V (CCI) were much larger than those obtained in other groups after application of same concn. ATP disodium (ATP) (p < 0.01). α,β-Methylene-ATP (α,β-meATP)-activated currents in DRG neurons of CCI rats were more obvious than those obtained in other group rats (p < 0.01).  The results showed that TMP may inhibit the primary afferent transmission of neuropathic pain induced by P2X3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5uaZHQkmC7Vg90H21EOLACvtfcHk0ljtUOT8ykBo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGrs7s%253D&md5=0b0698904231ccd13bb845a59fd10a4d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2008.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2008.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DF.%26atitle%3DEffect%2520of%2520tetramethylpyrazine%2520on%2520primary%2520afferent%2520transmission%2520mediated%2520by%2520P2%2520%25C3%2597%25203%2520receptor%2520in%2520neuropathic%2520pain%2520states%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2008%26volume%3D77%26spage%3D27%26epage%3D32%26doi%3D10.1016%2Fj.brainresbull.2008.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo</span>. <i>BMC Complementary Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">233</span>, <span class="refDoi"> DOI: 10.1186/s12906-017-1739-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1186%2Fs12906-017-1739-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28449676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=233&author=L.+Chenauthor=T.+Liuauthor=Q.+Wangauthor=J.+Liu&title=Anti-inflammatory+effect+of+combined+tetramethylpyrazine%2C+resveratrol+and+curcumin+in+vivo&doi=10.1186%2Fs12906-017-1739-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo</span></div><div class="casAuthors">Chen, Long; Liu, Tianjun; Wang, Qiangsong; Liu, Juan</div><div class="citationInfo"><span class="NLM_cas:title">BMC Complementary and Alternative Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233/1-233/10</span>CODEN:
                <span class="NLM_cas:coden">BCAMCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6882</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Resveratrol and curcumin, as natural flavones products, have good therapeutic effect in acute and chronic inflammation; on the other hand, tetramethylpyrazine (TMP) has angiogenesis and vessel protection effect as well as anti-inflammatory function.  In this paper, the anti-inflammatory effect of the tetramethylpyrazine, resveratrol and curcumin (TRC) combination in acute and chronic inflammation was reported in vivo.  Methods: The dose of the combined three natural products was optimized based on the acute paw swelling mouse model with a Uniform Design methodol.  The therapeutic effect of TRC combination on chronic inflammation was investigated by using the collagen-induced arthritis (CIA) rat model based upon the following indexes: the vol. of paw swelling, arthritis score, serum mediators and histol. examn. as well as immunohistochem. staining.  The levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) in serum were measured and the pathol. sections of liver and kidney were analyzed.  LD50 was measured based on the acute oral toxicity (AOT) std. method.  Results: The best formulation was the three components combined at the same mass proportion revealed by the Uniform Design methodol.  This combination could significantly reduce the paw swelling in acute paw swelling mouse model, could reduce paw swelling and alleviate the damage in joint structural of ankle, cartilages and fibrous tissue in CIA rat model.  The dose relationship was clear in both cases.  Immunohistochem. staining of ankle tissue revealed that TRC combination was able to inhibit the expression of NF-κB p65 and TNF-α which were closely related to the inflammatory process.  Anal. of serum mediators revealed TRC combination could inhibit the prodn. of TNF-α, IL-1β, and IL-6 in the serum.  Toxic study revealed this formulation was low toxic, LD50 was larger than 5 g/kg, both the level of ALT and AST and histopathol. in the liver and kidney exhibited no distinctions between the TRC combination and the blank group, no mortality occurred at the administered doses of 5 g/kg.  Conclusions: The results showed this formulation could provide a novel potent treatment for acute and chronic inflammation (RA) without side effect like gastric injury occurring in NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAiJiTlLXCxbVg90H21EOLACvtfcHk0ljtUOT8ykBo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitL%252FK&md5=4aaa59353f7d43541331c7e8fe776cc7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1186%2Fs12906-017-1739-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12906-017-1739-7%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DAnti-inflammatory%2520effect%2520of%2520combined%2520tetramethylpyrazine%252C%2520resveratrol%2520and%2520curcumin%2520in%2520vivo%26jtitle%3DBMC%2520Complementary%2520Altern.%2520Med.%26date%3D2017%26volume%3D17%26spage%3D233%26doi%3D10.1186%2Fs12906-017-1739-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huangfu, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. M.</span></span> <span> </span><span class="NLM_article-title">Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fcbdd.12537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25677093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKnsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=682-690&author=Y.+Chenauthor=Z.+X.+Ruanauthor=F.+Wangauthor=D.+S.+Huangfuauthor=P.+H.+Sunauthor=J.+Linauthor=W.+M.+Chen&title=Novel+Oxazolidinone+Antibacterial+Analogues+with+a+Substituted+Ligustrazine+C-ring+Unit&doi=10.1111%2Fcbdd.12537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit</span></div><div class="casAuthors">Chen, Yan; Ruan, Zhi-Xiong; Wang, Fang; Huangfu, De-Sheng; Sun, Ping-Hua; Lin, Jing; Chen, Wei-Min</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of novel oxazolidinone compds. with a substituted ligustrazine C-ring unit and different substituted groups at the C-5 side chain were designed and synthesized using linezolid as a lead and based on a scaffold hopping strategy.  Their antibacterial and anti-inflammatory activities were evaluated.  The results of in vitro antibacterial assays showed that all fourteen target compds. displayed potent activity against Gram-pos. pathogens, particularly I, II and 4 other compds.  Moreover, I and II exhibited significant inhibitory activities on the prodn. of inflammatory mediators, including nitric oxide, interleukin-6, and tumor necrosis factor-alpha.  Thus, these derivs. could serve as valuable candidates to develop anti-infective agents for the treatment of chronic wounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs5x0cVc4ABbVg90H21EOLACvtfcHk0ljtUOT8ykBo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKnsL3F&md5=304dc66cd8436863eda3ea916881abb1</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12537%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRuan%26aufirst%3DZ.%2BX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuangfu%26aufirst%3DD.%2BS.%26aulast%3DSun%26aufirst%3DP.%2BH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%2BM.%26atitle%3DNovel%2520Oxazolidinone%2520Antibacterial%2520Analogues%2520with%2520a%2520Substituted%2520Ligustrazine%2520C-ring%2520Unit%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D682%26epage%3D690%26doi%3D10.1111%2Fcbdd.12537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seetharamsingh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dange, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khairnar, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeraraghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalanka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1105-1110&author=B.+Seetharamsinghauthor=R.+Rameshauthor=S.+S.+Dangeauthor=P.+V.+Khairnarauthor=S.+Singhalauthor=D.+Upadhyayauthor=S.+Veeraraghavanauthor=S.+Viswanadhaauthor=S.+Vakkalankaauthor=D.+S.+Reddy&title=Design%2C+Synthesis%2C+and+Identification+of+Silicon+Incorporated+Oxazolidinone+Antibiotics+with+Improved+Brain+Exposure&doi=10.1021%2Facsmedchemlett.5b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure</span></div><div class="casAuthors">Seetharamsingh, B.; Ramesh, Remya; Dange, Santoshkumar S.; Khairnar, Pankaj V.; Singhal, Smita; Upadhyay, Dilip; Veeraraghavan, Sridhar; Viswanadha, Srikant; Vakkalanka, Swaroop; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1105-1110</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapeutic options for brain infections caused by pathogens with a reduced sensitivity to drugs are limited.  Recent reports on the potential use of linezolid in treating brain infections prompted us to design novel compds. around this scaffold.  Herein, we describe the design and synthesis of various oxazolidinone antibiotics with the incorporation of silicon.  Our findings in preclin. species suggest that silicon incorporation is highly useful in improving brain exposures.  Interestingly, three compds. from this series demonstrated up to a 30-fold higher brain/plasma ratio when compared to linezolid thereby indicating their therapeutic potential in brain assocd. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbe8J69irIubVg90H21EOLACvtfcHk0lh2vyScasqe5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWlt7rN&md5=46c49403d18d279226b5cdc8d1a94418</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00213%26sid%3Dliteratum%253Aachs%26aulast%3DSeetharamsingh%26aufirst%3DB.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DDange%26aufirst%3DS.%2BS.%26aulast%3DKhairnar%26aufirst%3DP.%2BV.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DUpadhyay%26aufirst%3DD.%26aulast%3DVeeraraghavan%26aufirst%3DS.%26aulast%3DViswanadha%26aufirst%3DS.%26aulast%3DVakkalanka%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Identification%2520of%2520Silicon%2520Incorporated%2520Oxazolidinone%2520Antibiotics%2520with%2520Improved%2520Brain%2520Exposure%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1105%26epage%3D1110%26doi%3D10.1021%2Facsmedchemlett.5b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0lh2vyScasqe5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manninen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allwine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovasz, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00194-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS0960-894X%2898%2900194-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=9871741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK1cXjsVyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1231-1236&author=D.+M.+Gleaveauthor=S.+J.+Bricknerauthor=P.+R.+Manninenauthor=D.+A.+Allwineauthor=K.+D.+Lovaszauthor=D.+C.+Rohrerauthor=J.+A.+Tuckerauthor=G.+E.+Zurenkoauthor=C.+W.+Ford&title=Synthesis+and+antibacterial+activity+of+%5B6%2C5%2C5%5D+and+%5B6%2C6%2C5%5D+tricyclic+fused+oxazolidinones&doi=10.1016%2FS0960-894X%2898%2900194-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones</span></div><div class="casAuthors">Gleave, D. Mark; Brickner, Steven J.; Manninen, Peter R.; Allwine, Debra A.; Lovasz, Kristine D.; Rohrer, Douglas C.; Tucker, John A.; Zurenko, Gary E.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1231-1236</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of conformationally restricted, [6,5,5] and [6,6,5] tricyclic fused oxazolidinones were synthesized and tested for antibacterial activity.  Several compds., e.g. I, in the trans-[6,5,5] series demonstrated potent in vitro and in vivo activity.  This work provides valuable information regarding the preferred conformational orientation of the oxazolidinones at the binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUIYes0rBV7Vg90H21EOLACvtfcHk0lh2vyScasqe5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsVyit7k%253D&md5=309a6e1105f09d7e03887c04abef86b4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900194-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900194-2%26sid%3Dliteratum%253Aachs%26aulast%3DGleave%26aufirst%3DD.%2BM.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DAllwine%26aufirst%3DD.%2BA.%26aulast%3DLovasz%26aufirst%3DK.%2BD.%26aulast%3DRohrer%26aufirst%3DD.%2BC.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activity%2520of%2520%255B6%252C5%252C5%255D%2520and%2520%255B6%252C6%252C5%255D%2520tricyclic%2520fused%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D1231%26epage%3D1236%26doi%3D10.1016%2FS0960-894X%2898%2900194-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone Antibacterial Agents. An Enantioselective Synthesis of the [6,5,5] Tricyclic Fused Oxazolidinone Ring System and Application to the Synthesis of a Rigid DuP 721 Analogue</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6470</span>– <span class="NLM_lpage">6474</span>, <span class="refDoi"> DOI: 10.1021/jo960945s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo960945s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XltVWksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=6470-6474&author=D.+M.+Gleaveauthor=S.+J.+Brickner&title=Oxazolidinone+Antibacterial+Agents.+An+Enantioselective+Synthesis+of+the+%5B6%2C5%2C5%5D+Tricyclic+Fused+Oxazolidinone+Ring+System+and+Application+to+the+Synthesis+of+a+Rigid+DuP+721+Analogue&doi=10.1021%2Fjo960945s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antibacterial agents. An enantioselective synthesis of the [6,5,5] tricyclic fused oxazolidinone ring system and application to the synthesis of a rigid DuP 721 analog</span></div><div class="casAuthors">Gleave, D. Mark; Brickner, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6470-6474</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An asym. synthesis of the parent tricyclic fused oxazolidinone I (R = H) was reported.  This compd. is a useful intermediate for the synthesis of oxazolidinone antibacterial agents.  A key step in the synthesis of I was an intramol. aryl N-lithio carbamate-epoxide cyclization which led to the formation of both five-membered rings, with complete regiochem. control.  Good enantioselectivity was achieved through the use of an asym. Sharpless epoxidn., which furnishes the epoxide product in ≥95% ee.  Oxazolidinone I was readily converted into I (R = acetyl), a tricyclic analog of the known antibacterial agent DuP 721.  Oxazolidinone I (R = acetyl) is a potent antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9KaPUXd4heLVg90H21EOLACvtfcHk0lgw6J_30Dlkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltVWksbg%253D&md5=31fcf031e4c0f9d91bb30a2078c1d907</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjo960945s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo960945s%26sid%3Dliteratum%253Aachs%26aulast%3DGleave%26aufirst%3DD.%2BM.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26atitle%3DOxazolidinone%2520Antibacterial%2520Agents.%2520An%2520Enantioselective%2520Synthesis%2520of%2520the%2520%255B6%252C5%252C5%255D%2520Tricyclic%2520Fused%2520Oxazolidinone%2520Ring%2520System%2520and%2520Application%2520to%2520the%2520Synthesis%2520of%2520a%2520Rigid%2520DuP%2520721%2520Analogue%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D6470%26epage%3D6474%26doi%3D10.1021%2Fjo960945s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, R.</span></span> <span> </span><span class="NLM_article-title">Stereocontrolled Synthesis of Tricyclic Fused Oxazolidinone as Antibacterial Agent</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570430438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fjhet.5570430438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD28XosFCru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=1071-1075&author=Y.+Cuiauthor=Y.+Dangauthor=Y.+Yangauthor=R.+Ji&title=Stereocontrolled+Synthesis+of+Tricyclic+Fused+Oxazolidinone+as+Antibacterial+Agent&doi=10.1002%2Fjhet.5570430438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Stereocontrolled synthesis of tricyclic fused oxazolidinone as antibacterial agent</span></div><div class="casAuthors">Cui, Yingjie; Dang, Yaxian; Yang, Yushe; Ji, Ruyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1071-1075</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">Tricyclic fused oxazolidinones (shown as I; R = H, Br) were synthesized as antibacterial agents in 12 and 11 steps resp.  The key intermediates (3R,3aS)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]-3a,4-dihydro-3H-[1,3]oxazolo[4,3-c][1,4]benzoxazin-1-one and (3R,3aS)-7-bromo-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]-3a,4-dihydro-3H-[1,3]oxazolo[4,3-c][1,4]benzoxazin-1-one were developed via opening of epoxides benzyl [2-[[(2R,3S)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]oxiran-2-yl]methoxy]phenyl]carbamate and benzyl [4-bromo-2-[[(2R,3S)-3-[[(1,1-dimethylethyl)dimethylsiloxy]methyl]oxiran-2-yl]methoxy]phenyl]carbamate and cyclization by the resulting oxygen anion attack.  The antibacterial activity of I was weak.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoltshfwhsCV7Vg90H21EOLACvtfcHk0lgw6J_30Dlkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosFCru7o%253D&md5=5982244c015d713e550cb5034926f75e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430438%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DR.%26atitle%3DStereocontrolled%2520Synthesis%2520of%2520Tricyclic%2520Fused%2520Oxazolidinone%2520as%2520Antibacterial%2520Agent%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D1071%26epage%3D1075%26doi%3D10.1002%2Fjhet.5570430438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0lgw6J_30Dlkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0lgw6J_30Dlkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyermann, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravestock, M. B.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1021/jm0400810</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0400810" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslKj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=499-506&author=F.+Reckauthor=F.+Zhouauthor=M.+Girardotauthor=G.+Kernauthor=C.+J.+Eyermannauthor=N.+J.+Halesauthor=R.+R.+Ramsayauthor=M.+B.+Gravestock&title=Identification+of+4-substituted+1%2C2%2C3-triazoles+as+novel+oxazolidinone+antibacterial+agents+with+reduced+activity+against+monoamine+oxidase+A&doi=10.1021%2Fjm0400810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A</span></div><div class="casAuthors">Reck, Folkert; Zhou, Fei; Girardot, Marc; Kern, Gunther; Eyermann, Charles J.; Hales, Neil J.; Ramsay, Rona R.; Gravestock, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones represent a new and promising class of antibacterial agents.  Current research in this area is mainly concd. on improving the safety profile and the antibacterial spectrum.  Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.  Recently, it was found that the 1,2,3-triazole is a good replacement for the conventional acetamide functionality found in oxazolidinones.  The authors now disclose the finding that 1,2,3-triazoles bearing a substituent like Me, small substituted Me, bromo, or a linear (sp-hybridized) group at the 4 position are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A.  The results are esp. promising for the development of oxazolidinones with an improved safety profile.  The MAO-A SAR can be rationalized on the basis of docking studies to a MAO-A/MAO-B homol. model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDPr2eh7f0ArVg90H21EOLACvtfcHk0liq0ZL4AZ_xlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslKj&md5=350b152fd789697c92694e1a747827de</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm0400810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0400810%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGirardot%26aufirst%3DM.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DEyermann%26aufirst%3DC.%2BJ.%26aulast%3DHales%26aufirst%3DN.%2BJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DGravestock%26aufirst%3DM.%2BB.%26atitle%3DIdentification%2520of%25204-substituted%25201%252C2%252C3-triazoles%2520as%2520novel%2520oxazolidinone%2520antibacterial%2520agents%2520with%2520reduced%2520activity%2520against%2520monoamine%2520oxidase%2520A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D499%26epage%3D506%26doi%3D10.1021%2Fjm0400810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brieland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brideau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dority, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadwood, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongliang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulavik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, J. V.</span></span> <span> </span><span class="NLM_article-title">Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5886</span>– <span class="NLM_lpage">5889</span>, <span class="refDoi"> DOI: 10.1021/jm070708p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070708p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12gs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5886-5889&author=T.+J.+Poelauthor=R.+C.+Thomasauthor=W.+J.+Adamsauthor=P.+A.+Aristoffauthor=M.+R.+Barbachynauthor=F.+E.+Boyerauthor=J.+Brielandauthor=R.+Brideauauthor=J.+Brodfuehrerauthor=A.+P.+Brownauthor=A.+L.+Choyauthor=M.+Dermyerauthor=M.+Dorityauthor=C.+W.+Fordauthor=R.+C.+Gadwoodauthor=D.+Hannaauthor=C.+Hongliangauthor=M.+D.+Hubandauthor=C.+Huberauthor=R.+Kellyauthor=J.+Y.+Kimauthor=J.+P.+Martinauthor=P.+J.+Paganoauthor=D.+Rossauthor=L.+Skerlosauthor=M.+C.+Sulavikauthor=T.+Zhuauthor=G.+E.+Zurenkoauthor=J.+V.+Prasad&title=Antibacterial+oxazolidinones+possessing+a+novel+C-5+side+chain.+%285R%29-trans-3-%5B3-Fluoro-4-+%281-oxotetrahydrothiopyran-4-yl%29phenyl%5D-2-+oxooxazolidine-5-carboxylic+acid+amide+%28PF-00422602%29%2C+a+new+lead+compound&doi=10.1021%2Fjm070708p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial Oxazolidinones Possessing a Novel C-5 Side Chain. (5R)-trans-3-[3-Fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxylic Acid Amide (PF-00422602), a New Lead Compound</span></div><div class="casAuthors">Poel, Toni-Jo; Thomas, Richard C.; Adams, Wade J.; Aristoff, Paul A.; Barbachyn, Michael R.; Boyer, Frederick E.; Brieland, Joan; Brideau, Roger; Brodfuehrer, Joanne; Brown, Alan P.; Choy, Allison L.; Dermyer, Michael; Dority, Michael; Ford, Charles W.; Gadwood, Robert C.; Hanna, Debra; Cai, Hongliang; Huband, Michael D.; Huber, Christopher; Kelly, Rose; Kim, Ji-Young; Martin, Joseph P., Jr.; Pagano, Paul J.; Ross, Daniel; Skerlos, Laura; Sulavik, Mark C.; Zhu, Tong; Zurenko, Gary E.; Prasad, J. V. N. Vara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5886-5889</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones possessing a C-5 carboxamide functionality (reverse amides) represent a new series of compds. that block bacterial protein synthesis.  These reverse amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus possess less potential for the side effects assocd. with MAO inhibition.  The title compd. (14) showed reduced in vivo myelotoxicity compared to linezolid in a 14-day safety study in rats, potent in vivo efficacy in murine systemic infection models, and excellent pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcqvXBXhlyY7Vg90H21EOLACvtfcHk0liq0ZL4AZ_xlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12gs7%252FM&md5=4444deb21162db7f82e60259a85f07d1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm070708p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070708p%26sid%3Dliteratum%253Aachs%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DBoyer%26aufirst%3DF.%2BE.%26aulast%3DBrieland%26aufirst%3DJ.%26aulast%3DBrideau%26aufirst%3DR.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BP.%26aulast%3DChoy%26aufirst%3DA.%2BL.%26aulast%3DDermyer%26aufirst%3DM.%26aulast%3DDority%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DGadwood%26aufirst%3DR.%2BC.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DHongliang%26aufirst%3DC.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DMartin%26aufirst%3DJ.%2BP.%26aulast%3DPagano%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DD.%26aulast%3DSkerlos%26aufirst%3DL.%26aulast%3DSulavik%26aufirst%3DM.%2BC.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DPrasad%26aufirst%3DJ.%2BV.%26atitle%3DAntibacterial%2520oxazolidinones%2520possessing%2520a%2520novel%2520C-5%2520side%2520chain.%2520%25285R%2529-trans-3-%255B3-Fluoro-4-%2520%25281-oxotetrahydrothiopyran-4-yl%2529phenyl%255D-2-%2520oxooxazolidine-5-carboxylic%2520acid%2520amide%2520%2528PF-00422602%2529%252C%2520a%2520new%2520lead%2520compound%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5886%26epage%3D5889%26doi%3D10.1021%2Fjm070708p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3697</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23721807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3697-3699&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+biological+evaluation+of+novel+benzoxazinyl-oxazolidinones+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3697-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of benzoxazinyl-oxazolidinones bearing 3-triazolylmethyl or 3-carboxamide side chain were designed and synthesized with the aim to develop antibacterial agents with improved properties.  In vitro antibacterial activities of these novel compds. were evaluated against a panel of resistant and susceptible Gram-pos. bacteria.  Most analogs bearing 3-triazolylmethyl showed good to moderate antibacterial activities.  Compd. I exhibited a fourfold increase in activity compared with linezolid against all the tested strains, which was identified to be a promising antibacterial agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGOMF4mbAZWbVg90H21EOLACvtfcHk0lgtQfDB7DEm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D&md5=6b94ab65a6988a6456e66f526f871ef4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzoxazinyl-oxazolidinones%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3697%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2203</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2015.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=25838143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2203-2210&author=T.+Xueauthor=S.+Dingauthor=B.+Guoauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+structure-activity+relationship+studies+of+novel+%5B6%2C6%2C5%5D+tricyclic+oxazolidinone+derivatives+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2015.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents</span></div><div class="casAuthors">Xue, Tao; Ding, Shi; Guo, Bin; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2203-2210</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our previous Letter, we reported the discovery of a novel benzoxazinyl-oxazolidinone antibacterial candidate I.  In order to identify a potential backup compd., extensive modifications on the B/C ring and C3 side chain were undertaken.  A series of novel [6,6,5] tricyclic analogs were synthesized and their in vitro antibacterial activities were tested against a panel of susceptible and resistant Gram-pos. pathogens.  Among of them, benzothiazinyl-oxazolidinones with acetamide or thioamide as C3 side chains exhibited moderate to good antibacterial activity, such as compds. II and III.  In vitro liver microsomal stability was further evaluated and the results manifested that compds. II and III were both metabolically stable in rat and human liver microsomes.  Addnl., insights gained from this investigation should provide directions for the further research of new oxazolidinone antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWKeyGmADQbVg90H21EOLACvtfcHk0lgtQfDB7DEm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOjt7w%253D&md5=d3062900e23c28723128541924869aba</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%2520%255B6%252C6%252C5%255D%2520tricyclic%2520oxazolidinone%2520derivatives%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2203%26epage%3D2210%26doi%3D10.1016%2Fj.bmcl.2015.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+Fluorine-Containing+Benzoxazinyl-oxazolidinones+for+the+Treatment+of+Multidrug+Resistant+Tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0lgtQfDB7DEm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Fluorine-Containing%2520Benzoxazinyl-oxazolidinones%2520for%2520the%2520Treatment%2520of%2520Multidrug%2520Resistant%2520Tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+Conformationally+Constrained+Oxazolidinone+with+Improved+Safety+and+Efficacy+Profiles+for+the+Treatment+of+Multidrug-Resistant+Tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0liFI3pNq4j11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Conformationally%2520Constrained%2520Oxazolidinone%2520with%2520Improved%2520Safety%2520and%2520Efficacy%2520Profiles%2520for%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3234</span>– <span class="NLM_lpage">3248</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c02153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmtVOktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=3234-3248&author=Y.+Wuauthor=B.+Wangauthor=H.+Luauthor=H.+Zhaoauthor=B.+Yangauthor=L.+Liauthor=Y.+Luauthor=D.+Zhangauthor=N.+Sunauthor=H.+Huang&title=Identification+of+Novel+Tricyclic+Benzo%5B1%2C3%5Doxazinyloxazolidinones+as+Potent+Antibacterial+Agents+with+Excellent+Pharmacokinetic+Profiles+against+Drug-Resistant+Pathogens&doi=10.1021%2Facs.jmedchem.0c02153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens</span></div><div class="casAuthors">Wu, Yongqi; Wang, Bin; Lu, Haijia; Zhao, Hongyi; Yang, Beibei; Li, Li; Lu, Yu; Zhang, Dongfeng; Sun, Ning; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3234-3248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-pos. bacteria, and Gram-neg. bacteria.  The studies identified a new compd. 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL).  Compd. 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase.  Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concn. (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%).  The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh8_qQMEyOLbVg90H21EOLACvtfcHk0liFI3pNq4j11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmtVOktr8%253D&md5=e42709b515626613fd559330cc8d0373</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02153%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Novel%2520Tricyclic%2520Benzo%255B1%252C3%255Doxazinyloxazolidinones%2520as%2520Potent%2520Antibacterial%2520Agents%2520with%2520Excellent%2520Pharmacokinetic%2520Profiles%2520against%2520Drug-Resistant%2520Pathogens%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D3234%26epage%3D3248%26doi%3D10.1021%2Facs.jmedchem.0c02153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baruah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzari, A.</span></span> <span> </span><span class="NLM_article-title">(S)□4□(4□aminobenzyl)□2□oxazolidinone based 2□azetidinones for antimicrobial application and luminescent sensing of divalent metal cations</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2511</span>, <span class="refDoi"> DOI: 10.1002/jhet.3965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fjhet.3965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslKnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=2498-2511&author=S.+Baruahauthor=M.+Aierauthor=A.+Puzari&title=%28S%29%E2%96%A14%E2%96%A1%284%E2%96%A1aminobenzyl%29%E2%96%A12%E2%96%A1oxazolidinone+based+2%E2%96%A1azetidinones+for+antimicrobial+application+and+luminescent+sensing+of+divalent+metal+cations&doi=10.1002%2Fjhet.3965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-4-(4-Aminobenzyl)-2-oxazolidinone based 2-azetidinones for antimicrobial application and luminescent sensing of divalent metal cations</span></div><div class="casAuthors">Baruah, Shyamal; Aier, Merangmenla; Puzari, Amrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2498-2511</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Design and synthesis of a new series of (S)-4-(4-aminobenzyl)-2-oxazolidinone based multifunctional azetidinones I (R = C6H5, 2,4-(Cl)2C6H3, 3,4-(OCH3)2C6H3, 3,4-(Cl)2C6H3) were accomplished.  Synthesis of the scaffolds was performed through a multi-step reaction process involving protection of amine functional group, conversion of protected (S)-4-(4-aminobenzyl)-2-oxazolidinone to its acetic acid deriv. II and then to acid chloride III, and finally coupled with different substituted arom. imines (E)-RCH=NR1 (R1 = (CH2)2CH3, C6H5) under mild reaction conditions in presence of an appropriate base.  The compds. I and II were screened for their antimicrobial activity against gram-pos. and gram-neg. bacteria and found to possess better and promising antimicrobial property than some of the reported antimicrobial drugs like disulfonamide and tetracycline.  Addnl., the scaffolds also exhibit prominent sensing property for divalent metal cations like Cu2+, Zn2+, and Ni2+, through fluorescence quenching effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2NnNYVnwoqrVg90H21EOLACvtfcHk0liFI3pNq4j11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslKnt7Y%253D&md5=ab14b69efaa12e57b698b31ab12d18e3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fjhet.3965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.3965%26sid%3Dliteratum%253Aachs%26aulast%3DBaruah%26aufirst%3DS.%26aulast%3DAier%26aufirst%3DM.%26aulast%3DPuzari%26aufirst%3DA.%26atitle%3D%2528S%2529%25E2%2596%25A14%25E2%2596%25A1%25284%25E2%2596%25A1aminobenzyl%2529%25E2%2596%25A12%25E2%2596%25A1oxazolidinone%2520based%25202%25E2%2596%25A1azetidinones%2520for%2520antimicrobial%2520application%2520and%2520luminescent%2520sensing%2520of%2520divalent%2520metal%2520cations%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2020%26volume%3D57%26spage%3D2498%26epage%3D2511%26doi%3D10.1002%2Fjhet.3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adil Zainel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapkaç, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaca Gençer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilgın, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaduman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaküçük-İyidoǧan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oruç-Emre, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koçyiǧit-Kaymakçıoǧlu, B.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of biological activities of 1,3-oxazolidinone derivatives bearing amide, sulfonamide, and thiourea moieties</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>, <span class="NLM_elocation-id">1800057</span> <span class="refDoi"> DOI: 10.1002/ardp.201800057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.201800057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&author=N.+Karamanauthor=R.+Adil+Zainelauthor=H.+A.+Kapka%C3%A7author=H.+Karaca+Gen%C3%A7erauthor=S.+Ilg%C4%B1nauthor=A.+B.+Karadumanauthor=A.+Karak%C3%BC%C3%A7%C3%BCk-%C4%B0yido%C7%A7anauthor=E.+E.+Oru%C3%A7-Emreauthor=B.+Ko%C3%A7yi%C7%A7it-Kaymak%C3%A7%C4%B1o%C7%A7lu&title=Design+and+evaluation+of+biological+activities+of+1%2C3-oxazolidinone+derivatives+bearing+amide%2C+sulfonamide%2C+and+thiourea+moieties&doi=10.1002%2Fardp.201800057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fardp.201800057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201800057%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DN.%26aulast%3DAdil%2BZainel%26aufirst%3DR.%26aulast%3DKapka%25C3%25A7%26aufirst%3DH.%2BA.%26aulast%3DKaraca%2BGen%25C3%25A7er%26aufirst%3DH.%26aulast%3DIlg%25C4%25B1n%26aufirst%3DS.%26aulast%3DKaraduman%26aufirst%3DA.%2BB.%26aulast%3DKarak%25C3%25BC%25C3%25A7%25C3%25BCk-%25C4%25B0yido%25C7%25A7an%26aufirst%3DA.%26aulast%3DOru%25C3%25A7-Emre%26aufirst%3DE.%2BE.%26aulast%3DKo%25C3%25A7yi%25C7%25A7it-Kaymak%25C3%25A7%25C4%25B1o%25C7%25A7lu%26aufirst%3DB.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520biological%2520activities%2520of%25201%252C3-oxazolidinone%2520derivatives%2520bearing%2520amide%252C%2520sulfonamide%252C%2520and%2520thiourea%2520moieties%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26doi%3D10.1002%2Fardp.201800057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrère-Kremer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">7-chloroquinoline-isatin conjugates: antimalarial, antitubercular, and cytotoxic evaluation</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1111%2Fcbdd.12273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=24341638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=622-629&author=R.+Rajauthor=C.+Biotauthor=S.+Carr%C3%A8re-Kremerauthor=L.+Kremerauthor=Y.+Gu%C3%A9rardelauthor=J.+Gutauthor=P.+J.+Rosenthalauthor=D.+Forgeauthor=V.+Kumar&title=7-chloroquinoline-isatin+conjugates%3A+antimalarial%2C+antitubercular%2C+and+cytotoxic+evaluation&doi=10.1111%2Fcbdd.12273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloroquinoline-isatin Conjugates: Antimalarial, Antitubercular, and Cytotoxic Evaluation</span></div><div class="casAuthors">Raj, Raghu; Biot, Christophe; Carrere-Kremer, Severine; Kremer, Laurent; Guerardel, Yann; Gut, Jiri; Rosenthal, Philip J.; Forge, Delphine; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of twenty piperazine-tethered 7-chloroquinoline-isatin hybrids have been synthesized via either direct nucleophilic substitution or Cu(Ι)Cl-mediated Mannich reaction.  These new conjugates were evaluated for their antimalarial and antitubercular efficacy against a chloroquine-resistant strain of Plasmodium falciparum and Mycobacterium tuberculosis, resp., while the cytotoxic profiles were evaluated against 3T6 cell line, a permanent mouse embryonic fibroblast cell line.  The most potent of the test compd. with IC50 of 0.22 μm against W2 strain of P. falciparum and 31.62 μm against the embryonic fibroblast cell line (cytotoxicity) displayed a high selective index of 143.73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyxMsit48IqrVg90H21EOLACvtfcHk0lheEvbj-E6LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWmsr0%253D&md5=4ab50cf9a231f0e9782062cdde98d69e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12273%26sid%3Dliteratum%253Aachs%26aulast%3DRaj%26aufirst%3DR.%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DCarr%25C3%25A8re-Kremer%26aufirst%3DS.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DForge%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3D7-chloroquinoline-isatin%2520conjugates%253A%2520antimalarial%252C%2520antitubercular%252C%2520and%2520cytotoxic%2520evaluation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D83%26spage%3D622%26epage%3D629%26doi%3D10.1111%2Fcbdd.12273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shalini</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Variedly connected 1,8-naphthalimide-7-chloroquinoline conjugates: Synthesis, anti-mycobacterial and cytotoxic evaluation</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">103241</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bioorg.2019.103241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=31518758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&pages=103241&author=+Shaliniauthor=M.+D.+Johansenauthor=L.+Kremerauthor=V.+Kumar&title=Variedly+connected+1%2C8-naphthalimide-7-chloroquinoline+conjugates%3A+Synthesis%2C+anti-mycobacterial+and+cytotoxic+evaluation&doi=10.1016%2Fj.bioorg.2019.103241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Variedly connected 1,8-naphthalimide-7-chloroquinoline conjugates: Synthesis, anti-mycobacterial and cytotoxic evaluation</span></div><div class="casAuthors">Shalini; Johansen, Matt D.; Kremer, Laurent; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103241</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis, anti-mycobacterial and cytotoxic evaluation of 4-substituted 1,8-naphthalimide-7-chloroquinoline conjugates I [R = Br, piperidin-1-yl, 4-morpholinyl, 4-(2-hydroxyethyl)piperazin-1-yl; n = 2,3,4,6,8] and II connected through varied linkers in order to study their structure-activity relationship was reported.  Simple alkyl chain linked conjugates showed better activity profiles without any cytotoxicity, while the inclusion of amide bond enhanced the cytotoxic tendency.  Copmd. II [R1 = piperidin-1-yl; n = 6] proved to be the most potent and non-cytotoxic with MIC99 of 6.25 μg/mL and selectivity index of > 16.  An interesting behavior of conjugates I and II in terms of activity and cytotoxicity was obsd. via switching over the nature of linker between two pharmacophores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZNc1EinryPbVg90H21EOLACvtfcHk0lheEvbj-E6LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhurrI&md5=7241f1b29ace5ce285d8cde0f90a5352</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103241%26sid%3Dliteratum%253Aachs%26aulast%3DShalini%26aulast%3DJohansen%26aufirst%3DM.%2BD.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DVariedly%2520connected%25201%252C8-naphthalimide-7-chloroquinoline%2520conjugates%253A%2520Synthesis%252C%2520anti-mycobacterial%2520and%2520cytotoxic%2520evaluation%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26spage%3D103241%26doi%3D10.1016%2Fj.bioorg.2019.103241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaduskar, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkahtani, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almehizia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangshetti, J. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluations and computational studies of N-(3-(−2-(7-Chloroquinolin-2-yl)vinyl) benzylidene)anilines as fungal biofilm inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmcl.2018.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=30595445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=623-630&author=F.+A.+K.+Khanauthor=R.+N.+Kaduskarauthor=R.+Patilauthor=R.+H.+Patilauthor=S.+A.+Ansariauthor=H.+M.+Alkahtaniauthor=A.+A.+Almehiziaauthor=D.+B.+Shindeauthor=J.+N.+Sangshetti&title=Synthesis%2C+biological+evaluations+and+computational+studies+of+N-%283-%28%E2%88%922-%287-Chloroquinolin-2-yl%29vinyl%29+benzylidene%29anilines+as+fungal+biofilm+inhibitors&doi=10.1016%2Fj.bmcl.2018.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluations and computational studies of N-(3-(-2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)anilines as fungal biofilm inhibitors</span></div><div class="casAuthors">Khan, Firoz A. Kalam; Kaduskar, Rashmi N.; Patil, Rajesh; Patil, Rajendra H.; Ansari, Siddique Akber; Alkahtani, Hamad M.; Almehizia, Abdulrahman A.; Shinde, Devanand B.; Sangshetti, Jaiprakash N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New chloroquinoline derivs. bearing vinyl benzylidene aniline substituents at 2nd position were synthesized and screed for biofilm inhibitory, antifungal and antibacterial activity.  The result of biofilm inhibition of C. albicans suggested that compds. N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)-4-(trifluoromethyl)aniline (IC50 value = 51.2 μM) and N-(3-(2-(7-chloroquinolin-2-yl)vinyl)benzylidene)-4-chloroaniline (IC50 value = 66.2 μM) possess promising antibiofilm inhibition when compared with the std. antifungal drug fluconazole (IC50 = 40.0 μM).  Two compds. N-(3-(2-(7-chloroquinolin-2-yl)vinyl)benzylidene)-4-chloroaniline (MIC = 94.2 μg/mL) and N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)aniline (MIC = 98.8 μg/mL) also exhibited good antifungal activity comparable to std. drug fluconazole (MIC = 50.0 μg/mL).  The antibacterial screening against four strains of bacteria viz.  E. coli, P. aeruginosa, B. subtilis, and S. aureus suggested their potential antibacterial activity and esp. all the compds. except N-(3-(2-(7-Chloroquinolin-2-yl)vinyl)benzylidene)-2-methylaniline were found more active than the std. drug ciprofloxacin against B. subtilis.  To further gain insights into the possible mechanism of these compds. in biofilm inhibition through the agglutinin like protein (Als), mol. docking and mol. dynamics simulation studies were carried out.  Mol. modeling studies suggested the clear role in inhibition of this protein and the resulting biofilm inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprdXjMPY62I7Vg90H21EOLACvtfcHk0lhCV9fNLuV3eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bN&md5=9af94cb65d08198e63f3497c43cabfa9</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DF.%2BA.%2BK.%26aulast%3DKaduskar%26aufirst%3DR.%2BN.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPatil%26aufirst%3DR.%2BH.%26aulast%3DAnsari%26aufirst%3DS.%2BA.%26aulast%3DAlkahtani%26aufirst%3DH.%2BM.%26aulast%3DAlmehizia%26aufirst%3DA.%2BA.%26aulast%3DShinde%26aufirst%3DD.%2BB.%26aulast%3DSangshetti%26aufirst%3DJ.%2BN.%26atitle%3DSynthesis%252C%2520biological%2520evaluations%2520and%2520computational%2520studies%2520of%2520N-%25283-%2528%25E2%2588%25922-%25287-Chloroquinolin-2-yl%2529vinyl%2529%2520benzylidene%2529anilines%2520as%2520fungal%2520biofilm%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D623%26epage%3D630%26doi%3D10.1016%2Fj.bmcl.2018.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of some novel precursors of oxazolidinone analogues of chloroquinoline for their antimicrobial and cytotoxic potential</span>. <i>J. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1007/s12039-013-0492-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs12039-013-0492-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2013&pages=1093-1101&author=K.+Deviauthor=K.+Asmatauthor=M.+Agrawalauthor=S.+Sharmaauthor=J.+Dwivedi&title=Synthesis+and+evaluation+of+some+novel+precursors+of+oxazolidinone+analogues+of+chloroquinoline+for+their+antimicrobial+and+cytotoxic+potential&doi=10.1007%2Fs12039-013-0492-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of some novel precursors of oxazolidinone analogues of chloroquinoline for their antimicrobial and cytotoxic potential</span></div><div class="casAuthors">Devi, Kavita; Asmat, Kavita; Agrawal, Meenakshi; Sharma, Swapnil; Dwivedi, Jaya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Sciences (Bangalore, India)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1093-1101</span>CODEN:
                <span class="NLM_cas:coden">JCSBB5</span>;
        ISSN:<span class="NLM_cas:issn">0974-3626</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Some 3-(3-(7-chloroquinolin-4-ylamino)propyl-2-imino-5-(4-chloro/nitro/methoxybenzylidene)) oxazolidin-4-one and 4-(3-(7-chloroquinolin-4-ylamino) propyl)-2(4-chloro/nitro/methoxybenzylidene)-1,6-dioxo-4,9-diazaspiro[4,4]nonane-3,8-dione derivs. were synthesized using appropriate synthetic route.  The newly prepd. compds. demonstrated inhibitory effects on the growth of a MCF7 (hormone-dependent breast carcinoma cell line), HT29 (colon carcinoma cell line on leukemia).  The MCF7 cell line is very susceptible towards compd. 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-chlorobenzylidene)-1,6-dioxo-4,9-diazaspiro[4,4]nonane-3,8-dione with IC50 values of 16 μg/mL.  Similarly, the HT29 cell line is moderately susceptible towards compds. 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-chlorobenzylidene)-1,6-dion-4,9-diazaspiro[4,4]nonane-3,8-dione and 4-(3-(7-chloroquinolin-4-ylamino)propyl)-2(4-methoxybenzylidene)-1,6-dion-4,9-diazaspiro[4,4]nonane-3,8-dione with IC 50 values of 32 and 49 μg/mL, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN7yJVW7YshbVg90H21EOLACvtfcHk0lhCV9fNLuV3eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurjO&md5=d8477fd76bd455ec142fe52af8b1f34f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs12039-013-0492-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12039-013-0492-9%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%26aufirst%3DK.%26aulast%3DAsmat%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDwivedi%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520some%2520novel%2520precursors%2520of%2520oxazolidinone%2520analogues%2520of%2520chloroquinoline%2520for%2520their%2520antimicrobial%2520and%2520cytotoxic%2520potential%26jtitle%3DJ.%2520Chem.%2520Sci.%26date%3D2013%26volume%3D125%26spage%3D1093%26epage%3D1101%26doi%3D10.1007%2Fs12039-013-0492-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, H. R.</span></span> <span> </span><span class="NLM_article-title">Review on Synthetic Chemistry and Antibacterial Importance of Thiazole Derivatives</span>. <i>Curr. Drug Discovery Technol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.2174/1570163814666170911144036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F1570163814666170911144036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=28901248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=214-228&author=A.+Kashyapauthor=N.+Adhikariauthor=A.+Dasauthor=A.+Shakyaauthor=S.+K.+Ghoshauthor=U.+P.+Singhauthor=H.+R.+Bhat&title=Review+on+Synthetic+Chemistry+and+Antibacterial+Importance+of+Thiazole+Derivatives&doi=10.2174%2F1570163814666170911144036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Review on Synthetic Chemistry and Antibacterial Importance of Thiazole Derivatives</span></div><div class="casAuthors">Kashyap, Ankita; Adhikari, Nayana; Das, Arpita; Shakya, Anshul; Ghosh, Surajit Kumar; Singh, Udaya Pratap; Bhat, Hans Raj</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-228</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Thiazole is one of the leading heterocyclic five-member ring compds. that contain nitrogen and sulfur atom.  Many natural and/or synthetic compds. contain thiazole as an essential moiety and possess diverse therapeutic activities.  The thiazole ring was modified at different positions to generate new mols. with potent antibacterial activities.  Thus, the present review enumerates the antibacterial importance of thiazole and its derivs.  Method: The mining of literature has been performed using different database which includes only peer-reviewed journals.  The quality of retrieved papers was appraised using std. tools.  Moreover, the significant papers were described in detail to focus on thiazole derivs. showing considerable antibacterial activity.  Result: The present review describes the chem., SAR (Structure Activity Relationship) studies and antibacterial importance of thiazole with different synthetic procedures.  Conclusion: This particular study certainly benefits the researchers interested in exploiting the antibacterial activity of thiazoles in search of novel agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaef4q5BNU7Vg90H21EOLACvtfcHk0lhCV9fNLuV3eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsr%252FM&md5=eac1445ad4366e6d03642ddbdeaa6cdc</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F1570163814666170911144036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163814666170911144036%26sid%3Dliteratum%253Aachs%26aulast%3DKashyap%26aufirst%3DA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DShakya%26aufirst%3DA.%26aulast%3DGhosh%26aufirst%3DS.%2BK.%26aulast%3DSingh%26aufirst%3DU.%2BP.%26aulast%3DBhat%26aufirst%3DH.%2BR.%26atitle%3DReview%2520on%2520Synthetic%2520Chemistry%2520and%2520Antibacterial%2520Importance%2520of%2520Thiazole%2520Derivatives%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2018%26volume%3D15%26spage%3D214%26epage%3D228%26doi%3D10.2174%2F1570163814666170911144036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmkshatriya, P. S.</span></span> <span> </span><span class="NLM_article-title">Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160506130731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F1568026616666160506130731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=27150376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWhtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2841-2862&author=M.+T.+Chhabriaauthor=S.+Patelauthor=P.+Modiauthor=P.+S.+Brahmkshatriya&title=Thiazole%3A+A+Review+on+Chemistry%2C+Synthesis+and+Therapeutic+Importance+of+its+Derivatives&doi=10.2174%2F1568026616666160506130731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives</span></div><div class="casAuthors">Chhabria, Mahesh T.; Patel, Shivani; Modi, Palmi; Brahmkshatriya, Pathik S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2841-2862</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Thiazole, a unique heterocycle contg. sulfur and nitrogen atoms, occupies an important place in medicinal chem.  It is an essential core scaffold present in many natural (Vitamin B1- Thiamine) and synthetic medicinally important compds.  The versatility of thiazole nucleus demonstrated by the fact that it is an essential part of penicillin nucleus and some of its derivs. which have shown antimicrobial (sulfazole), antiretroviral (ritonavir), antifungal (abafungin), antihistaminic and antithyroid activities.  The synthetic importance of thiazole derivs., its reduced forms and condensed derivs. have been increased much by their recent applications as anticancer (tiazofurin), anthelmintic, vulcanising accelerators (mercaptobenzothiazole) and photog. sensitizers.  Thiazole chem. has developed steadily after the pioneering work of Hofmann and Hantsch.  Bogert and co-workers made significant contribution to expand this field.  Mills established the importance of thiazole ring in cyanine dyes which is used as photog. sensitizer.  Benzothiazole, a fused deriv. of thiazole have also proved its com. value.  Present review describes chem. and biol. importance of thiazole and its condensed derivs. with an emphasis on recent developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvuNJYino70LVg90H21EOLACvtfcHk0lj3lWLssp03Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWhtLnJ&md5=68a9bfebbbee523315d49c735fb1d47f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160506130731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160506130731%26sid%3Dliteratum%253Aachs%26aulast%3DChhabria%26aufirst%3DM.%2BT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DP.%26aulast%3DBrahmkshatriya%26aufirst%3DP.%2BS.%26atitle%3DThiazole%253A%2520A%2520Review%2520on%2520Chemistry%252C%2520Synthesis%2520and%2520Therapeutic%2520Importance%2520of%2520its%2520Derivatives%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2841%26epage%3D2862%26doi%3D10.2174%2F1568026616666160506130731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteleone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayhoub, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammac, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seleem, M. N.</span></span> <span> </span><span class="NLM_article-title">Antibacterial Characterization of Novel Synthetic Thiazole Compounds against Methicillin-Resistant Staphylococcus pseudintermedius</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0130385</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0130385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1371%2Fjournal.pone.0130385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26086336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlGmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=H.+Mohammadauthor=P.+V.+Reddyauthor=D.+Monteleoneauthor=A.+S.+Mayhoubauthor=M.+Cushmanauthor=G.+K.+Hammacauthor=M.+N.+Seleem&title=Antibacterial+Characterization+of+Novel+Synthetic+Thiazole+Compounds+against+Methicillin-Resistant+Staphylococcus+pseudintermedius&doi=10.1371%2Fjournal.pone.0130385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial characterization of novel synthetic thiazole compounds against methicillin-resistant Staphylococcus pseudintermedius</span></div><div class="casAuthors">Mohammad, Haroon; Reddy, P. V. Narasimha; Monteleone, Dennis; Mayhoub, Abdelrahman S.; Cushman, Mark; Hammac, G. Kenitra; Seleem, Mohamed N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0130385/1-e0130385/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Staphylococcus pseudintermedius is a commensal organism of companion animals that is a significant source of opportunistic infections in dogs.  With the emergence of clin. isolates of S. pseudintermedius (chiefly methicillin-resistant S. pseudintermedius (MRSP)) exhibiting increased resistance to nearly all antibiotic classes, new antimicrobials and therapeutic strategies are urgently needed.  Thiazole compds. have been previously shown to possess potent antibacterial activity against multidrug-resistant strains of Staphylococcus aureus of human and animal concern.  Given the genetic similarity between S. aureus and S. pseudintermedius, this study explores the potential use of thiazole compds. as novel antibacterial agents against methicillin-sensitive S. pseudintermedius (MSSP) and MRSP.  A broth microdilution assay confirmed these compds. exhibit potent bactericidal activity (at sub-microgram/mL concns.) against both MSSA and MRSP clin. isolates while the MTS assay confirmed three compds. (at 10 μg/mL) were not toxic to mammalian cells.  A time-kill assay revealed two derivs. rapidly kill MRSP within two hours.  However, this rapid bactericidal activity was not due to disruption of the bacterial cell membrane indicating an alternative mechanism of action for these compds. against MRSP.  A multistep resistance selection anal. revealed compds. 4 and 5 exhibited a modest (twofold) shift in activity over ten passages.  Furthermore, all six compds. (at a sub-inhibitory concn.) demonstrated the ability to re-sensitize MRSP to oxacillin, indicating these compds. have potential use for extending the therapeutic utility of β-lactam antibiotics against MRSP.  Metabolic stability anal. with dog liver microsomes revealed compd. 3 exhibited an improved physicochem. profile compared to the lead compd.  In addn. to this, all six thiazole compds. possessed a long post-antibiotic effect (at least 8 h) against MRSP.  Collectively the present study demonstrates these synthetic thiazole compds. possess potent antibacterial activity against both MSSP and MRSP and warrant further investigation into their use as novel antimicrobial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMDR9JEWJ-LVg90H21EOLACvtfcHk0lj3lWLssp03Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlGmtbw%253D&md5=e5647a577a78937901f4f1ab522b4341</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0130385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0130385%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%26aulast%3DReddy%26aufirst%3DP.%2BV.%26aulast%3DMonteleone%26aufirst%3DD.%26aulast%3DMayhoub%26aufirst%3DA.%2BS.%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DHammac%26aufirst%3DG.%2BK.%26aulast%3DSeleem%26aufirst%3DM.%2BN.%26atitle%3DAntibacterial%2520Characterization%2520of%2520Novel%2520Synthetic%2520Thiazole%2520Compounds%2520against%2520Methicillin-Resistant%2520Staphylococcus%2520pseudintermedius%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0130385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, M. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimicrobial studies of thiazolotriazinones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5039</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2010.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20813429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KrtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=5039-43&author=M.+S.+Karthikeyan&title=Synthesis+and+antimicrobial+studies+of+thiazolotriazinones&doi=10.1016%2Fj.ejmech.2010.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimicrobial studies of thiazolotriazinones</span></div><div class="casAuthors">Karthikeyan, Mari Sithambaram</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5039-5043</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">6-Benzyl-3-phenylthiazolo-1,2,4-triazinones I (R = 4-Cl or 2,4-Cl2; R1 = 4-Cl, 4-Br, 4-MeO, 4-NO2, or 2,4-Cl2-5-F) were obtained by the initial reaction of 6-benzyl-3-mercapto-1,2,4-triazin-5-ones with phenacyl bromides followed by PPA cyclization.  The structures of the newly synthesized compds. were confirmed by IR, 1H NMR, mass and anal. data.  Compds. I (R = 4-Cl, R1 = 4-Cl, 2,4-Cl2-5-F; R = 2,4-Cl2, R1 = 4-Cl, 4-MeO) exhibited good antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMHYoBkEcJbVg90H21EOLACvtfcHk0lj3lWLssp03Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KrtrjP&md5=9ba386f76da0312dc337b2ae6db4768b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DKarthikeyan%26aufirst%3DM.%2BS.%26atitle%3DSynthesis%2520and%2520antimicrobial%2520studies%2520of%2520thiazolotriazinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D5039%26epage%3D43%26doi%3D10.1016%2Fj.ejmech.2010.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammar, Y. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some new 2-(3-pyridyl)-4,5-disubstituted thiazoles as potent antimicrobial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2012.12.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23357308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=270-279&author=S.+Bondockauthor=T.+Naserauthor=Y.+A.+Ammar&title=Synthesis+of+some+new+2-%283-pyridyl%29-4%2C5-disubstituted+thiazoles+as+potent+antimicrobial+agents&doi=10.1016%2Fj.ejmech.2012.12.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some new 2-(3-pyridyl)-4,5-disubstituted thiazoles as potent antimicrobial agents</span></div><div class="casAuthors">Bondock, Samir; Naser, Tamer; Ammar, Yousry A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270-279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a part of ongoing studies in developing new potent antimicrobial agents, a series of novel 2-(3-pyridyl)-4,5-disubstituted thiazoles was efficiently synthesized and characterized by spectral and elemental analyses.  The newly synthesized compds. were evaluated for their in vitro antimicrobial activity against ten bacterial and five fungal human pathogenic strains using the disk diffusion assay.  Among the synthesized compds., 5-acetyl-4-methyl-2-(3-pyridyl)thiazole exhibited twofold antibacterial activity of ampicillin in inhibiting the growth of Staphylococcus epidermidis (MIC 0.24 μg/mL) and also showed equipotent antifungal activity with amphotricin B against Geotricum candidum (MIC 0.48 μg/mL).  From structure-activity relationship (SAR) point of view, increasing the size of the substitutions either at position 4 or 5 on the thiazole nucleus decreased the antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYF-Kh_rbFPLVg90H21EOLACvtfcHk0lj3lWLssp03Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgsr0%253D&md5=0d2e833c871ffd5d1018273c39b8f860</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.050%26sid%3Dliteratum%253Aachs%26aulast%3DBondock%26aufirst%3DS.%26aulast%3DNaser%26aufirst%3DT.%26aulast%3DAmmar%26aufirst%3DY.%2BA.%26atitle%3DSynthesis%2520of%2520some%2520new%25202-%25283-pyridyl%2529-4%252C5-disubstituted%2520thiazoles%2520as%2520potent%2520antimicrobial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D270%26epage%3D279%26doi%3D10.1016%2Fj.ejmech.2012.12.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karuvalam, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haridas, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru
Row, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishikesan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, N. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2012.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22280817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=172-182&author=R.+P.+Karuvalamauthor=K.+R.+Haridasauthor=S.+K.+Nayakauthor=T.+N.+Guru%0ARowauthor=P.+Rajeeshauthor=R.+Rishikesanauthor=N.+S.+Kumari&title=Design%2C+synthesis+of+some+new+%282-aminothiazol-4-yl%29methylester+derivatives+as+possible+antimicrobial+and+antitubercular+agents&doi=10.1016%2Fj.ejmech.2012.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents</span></div><div class="casAuthors">Karuvalam, Ranjith P.; Haridas, Karickal R.; Nayak, Susanta K.; Guru Row, Tayur N.; Rajeesh, P.; Rishikesan, R.; Kumari, N. Suchetha</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-182</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 20 (2-aminothiazol-4-yl)methylester derivs. were synthesized in good yields and characterized by 1H NMR, 13C NMR, mass spectral and elemental analyses.  The crystal structure of I was detd. and data are referenced.  The compds. were evaluated for their preliminary in vitro antibacterial, antifungal activity and were screened for antitubercular activity against Mycobacterium tuberculosis H37Rv strain.  The synthesized compds. displayed interesting antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6HY93B1NqqrVg90H21EOLACvtfcHk0lgKIfAh2G0SHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOrsro%253D&md5=7594d0db699b54f406b915a8e224fdf4</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DKaruvalam%26aufirst%3DR.%2BP.%26aulast%3DHaridas%26aufirst%3DK.%2BR.%26aulast%3DNayak%26aufirst%3DS.%2BK.%26aulast%3DGuru%2BRow%26aufirst%3DT.%2BN.%26aulast%3DRajeesh%26aufirst%3DP.%26aulast%3DRishikesan%26aufirst%3DR.%26aulast%3DKumari%26aufirst%3DN.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520of%2520some%2520new%2520%25282-aminothiazol-4-yl%2529methylester%2520derivatives%2520as%2520possible%2520antimicrobial%2520and%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D172%26epage%3D182%26doi%3D10.1016%2Fj.ejmech.2012.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beniwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglan, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some novel oxazolidinone-thiazole hybrids as potential antimicrobial, antioxidant and UV mediated DNA damage protecting agents</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2249</span>, <span class="refDoi"> DOI: 10.1007/s00044-016-1663-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs00044-016-1663-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gis7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=2237-2249&author=K.+Kaurauthor=V.+Kumarauthor=V.+Beniwalauthor=V.+Kumarauthor=N.+Kumarauthor=V.+Sharmaauthor=S.+Jaglan&title=Synthesis+of+some+novel+oxazolidinone-thiazole+hybrids+as+potential+antimicrobial%2C+antioxidant+and+UV+mediated+DNA+damage+protecting+agents&doi=10.1007%2Fs00044-016-1663-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some novel oxazolidinone-thiazole hybrids as potential antimicrobial, antioxidant and UV mediated DNA damage protecting agents</span></div><div class="casAuthors">Kaur, Kamalneet; Kumar, Vinod; Beniwal, Vikas; Kumar, Vikas; Kumar, Neeraj; Sharma, Vishal; Jaglan, Sundeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2237-2249</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In search of a new class of biol. active agents, some novel oxazolidinone-thiazole hybrids 4a-m have been synthesized and characterized on the basis of a combined use of IR, NMR (1H, 13C) spectroscopy, mass spectrometry and elemental anal.  All compds. were evaluated for their antimicrobial, antioxidant and UV mediated DNA damage protective activity.  Among the series, compd. 4i emerged as the most potent antimicrobial agent, particularly, against Bacillus subtilis, Candida albicans and Saccharomyces cerevisiae in comparison to the std. drugs, Ciprofloxacin (antibacterial) and Amphotericin-B (antifungal).  Other promising antimicrobial agents including the compds. 4f-h.  In addn., all compds. 4a-m were found to show very high DNA damage protecting ability under UV irradn.  The antioxidant study revealed that the compds. 4d and 4j were found as the most potent antioxidants as compared to ascorbic acid, a ref. compd. considered in the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQECOF4HJWbVg90H21EOLACvtfcHk0lgKIfAh2G0SHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gis7zK&md5=a7f031f5e627f67d14191157369c28cb</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs00044-016-1663-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-016-1663-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBeniwal%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DJaglan%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520some%2520novel%2520oxazolidinone-thiazole%2520hybrids%2520as%2520potential%2520antimicrobial%252C%2520antioxidant%2520and%2520UV%2520mediated%2520DNA%2520damage%2520protecting%2520agents%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2016%26volume%3D25%26spage%3D2237%26epage%3D2249%26doi%3D10.1007%2Fs00044-016-1663-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelak, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerckens, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahan, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span> <span> </span><span class="NLM_article-title">Antibacterial agents that inhibit lipid A biosynthesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1126/science.274.5289.980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1126%2Fscience.274.5289.980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=8875939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADyaK28XmslKmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=980-982&author=H.+R.+Onishiauthor=B.+A.+Pelakauthor=L.+S.+Gerckensauthor=L.+L.+Silverauthor=F.+M.+Kahanauthor=M.+H.+Chenauthor=A.+A.+Patchettauthor=S.+M.+Gallowayauthor=S.+A.+Hylandauthor=M.+S.+Andersonauthor=C.+R.+Raetz&title=Antibacterial+agents+that+inhibit+lipid+A+biosynthesis&doi=10.1126%2Fscience.274.5289.980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial agents that inhibit lipid A biosynthesis</span></div><div class="casAuthors">Onishi, H. Russell; Pelak, Barbara A.; Gerckens, Lynn S.; Silver, Lynn L.; Kahan, Frederick M.; Chen, Meng-Hsin; Patchett, Arthur A.; Galloway, Susan M.; Hyland, Sheryl A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5289</span>),
    <span class="NLM_cas:pages">980-982</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lipid A constitutes the outer monolayer of the outer membrane of Gram-neg. bacteria and is essential for bacterial growth.  Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis.  The inhibitors are chiral hydroxamic acids bearing certain hydrophobic arom. moieties.  They may bind to a metal in the active site of the deacetylase.  The most potent analog (with an inhibition const. of about 50 nM) displayed a minimal inhibitory concn. of about 1 μg per mL against Escherichia coli, causes three logs of bacterial killing in 4 h, and cured mice infected with a lethal i.p. dose of E. coli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKgUe_5zI9rVg90H21EOLACvtfcHk0lgKIfAh2G0SHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmslKmsLw%253D&md5=d5098756849325110d7f1f4850322cba</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1126%2Fscience.274.5289.980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.274.5289.980%26sid%3Dliteratum%253Aachs%26aulast%3DOnishi%26aufirst%3DH.%2BR.%26aulast%3DPelak%26aufirst%3DB.%2BA.%26aulast%3DGerckens%26aufirst%3DL.%2BS.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DGalloway%26aufirst%3DS.%2BM.%26aulast%3DHyland%26aufirst%3DS.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%2BS.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26atitle%3DAntibacterial%2520agents%2520that%2520inhibit%2520lipid%2520A%2520biosynthesis%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D980%26epage%3D982%26doi%3D10.1126%2Fscience.274.5289.980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2038</span>– <span class="NLM_lpage">2050</span>, <span class="refDoi"> DOI: 10.2174/092986712800167374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.2174%2F092986712800167374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=22414079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2htbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=2038-2050&author=J.+Zhangauthor=L.+Zhangauthor=X.+Liauthor=W.+Xu&title=UDP-3-O-%28R-3-hydroxymyristoyl%29-N-acetylglucosamine+deacetylase+%28LpxC%29+inhibitors%3A+a+new+class+of+antibacterial+agents&doi=10.2174%2F092986712800167374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents</span></div><div class="casAuthors">Zhang, J.; Zhang, L.; Li, X.; Xu, W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2038-2050</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The rapid increase of health-threatening infections by Gram-neg. pathogens along with the emergence of multidrug-resistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets.  One of the promising targets in Gram-neg. bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).  LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A.  Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-neg. bacteria.  In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYTK2EcNm38rVg90H21EOLACvtfcHk0lh6kx3EY-r7Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2htbY%253D&md5=dc02cdeadab2b97151b6453e08301f92</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.2174%2F092986712800167374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712800167374%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DUDP-3-O-%2528R-3-hydroxymyristoyl%2529-N-acetylglucosamine%2520deacetylase%2520%2528LpxC%2529%2520inhibitors%253A%2520a%2520new%2520class%2520of%2520antibacterial%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D2038%26epage%3D2050%26doi%3D10.2174%2F092986712800167374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langsdorf, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malikzay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarr, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daubaras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravec, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozbal, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miesel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, C. A.</span></span> <span> </span><span class="NLM_article-title">Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1177/1087057109355319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1177%2F1087057109355319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20019290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFWmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=52-61&author=E.+F.+Langsdorfauthor=A.+Malikzayauthor=W.+A.+Lamarrauthor=D.+Daubarasauthor=C.+Kravecauthor=R.+Zhangauthor=R.+Hartauthor=F.+Monsmaauthor=T.+Blackauthor=C.+C.+Ozbalauthor=L.+Mieselauthor=C.+A.+Lunn&title=Screening+for+antibacterial+inhibitors+of+the+UDP-3-O-%28R-3-hydroxymyristoyl%29-N-acetylglucosamine+deacetylase+%28LpxC%29+using+a+high-throughput+mass+spectrometry+assay&doi=10.1177%2F1087057109355319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay</span></div><div class="casAuthors">Langsdorf, Erik F.; Malikzay, Asra; Lamarr, William A.; Daubaras, Dayna; Kravec, Cynthia; Zhang, Rumin; Hart, Richard; Monsma, Frederick; Black, Todd; Ozbal, Can C.; Miesel, Lynn; Lunn, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-61</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A high-throughput mass spectrometry assay to measure the catalytic activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, LpxC, is described.  This reaction is essential in the biosynthesis of lipopolysaccharide (LPS) of gram-neg. bacteria and is an attractive target for the development of new antibacterial agents.  The assay uses the RapidFire mass spectrometry platform to measure the native LpxC substrate and the reaction product and thereby generates a ratiometric readout with minimal artifacts due to detection interference.  The assay was robust in a high-throughput screen of a library of more than 700,000 compds. arrayed as orthogonal mixts., with a median Z' factor of 0.74.  Selected novel inhibitors from the screening campaign were confirmed as binding to LpxC by biophys. measurements using a thermal stability shift assay.  Some inhibitors showed whole-cell antimicrobial activity against a sensitive strain of Escherichia coli with reduced LpxC activity (strain D22; min. inhibitory concns. ranging from 0.625-20 μg/mL).  The results show that mass spectrometry-based screening is a valuable high-throughput screening tool for detecting inhibitors of enzymic targets involving difficult to detect reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF4SfcBGLJ7Vg90H21EOLACvtfcHk0lh6kx3EY-r7Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFWmu70%253D&md5=c37066b26757e2909e23c25037ef64b4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1177%2F1087057109355319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109355319%26sid%3Dliteratum%253Aachs%26aulast%3DLangsdorf%26aufirst%3DE.%2BF.%26aulast%3DMalikzay%26aufirst%3DA.%26aulast%3DLamarr%26aufirst%3DW.%2BA.%26aulast%3DDaubaras%26aufirst%3DD.%26aulast%3DKravec%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DR.%26aulast%3DMonsma%26aufirst%3DF.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DOzbal%26aufirst%3DC.%2BC.%26aulast%3DMiesel%26aufirst%3DL.%26aulast%3DLunn%26aufirst%3DC.%2BA.%26atitle%3DScreening%2520for%2520antibacterial%2520inhibitors%2520of%2520the%2520UDP-3-O-%2528R-3-hydroxymyristoyl%2529-N-acetylglucosamine%2520deacetylase%2520%2528LpxC%2529%2520using%2520a%2520high-throughput%2520mass%2520spectrometry%2520assay%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26spage%3D52%26epage%3D61%26doi%3D10.1177%2F1087057109355319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span> <span> </span><span class="NLM_article-title">Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">18433</span>– <span class="NLM_lpage">18438</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709412104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1073%2Fpnas.0709412104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=18025458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2ku7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=18433-18438&author=A.+W.+Barbauthor=L.+Jiangauthor=C.+R.+Raetzauthor=P.+Zhou&title=Structure+of+the+deacetylase+LpxC+bound+to+the+antibiotic+CHIR-090%3A+Time-dependent+inhibition+and+specificity+in+ligand+binding&doi=10.1073%2Fpnas.0709412104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding</span></div><div class="casAuthors">Barb, Adam W.; Jiang, Ling; Raetz, Christian R. H.; Zhou, Pei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18433-18438, S18433/1-S18433/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-neg. bacteria and a promising antibiotic target.  CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-neg. pathogens as effectively as ciprofloxacin or tobramycin.  In this study, we report the soln. structure of the LpxC-CHIR-090 complex.  CHIR-090 exploits conserved features of LpxC that are crit. for catalysis, including the hydrophobic passage and essential active-site residues.  CHIR-090 is adjacent to, but does not occupy, the UDP-binding pocket of LpxC, suggesting that a fragment-based approach may facilitate further optimization of LpxC inhibitors.  Addnl., we identified key residues in the Insert II hydrophobic passage that modulate time-dependent inhibition and CHIR-090 resistance.  CHIR-090 shares a similar, although previously unrecognized, chem. scaffold with other small-mol. antibiotics such as L-161,240 targeting LpxC, and provides a template for understanding the binding mode of these inhibitors.  Consistent with this model, we provide evidence that L-161,240 also occupies the hydrophobic passage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWHV0AFZnM7Vg90H21EOLACvtfcHk0lh6kx3EY-r7Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2ku7rP&md5=e54a3a1c978536947380f6f1bbdbc4bf</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709412104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709412104%26sid%3Dliteratum%253Aachs%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DZhou%26aufirst%3DP.%26atitle%3DStructure%2520of%2520the%2520deacetylase%2520LpxC%2520bound%2520to%2520the%2520antibiotic%2520CHIR-090%253A%2520Time-dependent%2520inhibition%2520and%2520specificity%2520in%2520ligand%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D18433%26epage%3D18438%26doi%3D10.1073%2Fpnas.0709412104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toone, E. J.</span></span> <span> </span><span class="NLM_article-title">Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.bmc.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21194954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=852-860&author=X.+Liangauthor=C.+J.+Leeauthor=X.+Chenauthor=H.+S.+Chungauthor=D.+Zengauthor=C.+R.+Raetzauthor=Y.+Liauthor=P.+Zhouauthor=E.+J.+Toone&title=Syntheses%2C+structures+and+antibiotic+activities+of+LpxC+inhibitors+based+on+the+diacetylene+scaffold&doi=10.1016%2Fj.bmc.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold</span></div><div class="casAuthors">Liang, Xiaofei; Lee, Chul-Jin; Chen, Xin; Chung, Hak Suk; Zeng, Daina; Raetz, Christian R. H.; Li, Yaoxian; Zhou, Pei; Toone, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compds. inhibiting LpxC in the lipid A biosynthetic pathway are promising leads for novel antibiotics against multidrug-resistant Gram-neg. pathogens.  The authors report the syntheses and structural and biochem. characterizations of LpxC inhibitors based on a diphenyl-diacetylene (1,4-diphenyl-1,3-butadiyne) threonyl-hydroxamate scaffold.  These studies provide a mol. interpretation for the differential antibiotic activities of compds. with a substituted distal Ph ring as well as the abs. stereochem. requirement at the C2, but not C3, position of the threonyl group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWL2QPzfjArLVg90H21EOLACvtfcHk0lhNnK033whS1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVCnuw%253D%253D&md5=10326af21364b0785a67692687b21385</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChung%26aufirst%3DH.%2BS.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26atitle%3DSyntheses%252C%2520structures%2520and%2520antibiotic%2520activities%2520of%2520LpxC%2520inhibitors%2520based%2520on%2520the%2520diacetylene%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D852%26epage%3D860%26doi%3D10.1016%2Fj.bmc.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toone, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span> <span> </span><span class="NLM_article-title">Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.chembiol.2010.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21167751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=38-47&author=C.+J.+Leeauthor=X.+Liangauthor=X.+Chenauthor=D.+Zengauthor=S.+H.+Jooauthor=H.+S.+Chungauthor=A.+W.+Barbauthor=S.+M.+Swansonauthor=R.+A.+Nicholasauthor=Y.+Liauthor=E.+J.+Tooneauthor=C.+R.+Raetzauthor=P.+Zhou&title=Species-specific+and+inhibitor-dependent+conformations+of+LpxC%3A+implications+for+antibiotic+design&doi=10.1016%2Fj.chembiol.2010.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design</span></div><div class="casAuthors">Lee, Chul-Jin; Liang, Xiao-Fei; Chen, Xin; Zeng, Dai-Na; Joo, Sang-Hoon; Chung, Hak-Suk; Barb, Adam W.; Swanson, Shauna M.; Nicholas, Robert A.; Li, Yao-Xian; Toone, Eric J.; Raetz, Christian R. H.; Zhou, Pei</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">LpxC is an essential enzyme in the lipid A biosynthetic pathway in gram-neg. bacteria.  Several promising antimicrobial lead compds. targeting LpxC have been reported, though they typically display a large variation in potency against different gram-neg. pathogens.  We report that inhibitors with a diacetylene scaffold effectively overcome the resistance caused by sequence variation in the LpxC substrate-binding passage.  Compd. binding is captured in complex with representative LpxC orthologs, and structural anal. reveals large conformational differences that mostly reflect inherent mol. features of distinct LpxC orthologs, whereas ligand-induced structural adaptations occur at a smaller scale.  These observations highlight the need for a mol. understanding of inherent structural features and conformational plasticity of LpxC enzymes for optimizing LpxC inhibitors as broad-spectrum antibiotics against gram-neg. infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbcwncn731jrVg90H21EOLACvtfcHk0lhNnK033whS1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars70%253D&md5=7aa1222210dfec8ad8675194b0b13731</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DJoo%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DH.%2BS.%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DSwanson%26aufirst%3DS.%2BM.%26aulast%3DNicholas%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DZhou%26aufirst%3DP.%26atitle%3DSpecies-specific%2520and%2520inhibitor-dependent%2520conformations%2520of%2520LpxC%253A%2520implications%2520for%2520antibiotic%2520design%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.chembiol.2010.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=623-628&author=H.+Kurasakiauthor=K.+Tsudaauthor=M.+Shinoyamaauthor=N.+Takayaauthor=Y.+Yamaguchiauthor=R.+Kishiiauthor=K.+Iwaseauthor=N.+Andoauthor=M.+Nomuraauthor=Y.+Kohno&title=LpxC+Inhibitors%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Oxazolidinones+as+Gram-negative+Antibacterial+Agents&doi=10.1021%2Facsmedchemlett.6b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents</span></div><div class="casAuthors">Kurasaki, Haruaki; Tsuda, Kosuke; Shinoyama, Mariko; Takaya, Noriko; Yamaguchi, Yuko; Kishii, Ryuta; Iwase, Kazuhiko; Ando, Naoki; Nomura, Masahiro; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-628</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report a scaffold-hopping approach to identify a new scaffold with a zinc binding headgroup.  Structural information was used to give novel oxazolidinone-based LpxC inhibitors.  In particular, the most potent compd., 23j, showed a low efflux ratio, nanomolar potencies against E. coli LpxC enzyme, and excellent antibacterial activity against E. coli and K. pneumoniae.  Computational docking was used to predict the interaction between 23j and E. coli LpxC, suggesting that the interactions with C207 and C63 contribute to the strong activity.  These results provide new insights into the design of next-generation LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRbZ4j4AMLZbVg90H21EOLACvtfcHk0lhNnK033whS1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlOmsbY%253D&md5=992199b55365298f2960ffc9ef88b4cd</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00057%26sid%3Dliteratum%253Aachs%26aulast%3DKurasaki%26aufirst%3DH.%26aulast%3DTsuda%26aufirst%3DK.%26aulast%3DShinoyama%26aufirst%3DM.%26aulast%3DTakaya%26aufirst%3DN.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DKishii%26aufirst%3DR.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DAndo%26aufirst%3DN.%26aulast%3DNomura%26aufirst%3DM.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DLpxC%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Oxazolidinones%2520as%2520Gram-negative%2520Antibacterial%2520Agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D623%26epage%3D628%26doi%3D10.1021%2Facsmedchemlett.6b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>352</i></span>, <span class="NLM_elocation-id">1900129</span> <span class="refDoi"> DOI: 10.1002/ardp.201900129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1002%2Fardp.201900129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ylurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2019&author=S.+Dingauthor=J.+C.+Jiauthor=M.+J.+Zhangauthor=Y.+S.+Yangauthor=R.+Wangauthor=X.+L.+Zhuauthor=L.+H.+Wangauthor=Y.+Zhongauthor=L.+Gaoauthor=M.+Luauthor=J.+Liuauthor=Y.+Chen&title=Exploration+of+the+structure-activity+relationship+and+druggability+of+novel+oxazolidinone-based+compounds+as+Gram-negative+antibacterial+agents&doi=10.1002%2Fardp.201900129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents</span></div><div class="casAuthors">Ding, Shi; Ji, Jing-Chao; Zhang, Ming-Juan; Yang, Yu-She; Wang, Rui; Zhu, Xing-Long; Wang, Li-Hong; Zhong, Yi; Gao, Le; Lu, Man; Liu, Ju; Chen, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1900129</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">To gain further knowledge of the structure-activity relationship and druggability of novel oxazolidinone-based UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) inhibitors as Gram-neg. antibacterial agents, compds. contg. the hydrophobic tails with different lengths and terminal substitutions were synthesized and their antibacterial activities against std. and clin. isolated Gram-neg. strains were evaluated.  We summarized their structure-activity relationships and found that oxazolidinone-based compds. exhibited a narrower antibacterial spectrum compared with threonine-based compds.  Furthermore, we parallelly compared the metabolic stabilities of the compds. with the classic threonine scaffold and the novel oxazolidinone scaffold in liver microsomes.  The results indicated that the druggability of the oxazolidinone scaffold may be inferior to the classic threonine scaffold in the design of LpxC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpguMarKAFN5rVg90H21EOLACvtfcHk0ljtR4LFA2Lj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ylurjM&md5=618d8ce37262d6a8d2f2464a028b78b3</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fardp.201900129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201900129%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DJ.%2BC.%26aulast%3DZhang%26aufirst%3DM.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BH.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DExploration%2520of%2520the%2520structure-activity%2520relationship%2520and%2520druggability%2520of%2520novel%2520oxazolidinone-based%2520compounds%2520as%2520Gram-negative%2520antibacterial%2520agents%26jtitle%3DArch.%2520Pharm.%26date%3D2019%26volume%3D352%26doi%3D10.1002%2Fardp.201900129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalia, V. C.</span></span> <span> </span><span class="NLM_article-title">Quorum sensing inhibitors: an overview</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2012.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.biotechadv.2012.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=23142623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCntbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=224-245&author=V.+C.+Kalia&title=Quorum+sensing+inhibitors%3A+an+overview&doi=10.1016%2Fj.biotechadv.2012.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Quorum sensing inhibitors: An overview</span></div><div class="casAuthors">Kalia, Vipin Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-245</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Excessive and indiscriminate use of antibiotics to treat bacterial infections has lead to the emergence of multiple drug resistant strains.  Most infectious diseases are caused by bacteria which proliferate within quorum sensing (QS) mediated biofilms.  Efforts to disrupt biofilms have enabled the identification of bioactive mols. produced by prokaryotes and eukaryotes.  These mols. act primarily by quenching the QS system.  The phenomenon is also termed as quorum quenching (QQ).  In addn., synthetic compds. have also been found to be effective in QQ.  This review focuses primarily on natural and synthetic quorum sensing inhibitors (QSIs) with the potential for treating bacterial infections.  It has been opined that the most versatile prokaryotes to produce QSI are likely to be those, which are generally regarded as safe.  Among the eukaryotes, certain legumes and traditional medicinal plants are likely to act as QSIs.  Such findings are likely to lead to efficient treatments with much lower doses of drugs esp. antibiotics than required at present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuSARllnsBRLVg90H21EOLACvtfcHk0ljtR4LFA2Lj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCntbjM&md5=c90645da9d9f8404d0042c66364455cf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2012.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2012.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DKalia%26aufirst%3DV.%2BC.%26atitle%3DQuorum%2520sensing%2520inhibitors%253A%2520an%2520overview%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2013%26volume%3D31%26spage%3D224%26epage%3D245%26doi%3D10.1016%2Fj.biotechadv.2012.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingender, J.</span></span> <span> </span><span class="NLM_article-title">The biofilm matrix</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">633</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1038%2Fnrmicro2415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20676145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFWlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=623-633&author=H.+C.+Flemmingauthor=J.+Wingender&title=The+biofilm+matrix&doi=10.1038%2Fnrmicro2415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The biofilm matrix</span></div><div class="casAuthors">Flemming, Hans-Curt; Wingender, Jost</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-633</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The microorganisms in biofilms live in a self-produced matrix of hydrated extracellular polymeric substances (EPS) that form their immediate environment.  EPS are mainly polysaccharides, proteins, nucleic acids and lipids; they provide the mech. stability of biofilms, mediate their adhesion to surfaces and form a cohesive, three-dimensional polymer network that interconnects and transiently immobilizes biofilm cells.  In addn., the biofilm matrix acts as an external digestive system by keeping extracellular enzymes close to the cells, enabling them to metabolize dissolved, colloidal and solid biopolymers.  Here we describe the functions, properties and constituents of the EPS matrix that make biofilms the most successful forms of life on earth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfq7HQglC-L7Vg90H21EOLACvtfcHk0ljtR4LFA2Lj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFWlur4%253D&md5=28ecf529c890b3eb5a906487b654c0e1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2415%26sid%3Dliteratum%253Aachs%26aulast%3DFlemming%26aufirst%3DH.%2BC.%26aulast%3DWingender%26aufirst%3DJ.%26atitle%3DThe%2520biofilm%2520matrix%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2010%26volume%3D8%26spage%3D623%26epage%3D633%26doi%3D10.1038%2Fnrmicro2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isabella, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglewski, B. H.</span></span> <span> </span><span class="NLM_article-title">Analysis of the hierarchy of quorum-sensing regulation in Pseudomonas aeruginosa</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1007/s00216-006-0964-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1007%2Fs00216-006-0964-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=17139483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2007&pages=469-479&author=V.+E.+Wagnerauthor=L.+L.+Liauthor=V.+M.+Isabellaauthor=B.+H.+Iglewski&title=Analysis+of+the+hierarchy+of+quorum-sensing+regulation+in+Pseudomonas+aeruginosa&doi=10.1007%2Fs00216-006-0964-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the hierarchy of quorum sensing regulation in Pseudomonas aeruginosa</span></div><div class="casAuthors">Wagner, Victoria E.; Li, Luen-Luen; Isabella, Vincent M.; Iglewski, Barbara H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">469-479</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Quorum sensing in Pseudomonas aeruginosa is known to regulate several aspects of pathogenesis, including virulence factor prodn., biofilm development, and antimicrobial resistance.  Recent high-throughput anal. has revealed the existence of several layers of regulation within the QS-circuit.  To address this complexity, mutations in genes encoding known or putative transcriptional regulators that were also identified as being regulated by the las and/or rhl QS systems were screened for their contribution in mediating several phenotypes, for example motility, secreted virulence products, and pathogenic capacity in a lettuce leaf model.  These studies have further elucidated the potential contribution to virulence of these genes within the QS regulon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5G4QzlH2qbVg90H21EOLACvtfcHk0lgyRsZQzOaeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFOnsQ%253D%253D&md5=76367be06596846b05709b391a65b947</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00216-006-0964-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-006-0964-6%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DV.%2BE.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DIsabella%26aufirst%3DV.%2BM.%26aulast%3DIglewski%26aufirst%3DB.%2BH.%26atitle%3DAnalysis%2520of%2520the%2520hierarchy%2520of%2520quorum-sensing%2520regulation%2520in%2520Pseudomonas%2520aeruginosa%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2007%26volume%3D387%26spage%3D469%26epage%3D479%26doi%3D10.1007%2Fs00216-006-0964-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">112252</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2Fj.ejmech.2020.112252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=32244097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmt1GgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2020&pages=112252&author=K.+Jiangauthor=X.+Yanauthor=J.+Yuauthor=Z.+Xiaoauthor=H.+Wuauthor=M.+Zhaoauthor=Y.+Yueauthor=X.+Zhouauthor=J.+Xiaoauthor=F.+Lin&title=Design%2C+synthesis%2C+and+biological+evaluation+of+3-amino-2-oxazolidinone+derivatives+as+potent+quorum-sensing+inhibitors+of+Pseudomonas+aeruginosa+PAO1&doi=10.1016%2Fj.ejmech.2020.112252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1</span></div><div class="casAuthors">Jiang, Kai; Yan, Xinlin; Yu, Jiahao; Xiao, Zijian; Wu, Hao; Zhao, Meihua; Yue, Yuandong; Zhou, Xiaoping; Xiao, Junhai; Lin, Feng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112252</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-amino-2-oxazolidinone compds. (I) [R = 4-FC6H4, 4-ClC6H4, 4-NO2C6H4, etc.; X = O, S; n = 1,2,3,4] was designed and synthesized using ZS-12 as the lead compd.  Compds. I were screened for inhibitory activities against QS using C. violaceum CV026 as a reporter strain.  Some of the compds. I showed good activities (IC50 range 3.69-63.58μM) and compd. I [R = 4-BrC6H4; X = O; n = 1] inhibition was the most significant (IC50= 3.686 ± 0.5790μM) against biofilm formation and virulence factors detn. of P. aeruginosa PAO1.  In vitro, compd. I [R = 4-BrC6H4; X = O; n = 1] significantly inhibited the formation of PAO1 biofilm (range 42.98%-17.67%), the prodn. of virulence factors (pyocyanin, elastase, rhamnolipid and protease) and bacterial motility.  Moreover, the combination of compd. I [R = 4-BrC6H4; X = O; n = 1] with an antibiotic (meropenem trihydrate) could significantly improve the antibiotic susceptibility of biofilm P. aeruginosa PAO1 cells.  In vivo, compd. I [R = 4-BrC6H4; X = O; n = 1] significantly prolonged the lifespan of wildtype Caenorhabditis elegans N2 infected by P. aeruginosa PAO1.  In conclusion, compd. I [R = 4-BrC6H4; X = O; n = 1] was a candidate agent for antibiotic-resistant P. aeruginosa PAO1 and provided a method for finding new antibacterial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzK3am2Lm-rVg90H21EOLACvtfcHk0lgyRsZQzOaeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmt1GgtL4%253D&md5=9207bc5a7e023d9c743200501c2e4791</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112252%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25203-amino-2-oxazolidinone%2520derivatives%2520as%2520potent%2520quorum-sensing%2520inhibitors%2520of%2520Pseudomonas%2520aeruginosa%2520PAO1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D194%26spage%3D112252%26doi%3D10.1016%2Fj.ejmech.2020.112252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyskiel, C.</span></span> <span> </span><span class="NLM_article-title">To be or not to be exclusive: the sutezolid story</span>. <i>Lancet Glob. Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e91</span> <span class="refDoi"> DOI: 10.1016/S2214-109X(15)00283-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1016%2FS2214-109X%2815%2900283-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=26823223" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&author=C.+Wyskiel&title=To+be+or+not+to+be+exclusive%3A+the+sutezolid+story&doi=10.1016%2FS2214-109X%2815%2900283-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2815%2900283-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252815%252900283-1%26sid%3Dliteratum%253Aachs%26aulast%3DWyskiel%26aufirst%3DC.%26atitle%3DTo%2520be%2520or%2520not%2520to%2520be%2520exclusive%253A%2520the%2520sutezolid%2520story%26jtitle%3DLancet%2520Glob.%2520Health%26date%3D2016%26volume%3D4%26doi%3D10.1016%2FS2214-109X%2815%2900283-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1164/rccm.200904-0611OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1164%2Frccm.200904-0611OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=19520903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=371-376&author=K.+N.+Williamsauthor=S.+J.+Bricknerauthor=C.+K.+Stoverauthor=T.+Zhuauthor=A.+Ogdenauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+L.+Nuermberger&title=Addition+of+PNU-100480+to+first-line+drugs+shortens+the+time+needed+to+cure+murine+tuberculosis&doi=10.1164%2Frccm.200904-0611OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span></div><div class="casAuthors">Williams, Kathy N.; Brickner, Steven J.; Stover, Charles K.; Zhu, Tong; Ogden, Adam; Tasneen, Rokeya; Tyagi, Sandeep; Grosset, Jacques H.; Nuermberger, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model.  To investigate whether the addn. of PNU-100480 to the std. first-line regimen of rifampin, isoniazid, and pyrazinamide could shorten the duration of treatment necessary to prevent relapse after treatment discontinuation.  Following aerosol infection with Mycobacterium tuberculosis H37Rv and a 13-day incubation period, control mice were treated with the first-line regimen while test mice received the same regimen with PNU-100480 or linezolid added for the first 2 or 4 mo.  Efficacy was assessed on the basis of quant. cultures of lung homogenates performed monthly during treatment and 3 mo after completion of 3, 4, 5, or 6 mo of treatment to det. the relapse rate.  After 2 mo of treatment, mice receiving PNU-100480 in addn. to the first-line regimen had lung CFU counts two orders of magnitude lower than control mice receiving the first-line regimen alone.  Relapse rates after 4 mo of treatment were 90, 35, and 5% when PNU-100480 was added to the first-line regimen for 0, 2, and 4 mo, resp.  When the total treatment duration was 3 mo, relapse rates were 85 and 35 to 45% when mice received PNU-100480 for 2 and 3 mo, resp.; all control mice remained culture pos. at the time of treatment completion with 17 to 72 CFU per lung.  Addn. of linezolid to the first-line regimen had an antagonistic effect resulting in higher CFU counts and failure to render mice culture-neg. in 4 mo of treatment.  Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clin. testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnFWkF1J81fbVg90H21EOLACvtfcHk0lgyRsZQzOaeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L&md5=c4f5928eaf02b292e40d8b724ade1897</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0611OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0611OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DAddition%2520of%2520PNU-100480%2520to%2520first-line%2520drugs%2520shortens%2520the%2520time%2520needed%2520to%2520cure%2520murine%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D371%26epage%3D376%26doi%3D10.1164%2Frccm.200904-0611OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0lhOcRyFalXi8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/AAC.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2FAAC.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0lhOcRyFalXi8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2FAAC.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span>; <span class="NLM_string-name">Brown, D.</span>; <span class="NLM_string-name">Swift, M.</span>; <span class="NLM_string-name">Files, K.</span>; <span class="NLM_string-name">Fikes, S.</span>; <span class="NLM_string-name">Drusano, G. L.</span></span> <span> </span><span class="NLM_article-title">Clinical Doses of PNU-100480 (U, Sutezolid) Plus Rifampin (r) Synergistically Kills <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) while Linezolid (1) Plus R Does Not</span>. In  <i>52nd Interscience Conference of Antimicrobialgents and Chemotherapy (ICAAC)</i>, <span class="NLM_publisher-loc">San Francisco, CA</span>, Sept 9–12, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Louie&author=D.+Brown&author=M.+Swift&author=K.+Files&author=S.+Fikes&author=G.+L.+Drusano&title=Clinical+Doses+of+PNU-100480+%28U%2C+Sutezolid%29+Plus+Rifampin+%28r%29+Synergistically+Kills+Mycobacterium+tuberculosis+%28Mtb%29+while+Linezolid+%281%29+Plus+R+Does+Not"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLouie%26aufirst%3DA.%26atitle%3DClinical%2520Doses%2520of%2520PNU-100480%2520%2528U%252C%2520Sutezolid%2529%2520Plus%2520Rifampin%2520%2528r%2529%2520Synergistically%2520Kills%2520Mycobacterium%2520tuberculosis%2520%2528Mtb%2529%2520while%2520Linezolid%2520%25281%2529%2520Plus%2520R%2520Does%2520Not%26jtitle%3D52nd%2520Interscience%2520Conference%2520of%2520Antimicrobialgents%2520and%2520Chemotherapy%2520%2528ICAAC%2529%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DDG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DDG','PDB','6DDG'); return false;">PDB: 6DDG</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00480&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00480%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00480" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995cccea8e3d42","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
